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  OF	  ABBREVIATIONS	  
4EBP1:	  eukaryotic	  translation	  initiation	  factor	  4E-­‐binding	  protein	  1	  
ACC:	  acetyl-­‐CoA	  carboxylase	  
ACO:	  acyl	  CoA	  oxidase	  
AGEs:	  advanced	  glycation	  end-­‐products	  
AMPK:	  AMP	  activated	  protein	  kinase	  	  
ANP:	  atrial	  natriuretic	  peptide	  
AS160:	  Akt	  substrate	  160	  
Atg:	  autophagy	  related	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ATP:	  adenosine	  triphosphate	  
βARKO:	  beta	  cell	  selective	  androgen	  receptors	  deficiency	  
BNP:	  brain	  natriuretic	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β-­‐MHC:	  beta	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BP:	  blood	  pressure	  
BW:	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  weight	  
CPT-­‐I/II:	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  palmitoyl	  transferase	  I/II	  
CRP:	  C-­‐reactive	  protein	  
CTD:	  control	  diet	  	  
DAG:	  diacylglycerol	  
DBP:	  diastolic	  blood	  pressure	  	  
Ca2+:	  calcium	  
CD36:	  cluster	  of	  differentiation	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CO:	  cardiac	  output	  
CoA:	  Coenzyme	  A	  
CT:	  carnitine/acylcarnitine	  transferase	  
CHD:	  coronary	  heart	  disease	  
CVD:	  cardiovascular	  disease	  





EDPVR:	  end-­‐diastolic	  pressure	  volume	  relationship	  
EF:	  ejection	  fraction	  
EGF:	  epidermal	  growth	  factor	  
ER:	  estrogen	  receptor	  
ERE:	  estrogen	  receptor	  element	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ERα:	  estrogen	  receptor	  alpha	  	  
ERβ:	  estrogen	  receptor	  beta	  	  
ER	  stress:	  endoplasmic	  reticulum	  stress	  
ERE:	  estrogen	  response	  element	  	  
ERK:	  extracellular	  signal-­‐regulated	  kinase	  
ERR:	  estrogen	  related	  receptor	  	  
ESPVR:	  end-­‐systolic	  pressure	  volume	  relationship	  
FA:	  fatty	  acid	  
FABPpm:	  plasma	  membrane	  isoform	  of	  fatty	  acid	  binding	  protein	  
FACS:	  fatty	  acyl	  CoA	  synthetase	  
FADH2:	  flavin	  adenine	  dinucleotide	  
FAO:	  fatty	  acid	  oxidation	  
FAT:	  fatty	  acid	  transporter	  
FATP	  1/6:	  fatty	  acid	  transport	  protein	  	  
FFA:	  free	  fatty	  acid	  
FOXO:	  forkhead	  box	  O	  	  
FS:	  fractional	  shortening	  	  
FSH:	  follicle-­‐stimulating	  hormone	  	  
GAPDH:	  glyceraldehyde-­‐3-­‐phosphate-­‐dehydrogenase	  
GH:	  growth	  hormone	  
GLUT:	  glucose	  transporter	  
GnRH:	  gonadotropin-­‐releasing	  hormone	  	  
GO:	  glucose	  oxidation	  
GPER:	  G-­‐protein-­‐coupled	  receptor	  estrogen	  receptor	  
GSIS:	  glucose-­‐stimulated	  insulin	  secretion	  
GSK3:	  glycogen	  synthase	  kinase	  3	  
GTT:	  glucose	  test	  tolerance	  
GW:	  gastrocnemius	  weight	  
HF:	  heart	  failure	  
HFD:	  high	  fat	  diet	  
HFpEF:	  heart	  failure	  with	  preserved	  ejection	  fraction	  
HFrEF:	  heart	  failure	  with	  reduced	  ejection	  fraction	  
HRT:	  hormonal	  replacement	  therapy	  
Hsp:	  heat	  shock	  protein	  
IκBα:	  I	  kappa	  B	  alpha	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i.p.:	  intraperitoneal	  
IR:	  ischemia-­‐reperfusion	  	  
IRS:	  insulin	  receptor	  substrate	  	  
IVCT:	  isovolumic	  contraction	  time	  
IVRT:	  isovolumic	  relaxation	  time	  
JNK:	  c-­‐Jun	  N-­‐terminal	  kinase	  
KO:	  knock-­‐out	  
LA:	  left	  atria	  
LC3B:	  microtubule-­‐associated	  protein	  1	  light	  chain	  3	  beta	  
LH:	  luteinizing	  hormone	  	  
LW:	  liver	  weight	  
LV:	  left	  ventricle	  	  
MCD:	  malonyl	  CoA	  decarboxylase	  
MCP-­‐1:	  monocyte	  chemotactic	  protein-­‐1	  
MEF2C:	  myocyte	  enhancing	  factor-­‐2C	  
MMP:	  matrix	  metalloproteinase	  
mTOR:	  mammalian	  or	  mechanistic	  target	  of	  rapamycin	  
NADH2:	  nicotinamide	  adenine	  dinucleotide	  	  
NF-­‐κB:	  nuclear	  factor	  kappa-­‐light-­‐chain-­‐enhancer	  of	  activated	  B	  cells	  	  
p70-­‐S6K1:	  p70	  ribosome	  S6	  kinase	  1	  
OVX:	  ovariectomy/ovariectomized	  
PDC:	  pyruvate	  dehydrogenase	  complex	  
PDH:	  pyruvate	  dehydrogenase	  
PDK:	  pyruvate	  dehydrogenase	  kinase	  
Ped:	  end-­‐diastolic	  pressure	  
PGC1α:	  peroxisome-­‐proliferator	  activated	  receptor	  gamma	  coactivator	  1	  alpha	  
PHLPP1/2:	  PH-­‐domain	  leucine	  rich	  repeat	  containing	  protein	  phosphatase	  1/2	  
PI3K:	  phosphoinositol	  3	  kinase	  
PIP3:	  phosphatidylinositol	  (3,4,5)	  triphosphates	  
PKB:	  protein	  kinase	  B	  (Akt)	  
PKC:	  protein	  kinase	  C	  
PLN:	  phospholamban	  
PP1:	  protein	  phosphatase-­‐1	  
PPAR:	  peroxisome-­‐proliferator	  activated	  receptor	  
PP2A:	  protein	  phosphatases	  2A	  
PSR:	  Picrosirius	  Red	  	  
PTEN:	  phosphatase	  and	  tensin	  homolog	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PV:	  pressure-­‐volume	  
PVL:	  pressure-­‐volume	  loop	  
RT:	  room	  temperature	  
RV:	  right	  ventricle	  
SBP:	  systolic	  blood	  pressure	  
SERCA:	  sarcoplasmic	  reticulum	  calcium-­‐ATPase	  2	  
SIRT:	  silent	  information	  regulation	  	  
SP1:	  specificity	  protein	  1	  
SR:	  sarcoplasmic	  reticulum	  
StAR:	  stereoidenogenic	  acute	  regulatory	  protein	  	  
STZ:	  streptozotocine	  
SV:	  stroke	  volume	  
T2DM:	  type	  II	  diabetes	  mellitus	  
TAG:	  triacylglycerol	  
TCA:	  tricarboxylic	  acid	  cycle	  
TEM:	  transmission	  electron	  microscopy	  
TFAM:	  mitochondrial	  transcription	  factor	  A	  
TFBM2:	  mitochondrial	  transcription	  factor	  B2	  
TIMP:	  tissue	  inhibitor	  of	  metalloproteinase	  
TL:	  tibia	  length	  
TNFα:	  tumor	  necrosis	  factor	  alpha	  
TSC1/2:	  tuberous	  sclerosis	  complex	  1/2	  
VFW:	  visceral	  fat	  weight	  
VW:	  ventricular	  weight	  
WGA:	  wheat	  germ	  agglutinin	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Summary	  
	  
Men	   are	   at	   higher	   risk	   to	   develop	  obesity,	   cardiovascular	   disease	   and	  hypertension	   than	  
women.	   However,	   this	   tendency	   is	   inversed	   in	   the	   postmenopausal	   population	   when	  
women	   lose	   their	   advantage	   while	   ovarian	   hormone	   levels	   decrease.	   This	   raises	   the	  
question	   as	   to	   why	   and	   how	   this	   occurs.	   Many	   studies	   suggested	   that	   estrogen	   is	  
cardioprotective,	   however	   the	   underlying	   mechanisms	   are	   still	   unknown.	   Additionally,	  
hormone	   replacement	   therapies	   failed	   to	   prove	   the	   beneficial	   effect	   of	   estrogen	   on	   the	  
cardiovascular	   system.	   Hence	   the	   need	   to	   characterize	   and	   better	   understand	   the	  
mechanisms	  underlying	  the	  effects	  of	  estrogen	  in	  the	  cardiovascular	  system.	  Thus,	  the	  aim	  
of	   this	   thesis	   project	   was	   to	   describe	   gender-­‐	   and	   ovarian	   hormone-­‐specific	   effects	   of	  
obesity	  in	  the	  heart.	  To	  this	  end	  we	  analyzed	  the	  effect	  of	  HFD,	  gender	  and	  ovariectomy	  on	  
cardiac	   function	   and	   structure	   and	   investigated	   the	   mechanisms	   involved	   in	   a	   mouse	  
model.	  
	  
Male	  and	  female	  mice	  were	  fed	  for	  22	  weeks	  with	  a	  regular	  chow	  diet	  and	  a	  high-­‐fat	  diet	  
(HFD)	  containing	  45%	  calories	  derived	  from	  saturated	  fat	  and	  17%	  from	  sucrose	  aiming	  to	  
mimic	   the	   diet	   used	   in	   western	   countries,	   which	   contains	   a	   lot	   of	   saturated	   fat	   and	  
carbohydrates.	   The	   following	   gender-­‐specific	   changes	   were	   demonstrated	   after	   HFD	  
feeding.	   At	   the	   systemic	   level,	   male	   showed	   a	   stronger	   increase	   of	   plasma	   insulin	   than	  
female	  mice,	   suggestive	   of	   higher	   insulin	   sensitivity	   in	   the	   female	  mice.	   Cardiac	   function	  
analysis	   revealed	   that	   the	  peak	   filling	   and	  emptying	   rates	  were	  decreased	  by	   the	  HFD	   in	  
male	  mice	  only,	  suggesting	  that	  their	  ventricular	  relaxation	   is	   impaired.	  As	  for	  the	  female	  
mice,	   they	  exhibited	  decreased	  E/A	   ratios	   as	  well	   as	   a	  moderate	  wall	   thickness	   increase,	  
suggestive	   of	   mild	   diastolic	   dysfunction	   and	   cardiac	   remodeling,	   respectively.	   Ejection	  
fractions	  were	  preserved	  in	  these	  female	  mice.	  
	  
To	   evaluate	   the	   role	   of	   female	   hormones	   in	   changing	   cardiac	   structure	   and	   function,	  we	  
ablated	   the	   ovaries	   (OVX)	   4	   weeks	   before	   starting	   the	   diet.	   At	   the	   systemic	   level,	   we	  
demonstrated	   that	   ovarian	   hormones	   are	   involved	   in	   increasing	   plasma	   insulin	   and	  
maintaining	   glucose	   tolerance	   in	   response	   to	   HFD,	   since	   the	   OVX-­‐female	  mice	  were	   not	  
able	  to	  increase	  plasma	  insulin	   levels	  and	  had	  greater	  glucose	  intolerance	  than	  the	  sham-­‐
female	  mice	   after	  HFD.	  When	   investigating	   cardiac	   function,	  we	   revealed	   that	   the	   sham-­‐
female	   but	   not	   the	   OVX-­‐female	   mice	   were	   able	   to	   reduce	   the	   end-­‐diastolic	   pressure	   in	  
response	   to	   HFD.	   This	   difference	   unveiled	   that	   OVX-­‐female	   had	   higher	   end-­‐diastolic	  
pressures	  than	  sham-­‐female	  mice	  after	  HFD	  following	  cardiac	  stress	   induced	  by	  the	  beta-­‐
adrenergic	  agonist	  dobutamine.	  This	  suggests	  that	  estrogen	  is	  implicated	  in	  the	  adaptation	  
to	  the	  increased	  cardiac	  work	  induced	  by	  dobutamine.	  Finally,	  we	  demonstrated	  that	  OVX-­‐
female	   had	   higher	   cardiac	   PDK4	   mRNA	   than	   sham-­‐female	   mice	   when	   fed	   with	   regular	  
chow,	   suggesting	   that	   ovarian	   hormones	   are	   important	   for	   preserving	   normal	   glucose	  
oxidation.	  In	  conclusion,	  these	  data	  suggest	  that	  estrogen	  plays	  a	  role	  in	  insulin	  and	  glucose	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The	  prevalence	  of	  obesity	  and	  insulin	  resistance	  increased	  in	  the	  developed	  and	  emerging	  
countries,	   obesity	   has	   more	   than	   doubled	   since	   1980	   (WHO,	   2016).	   Although	   genetic	  
factors	  have	  been	  implicated	  in	  the	  onset	  of	  insulin	  resistance,	  this	  pathology	  is	  principally	  
due	   to	   feeding	   behavior	   and	   the	   increase	   of	   sedentary	   lifestyle.	   Metabolic	   syndrome	   is	  
characterized	   by	   the	   association	   of	   obesity,	   diabetes,	   and	   cardiovascular	   disease	   and	   is	  
described	   as	   an	   abdominal	   obesity	   with	   increased	   triglyceride,	   decreased	   high-­‐density	  
lipoprotein	   cholesterol,	   glucose	   intolerance	   and	   hypertension.1	   The	   associated	   increased	  
prevalence	   for	   cardiovascular	   disease	   (CVD)	   is	   linked	   to	   a	   higher	   risk	   to	   develop	  
atherosclerosis	   and	   myocardial	   ischemia,	   hypertension	   and	   diabetic	   cardiomyopathy,	  
hypercoagulability,	  sleep-­‐disordered	  breathing	  and	  atrial	  fibrillation.	  
	  
Different	  observations	  from	  clinical	  studies	  introduced	  that	  premenopausal	  women	  present	  
a	   lesser	   risk	   to	   develop	   cardiovascular	   diseases	   than	   age-­‐matched	   men.2-­‐4	   Hence,	   the	  
statement	  that	  female	  hormones	  are	  cardioprotective,	  which	  has	  been	  proved	  at	  preclinical	  
levels.	   Nevertheless,	   different	   hormonal	   replacement	   therapies	   (HRT)	   studies	   failed	   to	  
prove	  any	  benefits	  on	  CVD.5,6	  The	  disparity	  between	  these	  clinical	  trials	  and	  experimental	  
models	  is	  not	  yet	  clearly	  understood.	  However,	  it	  is	  noteworthy	  that	  a	  “timing	  hypothesis”	  
has	   been	   proposed	   since	   HRT	   in	   younger	   patients,	   who	   are	   still	   in	   the	   perimenopausal	  
period,	   showed	   improved	   cardiovascular	   benefits.	   In	   2014,	   new	   clinical	   trials	   have	   been	  
designed	  to	  explore	  this	  finding,	  and	  similarly	  the	  early	  HRT	  improved	  cardiovascular	  risks.7	  
Recently,	   trials	   performed	   by	   Manson	   et	   al.	   within	   the	   scope	   of	   the	   women	   health	  
initiative,	  have	  driven	  to	  the	  statement	  that	  HRT	  “has	  a	  harmful	  effect	  on	  coronary	  heart	  
disease	   among	   older	   women,	   whereas	   the	   results	   in	   younger	   women	   remain	  
inconclusive”.8	  More	   in	   detail	   they	   affirmed	   that	   conjugated	   equine	   estrogen	   treatment	  
was	   protective	   for	   myocardial	   infarction,	   coronary	   artery	   bypass	   grafting/percutaneous	  
coronary	  intervention	  and	  all	  cardiovascular	  events,	  and	  had	  a	  harmful	  effect	  on	  deep	  veins	  
thrombosis	  in	  early	  menopausal	  women	  only,	  strengthening	  the	  age-­‐dependent	  effects.	  	  
	  
Estrogen	   deficiency	   is	   associated	  with	   insulin	   resistance,	   impaired	   glucose	   tolerance	   and	  
increased	   abdominal	   fat.	   Obesity	   is	   a	   high-­‐risk	   factor	   for	   the	   development	   of	   type	   II	  
diabetes	   mellitus	   (T2DM).	   Diabetic	   patients	   have	   a	   higher	   risk	   to	   develop	   CVD,	   and	  
interestingly	   the	   female	   advantage	   regarding	   the	   cardiovascular	   risk	   incidence	   is	   not	  
anymore	  found	  in	  the	  context	  of	  T2DM.9,10	  Indeed,	  the	  Framingham	  Heart	  Study	  revealed	  a	  
5-­‐fold	  increase	  in	  risk	  of	  heart	  failure	  (HF)	  in	  diabetic	  women	  compared	  to	  a	  2-­‐fold	  increase	  
in	  males.2	  This	  difference	  might	  be	   linked	   to	   increased	   susceptibility	   to	  develop	  coronary	  
disease,	   impaired	   insulin	   sensitivity,	   and	   hyperglycemia.	   Diabetic	   females	   are	   also	   more	  
prone	  to	  develop	  acute	  myocardial	  infarction	  than	  diabetic	  males.11,12	  As	  previously	  noted,	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menopause	  in	  women	  increases	  the	  CVD	  risk	  and	  is	  associated	  with	  an	  enhanced	  incidence	  
of	   insulin-­‐resistance	   and	   diabetes,	   but	  whether	   estrogen	   deficiency	   exacerbates	   the	   CVD	  
risk	   in	   diabetic	   compared	   to	   non-­‐diabetic	  women	   is	   still	   unknown.	   It	   has	   been	   observed	  
that	   T2DM	   females	   are	   more	   susceptible	   to	   develop	   other	   cardiovascular	   risk	   factors	  
(dyslipidemia,	  obesity,	  hypertension)	  and	  that	  these	  risks	  have	  a	  greater	  probability	  to	  lead	  
to	  CVD.13	  	  
	  
Hereafter,	   I	   will	   introduce	   the	   cardiovascular	   system	   (CVS)	   as	   well	   as	   two	   well-­‐known	  
methods	  to	  investigate	  cardiac	  function,	  echocardiography	  and	  pressure	  volume	  loop	  (PVL),	  
relevant	   for	   the	   understanding	   of	   my	   thesis	   project.	   This	   general	   introduction	   will	   be	  
followed	   by	   key	   information	   about	   cardiac	  metabolism	   and	   CVD,	   and	   a	   summary	   of	   the	  
existing	   literature	  on	  the	  role	  of	  estrogen	   in	  this	  context.	  My	   introduction	  concludes	  with	  
the	  overall	  aims	  of	  my	  studies.	  
	  
 1.1 Cardiovascular	  system	  	  
1.1.1 General	  	  
The	  cardiovascular	  system	  (CVS)	  is	  composed	  of	  the	  heart	  and	  the	  blood	  vessels.	  The	  heart	  
is	   divided	   in	   four	   chambers:	   left/right	   atria,	   and	   left/right	   ventricles	   (LV	   and	   RV	  
respectively).	   The	   left	   ventricle	   receives	   the	   blood	   from	   the	   pulmonary	   system	   via	   the	  
pulmonary	   veins	   and	   redistributes	   it	   to	   all	   the	   organs	   as	   a	   pump,	   whereas	   the	   right	  
ventricle	   gathers	   blood	   coming	   from	   the	   organs	   via	   the	   inferior	   and	   superior	   vena	   cava,	  
before	  to	  send	  it	  to	  the	  pulmonary	  system	  for	  replenishment.	  Figure	  1	  shows	  the	  anatomy	  
of	  the	  heart	  with	  its	  four	  chambers	  and	  the	  major	  veins	  and	  arteries.	  
	  
Blood	  vessels	  transport	  the	  blood	  from	  the	  heart	  to	  the	  organs	  and	  back	  from	  the	  organs	  to	  
the	  heart.	  Different	  types	  of	  blood	  vessels	  exist	  with	  different	  characteristics.	  The	  arterial	  
vessels	  are	  composed	  of	  endothelial	  and	  smooth	  muscle	  cells	  as	  well	  as	  connective	  tissue	  
with	  high	  elastic	  properties.	   Importantly,	   they	  possess	  a	   thick	  wall	   to	  cope	  with	  the	  high-­‐
pressure	  blood	  coming	  from	  the	  left	  ventricle,	  and	  are	  branching	  into	  arterioles.	  Arterioles	  
are	   highly	   resistant	   and	   contain	   a	   high	   density	   of	   smooth	   muscle	   cells	   innervated	   by	  
sympathetic	   adrenergic	   nerve	   fibers,	   which	   give	   them	   the	   susceptibility	   to	   trigger	  
vasoconstriction	   or	   vasodilatation	   stimulation	   of	   α1	   and	   β2	   adrenergic	   receptors,	  
respectively.	  Finally,	  arterioles	  distribute	  the	  blood	  into	  capillaries,	  which	  constitute	  the	  site	  
of	  nutrient	  and	  gas	  exchange	  between	  blood	  and	  tissues.	  The	  blood	  that	  results	  from	  this	  
exchange	  will	   return	   to	   the	   right	  atria	   via	   venules	  and	  veins.	   The	  veins	  are	  not	  as	   rich	   in	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elastic	  tissue	  as	  the	  arteries	  hence	  their	  particularity	  to	  have	  a	  large	  capacitance,	  meaning	  















Figure	  1:	  Schematic	  representation	  of	  the	  anatomy	  of	  the	  heart.	  
The	  heart	   is	  composed	  of	   four	  chambers:	   the	  right	  and	   left	  atria	  and	  the	  right	  and	   left	  ventricles.	  
Blood	  coming	  from	  the	  lungs	  enters	  the	  left	  atrium	  via	  the	  pulmonary	  veins.	  When	  the	  left	  ventricle	  
pressure	   is	   higher	   than	   the	   atrium	  pressure,	   the	  mitral	   valve	  opens	   and	  blood	   flows	   into	   the	   left	  
ventricle	  during	  the	  relaxation	  phase.	  While	  the	  left	  ventricle	  contracts	  the	  pressure	  increases	  until	  
it	   gets	   higher	   than	   the	   aortic	   pressure.	   At	   this	  moment,	   the	   aortic	   valve	   opens	   and	   the	   blood	   is	  
ejected	  into	  the	  aorta	  to	  perfuse	  organs	  with	  oxygenated	  blood.	  After	  passage	  through	  the	  organs,	  
the	   deoxygenated	   blood	   comes	   back	   to	   the	   right	   atrium	   via	   the	   inferior	   and	   superior	   vena	   cava.	  
Similar	   as	   for	   the	   left	   ventricle,	   the	  blood	   is	   filling	   the	   right	   ventricle	  before	   to	  be	  ejected	   to	   the	  
lungs	  through	  the	  left	  pulmonary	  arteries	  to	  be	  reoxygenated.	  Copied	  from	  “Essentials	  of	  Anatomy	  
and	  Physiology”,	  6th	  Edition-­‐	  Seeley,	  Stefens,	  Tate.	  
	  
1.1.2 Blood	  circuit	  	  
The	  heart	  propels	   the	  blood	   rich	   in	  oxygen	   from	   the	   left	   ventricle	   into	   the	  arterial	  blood	  
vessels	  through	  the	  aorta,	  to	  reach	  the	  peripheral	  capillaries.	   It	   is	   in	  the	  capillaries	  where	  
nutrients,	  gases,	  water	  and	  solutes	  are	  exchanged	  between	  the	  blood	  and	  the	  tissues.	  The	  
blood	  continues	   its	  way	  to	  the	  venules	  and	  veins	  before	  to	  reach	  the	  right	  atrium	  via	  the	  
vena	  cava.	  The	  blood	  flows	  then	  into	  the	  right	  ventricle	  and	  is	  propelled	  into	  the	  pulmonary	  
artery	  to	  the	  lungs	  where	  exchanges	  will	  also	  happen	  between	  the	  blood	  and	  the	  alveolar	  
gas.	  This	  blood	  rich	  in	  oxygen	  will	  return	  to	  the	  left	  atria	  (LA)	  by	  the	  pulmonary	  veins	  and	  a	  
new	  cycle	  will	  start.	  
	  
The	  cardiac	  output	   is	   the	  rate	  at	  which	  blood	   is	  ejected	  by	   the	  heart	   (L/min).	  Each	  organ	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tract,	   and	   skeletal	   muscles	   receive	   the	   highest	   percentage	   of	   cardiac	   output,	   with	   25%	  
each,	  the	  brain	  receives	  15%	  and	  the	  skin	  and	  the	  coronaries	  5%	  of	  the	  cardiac	  output.	  All	  
these	  attributed	  percentages	  of	  cardiac	  output	  are	  susceptible	  to	  change	  according	  to	  the	  
























Figure	  2:	  Electrical	  and	  mechanical	  events	  of	  a	  cardiac	  cycle	  within	  the	  left	  ventricle.	  
The	  LV	  volume	  at	  peak	  dV/dt	  max	  was	  added	  as	  well	  as	  the	  peak	  dV/dt	  min,	  which	  occurs	  during	  LV	  
ejection.	  Copied	   from	  “Handbook	  of	   cardiac	   anatomy,	  physiology,	   and	  devices”,	   Springer,	   Paul	  A.	  
Iaizzo.	  
	  
1.1.3 Cardiac	  cycle	  	  
The	   normal	   heart	   rate	   is	   60-­‐80	   beats	   per	  minute	   at	   a	   resting	   state.	   The	   cardiac	   cycle	   is	  
divided	   into	  4	  phases,	  which	  take	  place	  within	   less	  than	  a	  second.	  The	  different	  electrical	  
and	  mechanical	  events	  of	  a	  cardiac	  cycle	  in	  a	  normal	  left	  heart	  are	  shown	  in	  Figure	  2.15	  The	  
blood	  coming	  from	  the	  veins	  enter	  the	  atria	  and	  when	  the	  pressure	  is	  sufficiently	  high	  the	  
cuspide	  valve	  (atrioventricular:	  mitral	  for	  the	  LV	  and	  tricuspide	  for	  the	  RV)	  opens	  to	  let	  the	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blood	  flow	  passively	  into	  the	  relaxed	  ventricle,	  this	  is	  the	  diastole.	  Active	  atrial	  contraction	  
pushes	  further	  blood	  volume	  into	  the	  LV,	  the	  LV	  pressure	  becomes	  higher	  than	  the	  atrium,	  
and	   the	   atrio-­‐ventricular	   valve	   closes	   marking	   the	   end	   of	   the	   diastole.	   The	   electrical	  
stimulus	  of	  the	  sinus	  node	  that	   induced	  atrial	  contraction	  (atrial	  systole)	   is	  propagated	  to	  
the	  ventricles	  through	  His	  bundle	  and	  left	  and	  right	  bundle	  branches.	  This	  depolarization	  of	  
ventricular	   cells	   will	   trigger	   the	   contraction	   and	   increase	   progressively	   intraventricular	  
pressures	   until	   they	   are	   above	   those	   in	   the	   atria,	   which	   results	   in	   the	   closure	   of	   the	  
atrioventricular	   valves.	   The	   ventricular	   pressure	   continues	   to	   rise,	   this	   is	   the	   isovolumic	  
contraction,	   until	   it	   is	   above	   the	   pressure	   in	   the	   semilunar	   valves	   (pulmonary	   and	   aortic	  
valve).	  Blood	  is	  rapidly	  ejected	  from	  the	  ventricle	  to	  the	  aorta	  and	  pulmonary	  artery	  where	  
the	   pressures	   rise	   while	   the	   ventricles	   continue	   to	   contract,	   this	   phase	   is	   called	   rapid	  
ejection	  phase.	  In	  the	  right	  ventricle,	  similar	  steps	  are	  present,	  but	  the	  pressure	  developed	  
and	  required	  to	  open	  the	  pulmonary	  valve	  are	  lower	  because	  the	  resistance	  is	  lower	  in	  the	  
pulmonary	   vascular	   system.	   The	   ventricles	   decrease	   their	   contraction	   and	   the	  
intraventricular	   pressures	   decrease	   below	   those	   in	   the	   aorta	   and	   pulmonary	   arteries	  
provoking	   a	   rapid	   closure	   of	   the	   semilunar	   valves.	   Rapidly,	   the	   intraventricular	   pressures	  
fall	   and	   the	   ventricles	   relax.	   All	   the	   cardiac	   valves	   are	   closed,	   this	   is	   the	   isovolumetric	  
relaxation	  phase.	  	  
1.1.4 Echocardiography	  
Echocardiography	   is	   a	   non-­‐invasive	   method	   used	   to	   evaluate	   cardiac	   morphology	   and	  
function	   in	   patients	   and	   has	   also	   been	   adapted	   for	   the	   analysis	   of	   murine	   models.16,17	  
Different	  parameters	  assessed	  by	  echocardiography	  are	  important	  to	  evaluate	  systolic	  and	  
diastolic	  dysfunction.	  The	  2D	   imaging	  “B-­‐mode”	   is	  used	  to	  obtain	  a	  parasternal	  short	  and	  
long	   axis	   view	   (Figure	   3)	   and	   visualize	   the	   LV	   anterior	   and	   posterior	  walls	   as	  well	   as	   the	  
intraventricular	   septal	   and	   lateral	  wall.	   The	   LV	   internal	   dimension	   corresponds	   to	   the	   LV	  
lumen.	   The	   1D	   imaging	   “M-­‐mode”	   is	   used	   to	   obtain	   fine	   measurements	   of	   cardiac	  
dimensions	  (Figure	  4).	  These	  parameters	  are	  used	  to	  assess	  systolic	  function.	  
	  
Ejection	   fraction	   (EF)	   and	   fractional	   shortening	   (FS)	   are	   commonly	   used	   to	   study	   systolic	  
function	  in	  a	  clinical	  setting	  and	  also	  in	  animal	  experimentation.	  The	  EF	  corresponds	  to	  the	  
ratio	  between	  the	  stroke	  volume	  (SV)	  and	  the	  end-­‐diastolic	  volume.	  The	  SV	  is	  the	  amount	  
of	   blood	   expelled	   during	   one	   cardiac	   cycle.	   Thus,	   the	   ejection	   fraction	   is	   the	   actual	  
percentage	   of	   blood	   ejected	   during	   one	   cycle.	   In	   non-­‐pathologic	   cases,	   the	   fractional	  
shortening	   reflects	   the	   EF	   and	   is	   similarly	   used	   to	   estimate	   myocardial	   contractility.	   In	  
ischemia	  or	  myocardial	   infarction	  models,	  EF	  calculation	  may	  not	  be	  accurate	  because	  of	  
the	  changes	  in	  cardiac	  geometry,	  and	  FS	  is	  preferentially	  used	  to	  describe	  systolic	  function.	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The	  EF	  and	  FS	  parameters	  are	  afterload-­‐dependent,	  which	  is	  their	  main	  limitation.	  Indeed,	  
an	   increase	   in	   systemic	   blood	   pressure	   and	   myocardial	   stiffness	   will	   reduce	   these	  
parameters.	   The	   LV	  posterior	   thickening	   is	   also	  used	   as	   a	   parameter	   of	   systolic	   function.	  
These	  parameters	  are	  calculated	  according	  to	  the	  following	  formulas:17-­‐20	  
− Stroke	  volume	  =	  end-­‐diastolic	  volume	  –	  end-­‐systolic	  volume	  
− EF	  =	  stroke	  volume	  /	  end-­‐diastolic	  volume	  (x	  100,	  %)	  
− FS	   =	   (LV	   end-­‐diastolic	   diameter	   –	   LV	   end-­‐systolic	   diameter)	   /	   LV	   end-­‐diastolic	  
diameter	  (x	  100,	  %)	  
− LV	  posterior	  wall	  thickening	  =	  (Posterior	  wall	  thickness	  at	  systole	  –	  Posterior	  wall	  
thickness	  at	  diastole)	  /	  Posterior	  wall	  thickness	  at	  diastole	  (x100,	  %)	  
Another	   parameter	   recorded	   by	   echocardiography	   is	   the	   cardiac	   output	   (CO).	   It	   is	   the	  
volume	  of	  blood	  pumped	  out	  of	  the	  left	  or	  right	  ventricle	  per	  unit	  of	  time	  (L/min).	  This	   is	  
the	  product	  of	  heart	  rate	  (beats/min)	  and	  stroke	  volume	  (L/beat).	  The	  LV	  mass	  as	  well	  as	  
wall	   thickness	  are	  also	  calculated	  from	  echocardiography.	  The	  LV	  mass	   is	  measured	  using	  
M-­‐mode	   from	   targeted	   short	   axis	   view	  or	   a	   parasternal	   long	   axis	   view	  at	   the	   end	  of	   the	  
diastole	   in	  which	   the	  ventricular	  dimension	  or	   volume	   is	   the	   largest.	  Geometric	   formulas	  
are	  used	  to	  calculate	  the	  volume	  of	  the	  LV	  myocardium,	  which	  is	  then	  converted	  to	  mass	  by	  
multiplying	   this	   volume	   of	   the	   myocardium	   by	   the	   myocardial	   density	   (1.04	   g/mL),	   the	  
formula	  used	  is	  as	  follow:21	  
LV	  mass	  =	  0.8	  x	  1.04	  x	  [(IVS+LVID+PWT)3	  –	  LVID3)]	  +	  0.6g	  












Figure	  3:	  Representative	  2D	  echocardiographic	  image	  of	  mouse	  cardiac	  tissue	  using	  the	  B-­‐
mode.	  
A:	   long-­‐axis	   view;	   B:	   short-­‐axis	   view;	   LV,	   left	   ventricle;	   RA,	   right	   atrium;	   LA,	   left	   atrium;	   SW,	  
intraventricular	  septal	  wall;	  AW,	  anterior	  wall;	  LW,	  lateral	  wall;	  PW,	  posterior	  wall;	  LVID,	  LV	  internal	  
dimension;	  PM,	  papillary	  muscle.	  































Figure	  4:	  Representative	  1D	  echocardiography	   images	  of	  mouse	  cardiac	  tissue	  using	  the	  
M-­‐mode.	  	  
The	  M-­‐mode	   cursor	   was	   positioned	   perpendicular	   to	   the	   interventricular	   septum	   wall	   (SW)	   and	  
posterior	  wall	   (PW)	   of	   the	   LV	   at	   the	   level	   of	   the	   papillary	  muscles.	   LV	   end-­‐systolic	   and	   -­‐diastolic	  
dimensions,	   as	   well	   as	   diastolic	   and	   systolic	   LV	   wall	   thickness	   were	  measured.	   ESD,	   end-­‐systolic	  
diameter;	  EDD,	  end-­‐diastolic	  diameter;	  LVAWs,	  LV	  anterior	  wall	  at	  systole;	  LVAWd,	  LV	  anterior	  wall	  
at	  diastole.	  
	  
Cardiac	   remodeling	   is	   defined	   as	   alterations	   in	   size,	   geometry,	   shape,	   composition	   and	  
function	   of	   the	   heart	   induced	   by	   cardiac	   load	   or	   injury.22	   Cardiac	   remodeling,	   or	   more	  
precisely	   LV	   remodeling,	   is	   observed	   in	   pathologic	   conditions	   such	   as	   hypertension.	   This	  
adaptive	  response	   is	   the	  consequence	  of	   increase	  LV	  workload	  to	  overcome	  the	  elevated	  
aortic	   pressure	   and	   is	   leading	   to	   LV	  wall	   hypertrophy.	   This	   compensatory	  hypertrophy	   in	  
response	   to	   systemic	   hypertension	   is	   explained	   by	   the	   Laplace	   law,23	   which	   states	   that	  
pressure	   correlates	  directly	  with	   tension	  and	  wall	   thickness	   and	   inversely	   correlates	  with	  
the	  radius	  as	  described	  with	  the	  following	  formula:	  
T=P	  x	  r/2h	  
(T:	  tension	  or	  stress	  in	  the	  LV	  wall;	  P:	  LV	  pressure;	  r:	  radius;	  h:	  LV	  wall	  thickness)	  
In	   other	   words,	   the	   Laplace	   law	   says	   that	   the	   greater	   the	   thickness	   of	   the	   LV	   wall,	   the	  
greater	  the	  pressure	  can	  be	  developed,	  and	  this	  is	  also	  why	  the	  LV	  is	  thicker	  than	  the	  RV	  as	  
it	  has	   to	  develop	  more	  pressure	   to	  expel	   the	  blood.	  A	  sustained	  elevated	  blood	  pressure	  
will	  increase	  the	  LV	  wall	  stress	  and	  results	  in	  LV	  wall	  thickening	  and	  LV	  mass	  elevation.	  This	  
adaptive	  response	  leads	  to	  the	  normalization	  of	  the	  wall	  stress	  and	  the	  onset	  of	  concentric	  
hypertrophy	   as	   a	   result	   of	   a	   pressure	   overload.	   In	   case	   of	   increased	   blood	   volume,	   the	  
chamber	  radius	  would	   increase	  resulting	   in	  eccentric	  hypertrophy	  (volume	  overload).	  The	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(RWT).	  The	  relative	  wall	  thickness	  derives	  from	  the	  Laplace	  law	  and	  is	  defined	  as	  the	  ratio	  
of	  twice	  the	  LV	  posterior	  wall	  thickness	  to	  the	  LV	  internal	  diameter	  measured	  at	  the	  end-­‐
diastole.	  Together	  with	  the	  LV	  mass,	  the	  RWT	  can	  describe	  four	  LV	  geometric	  patterns:21,24	  
1. normal	  LV	  geometry:	  normal	  LV	  mass	  and	  lower	  value	  of	  RWT	  
2. eccentric	  LV	  hypertrophy:	  	  increased	  LV	  mass	  and	  lower	  value	  of	  RWT	  (≤0.42)	  
3. concentric	  LV	  hypertrophy:	  increased	  LV	  mass	  and	  RWT	  (>0.42)	  
4. concentric	  LV	  remodeling:	  normal	  LV	  mass	  and	  increased	  RWT	  
Hypertrophy	  is	  the	  main	  mechanism	  used	  by	  the	  heart	  to	  reduce	  LV	  wall	  stress	  to	  palliate	  
pressure	  overload.	   It	   involves	  different	  cellular	  events	  such	  as	   increased	  protein	  synthesis	  
and	   stability.	   In	   concentric	   hypertrophy	   the	   width	   of	   the	   cardiomyocytes	   is	   increased	  
through	   the	  parallel	   addition	  of	   sarcomeres	   (the	   force-­‐generating	  units).	   As	   for	   eccentric	  
hypertrophy,	  it	  is	  characterized	  by	  increased	  cardiomyocyte	  length	  caused	  by	  the	  addition	  




















Figure	  5:	  Representative	  echocardiography	  images	  of	  mouse	  cardiac	  tissue.	  
A:	  pulse-­‐waved	  Doppler	  is	  used	  to	  determine	  the	  intramitral	  flow	  velocity	  at	  early	  (E)	  passive	  filling	  
of	  the	  ventricle	  and	  late	  active	  atrial	  (A)	  systole.	  The	  isovolumic	  relaxation	  and	  contraction	  time	  and	  
the	  ejection	  time	  are	  also	  measured	  via	  this	  method.	  B:	  tissue	  Doppler	  imaging	  to	  measure	  velocity	  
and	   wall	   motion.	   AW,	   anterior	   wall;	   ET,	   ejection	   time;	   IVCT,	   isovolumic	   contraction	   time;	   IVRT,	  
isovolumic	  relaxation	  time;	  LV,	  left	  ventricle;	  MVAL,	  mitral	  valve	  anterior	  leaflet;	  MVPL,	  mitral	  valve	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Left	   diastolic	   function	   can	   be	   evaluated	   by	   echocardiography	   using	   the	   following	   three	  
parameters:	  	  
1) The	  mitral	   inflow	  pattern,	   including	  the	  measure	  of	  the	  E/A	  ratio,	  the	  deceleration	  
time	  and	  the	  isovolumic	  relaxation	  time.	  	  
2) The	  mitral	   annulus	   velocity	   recorded	   with	   tissue	   Doppler:	   E/E’	   ratio,	   which	   is	   an	  
indicator	  of	  LV	  relaxation.	  
3) The	  pulmonary	  venous	  inflow	  pattern	  
	  
The	   pulse-­‐waved	   Doppler	   tool	   appreciates	   the	   blood	   flow	   velocity,	   to	   study	   diastolic	  
function	  imaging	  the	  evaluation	  of	  the	  transmitral	  flow	  patterns	  is	  essential.	  This	  is	  because	  
the	  velocity	  curve	  reflects	  the	  instantaneous	  pressure	  gradient	  between	  the	  LA	  and	  the	  LV.	  
As	  the	  pressure	  difference	  is	  high,	  the	  velocity	  will	  be	  higher	  at	  this	  time	  point.	  When	  the	  
pressure	   in	   the	   atrium	   equals	   the	   pressure	   of	   the	   ventricle,	   no	   pressure	   gradient	   exists	  
anymore	   and	   the	   flow	   ceases.	   Pulse-­‐waved	  Doppler	   records	  mitral	   inflow	   velocity	   at	   the	  
mitral	   valve	   leaflet	   tips	   level.	   Two	  waves	   are	   then	   visualized,	   one	   representing	   the	   early	  
passive	  filling	  of	  the	  LV	  (E-­‐wave)	  and	  one	  representing	  the	  late	  active	  filling	  in	  response	  to	  
atrial	  systole	  (A-­‐wave)	  (Figure	  5).	  The	  atrial	  contraction	  contributes	  to	  20%	  of	  the	  LV	  filling	  
in	  young,	  healthy	  subjects,	  and	  this	  proportion	  increases	  with	  aging	  without	  exceeding	  50%	  
generally.	   Loading	   conditions	   and	   filling	   pressure	   determine	   the	   mitral	   flow	   pattern,	   an	  
increased	   LA	  pressure	  will	   lead	   to	   an	   increased	  peak	   E-­‐wave	   velocity.	  On	   the	   contrary,	   a	  
decreased	  LA	  pressure	  can	  lead	  to	  a	  decrease	  in	  peak	  E-­‐wave	  velocity	  as	  well	  as	  an	  increase	  
in	  deceleration	  time	  independently	  from	  the	  intrinsic	  relaxation	  properties	  of	  the	  LV	  which	  
rely	   on	   the	   distensibility,	   elasticity,	   wall-­‐thickness,	   cavity	   dimensions	   and	   pericardial	  
constraint.	  	  
	  
These	  parameters	  are	  used	  to	  describe	  the	  progression	  of	  diastolic	  dysfunction	  into	  several	  
grades:	  26-­‐28	  
− Normal	  diastolic	  function:	  E>A,	  normal	  LV	  filling	  
− Grade	  1:	  E<A,	  impaired	  relaxation	  
− Grade	  2:	  E>A,	  pseudonormal	  mitral	  valve	  inflow	  
− Grade	  3:	  E>>A,	  restrictive	  filling	  
	  
Diastole	  consists	  of	  4	  phases:29	  
1-­‐ isovolumetric	   relaxation,	   which	   starts	   from	   the	   end-­‐systole	   until	   the	   LV	   pressure	  
falls	   below	   atrial	   pressure	   causing	   the	   mitral	   valve	   opening.	   This	   ATP-­‐dependent	  
process	  is	  initiated	  by	  the	  release	  of	  the	  actin-­‐myosin	  cross-­‐bridges.	  	  
2-­‐ the	  rapid	  early	  ventricular	  filling	  ensues	  where	  blood	  flows	  from	  the	  LA	  to	  the	  LV	  by	  
active	  and	  passive	  process,	  this	  phase	  corresponds	  to	  the	  E-­‐wave.	  
Introduction	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3-­‐ diastasis	   corresponds	   to	   the	   completion	   of	   the	   active	   ventricular	   relaxation,	   the	  
pressure	   between	   the	   LA	   and	   LV	   are	   nearly	   equal	   causing	   a	   slower	   blood	   flow	  of	  
atrial	  filling	  from	  the	  pulmonary	  venous	  flow.	  
4-­‐ atrial	   systole	   takes	   place,	   the	   atria	   contracts	   then,	   increasing	   the	   transmitral	  
pressure	  gradient	  and	  leading	  to	  the	  acceleration	  of	  blood	  flow	  from	  the	  atria	  to	  the	  
ventricle,	  this	  phase	  corresponds	  to	  the	  A-­‐wave.	  
	  
Diastolic	   filling	  depends	  on	  creating	  and	  maintaining	  a	  pressure	  gradient	  between	   the	  LA	  
and	  the	  LV,	  which	  determines	  the	  blood	  flow	  rate.	  Blood	  is	  first	  pulled	  out	  from	  the	  atria	  to	  
the	   ventricle	   because	   the	   LV	  pressure	   is	   rapidly	   decreased	  during	   relaxation	   leading	   to	   a	  
suction	   phenomenon.	   This	   happens	   during	   the	   early	   diastole.	   In	   late	   diastole,	   the	   atria	  
contracts,	  the	  pressure	   is	   increased	  above	  ventricle	  pressure	  and	  the	  blood	  is	  pushed	  out	  
through	  the	  valve	  to	  the	  LV.28	  	  
	  
The	   deceleration	   time,	   the	   isovolumic	   relaxation	   time	   of	   mitral	   inflow	   (IVRT)	   and	   the	  
isovolumic	   contraction	   time	   (IVCT)	   are	   also	   used	   as	   indicators	   of	   diastolic	   function.	   The	  
deceleration	   time	   of	   the	   early	   filling	   velocity	   is	   the	   time	   interval	   from	   early	   peak	   inflow	  
velocity	  (E-­‐wave)	  to	  the	  end	  of	  the	  rapid	  early	  filling	  phase.	  This	  data	  is	  obtained	  by	  tracing	  
the	  deceleration	  curve	   from	   the	  maximal	  point	  of	   the	  E-­‐wave	  velocity	   to	   the	  baseline.	   In	  
other	   words,	   the	   deceleration	   time	   represents	   the	   time	   needed	   for	   the	   pressure	   to	   be	  
equal	  between	  the	  LA	  and	  the	  LV.	  
	  
The	   IVRT	   is	   the	   interval	   of	   time	   between	   the	   closing	   of	   the	   aortic	   valve	   to	   mitral	   valve	  
opening	  and	   the	   start	  of	   the	   transmitral	   flow.	  This	  parameter	  depends	  on	   the	   rate	  of	   LV	  
relaxation	   and	   LA	   pressure.	   A	   prolongation	   of	   the	   IVRT	   is	   associated	   with	   impaired	  
relaxation	  while	  a	  shorter	  IVRT	  is	  associated	  with	  an	  elevation	  of	  atrial	  pressure.	  
	  
Additionally,	   tissue	  Doppler	   imaging	   is	  used	   to	  measure	  velocity	  of	  myocardial	  motion.	   It	  
measures	   peak	  myocardial	   velocities	   at	   the	  mitral	   annulus	   or	   the	   LV	   posterior	   wall.	   The	  
waveform	  will	  show	  four	  peaks:	   (1)	   IVRT,	   (2)	   the	  E’	  wave	  which	  represents	  the	  motion	  of	  
the	  mitral	   annulus	   during	   early	   LV	   diastolic	   filling,	   (3)	   the	   A’	   wave	   corresponding	   to	   the	  
atrial	   systole	   during	   late	   filling	   and	   (4)	   the	   IVCT.	   These	   parameters	   are	   important	   to	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1.1.5 Ventricular	  pressure-­‐volume	  loop	  	  
The	   pressure-­‐volume	   loop	   (PVL)	  method	   is	   the	   “gold-­‐standard”	  method	   to	   study	   cardiac	  
function.	  It	  was	  initially	  used	  in	  large	  animals	  and	  human	  and	  was	  progressively	  adapted	  to	  
be	  used	  in	  small	  animals	  such	  as	  mice.	  Unlike	  the	  echocardiography	  and	  cardiac	  MRI,	  this	  
method	   assesses	   systolic	   and	   diastolic	   dysfunction	   in	   a	   load-­‐dependent	   or	   -­‐independent	  
manner.	   PVL	   is	   commonly	   used	   to	   assess	   real-­‐time	   cardiac	   function	   and	   is	   sometimes	  
combined	  with	  a	  cardiac	  stress	  inducer	  such	  as	  the	  β-­‐adrenergic	  agonist	  dobutamine.	  The	  
technique	   uses	   a	   pressure-­‐conductance	   catheter,	   which	   is	   inserted	   into	   the	   left	   or	   right	  














Figure	  6:	  Example	  of	  a	  pressure-­‐volume	  loop	  describing	  each	  step	  of	  a	  cardiac	  cycle.	  
As	  soon	  as	  the	  mitral	  valve	  opens	  (1),	  the	  blood	  starts	  to	  fill	  the	  left	  ventricle	  passively	  to	  reach	  the	  
end-­‐diastolic	  volume	  (Ved),	  this	  is	  the	  diastolic	  filling,	  which	  ends	  with	  the	  closing	  of	  the	  mitral	  valve	  
(2).	  During	  this	  filling,	  the	  pressure	  progressively	  raises	  up	  to	  reach	  the	  end-­‐diastolic	  pressure	  (Ped).	  
During	   the	   isovolumic	   contraction,	   the	   LV	   starts	   to	   contract,	   and	   when	   the	   LV	   pressure	   (Pes)	   is	  
higher	  than	  the	  aortic	  pressure,	   the	  aortic	  valve	  opens	  (3)	  and	  the	  blood	   is	  ejected	   into	  the	  aorta	  
during	   the	   systolic	   ejection.	   The	   pressure	   reached	   in	   the	   aorta	   is	   then	   really	   high	   leading	   to	   the	  
aortic	  valve	  closure	  (4)	  followed	  by	  isovolumic	  relaxation.	  At	  this	  stage,	  the	  pressure	  decreases	  and	  
the	   LV	   starts	   to	   relax.	   	   The	   amount	   of	   blood	   left	   in	   the	   ventricle	   is	   low	   and	   represents	   the	   end-­‐
systolic	   volume	   (Ves).	   A	   new	   cardiac	   cycle	   can	   start	   again.	   Ped,	   end-­‐diastolic	   pressure;	   Pes,	   end-­‐





















1. Mitral	  valve	  opens	  
2. Mitral	  valve	  closes	  
3. Aortic	  valve	  opens	  
4. Aortic	  valve	  closes	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The	  catheter	  is	  comprised	  of	  one	  pressure	  and	  two	  conductance	  sensors.	  The	  latter	  allows	  
an	   estimation	   of	   the	   blood	   pool	   by	   employing	   the	   relationship	   between	   electrical	  
conductance	  and	  volume	  using	  the	  following	  formula:31	  
V	  =	  1/α 	  (ρL2)(G–Gp)	  
ρ:	  blood	  resistivity;	  L:	  distance	  between	  sensing	  electrodes;	  G:	  conductance	  (measured	  as	  a	  
voltage);	   Gp:	   parallel	   conductance	   induced	   by	   the	   conductivity	   of	   the	   muscle	   wall	   and	  
surrounding	  tissues;	  α:	  gain	  coefficient	  (volume	  correction/calibration	  factor).	  
 
The	   ventricular	   pressure-­‐volume	   loop,	   as	   its	   name	   suggests,	   is	   a	   loop	   representing	   the	  
pressure	  and	  volume	  changes	  during	  a	  cardiac	  cycle.	   It	   is	  displayed	  by	  plotting	  ventricular	  
pressure	  (y	  axis)	  against	  ventricular	  volume	  (x	  axis).	  This	  loop	  describes	  the	  4	  phases	  of	  the	  
cardiac	   cycle:	   diastolic	   filling,	   isovolumic	   contraction,	   systolic	   ejection	   and	   isovolumic	  
relaxation	  (Figure	  6).	  The	  opening	  and	  closing	  of	  the	  valves	  depend	  on	  the	  pressure	  on	  both	  
sides	  of	  them.	  Due	  to	  the	  pressure	  gradient,	  the	  mitral	  valve	  opens	  (1)	  and	  the	  blood	  flows	  
from	  the	  LA	  to	  the	  LV,	  this	  corresponds	  to	  the	  diastolic	  filling	  where	  the	  cardiac	  muscle	  is	  
relaxed.	   The	   LV	   volume	   attains	   its	  maximum;	   this	   is	   the	   end-­‐diastolic	   volume	   (140	  ml	   in	  
human),	   whereas	   the	   pressure	   is	   really	   low	   (end-­‐diastolic	   pressure)	   (2).	   The	   LV	   then	  
contracts,	  thereby	  inducing	  a	  drastic	  increase	  in	  pressure,	  this	  is	  the	  isovolumic	  contraction	  
phase.	   At	   the	  moment	   that	   the	   LV	   pressure	   becomes	   higher	   than	   the	   aortic	   pressure	   it	  
causes	   the	   aortic	   valve	   to	   open	   (3).	   The	   LV	   continues	   to	   contract	   and	   the	   blood	   is	   thus	  
rapidly	  ejected	  out	  of	  the	  LV	  into	  the	  aorta	  driven	  by	  the	  pressure	  gradient.	  The	  pressure	  
remains	  high	  due	  to	  the	  still	  on-­‐going	  ventricular	  contraction	  while	  the	  volume	  decreases	  
rapidly	  in	  the	  LV.	  The	  remaining	  blood	  volume	  in	  the	  LV	  is	  the	  end-­‐systolic	  volume	  (70	  ml).	  
The	   stroke	   volume	   corresponds	   to	   the	   volume	   ejected	   during	   one	   cardiac	   cycle	   and	  
represents	   the	   width	   of	   the	   pressure-­‐volume	   loop,	   in	   human	   the	   SV	   is	   equal	   to	   70	   ml.	  
Finally,	  the	  systole	  ends,	  ventricular	  pressure	  goes	  down	  below	  aortic	  pressure	   leading	  to	  
the	  closing	  of	  the	  aortic	  valve	  (4),	  the	  ventricle	  relaxes,	  this	  corresponds	  to	  the	  isovolumic	  
relaxation	  phase.	  A	  new	  cardiac	  cycle	  can	  start,	  the	  pressure	  in	  the	  LV	  has	  fallen	  to	  a	  lower	  
level	  than	  in	  the	  atria,	  the	  mitral	  valve	  opens	  and	  the	  blood	  flows	  in	  passively	  then	  actively	  
when	  the	  atria	  contracts.	  	  
	  
To	  study	  cardiac	  function,	   it	   is	   important	  to	  understand	  a	  few	  key	  words.	  The	  afterload	  is	  
the	   load	   against	   which	   the	   heart	   has	   to	   fight	   during	   ejection	   and	   is	   determined	   by	   the	  
arterial	  system.	  Aortic	  pressure,	  ejection	  wall	  stress,	  total	  peripheral	  resistance	  and	  arterial	  
impedance	   are	   used	   to	   characterize	   afterload.	   The	   velocity	   of	   cardiac	   fiber	   shortening	   is	  
maximal	   when	   afterload	   is	   equal	   to	   zero	   and	   inversely,	   it	   decreases	   when	   afterload	  
increases.	  The	  preload	  on	   the	  other	  hand	   is	   the	   load	  received	  by	   the	  heart	  at	   the	  end	  of	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diastole	  and	  results	  from	  passive	  and	  active	  emptying	  of	  the	  atrium	  into	  the	  ventricle.	  The	  
end-­‐diastolic	  volume	  and	  pressure	  as	  well	  as	  the	  end-­‐diastolic	  wall	  stress	  give	  information	  
about	   the	  preload.	  Mitral	   stenosis	  or	  ventricular	  hypertrophy	  will	   affect	   the	  preload.	  The	  
Frank-­‐Starling	   curve	   describes	   the	   relationship	   between	   preload	   and	   stroke	   volume.	   The	  
Frank-­‐Starling	   relationship	   states	   that	   "the	   volume	   of	   blood	   ejected	   by	   the	   ventricle	  
depends	  on	  the	  volume	  present	  in	  the	  ventricle	  at	  the	  end	  of	  the	  diastole”.32-­‐36	  The	  volume	  
present	  at	  the	  end	  of	  the	  diastole	  depends	  on	  the	  volume	  of	  blood	  returned	  to	  the	  heart	  
that	  is	  to	  say	  the	  venous	  return.	  In	  other	  words,	  Frank	  and	  Starling	  demonstrated	  that	  an	  
increase	   in	   ventricular	   filling,	   which	   is	   translated	   by	   an	   increased	   sarcomere	   length,	  
promotes	  an	  increase	  in	  the	  pressure	  developed	  during	  systole,	  which	  corresponds	  to	  the	  



















Figure	  7:	  Example	  of	  a	  pressure-­‐volume	  loop	  describing	  the	  ESPVR	  and	  EDPVR.	  
The	  venous	   return	   is	   first	  decreased	  during	  vena	  cava	  occlusion	  and	   then	  progressively	   increased	  
which	   corresponds	   to	   increasing	   the	  preload,	  which	   is	   demonstrated	  here	  by	   a	   shift	   of	   the	   loops	  
toward	  the	  right	  side.	  A	  group	  of	  pressure	  volume	  loops	  linked	  by	  a	  line	  connecting	  their	  intercept	  is	  
then	  created	  at	  the	  end-­‐systole	  point	  for	  the	  end-­‐systolic	  pressure	  volume	  relationship	  (ESPVR)	  and	  
at	  the	  end-­‐diastole	  for	  the	  the	  end-­‐diastolic	  pressure	  volume	  relationship	  (EDPVR).	  The	  ESPVR	  is	  the	  
relationship	   between	   the	   LV	   pressure	   and	   volume	   at	   its	   maximal	   activation	   at	   the	   end	   of	   the	  
systole.	  The	  slope	  of	  this	  relationship	  corresponds	  to	  the	  dP/dV	  and	  represents	  the	  elastance,	  which	  
is	   used	   as	   an	   index	   of	   contractility.	   The	   EDPVR	   is	   the	   relationship	   between	   the	   LV	   pressure	   and	  
volume	   at	   its	   complete	   relaxation,	   the	   inverse	   of	   the	   slope	   of	   this	   line	   is	   used	   as	   measure	   of	  
compliance.	  


















ESPVR:	Pes	= 	3.376	*	Ves	+ 	28.275, 	r² 	= 	0.9589
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To	   study	   the	   influence	   of	   load	   on	   cardiac	   function,	   additional	   manipulations	   can	   be	  
performed.	   For	   instance,	   occlusion	   and	   subsequent	   opening	   of	   the	   inferior	   vena	   cava	  
decreases	  and	  increases	  the	  venous	  return,	  which	  is	  translated	  by	  decreased	  and	  increased	  
preload,	   respectively.	   This	  blood	   flow	  occlusion/release	  method	  will	   cause	  an	   increase	  of	  
the	   stroke	   volume	   as	   the	   end-­‐diastolic	   volume	   increases	   and	   consequently	   the	   cardiac	  
fibers	  length	  (Frank-­‐Starling	  law).	  An	  increase	  of	  the	  afterload	  can	  also	  be	  visualized	  on	  the	  
PV	  loops.	  This	  effect	  can	  be	  due	  to	  an	  increased	  aortic	  pressure	  and	  will	  cause	  a	  decreased	  
stroke	  volume	  since	  the	  ventricle	  is	  contracting	  more	  during	  the	  isovolumic	  contraction	  to	  
overpass	   the	  aortic	  pressure	  and	   trigger	   the	  opening	  of	   the	  aortic	  valves	   than	  during	   the	  
actual	   ejection	   contraction.	   Thus,	   less	   blood	   is	   ejected	   and	   the	   end-­‐systolic	   volume	  
increases.	  Finally,	  it	  is	  possible	  to	  increase	  contractility	  either	  intrinsically	  by	  using	  specific	  
experimental	   stress	   models,	   or	   extrinsically	   by	   using	   pharmacological	   drugs	   such	   as	  
adrenergic	  agonists.	  In	  such	  cases,	  the	  ventricle	  can	  develop	  a	  greater	  pressure	  and	  tension	  
to	   eject	   a	   larger	   amount	   of	   blood.	   The	   stroke	   volume	   is	   increased	   and	   the	   end-­‐systolic	  
volume	  decreases.	  
	  
Using	  this	  pressure-­‐volume	  loop	  technique,	  many	  parameters	  can	  be	  measured	  to	  evaluate	  
cardiac	  real-­‐time	  function.	  The	  most	  commonly	  used	  and	  the	  most	  relevant	  hemodynamic	  
parameters	  are	  the	  end-­‐diastolic	  and	  end-­‐systolic	  pressures	  and	  volumes.	  The	  end-­‐systolic	  
pressure-­‐volume	  relationship	   (ESPVR)	   is	  also	  appreciated	   to	  evaluate	  cardiac	  elastance	  as	  
an	   index	   of	   contractility.37	   It	   corresponds	   to	   the	   relationship	   between	   LV	   pressure	   and	  
volume	   at	   its	   maximal	   activation	   (end-­‐systole).	   The	   elastance	   parameter	   is	   obtained	   by	  
changing	   the	   loading	   conditions.38	   In	   our	   experiment	   we	   decreased	   the	   venous	   return	  
(preload)	  via	  occlusion	  of	  the	  vena	  cava.	  A	  group	  of	  PV	  loops	  related	  by	  a	   line	  connecting	  
their	   intercept	   is	   then	   generated.	   The	   slope	   of	   this	   line	   is	   expressed	   as	   dP/dV	   and	  
represents	  the	  elastance,	  which	  is	  used	  as	  index	  of	  contractility	  and	  describes	  the	  strength	  
of	   the	   cardiac	  muscle	  or	   ventricle	   (Figure	   7).	   Similarly,	   the	   end-­‐diastolic	   pressure-­‐volume	  
relationship	   (EDPVR)	   is	  also	  obtained	  during	   the	  vena	  cava	  occlusion,	  and	  corresponds	   to	  
the	  relationship	  between	  LV	  pressure	  and	  volume	  at	  its	  complete	  relaxation	  (end-­‐diastole).	  
It	   is	  a	  measure	  of	  compliance,	  which	  is	  inversely	  proportional	  to	  the	  slope	  of	  the	  EDPVR39	  
and	  it	  describes	  the	  diastolic	  properties	  of	  the	  ventricle,	  meaning	  its	  stiffness	  (Figure	  7).	  
	  
Other	   indices	   of	   ventricular	   function	   can	   be	   derived	   from	   the	   PVL	   technique.	   The	   first	  
derivative	  of	  the	  changes	  in	  pressure	  is	  obtained	  from	  the	  slope	  of	  the	  change	  in	  pressure	  
with	   respect	   to	   the	   change	   in	   time.	   The	   peak	   maximal	   value	   dP/dt	   max	   is	   a	   load-­‐
independent	   contractility	   index,31	   the	   peak	   minimal	   value	   dP/dt	   min	   is	   used	   to	   assess	  
diastolic	  function.40	  The	  isovolumic	  relaxation	  constant	  tau	  also	  known	  as	  time	  constant	  is	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derived	   from	   the	   time	   taken	   by	   the	   pressure	   to	   fall	   from	   the	   point	   of	   dP/dt	  min	   to	   the	  
inverse	   natural	   log	   of	   that	   pressure.	   Tau	   is	   a	   preload-­‐independent	   measure	   of	   diastolic	  
function	  making	  it	  a	  reliable	  measurement	  to	  assess	  diastolic	  dysfunction.	  This	  parameter	  is	  
calculated	  as	  follows:	  
P(t)=	  e-­‐t/τ 	  
P:	  pressure	  at	  a	  time	  t;	  Τ:	  relaxation	  constant	  Tau	  
	  
The	  LV	  volume	  during	  the	  peak	  rate	  of	  early	  diastolic	  filling	  dV/dt	  max	  corresponds	  to	  the	  E-­‐
wave	  visible	  by	  Doppler.	  The	  volume	  during	  the	  peak	  rate	  of	  ejection	   is	  called	  dV/dt	  min.	  
These	  peaks	  correspond	  to	  the	  steepest	  tangents	  to	  the	  first	  part	  of	  the	  early	  filling	  curve	  
and	  the	  ejection	  curve	  respectively	  (Figure	  2).	  They	  are	  expressed	  in	  microliters	  per	  second.	  
	  
 1.2 Cardiac	  metabolism	  
The	  heart	  brings	  nutrients	  and	  oxygen	  supply	  to	  the	  body.	   Its	  constant	  activity	  makes	   it	  a	  
highly	   energy-­‐demanding	   organ,	   which	   relies	   mainly	   on	   fatty	   acid	   (FA)	   oxidation	   (FAO).	  
Indeed,	   under	   basal	   conditions	   and	   in	   a	   healthy	   heart	   the	   maintenance	   of	   continuous	  
contraction	  and	  relaxation	  depends	   for	  70%	  on	  FAO,	  whereas	  30%	  of	  energy	   is	  produced	  
through	  glucose	  oxidation	   (GO).	   In	   the	  healthy	  heart,	   the	  glucose	  transporter	  GLUT4	   (see	  
1.2.3)	  and	  the	  FA	  translocase	  FAT/CD36	  (see	  1.2.1)	  are	  translocated	  to	  the	  cardiomyocyte	  
sarcolemma	  to	  increase	  glucose	  and	  FA	  uptake	  when	  cardiac	  work	  increases.41,42	  However,	  
glucose	  metabolism	  takes	  over	  the	  fatty	  acid	  metabolism	  during	  a	  period	  of	  stress,	  such	  as	  
hypertrophy	  or	  infarct	  event	  to	  switch	  to	  a	  more	  oxygen-­‐efficient	  energy	  substrate	  to	  meet	  
the	   increased	   cardiac	   work.43	   The	   vascular	   system	   and	   the	   heart	   are	   closely	   linked	   and	  
tightly	  regulated	  to	  maintain	  a	  physiological	  condition.	  The	  appearance	  of	  disequilibrium	  is	  
often	   associated	   with	   the	   onset	   of	   a	   disease.	   In	   a	   fasting	   state,	   free	   fatty	   acids	   (FFA)	  
released	  from	  adipose	  tissue	  (lipolysis)	  are	  used	  for	  oxidative	  ATP	  generation	  in	  peripheral	  
tissues	   and	   liver	   where	   gluconeogenesis	   will	   take	   place	   to	   maintain	   plasma	   glucose.	  
Inversely,	   in	   a	   fed	   status	  ATP	  will	   be	  produced	  preferentially	   from	  GO	  due	   to	  a	  high	  and	  
increased	  availability	  of	  glucose;	  FA	  synthesis	  will	  also	  be	  promoted.	  A	  high	  fat	  diet	  (HFD)	  
will	   increase	   the	   use	   of	   FA	   for	   the	   production	   of	   energy.	   Randle	   had	   first	   depicted	   this	  
phenomenon	   in	   isolated	   rat	   heart	   and	   diaphragmatic	  muscle	   preparations.	   He	   described	  
this	   as	   a	   competition	   between	   glucose	   and	   fatty	   acid	   uptake	   and	   oxidation.44	   Indeed,	  
glucose	  and	  lipids	  are	  the	  main	  sources	  of	  cellular	  energy,	  they	  can	  compete	  and	  interact	  
with	  each	  other.	  Metabolic	   flexibility	   is	  defined	  as	   the	  ability	  of	  an	  organism	   to	  adapt	   its	  
energy	  use	  to	  the	  energy	  availability	  that	  is	  to	  say	  use	  preferentially	  glucose	  and	  lipids	  and	  
to	  switch	  rapidly	  between	  them	  when	  necessary.45,46	  The	  inability	  to	  adapt	  fuel	  oxidation	  to	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nutrient	   availability	   is	   often	   connected	   to	   T2DM,	   ectopic	   lipid	   accumulation	   and	  
mitochondrial	  dysfunction,46,47	  and	  is	  termed	  metabolic	  inflexibility.	  	  
	  
	  
Figure	  8:	  Overview	  of	  metabolic	  pathways	  in	  the	  heart.	  
Upon	  insulin	  stimulation,	  GLUT4	  and	  CD36	  translocate	  to	  the	  sarcolemma	  to	  allow	  glucose	  and	  fatty	  
acids	  to	  enter	  the	  cell.	  After	  FA	  entry	  into	  the	  cytoplasm	  via	  the	  transporter	  CD36,	  it	  is	  transferred	  
into	  the	  mitochondria	  via	  a	  specific	  transporter	  CPT-­‐Iβ.	  Once	  in	  the	  mitochondria	  it	  is	  converted	  into	  
acetyl-­‐CoA	   to	   enter	   the	   Krebs	   cycle.	   At	   this	   stage	   reducing	   equivalent	   NADH2	   and	   FADH2	   are	  
released	  to	  participate	   in	   the	  production	  of	  proton	  gradient	  via	   the	  electron	  transport	  chain.	  This	  
proton	   gradient	   is	   responsible	   for	   the	   ATP	   synthesis.	  PPARα	   transactivates	   most	   of	   the	   genes	  
involved	  in	  fatty	  acid	  utilization.	  CPT-­‐Iβ	  can	  be	  inhibited	  in	  an	  allosteric	  way	  by	  malonyl	  CoA.	  Steady	  
state	   levels	   of	   malonyl	   CoA	   are	   maintained	   by	   synthesis	   via	   acetyl-­‐CoA	   carboxylase	   (ACC)	   and	  
degradation	  via	  malonyl	  CoA	  decarboxylase	  (MCD).	  ACC	  is	  itself	  inhibited	  by	  AMPK	  protein	  whereas	  
MCD	  is	  activated	  by	  PPARα.	  	  Glucose	  metabolism	  consists	  of	  glycolysis	  and	  glucose	  oxidation,	  which	  
take	  place	   in	   the	   cytosol	   and	  mitochondria,	   respectively.	  Glycolysis	   starts	  with	   glucose	  entry	   into	  
the	   cytosol	   via	   a	   glucose	   transporter	   (GLUT).	   Glucose	   is	   then	   phosphorylated	   into	   glucose-­‐6-­‐
phosphate,	   finally	   pyruvate	   is	   the	   last	   molecule	   produced	   during	   glycolysis.	   Pyruvate	   is	   then	  
transported	   into	   the	   mitochondra	   where	   it	   undergoes	   oxidative	   decarboxylation	   by	   pyruvate	  
dehydrogenase	  (PDH)	  to	  acetyl-­‐CoA	  to	  enter	  the	  Krebs	  cycle.	  The	  rest	  of	  the	  cascade	  is	  identical	  to	  
FA	  oxidation.	  PDH	  is	  the	  rate-­‐limiting	  enzyme	  in	  glucose	  oxidation.	  PDH	  activity	  is	  modulated	  by	  its	  
phosphorylation	   state,	   which	   depends	   on	   two	   enzymes:	   pyruvate	   dehydrogenase	   kinase	   (PDK)	  
inhibits	   whereas	   pyruvate	   dehydrogenase	   phosphatase	   (PDHP)	   enhances	   it.	   ACC,	   acetyl-­‐CoA	  
carboxlyase;	   ATP,	   adenosine	   triphosphate;	   CAT:	   carnitine	   acetyl	   transferase;	   CPT-­‐I/II,	   carnitine	  
palmitoyl	   transferase	   I/II;	   FACS,	   fatty	   acyl	   CoA	   synthetase;	   FADH2,	   reduced	   flavin	   adenine	  
dinucleotide;	   G:	   glucose;GSK3β,	   glycogen	   synthase	   kinase	   3β;	   NADH,	   nicotinamide	   adenine	  
dinucleotide;	  PDH:	  pyruvate	  dehydrogenase	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The	  accumulation	  of	  these	  lipids	  intermediates	  has	  been	  implicated	  in	  the	  development	  of	  
insulin	   resistance,	  cardiac	  dysfunction	  and	  heart	   failure.	  CPT-­‐I	  catalyzes	   the	  conversion	  of	  
long-­‐chain	   acyl	   CoA	   to	   long-­‐chain	   acylcarnitine,	   which	   is	   translocated	   across	   the	   inner	  
mitochondrial	   membrane	   via	   the	   carnitine/acylcarnitine	   transferase	   (CT).	   Once	   in	   the	  
matrix,	  the	  acylcarnitine	  is	  converted	  back	  to	  long-­‐chain	  acyl	  CoA	  by	  CPT-­‐II,	  present	  on	  the	  
inner	  mitochondrial	  membrane.	  The	   long-­‐chain	  acyl	  CoA	  produced	  enters	   the	  β-­‐oxidation	  
pathway.	  Each	  cycle	  of	  β-­‐oxidation	  involves	  the	  production	  of	  acetyl-­‐CoA	  that	  can	  enter	  the	  
TCA	   cycle.	   The	   two	   dinucletotide	   flavin	   adenine	   dinucleotide	   (FADH2)	   and	   nicotinamide	  
adenine	   dinucleotide	   (NADH2)	   participate	   in	   the	   production	   of	   a	   proton	   gradient	   via	   the	  
electron	   transport	   chain	   that	   eventually	   induces	   ATP	   synthesis.	   Figure	   8	   represents	   an	  
overview	  of	  the	  main	  pathways	  involved	  in	  cardiac	  metabolism.	  
1.2.1 Fatty	  acid	  metabolism:	  introduction	  
Fatty	   acid	   metabolism	   is	   comprised	   of	   different	   steps	   regrouping	   FA	   entering	   in	   the	  
cytoplasm,	   FAO	   and	   ATP	   production	   in	   the	   mitochondria.	   Free	   fatty	   acids	   derived	   from	  
albumin	   and	   lipoprotein-­‐triacylglycerol	   (TAG)	   enter	   the	   cytoplasm	  by	  passive	   diffusion	  or	  
via	  carriers:	  the	  fatty	  acid	  translocase	  FAT/CD36,	  which	  takes	  up	  50-­‐60%	  of	  the	  cardiac	  FA,48	  
the	   plasma	   membrane	   isoform	   of	   fatty	   acid	   binding	   protein	   (FABPpm)	   and	   fatty	   acid	  
transport	   protein	   (FATP)1/6.	   In	   the	   cytoplasm,	   FA	   are	   converted	   into	   long-­‐chain	   acyl	  
coenzyme	   A	   (CoA)	   esters	   by	   the	   fatty	   acyl	   CoA	   synthetase	   (FACS),	   which	   can	   serve	   for	  
synthesis	  of	   intracellular	   lipid	   intermediates	  or	   transfer	   to	  carnitine	  and	  be	   taken	  up	   into	  
the	   mitochondria	   by	   the	   carnitine	   palmitoyltransferase	   (CPT)-­‐I.	   Fatty	   acid	   can	   also	   form	  
complex	  lipids	  such	  as	  TAG,	  diacylglycerol,	  and	  ceramides.	  
1.2.2 Fatty	  acid	  metabolism:	  regulation	  
Fatty	   acid	   metabolism	   is	   regulated	   by	   different	   players	   such	   as	   insulin,	   peroxisome-­‐
proliferator	   activated	   receptor	   (PPAR),	   malonyl	   CoA	   decarboxylase	   (MCD),	   AMP	   protein	  
activated	   kinase	   (AMPK)α,	   and	   others.	   Insulin	   is	   a	   regulator	   of	   FA	   and	   glucose	   cellular	  
uptake.	   Upon	   insulin	   binding	   to	   its	   membrane	   receptor,	   Akt	   is	   activated	   through	   PI3K,	  
which	   in	   turn	   will	   activate	   the	   translocation	   of	   GLUT4	   and	   CD36	   from	   endosomal	  
compartments	  towards	  the	  cellular	  membrane.49	  
	  
Peroxisome	  proliferator-­‐activated	  receptors	  are	  a	  family	  of	  nuclear	  hormones	  that	  function	  
as	   transcription	   factors	   and	   play	   a	   pivotal	   role	   in	   lipid	   metabolism50	   and	   inflammatory	  
responses.51	   Three	   different	   types	   exist:	   α,	   β/δ,	   and	   γ.52	   PPARα	   is	   important	   during	  
prolonged	  fasting	  and	  promotes	  ketogenesis	  and	  FAO,	  which	   is	  associated	  with	   increased	  
pyruvate	   dehydrogenase	   kinase	   (PDK)	   expression.	   The	   PPARα	   agonist	   WY-­‐14,643	   was	  
described	  as	  an	  inducer	  of	  both	  PDK4	  mRNA	  and	  protein	  levels	  in	  mouse	  skeletal	  muscle.53	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PPARγ	   is	   highly	   expressed	   in	   adipose	   tissue	  where	   it	   regulates	   adipogenesis	   and	   glucose	  
metabolism.	   The	   PPARγ	   agonist	   rosiglitazone	   was	   able	   to	   increase	   the	   level	   of	   PDK4	   in	  
adipose	  tissue	  but	  not	  in	  the	  liver	  or	  muscle,	  suggesting	  a	  tissue-­‐specific	  action.54	  
	  
In	   the	   heart,	   PPARα	   is	   the	  most	   abundant	   and	   is	   present	   at	   high	   levels	   due	   to	   the	   high	  
energetic	  demand	  of	  the	  heart,	  while	  PPARγ	  is	  much	  less	  represented.55	  Only	  little	  is	  known	  
about	  the	  role	  of	  PPARγ	   in	  the	  heart.	  A	  specific	  cardiac	  deletion	  of	  PPARγ	   in	  mice	  caused	  
hypertrophy	   with	   preserved	   cardiac	   function,	   and	   paradoxically	   using	   a	   PPARγ	   agonist	  
induced	  the	  same	  effect56	  highlighting	  the	  complex	  role	  of	  PPARγ	  in	  the	  heart.	  On	  the	  other	  
hand,	  much	  more	  is	  known	  about	  PPARα.55	  PPARα	  overexpression	  in	  mice	  is	  responsible	  for	  
an	  increased	  β-­‐oxidation	  of	  FA,	  accumulation	  of	  triglycerides	  and	  also	  a	  decrease	  in	  glucose	  
oxidation.57	   Similar	   results	   were	   observed	   after	   pharmacologic	   activation	   of	   PPARα.58	  
Conversely,	   PPARα	   deletion	   reduced	   β-­‐oxidation	   and	   enhanced	   glucose	   oxidation.	   Mice	  
also	   presented	   cardiac	   fibrosis	   and	   an	   impaired	   cardiac	   output	   while	   workload	   was	  
increased.59,60	  PPARα	  plays	  a	  critical	   role	  by	  transactivating	  most	  of	   the	  genes	   involved	   in	  
myocardial	   fatty	   acid	   utilization.	   Among	   these,	   an	   important	   regulatory	   protein	   is	   CPT-­‐I,	  
which,	  as	  already	  described	  under	  1.2.1,	   is	   involved	  in	   lipid	  uptake	  into	  the	  mitochondria.	  
CPT-­‐Iβ	   (cardiac	   isoform)	  can	  be	   inhibited	   in	  an	  allosteric	  way	  by	   the	  malonyl	  CoA.	  Steady	  
level	  of	  malonyl	  CoA	  is	  maintained	  by	  synthesis	  via	  the	  acetyl-­‐CoA	  carboxylase	  (ACC)	  and	  by	  
degradation	   induced	   by	   the	  MCD.	   ACC	   is	   itself	   inhibited	   by	   AMPKα	   protein	  whereas	   the	  
MCD	  is	  activated	  by	  PPARα.	  Therefore,	  malonyl	  CoA	  expression	  is	  reduced	  by	  activation	  of	  
PPARα	  or	  AMPKα,	  and	  this	  will	  lead	  to	  an	  increased	  activity	  of	  CPT-­‐I.	  	  	  
	  
As	   already	  mentioned,	   in	   normal	   conditions	   the	   heart	   uses	   up	   to	   70%	   from	   FAO	   for	   its	  
needs.	  In	  obesity,	  when	  FA	  supplies	  increase,	  the	  heart	  switches	  toward	  an	  almost	  exclusive	  
FA	  use.	  This	  is	  explained	  by	  the	  fact	  that	  insulin	  resistance,	  often	  encountered	  in	  diabetes,	  
increases	  FFA	  levels	  since	  lipolysis	  in	  adipocytes	  is	  enhanced,	  which	  is	  normally	  inhibited	  by	  
insulin.61	  Moreover	  as	  insulin	  is	  stimulating	  glucose	  uptake	  by	  inducing	  GLUT4	  transcription	  
and	  translocation,	  impaired	  insulin	  signaling	  reduces	  insulin-­‐stimulated	  glucose	  transport.62	  	  
	  
Another	   type	  of	   FA	  oxidation	   is	  peroxisomal	  FAO,	  which	   is	   specific	   for	   the	   long-­‐chain	  FA.	  
Specific	  enzymes	  will	   in	   this	  case	  break	  down	  this	   long-­‐chain	  FA	   into	  shorter	  ones,	  which	  
are	   able	   to	   enter	   the	   mitochondrion	   and	   be	   processed	   in	   the	   FAO.63	   The	   excessive	  
activation	  of	   the	  FAO	  pathway	   induces	   the	  accumulation	  of	   lipid	  metabolic	   intermediates	  
responsible	   of	   cellular	   damage	   such	   as	   apoptosis,	   oxidative	   stress	   and	   endoplasmic	  
reticulum	   (ER)	   stress.	   This	   defense	   mechanism	   is	   known	   as	   lipotoxicity	   and	   is	   often	  
associated	   with	   cardiac	   dysfunction.	   This	   happens	   when	   fat	   accumulation	   exceeds	   the	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oxidation	   rat	   and	   induces	   an	   ectopic	   accumulation	   of	   lipids	   in	   the	   myocardium,	   which	  
impairs	   left	   ventricle	   function.	   This	   lipid	   accumulation	   has	   been	   associated	   with	   cardiac	  
hypertrophy,	  dysfunction	  and	  apoptosis.64	  In	  different	  animal	  models,	  the	  increase	  in	  fatty	  
acid	   uptake	   is	   strongly	   associated	   with	   cardiomyopathy.65,66	   However,	   in	   human	   this	  
association	  between	  higher	   FA	  uptake	   and	   cardiomyopathy	   is	   not	   found	  despite	   the	   fact	  
that	  studies	  have	  demonstrated	  that	  excess	  lipid	  accumulation	  occurs	  in	  obese	  and	  insulin-­‐
resistance	  patients.67,68	  Thus	  obese	  and	  T2DM	  patients	  affected	  by	  heart	  failure	  can	  adapt	  
to	   the	   increase	   circulating	   lipids	   and	   do	   not	   exhibit	   acute	   myocardial	   lipotoxicity	  
characteristics.69	   Moreover,	   humans	   have	   been	   described	   to	   be	   able	   to	   reverse	   lipid	  
accumulation	   as	   mechanical	   unloading	   corrects	   metabolic	   disruption	   and	   myocardial	  
lipotoxicity	  in	  advanced	  heart	  failure	  and	  also	  reverses	  insulin	  resistance.70	  	  
1.2.3 Glucose	  metabolism:	  introduction	  
As	  mentioned	  above,	  in	  normal	  conditions	  glucose	  counts	  for	  30%	  of	  the	  cardiac	  energetic	  
supply,	   but	   under	   stress	   conditions	   a	   shift	   from	   the	   fatty	   acid	   oxidation	   towards	   glucose	  
oxidation	  is	  observed	  to	  increase	  ATP	  production,	  as	  glucose	  oxidation	  produces	  more	  ATP	  
molecules	  than	  fatty	  acid	  oxidation	  for	  the	  same	  oxygen	  use.	  Glucose	  metabolism	  consists	  
of	  glucose	  uptake,	  glycolysis	  and	  glucose	  oxidation,71	  which	   take	  place	   in	   the	  cytosol	  and	  
mitochondrion	  respectively.	  Glycolysis	   is	  preceded	  by	   the	  glucose	  uptake	   into	   the	  cytosol	  
via	   glucose	   transporters	   (GLUT).	   The	   glucose	   is	   then	   phosphorylated	   into	   Glucose-­‐6-­‐
phosphate	  and	  after	  different	  enzymatic	  reactions	  pyruvate	  is	  generated	  as	  final	  product	  of	  
glycolysis,	  with	  1	  ATP	  molecule	  being	  produced	  during	   this	  process.	  The	  pyruvate	   is	   then	  
transported	   into	   the	   mitochondrion	   by	   a	   specific	   transporter	   named	   mitochondrial	  
pyruvate	   carrier	   (MCP)1	   and	  MCP2,72,73	  where	   it	   undergoes	   oxidative	   decarboxylation	   by	  
the	  pyruvate	  dehydrogenase	  (PDH)	  to	  Acetyl-­‐CoA	  to	  enter	  the	  Krebs	  cycle.	  The	  rest	  of	  the	  
events	   in	   this	   cascade	  are	   similar	   to	   those	   for	   fatty	   acid	  oxidation.	   The	   final	  ATP	  yield	  of	  
glucose	   oxidation	   is	   36	   ATP,	   whereas	   lipid	   metabolism	   is	   able	   to	   produce	   more	   ATP	  
depending	   on	   the	   nature	   of	   the	   lipids	   (for	   example	   106	   ATP	   for	   palmitate),	   but	   glucose	  
oxidation	   is	  more	  effective	  than	  FA	  oxidation	  as	  the	  oxygen	  needed	  to	  produce	  the	  same	  
amount	  of	  ATP	  is	  lower.	  
	  
Different	   isoforms	  of	   glucose	   transporters	   exist.	  GLUT1	   is	   predominant	   in	   the	   fetal	   heart	  
while	  during	  adulthood	  more	  GLUT4	  is	  present.74	  Mice	  presenting	  a	  heterozygous	  deletion	  
of	   GLUT4	   exhibit	   a	   phenotype	   of	   human	   cardiomyopathy,	   suggesting	   that	   decreased	  
glucose	  utilization	   is	  deleterious	  for	  the	  heart.75	  Consistently,	   increased	  glucose	  supply	  by	  
overexpression	  of	  GLUT4	  in	  the	  db/db	  obese	  mouse	  model	  has	  been	  reported	  to	  decrease	  
FA	  utilization	  and	  to	  be	  cardioprotective.75	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1.2.4 Glucose	  metabolism	  regulation	  
Pyruvate	  dehydrogenase	  complex	  
Metabolic	  flexibility	  in	  mammals	  involves	  the	  pyruvate	  dehydrogenase	  complex	  (PDC).	  PDC	  
is	   a	  mitochondrial	  multi-­‐enzyme	   complex	   that	   catalyzes	   the	   oxidative	   decarboxylation	   of	  
pyruvate.76	   It	   ensures	   the	   conversion	   of	   pyruvate,	   CoA	   and	  NAD+	   into	   acetyl-­‐CoA,	   NADH	  
and	   CO2.77	   PDC	   is	   involved	   in	   glucose	   as	   well	   as	   fatty	   acid	   metabolism	   since	   the	   main	  
product	  of	  pyruvate	  decarboxylation,	  a	  CoA-­‐activated	  two-­‐carbon	  unit,	  can	  be	  condensed	  
with	  the	  oxaloacetate	  during	  the	  first	  reaction	  of	  the	  tricarboxylic	  acid	  (TCA)	  cycle	  or	  could	  
be	  used	  for	  fatty	  acid	  and	  cholesterol	  synthesis.78	  Therefore,	  PDC	  links	  glycolysis	  with	  TCA	  
cycle	  and	  lipid	  biosynthesis.	  PDC	  is	  the	  rate-­‐limiting	  enzyme	  complex	  in	  glucose	  oxidation.	  It	  
consists	   of	   3	   enzymes	   present	   in	   multiple	   copies:	   pyruvate	   dehydrogenase	   (PDH,	   E1),	  
dihydrolipoamide	   transacetylase	   (E2),	   and	   dihydrolipoamide	   dehydrogenase	   (E3).	   The	   E1	  
enzyme	  is	  a	  tetramer	  comprised	  of	  2	  α	  and	  2	  β	  subunits.	  The	  key	  regulatory	  subunit	  of	  PDH	  
is	   its	   E1-­‐α	   subunit	   and	   its	   activity	   can	   be	  modulated	   by	   a	   family	   kinase	   called	   pyruvate	  
dehydrogenase	  kinase	  (PDK).	  PDKs	  reversibly	  phosphorylate	  PDH	  at	  3	  specific	  serine	  sites:	  
S232,	  S293,	  S300	  within	  the	  α	  subunit,76,79	  consequently	  inactivating	  its	  enzymatic	  activity.	  
On	   the	   other	   hand,	   PDH	   activity	   is	   increased	   by	   pyruvate	   dehydrogenase	   phosphatase	  
which	  dephosphorylates	  PDH.	  In	  the	  healthy	  and	  fed	  state,	  PDH	  is	  in	  an	  activated	  state	  but	  
when	  carbohydrates	  supply	  is	  low,	  its	  inhibition	  is	  primordial	  for	  glucose	  synthesis.80	  When	  
PDH	   is	   inhibited	   by	   PDKs,	   acetyl-­‐CoA	   levels	   are	   decreased	   and	   the	   malonyl-­‐CoA,	   which	  
inhibits	  the	  CPT-­‐Iβ	  transferase,	  is	  reduced.81	  Thus,	  an	  upregulation	  of	  PDK	  results	  indirectly	  
in	  a	  facilitated	  fatty	  acid	  oxidation,	  which	  is	  necessary	  as	  glucose	  oxidation	  is	  blunted.82	  This	  
mechanism	  could	  explain	   the	   interaction	  and	   competition	  between	   these	   two	   sources	  of	  
energy.	   Additionally,	   the	   acetyl-­‐CoA	   and	   NADH	   produced	   during	   fatty	   acid	   oxidation	   are	  
able	  to	  stimulate	  PDK	  activity	  in	  skeletal	  muscle.83	  	  
	  
Pyruvate	  dehydrogenase	  complex	  kinase	  
Four	   isoforms	   of	   PDK	   exist	   from	   PDK1	   to	   PDK4,	   which	   are	   expressed	   in	   a	   tissue-­‐specific	  
manner.84	  PDK1	  is	  found	  in	  the	  heart85	  and	  pancreatic	  islets.86	  PDK2	  is	  highly	  expressed	  in	  
the	  heart,	  liver	  and	  kidney	  of	  humans	  and	  rodents,83	  while	  PDK3	  is	  only	  found	  in	  testis	  and	  
brain.84	  In	  the	  heart,	  skeletal	  muscle,	  lactating	  mammary	  gland	  and	  liver	  PDK4	  is	  the	  most	  
expressed	   isoform.	   In	   starved	   and	   insulin-­‐resistant	   animal	   models	   PDK2	   and	   PDK4	   are	  
highly	  expressed	   in	   liver,	  muscle,	  kidney	  and	  heart	  tissue.	  Their	  expression	   is	   increased	   in	  
conditions	   of	   reduced	   insulin	   levels	   or	   impaired	   insulin	   signaling.	   Indeed,	   in	   STZ-­‐induced	  
type	  1	  diabetic	   rats	   PDK4	  expression	  was	   increased	   in	   the	  heart	   and	   skeletal	  muscle.87,88	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An	   upregulation	   of	   PDK	   decreases	   PDH	   activity,	   which	   has	   been	   observed	   in	   metabolic	  
disorders	   such	   as	   diabetes,90,91	   heart	   disease92,93	   and	   fatty	   liver.94	   PDK4	   deficiency	   is	  
responsible	   for	   an	   inhibition	   of	   fatty	   acid	   oxidation	   and	   increased	   glucose	   oxidation	  
because	   of	   PDH	   activation.	   The	   subsequent	   increased	   acetyl-­‐CoA	   concentration	   induces	  
increased	  malonyl	  CoA	  levels	  that	  will	  in	  turn	  inhibit	  the	  rate	  of	  fatty	  acid	  oxidation.81	  PDKs	  
can	  be	  regulated	  by	  metabolites	  and	  transcription	  factors	  such	  as	   insulin,	  glucocorticoids,	  
thyroid	   hormones	   and	   fatty	   acids	   depending	   on	   the	   conditions	   and	   tissues.	   PDKs	   are	  
positively	   modulated	   by	   different	   stimuli	   such	   as	   high	   level	   of	   acetyl-­‐CoA,	   NADH,	   ATP,	  
starvation	   or	   nutrient	   deprivation,	   whereas	   pyruvate	   inhibits	   its	   transcription.	   Indeed,	  
during	  energy	  deprivation,	  the	  reduced	  availability	  of	  glucose,	  together	  with	  the	  decreased	  
insulin	   concentrations,	   induce	   a	   decrease	   of	   glucose	   utilization	   to	   conserve	   it	   for	   organs	  
highly	  dependent	  on	  glucose	  metabolism	  such	  as	  the	  brain,	  in	  favor	  of	  the	  use	  of	  long-­‐chain	  
fatty	  acid	  oxidation	  for	  energy	  production.77	  	  
	  
PDKs	   are	   regulated	   by	   multiple	   factors	   at	   the	   transcriptional	   level.	   Insulin	   represses	   its	  
expression	  via	  forkhead	  box	  O	  (FOXO)	  modulation.	  The	  human	  PDK4	  gene	  has	  three	  insulin	  
responses	  sequences	  (IRSs)	  that	  are	  binding	  FOXO1	  and	  FOXO3.95	  Overexpression	  of	  FOXO1	  
and	   FOXO3	   increased	   basal	   and	   dexamethasone-­‐induced	   expression	   of	   PDK4	   in	   HepG2	  
cells,	   which	   was	   abolished	   by	   mutation	   of	   the	   IRSs	   in	   the	   PDK4	   promoter.95	   In	   murine	  
muscle	   and	   C2C12	   cells,	   FOXO	   was	   induced	   by	   nutrient	   deprivation,	   which	   mediated	  
upregulation	   of	   PDK4	   gene	   expression.	   96	   In	   the	   same	   cell	   type,	   it	   was	   described	   that	  
overexpression	   of	   the	   FA	   transporter	   CD36	   induced	   FOXO1	   expression	   and	   is	   thus	  
participating	  in	  the	  upregulation	  of	  PDK4	  expression.97	  
	  
Upregulation	   of	   PDK	   transcription	   is	   induced	   by	   several	   nuclear	   hormone	   receptors	  
including	   PPAR,	   estrogen	   related	   receptor	   (ERR),	   thyroid	   hormone	   receptor,	   and	  
glucocorticoid	   receptor,	   which	   are	   activated	   by	   starvation	   or	   increased	   fatty	   acid	   levels.	  
PDKs	  are	  also	  modulated	  by	  other	  factors	  such	  as	  growth	  hormone	  (GH),	  but	  its	  effect	  on	  
PDKs	  remains	  controversial.	  Some	  studies	  showed	  that	  GH	  is	  able	  to	  increase	  PDH	  activity	  
in	  rat	  myocardium,98	  whereas	  recent	  studies	  demonstrated	  the	  inverse	  effect,	  namely	  that	  
GH	   increased	   PDK4.99,100	   In	   the	   liver	   of	   fasting	  mice,	   GH	   has	   opposite	   effects	   to	   that	   of	  
insulin	  since	  it	  activates	  PDK4	  expression	  by	  stimulating	  JNK	  signaling,	  leading	  to	  activation	  
of	   the	   STAT5	  pathway	   to	   increase	   gluconeogenesis.	  A	   clinical	   study	   showed	   that	  GH	  was	  
able	   to	   promote	   lipolysis	   and	   reduce	   insulin	   sensitivity	   by	   upregulation	   of	   PDK4	   mRNA	  
leading	  to	  a	  decrease	  in	  PDH	  activity	  similar	  to	  the	  effect	  observed	  during	  fasting.101	  Along	  
similar	   lines,	   the	   antidiabetic	   Metformin	   inhibits	   the	   PDK4	   activation	   by	   GH	   via	   the	  
inhibition	  of	  the	  binding	  of	  STAT5	  to	  the	  PDK4	  promoter.100	  Finally,	  adiponectin	  and	  AMPKα	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are	   two	   others	   factors	   involved	   in	   PDK	   regulation.	   In	   skeletal	   muscle,	   it	   is	   known	   that	  
adiponectin	  can	  activate	  AMPKα	  and	  this	  leads	  to	  fatty	  acid	  oxidation.102	  
	  
Free	   fatty	  acids	  and	  derivatives	  as	  endogenous	  PPAR	   ligands	  have	  been	   implicated	   in	   the	  
increased	  PDK	  expression	  observed	   in	   fasting	  states	  and	  diabetes.	   Indeed,	   long-­‐chain	  FAs	  
such	   as	   palmitate	   and	   oleate	   directly	   induce	   PDK4	   in	   skeletal	   muscle	   and	   hepatoma	  
cells.53,97,103	   Additionally,	   indirectly	   increased	   supplies	   of	   FAs	   for	   example	   by	   increased	  
cardiac	   lipoprotein	   lipase	   or	   hepatic	   lipase	   have	   been	   shown	   to	   increase	   PDK4	   mRNA	  
expression	  via	  interaction	  with	  PPARα	  and	  PPARβ/δ.104,105	  
	  
In	  healthy	  individuals,	  upon	  insulin	  stimulation,	  the	  skeletal	  muscle,	  which	  is	  the	  major	  site	  
for	  glucose	  and	  fatty	  acids	  oxidation,	   is	  able	  to	  switch	  from	  lipid	  to	  glucose	  oxidation	  and	  
suppresses	  lipid	  catabolism	  in	  favor	  of	  increased	  glucose	  uptake,	  oxidation	  and	  storage.106	  
However,	  insulin-­‐resistant	  obese	  and	  T2DM	  patients	  had	  greater	  rates	  of	  lipid	  oxidation	  in	  
skeletal	   muscle	   than	   lean	   individuals	   during	   insulin	   infusion,	   suggesting	   that	   they	   had	  
metabolic	   inflexibility.106	   Furthermore,	   methylation	   of	   the	   PDK4	   promoter	   at	   specific	  
cytosine	   sites	  was	   reduced	   in	   T2DM	   patients,	   suggesting	   that	   epigenetic	  modification	   of	  
mitochondrial	   genes	   regulate	   substrate	   switching.107	   In	   the	   liver,	   inactivation	   of	   PDH	   by	  
PDKs	   can	   downregulate	   the	   conversion	   of	   pyruvate	   to	   acetyl-­‐CoA	   ending	   in	   a	   shift	   of	  
pyruvate	   from	   TCA	   cycle	   toward	   gluconeogenesis.108	   PDK4	   can	   interact	   with	   FAT/CD36,	  
PPARβ/δ	   and	   FOXO1.97	   Under	   fasting	   conditions,	   CD36	   facilitates	   fatty	   acid	   flux,	   which	  
activates	  PPARβ/δ	  that	  in	  turn	  will	  activate	  FOXO	  and	  PDK4	  transcription	  to	  inhibit	  glucose	  
oxidation.	  Together	  with	  the	  increase	  in	  fatty	  acid	  flux,	  the	  decreased	  insulin	  concentration	  
is	  responsible	  of	  a	  downregulation	  of	  Akt,	  which	  induces	  activation	  of	  FOXO1.109	  In	  skeletal	  
muscle,	   FOXO1	   recruits	   CD36	   to	   the	   plasma	   membrane	   and	   activates	   lipoprotein	   lipase	  
(hydrolyzes	  plasmatic	  triglycerides	  and	  lipoproteins)	  enhancing	  fatty	  acid	  utilization.97	  
	  
In	   T2DM	   patients,	   PDK2	   and	   PDK4	  mRNA	  were	   found	   increased	   in	   skeletal	  muscle	   after	  
overnight	  fasting,	  which	  is	  coherent	  with	  the	  insulin	  resistance	  and	  metabolic	  inflexibility	  of	  
these	   patients.107	  Moreover,	   4h	   of	   lipid	   infusion	   in	   humans	   decreases	   insulin-­‐stimulated	  
glucose	  uptake	  and	  PI3K	  in	  muscle.110	  Similarly,	  Tsintzas	  et	  al.	  observed	  in	  healthy	  men	  that	  
lipid	   infusion	   during	   a	   hyperinsulinemic-­‐euglycemic	   clamp	   experiment	   attenuated	   the	  
suppression	  of	  PDK4	  expression	  induced	  by	  insulin,	  and	  that	  this	  effect	  was	  independent	  of	  
Akt	   mediated	   pathway	   stimulation.	   This	   indicates	   that	   in	   healthy	   conditions	   the	   lipid	  
accumulation	   plays	   a	   more	   important	   role	   than	   insulin	   stimulation	   in	   the	   regulation	   of	  
skeletal	  muscle	  PDK4	  expression.111	  On	  the	  contrary,	  the	  suppression	  of	  PDK4	  expression	  by	  
insulin	  was	  independent	  of	  insulin's	  effect	  on	  plasma	  FA	  levels,	  indicating	  that	  the	  observed	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increased	   PDK4	   expression	   in	   starvation	   and	   diabetes	   could	   be	   due	   to	   insulin	   deficiency	  
rather	  than	  increased	  levels	  of	  FA.112	  
	  
In	  conclusion,	  targeting	  PDK	  to	  inhibit	  its	  activity	  would	  be	  a	  promising	  therapeutic	  solution	  
for	   patients	   suffering	   from	   metabolic	   disease.	   Indeed,	   inhibiting	   PDK	   would	   lead	   to	   an	  
enhanced	  PDH	  activity	  and	  would	  help	   to	   restore	  a	  normal	   insulin	  activity	  and	   lower	   the	  
blood	  glucose	  concentration.	  
1.2.5 From	  obesity	  to	  Type	  2	  diabetes:	  mechanisms	  
Obesity	   (body	   mass	   index	   >30	   kg/m2)	   may	   be	   associated	   with	   several	   disorders:	   type	   2	  
diabetes	   mellitus,	   hypertension,	   hypercholesterolemia,	   hypertriglyceridemia,	   and	   non-­‐
alcoholic	  fatty	  liver	  disease.	  Obesity	  increases	  the	  risk	  of	  insulin	  resistance,	  type	  2	  diabetes,	  
cancer,	  dyspnea	  and	  other	  chronic	  diseases	  and	  most	  weighty	  cardiovascular	  diseases.113,114	  
During	   the	   last	   decades	   this	   disease	   has	   become	   a	   worldwide	   health	   problem	   and	   the	  
prevalence	   numbers	   are	   alarming.	   In	   2014,	   39%	   of	   adults	   aged	   18	   years	   and	   over	   were	  
overweight	  (1.9	  billion)	  and	  13%	  were	  obese	  (World	  Health	  Organization,	  WHO,	  June	  2016).	  	  
	  
The	  excess	  of	  calories	   ingested	   lead	   to	  an	   increase	   in	  body	  weight	   together	  with	  adipose	  
tissue	   mass.	   This	   adiposity	   and	   adipocyte	   malfunction	   lead	   to	   dysregulation	   of	   adipose	  
tissue-­‐derived	   secretory	   factors	   called	   adipokines	   (e.g.	   leptin)	   that	   can	   participate	   in	   the	  
development	  of	  metabolic	  disease	  because	  of	   their	   role	   in	  glucose	  and	   lipid	  homeostasis	  
and	   inflammatory	   responses.115,116	   Among	   the	   adipokines	   secreted	   by	   the	   endocrine	  
adipose	   tissue	   are	   chemokines,	   cytokines	   and	   hormones.	   In	   obesity,	   adipocytes	   increase	  
the	   secretion	   of	   pro-­‐inflammatory	   chemokines	   and	   cytokines,117,118	   including	   monocyte	  
chemotactic	  protein	  (MCP)-­‐1,	  tumor	  necrosis	  factor	  α	  (TNFα),	  IL	  (interleukin)-­‐1,	  IL-­‐6	  and	  IL-­‐
8	   that	   promote	   insulin	   resistance.119-­‐121	   Macrophages	   are	   actually	   responsible	   for	   the	  
release	  of	  pro-­‐inflammatory	   cytokines	   such	  as	   TNFα,	   and	  macrophage	   content	   correlates	  
positively	  with	  adipocyte	  size	  and	  body	  mass.122	  
	  
It	  has	  been	  described	  that	  insulin	  signaling	  is	  blunted	  in	  adipose	  tissue,	  skeletal	  muscle	  and	  
liver	   in	   obesity-­‐induced	   T2DM.123	   One	   of	   the	   consequences	   is	   that	   glucose	   transport	   is	  
reduced	   in	   these	   tissues.	   A	   major	   role	   of	   insulin	   in	   adipose	   tissue	   is	   to	   inhibit	   lipolysis.	  
Because	  of	  its	  resistance	  to	  insulin	  and	  accumulation	  of	  fat,	  the	  adipose	  tissue	  will	  release	  
free	   fatty	   acids,	   which	  may	   participate	   in	   the	  modulation	   of	   insulin	   sensitivity.124,125	   The	  
adipokine	   adiponectin,	   known	   to	   increase	   insulin	   sensitivity,	   is	   reduced	   with	   increased	  
adiposity.	   The	   cause	   of	   insulin	   resistance	   in	   skeletal	   muscle	   and	   liver	   are	   multiple,	   and	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lipotoxicity	   is	   one	   of	   them.	   This	   is	   due	   to	   an	   increase	   in	   lipid	   deposits	   that	   enhances	  
triglyceride	  and	  toxic	  lipid	  intermediates	  such	  as	  ceramide	  and	  diacylglycerol	  (DAG).126	  
	  
The	   increased	   activation	   of	   nutrient-­‐sensing	   pathways	   such	   as	   the	   hexosamine	   synthetic	  
pathway	  impairs	  directly	  the	  insulin	  pathway.127	  Free	  fatty	  acids	  can	  act	  as	  ligands	  for	  the	  
toll-­‐like	   receptor	   (TLR)	   4	   complex128	   and	   stimulate	   macrophages	   to	   secrete	   cytokines.129	  
The	  toll-­‐like	  receptor	  and	  c-­‐Jun	  N-­‐terminal	  kinase	  (JNK)	  are	  also	  known	  to	  influence	  insulin	  
function	   as	   they	   mediate	   increased	   inflammation,	   which	   impairs	   the	   insulin	   pathway.130	  
Moreover,	  mitochondrial	  dysfunction	  has	  been	  described	  in	  insulin	  resistant	  states,	  without	  
knowing	   if	   this	   phenomenon	   is	   directly	   affecting	   insulin	   sensitivity	   or	   if	   it	   is	   the	  
consequence	   of	   insulin	   resistance.131	   In	   the	   diabetic	   heart,	   an	   impairment	   in	   insulin-­‐
stimulated	   glucose	   utilization	   was	   described,	   however	   preclinical	   and	   clinical	   studies	  
showed	   that	   insulin	   signaling	   was	   maintained,	   suggesting	   that	   some	   pathway	   might	   be	  
upregulated	  in	  response	  to	  hyperinsulinemia	  underlying	  systemic	  insulin	  resistance.132,133	  
	  
Peterson	  et	  al.	  described	  the	  effect	  of	  obesity	  on	  cardiac	  metabolism	  in	  women.	  They	  noted	  
that	  myocardial	   fatty	   acid	   uptake,	   utilization	   and	  oxidation	   as	  well	   as	  myocardial	   oxygen	  
consumption	  were	  increased	  in	  proportion	  to	  body	  mass	  index	  and	  glucose	  intolerance.134	  
This	  suggests	  that	  cardiac	  metabolism	  is	  enhanced	  together	  with	  the	  grade	  of	  obesity	  and	  
glucose	  intolerance,	  consistent	  with	  the	  Randle	  principle.	  
1.2.6 Obesity	  and	  Type	  2	  diabetes:	  players	  
Obesity	  causes	  an	  increase	  in	  circulating	  FA	  levels,	  which	  leads	  to	  PPARα	  activation	  and	  in	  
turn	   increases	   FAO.135	   As	   described	   under	   1.2.2,	   PPARα	   is	   regulating	   genes	   implicated	   in	  
fatty	  acid	  uptake	  (FAT,	  CD36,	  FATP,	  and	  FABP),	  in	  the	  generation	  of	  fatty	  acyl	  CoA	  (FACS),	  as	  
well	  as	  mitochondrial	  fatty	  acid	  uptake	  (CPT-­‐I/II).	  PPARα	  also	  activates	  the	  acyl	  CoA	  oxidase	  
(ACO),	   which	   participates	   in	   peroxisomal	   FAO	   and	   enzymes	   involved	   in	  mitochondrial	   β-­‐
oxidation.	   It	  has	  been	  proposed	  that	  the	  increased	  FA	  utilization	  induced	  by	  PPARα	  is	  not	  
an	  early	  event	   in	  obesity	   since	  obese	  mice	  showed	   increased	   fatty	  acid	  oxidation	  already	  
before	  any	  changes	  in	  PPARα	  regulated	  target	  genes	  occurred.136	  Additionally,	  Wright	  et	  al.	  
demonstrated	   that	   FAO	  was	   increased	   after	   2	  wks	   of	   high	   fat	   feeding,	   and	   this	  was	   not	  
associated	  with	  changes	  in	  PPARα	  target	  genes	  and	  was	  also	  independent	  of	  an	  increase	  in	  
circulating	   FA	   or	   triglycerides.	   In	   the	   same	   study,	   they	   described	   that	   insulin-­‐stimulated	  
glucose	   uptake	   and	  GLUT4	   translocation	   in	   the	  myocardium	  were	   impaired	   and	   this	  was	  
accompanied	   by	   hyperinsulinemia,	   while	   interestingly	   the	   Akt	   pathway	   upon	   insulin	  
stimulation	  was	  not	  altered.133	  PPARα	   target	  genes	  were	  only	  activated	  after	  5	  wks,	   thus	  
PPARα	  activation	  may	  have	  a	  role	  to	  sustain	  this	  metabolic	  change	  but	  not	  at	  early	  stages	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of	   the	   pathology,	   where	   a	   defect	   in	   glucose	   transport	   seems	   to	   be	   happening	   as	   a	   first	  
answer	  to	  cardiac	  metabolic	  adaptation	  to	  high	  fat	  diet.	  Abel	  proposed	  that	  this	  adaptation	  
where	  glucose	  utilization	   is	   reduced	   is	   the	   leading	  cause	  for	  a	  secondary	   increase	   in	   fatty	  
acid	  oxidation	  as	  the	  Randle	  cycle	  describes	  it.108	  During	  minor	  ischemia,	  FFA	  are	  the	  main	  
source	  of	   fuel	  and	  glycolysis	   is	   still	  active	  while	  glucose	   is	  used	   for	   lactate	  production	   for	  
anaerobic	   ATP	   production.137	   Therefore,	   it	   would	   be	   interesting	   to	   use	   a	   PDK4	   inhibitor	  
such	  as	  dichloroacetate	  to	   increase	  ATP	  production	  and	  Ca2+	  uptake,	  or	  an	  inhibitor	  of	  FA	  
oxidation,	   and	   also	   enhance	   glucose,	   insulin	   and	   potassium	   levels	   to	   increase	   cardiac	  
efficiency	  during	  ischemia.137	  	  
	  
The	   increased	   fatty	  acid	   transporter	   (CD36)	   translocation	   to	   the	  membrane	   following	  Akt	  
activation	   by	   the	   insulin	   pathway	   is	   also	   participating	   in	   the	   increased	   use	   of	   FA	   in	   a	  
diabetic	  heart	  as	  described	  in	  a	  db/db	  mouse	  model	  and	  in	  fa/fa	  Zucker	  rats,	  as	  well	  as	  in	  
rats	   fed	  with	   high	   fat	   diet.138-­‐140	   Paradoxically,	   insulin	   also	   acutely	   inhibits	   FAO,	   and	   this	  
phenomenon	  could	  be	  explained	  by	  the	  fact	  that	  most	  of	  the	  FAO	  is	  using	  an	  endogenous	  
pool	  of	  triacylglycerol141	  and	  that	  in	  normal	  conditions,	  insulin	  might	  stimulate	  the	  refilling	  
of	   this	   pool	   by	   increasing	   the	   CD36	   translocation.	   As	   cardiac	   Akt	   signaling	   is	   intact	   in	  
obesity,	  Abel	  proposed	  that	  this	  effect	  could	  participate	  in	  the	  increased	  cardiac	  lipotoxicity	  
when	  hyperinsulinemia	  is	  established.74	  
	  
Fatty	  acid	  oxidation	  produces	  more	  mitochondrial	  ROS	  than	  pyruvate	  oxidation.	  Anderson	  
et	  al.	   showed	   that	  an	  attenuation	  of	  mitochondrial	  ROS	  production	  completely	  preserves	  
insulin	   sensitivity	   despite	   high	   fat	   feeding	   in	   both	   humans	   and	   rodents.142	   They	   also	  
demonstrated	   that	   in	   mice,	   overexpression	   of	   a	   mitochondrial	   catalase	   reduced	   ROS	  
production	  and	  similarly	  these	  mice	  were	  protected	  against	  insulin	  resistance	  after	  high	  fat	  
feeding.	   In	   vitro	   studies	  demonstrated	   that	   acetylation	  of	   cardiac	  mitochondria	   increases	  
ROS	   production	   and	   inhibits	   pyruvate	   oxidation,	   proposing	   that	   the	   acetylation	   of	  
mitochondrial	  proteins	  is	  implicated	  in	  metabolic	  inflexibility.143	  
1.2.7 Akt	  and	  metabolism	  
Akt,	  also	  known	  as	  protein	  kinase	  B	  (PKB),	  is	  a	  serine/threonine	  kinase	  involved	  in	  various	  
cellular	  mechanisms	  including	  protein	  synthesis,	  growth,	  proliferation,	  survival,	  metabolism	  
and	   others.144	   Figure	   9	   describes	   the	   signaling	   between	   insulin/Akt	   and	   the	   mammalian	  
target	   of	   rapamycin	   (mTOR)	   and	   some	   of	   their	   roles.	   Akt	   signaling	   can	   be	   activated	   by	  
receptor	  tyrosine	  kinases,	   integrins,	  B	  and	  T	  cell	   receptors,	  cytokine	  receptors,	  G-­‐protein-­‐
coupled	  receptors	  and	  other	  factors.	  Insulin	  pathway	  activation	  results	  in	  the	  production	  of	  
membrane	   lipid	   phosphatidylinositol	   (3,4,5)	   triphosphates	   (PIP3)	   by	   the	   activated	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phosphoinositide	  3-­‐kinase	  (PI3K),	  which	  allow	  proteins	  with	  PH	  domains,	  such	  as	  Akt	  and	  its	  
upstream	  activator	   PDK1,	   to	   be	   recruited	   at	   the	  membrane.	   PDK1	  phosphorylates	  Akt	   at	  
T308	   its	  main	   activity	   site,	   whereas	  mTORC2	   phosphorylates	   Akt	   at	   S473	   resulting	   in	   its	  
maximal	   activation.145	   Akt	   can	   be	   dephosphorylated	   by	   protein	   phosphatases	   2A	   (PP2A)	  
and	   the	   PH-­‐domain	   leucine	   rich	   repeat	   containing	   protein	   phosphatases	   (PHLPP1/2).	   Akt	  
signaling	  can	  also	  be	   inhibited	  by	  the	  tumor	  suppressor	  phosphatase	  and	  tensin	  homolog	  


















Figure	  9:	  Insulin/Akt/mTOR	  signaling.	  
Insulin	   is	   the	   main	   anabolic	   hormone	   in	   mammals	   and	   plays	   an	   essential	   role	   in	   metabolic	  
homeostasis.	  Upon	   insulin	  binding	  to	   its	  cell	  membrane	  receptor,	   the	   insulin	   receptor	  substrate-­‐1	  
(IRS-­‐1)	   is	  phosphorylated,	  which	   leads	  to	  the	  activation	  of	  the	  phosphatidylinositol	  3-­‐kinase	  (PI3K)	  
and	   Akt.	   Activation	   of	   the	   Akt	   pathway	   promotes	   different	   cellular	   mechanisms	   including	  
translocation	   of	   the	   glucose	   transporter	   GLUT4	   to	   the	   cell	   membrane,	   activation	   of	   mTOR	   and	  
mitogen-­‐activated	  protein	  kinase	  pathways.	  Akt	  also	  inhibits	  autophagy	  via	  FOXO,	  and	  inflammation	  
by	  activating	  IKKβ.	  	  	  	  	  	  	  inhibitory	  phosphorylation,	  	  	  	  	  	  	  activation	  phosphorylation	  
	  
	  
Upon	  normal	  insulin	  stimulation,	  Akt	  gets	  activated	  which	  in	  turn	  affects	  many	  substrates.	  
Akt	   increases	   mTORC1	   activation,	   it	   induces	   GLUT4	   and	   CD36	   translocation	   to	   the	  
membrane,	  and	  it	  inhibits	  FOXO	  and	  GSK3β	  to	  downregulate	  autophagy	  and	  apoptosis.	  Akt	  
controls	   cell	   growth	   through	   its	   regulation	   of	   mTORC1	   signaling,	   it	   inhibits	   by	  
phosphorylation	   the	   GTPase	   activity	   of	   tuberous	   sclerosis	   complex	   (TSC)	   allowing	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in	   glucose	   metabolism	   via	   its	   phosphorylation	   of	   160	   kDa	   substrate	   of	   the	   Akt	   Ser/Thr	  
kinase,	   known	  as	  AS160	  or	   TBC1D4,	   at	  many	   sites.	  AS160	   is	   a	  Rab-­‐GTPase	   that	   regulates	  
GLUT4	  trafficking,	   its	  phosphorylation	  site	  Thr642	   is	  necessary	   for	  GLUT4	  translocation	  to	  
the	   membrane	   to	   allow	   glucose	   uptake.	   Under	   normal	   conditions,	   the	   Rab-­‐GTPase	  
activating	  domain	  of	  AS160	  catalyzes	  the	  hydrolysis	  of	  Rab-­‐GTP	  to	  Rab-­‐GDP,	  which	  is	  bound	  
to	  the	  GLUT4	  vesicles	  in	  the	  cytoplasm	  and	  inhibits	  its	  exocytosis.	  Upon	  insulin	  stimulation,	  
AS160	  is	  phosphorylated	  and	  Rab-­‐GDP	  becomes	  less	  abundant	  and	  releases	  its	  inhibition	  to	  
promote	  GLUT4	  translocation.	  On	  the	  other	  hand,	  AMPKα	  can	  also	  phosphorylate	  AS160	  to	  
induce	   contraction-­‐stimulated	   translocation	   of	   transporter	   GLUT4.	   Additionally,	   Akt	   is	   a	  
major	  mediator	  of	  cell	  survival	  by	  its	  direct	  inhibition	  of	  pro-­‐apoptotic	  proteins	  such	  as	  Bad	  
or	  the	  inhibition	  of	  pro-­‐apoptotic	  signal	  produced	  by	  transcription	  factor	  such	  as	  FOXO.	  Akt	  
also	  inhibits	  the	  glycogen	  synthase	  kinase	  (GSK)	  and	  AMPK,	  which	  result	  in	  cardiac	  glycogen	  
synthesis	  and	  accumulation.146	  
1.2.8 mTOR	  and	  metabolism	  
mTOR	  is	  a	  serine/threonine	  kinase	  that	  is	  responsible	  for	  protein	  synthesis	  and	  inhibition	  of	  
autophagy.	  mTOR	  is	  sensitive	  to	  growth	  factors,	  nutrient	  signals,	  energy	  levels	  and	  stress147	  
and	   is	   activated	   under	   nutrient	   rich	   conditions	  where	   it	   will	   increase	   cell	   growth.	  mTOR	  
forms	   together	   with	   several	   other	   proteins	   2	   different	   complexes	   called	   mTORC1	   and	  
mTORC2.148	   mTORC1	   is	   composed	   of	   mTOR,	   RAPTOR,	   PRAS40,	   DEPTOR	   and	   MLST8.	  
mTORC2	   regulates	   cytoskeleton	   organization,	   contraction,	   ion	   channels	   and	   autophagy	  
through	  Akt.	   It	   is	   composed	  of	  RICTOR,	  SIN1,	  PRR5,	  DEPTOR,	  and	  MLST8.	   Figure	  9	   shows	  
part	   of	   the	  mTOR	   signaling	   cascade	   induced	  by	   insulin.	   Following	  Akt	   activation	  by	  PDK1	  
and	  mTORC2,	  Akt	  activates	  mTORC1	  via	  inhibition	  of	  the	  TSC1/2	  complex,	  which	  releases	  its	  
inhibition	  on	  Rheb.	  GTP	  bound	  Rheb	  then	  accumulates	  and	  eventually	  activates	  mTORC1.	  
The	   two	  principal	  downstream	   targets	  of	  mTORC1	  are	  p70	   ribosome	  S6	  kinase	   (p70-­‐S6K)	  
and	  eukaryotic	  initiation	  factor	  4E-­‐binding	  protein	  1	  (4EBP1)	  that	  trigger	  protein	  synthesis.	  
mTORC1	  also	  inhibits	  autophagy	  via	  the	  inhibitory	  phosphorylation	  of	  ULK1.	  The	  activation	  
of	   mTORC1	   causes	   an	   inhibitory	   phosphorylation	   of	   IRS-­‐1	   via	   p70-­‐S6K1	   by	   a	   negative	  
feedback	  loop	  mechanism,	  which	  provokes	  proteasomal	  degradation	  of	  IRS-­‐1	  and	  leads	  to	  
insulin-­‐stimulated	   signaling	   impairment.149	   It	   was	   reported	   that	   p70-­‐S6K1	   deletion	  	  
improves	  insulin	  sensitivity	  in	  mice,150	  and	  therefore	  chronic	  activation	  of	  mTORC1	  could	  be	  
related	   to	   insulin	   resistance	   onset.	   Additionally,	   mTORC1	   also	   activates	   Grb10	   protein,	  
which	   similar	   to	   p70-­‐S6K1	   negatively	   regulates	   the	   insulin/IGF1	   receptor	   signaling	   via	   its	  
inhibition	  of	  IRS-­‐1	  phosphorylation	  and	  the	  subsequent	  recruitment	  of	  PI3K.	  151,152	  mTORC2	  
can	  be	   activated	  by	   PI3K	   to	   regulate	   actin	   cytoskeleton	  organization	   and	   cell	   survival	   via	  
Introduction	  
	  
	   42	  
protein	  kinase	  C	  (PKC)	  and	  Akt	  activation.	  Additionally,	  mTORC2	  can	  activate	  Rho-­‐GTPases	  
to	  control	  cell-­‐cell	  contacts.	  
	  
Given	   its	   key	   function	   in	   modulating	   protein	   turnover	   and	   energy	   metabolism,	   it	   is	   not	  
surprising	  that	  many	  studies	  suggested	  a	  primordial	  role	  of	  mTOR	  in	  cardiac	  function.	  Zhu	  
et	   al.	   recently	   showed	   that	   cardiomyocyte-­‐specific	   deletion	   of	   mTOR	   is	   responsible	   for	  
more	   than	   90%	   of	   embryonic	   lethality.153	   Moreover,	   Shende	   et	   al.	   found	   that	   cardiac-­‐
specific	   deletion	   of	   the	   gene	   encoding	   for	   RAPTOR	   in	   adult	   mice	   induces	   severe	   heart	  
failure	   accompanied	  by	  high	  mortality	   6	  wks	   after	   the	  deletion.154	   They	   showed	   that	   the	  
mice	  developed	  cardiac	  dilation	  and	  dysfunction	  accompanied	  with	  apoptosis,	   autophagy	  
and	  mitochondrial	  dysfunction.	  In	  these	  mice,	  a	  switch	  from	  FAO	  to	  GO	  was	  also	  observed.	  
Using	  the	  same	  model,	  the	  research	  group	  also	  showed	  that	  transaortic	  banding	   inducing	  
cardiac	   pressure	   overload	   does	   not	   lead	   to	   adaptive	   hypertrophy	   but	   achieves	   to	   the	  
development	  of	  heart	  failure.154	  mTOR	  is	  an	   important	  player	   in	  metabolism	  regulation	  in	  
particular	  mitochondrial	  metabolism	  partially	  via	  the	  regulation	  of	  PPARγ	  coactivator	  (PGC)-­‐
1α	   expression	   and	   activation	   in	   skeletal	   muscle	   and	   C2C12	   cells.155	   In	   a	   mouse	   model,	  
mTOR	   was	   described	   to	   be	   involved	   in	   cardiac	   metabolism	   as	   cardiac	   mTOR	   disruption	  
induced	   during	   adulthood	   decreases	   FAO	   and	   increases	   GO.156	   This	   was	   in	   line	  with	   the	  
decrease	   expression	   of	   FA	   metabolism	   genes	   such	   as	   FABP3,	   medium-­‐chain	   acyl-­‐CoA	  
dehydrogenase,	   hydroxyacyl-­‐CoA	   dehydrogenase/3-­‐ketoacyl-­‐CoA	   thiolase/enoyl-­‐CoA	  
hydratase	  (trifunctional	  protein)-­‐α	  and	  β	  as	  well	  as	  the	  decrease	  enzymatic	  activity	  of	  CPT-­‐
I/II.	   These	   changes	   were	   not	   associated	   with	   reduced	   FAO	   gene	   regulator	   PGC1α.156	   In	  
contrast,	   cardiac-­‐specific	   deletion	   of	   RAPTOR	   downregulated	   ERRα,	   PGC1α	   and	   PPARα.	  
Similarly,	   glucose	   use	   was	   increased	   while	   FAO	   was	   decreased	   together	   with	   a	   reduced	  
CPT-­‐1β	   and	   MCD-­‐1	   expression	   levels.154	   These	   changes	   were	   observed	   when	   cardiac	  
function	   was	   not	   altered	   yet.	   mTOR	   regulates	   metabolism	   but	   it	   is	   also	   regulated	   by	  
metabolic	   dysfunction.	   mTORC1	   is	   activated	   during	   nutritional	   excess,	   obesity	   and	  
metabolic	   syndrome	   in	   liver,	   skeletal	   muscle,	   and	   adipose	   tissue.157-­‐161	   The	   Akt/mTOR	  
pathway	   activation	   is	   increased	   in	   the	   vasculature	   in	   HFD-­‐induced	   obesity	   and	   provokes	  
endothelial	  senescence	  and	   increase	  peripheral	   ischemia	  risk.	  These	  effects	  were	  rescued	  
by	  rapamycin	  treatment,	  proving	  that	  mTOR	  is	  specifically	  involved	  in	  these	  effects.162	  
	  
 1.3 Metabolic	  cardiovascular	  disease	  and	  heart	  failure	  
Cardiovascular	   diseases	   are	   the	   leading	   cause	   of	  worldwide	   death.	   In	   Europe,	   46%	   of	   all	  
deaths	  (4.1	  million	  in	  2013)	  were	  attributed	  to	  CVD,163	  which	  affected	  more	  women	  (51%)	  
than	  men	  (42%).163	  In	  Switzerland,	  in	  2010,	  181.2	  and	  80.4	  men	  out	  of	  100	  000	  died	  from	  
CVD	  and	  coronary	  heart	  diseases	  (CHD),	  respectively.	  For	  women,	  these	  rates	  were	  lower:	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115.9	   for	   CVD	   and	   38.4	   for	   CHD.164	   Men	   are	   at	   higher	   risk	   to	   develop	   obesity,	  
cardiovascular	  disease	  and	  hypertension	  than	  women.	  However,	  this	  tendency	  	  inverses	  in	  
the	  postmenopausal	  population	  meaning	   that	  women	   lose	   their	   advantage	  while	  ovarian	  
hormone	   levels	  decrease.165,166	  The	   risk	   factors	  are	  multiple	  and	   the	  mechanisms	  are	  not	  
fully	  understood.	  Among	   them	  obesity,	  diabetes,	   and	  hypertension	  as	   the	  most	   common	  
and	  important.	  	  
Metabolic	   disorders	   such	   as	   diabetes,	   insulin	   resistance	   and	   obesity	   are	   tightly	   linked	   to	  
CVD	  occurrence.	  Metabolic	   syndrome	   is	   the	  most	   studied	   disease	   since	   it	   affects	   a	   large	  
population.	  Numerous	   studies	  have	  demonstrated	   that	  metabolic	   syndrome	   is	  associated	  
with	   left	   ventricle	   remodeling	   and	   dysfunction.	   The	   hallmarks	   of	   metabolic	   disease	   are	  
obesity,	   insulin	   resistance,	   glucose	   resistance	   and	   dyslipidemia.	   The	   incidence	   of	   obesity	  
and	  diabetes	  has	  increased	  considerably	  over	  the	  past	  decades	  due	  to	  a	  sedentary	  lifestyle	  
and	  the	  excess	  of	   ingested	  calories.	  The	  major	  cause	  of	  morbidity	  and	  mortality	   in	  obese	  
and	  diabetic	  patients	  are	  cardiovascular	  events,	  heart	  failure	  is	  particularly	  increased	  even	  
after	   correction	   for	   risk	   factors	   such	  as	  hypertension	  or	   ischemic	  heart	  disease.167	  Rubler	  
was	   the	   first	   to	   describe	   an	   association	   between	  diabetes	   and	   increase	   heart	   failure	   risk	  
without	  signs	  of	  hypertension,	  myocardial	  ischemia	  or	  valvular	  heart	  disease.168	  He	  named	  
this	   condition	   “diabetic	   cardiomyopathy”	   and	   it	  was	   defined	   as	   a	   ventricular	   dysfunction	  
without	   hypertension	   or	   coronary	   heart	   disease.	   Thus,	   diabetic	   cardiomyopathy	   is	  
associated	  with	  systemic	  metabolic	  disorders	  such	  as	  obesity	  and	  sustained	  diabetes,	  and	  is	  
characterized	  by	  structural	  and	  functional	  alterations	  and	  interstitial	  fibrosis	  independently	  
of	  hypertension	  or	  coronary	  artery	  disease.169,170	  Heart	  failure	  is	  defined	  as	  an	  insufficient	  
cardiac	  performance	  to	  maintain	  a	  blood	  flow	  to	  perfuse	  all	  the	  organs.	  It	  is	  characterized	  
by	  dyspnea,	  fatigue	  and	  fluid	  retention.	  Heart	  failure	  can	  be	  categorized	  into	  two	  different	  
groups:	  heart	  failure	  with	  reduced	  ejection	  fraction	  (HFrEF)	  where	  both	  cardiac	  systolic	  and	  
diastolic	  functions	  are	  altered	  and	  in	  contrast	  heart	  failure	  with	  preserved	  ejection	  fraction	  
(HFpEF)	  where	   only	   the	   diastolic	   function	   is	   altered,	   both	   are	   equally	   distributed.171	   The	  
HFpEF	  affects	  a	  large	  population	  and	  the	  risk	  factors	  include	  hypertension,172	  older	  age	  and	  
female	   sex,173,174	  which	  are	   the	  most	   important,	   and	  also	  obesity175	   and	  diabetes.176	   This	  
pathology	   involves	   diastolic	   dysfunction,	   characterized	   by	   an	   impaired	   LV	   relaxation,	  
decreased	  LV	  compliance,	  longitudinal	  LV	  systolic	  dysfunction,	  abnormal	  ventriculo-­‐arterial	  
coupling,	   and	   pulmonary	   hypertension	   (associated	  with	   RV	   remodeling	   and	   dysfunction).	  
Some	  studies	   show	  that	  both	  diastolic	  and	  systolic	   function	  are	  altered	   in	  obese	  patients	  
with	  absence	  of	  clinical	  heart	  disease.177	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1.3.1 Cardiac	  changes	  in	  obesity	  and	  diabetes	  
Different	   research	   groups	   described	   that	   high	   fat	   diet-­‐induced	   metabolic	   syndrome	  
provokes	   structural	   and	   functional	   cardiac	   alterations,	   since	   fractional	   shortening	   was	  
found	  decreased,	  while	  ventricular	  wall	  thickness,	  left	  ventricular	  end-­‐diastolic	  and	  systolic	  
pressures	  were	   increased.113,114,178	  Cardiomyocyte	  contractility	  has	  also	  been	  shown	  to	  be	  
impaired	   as	   the	   peak	   shortening	   and	   maximal	   contraction	   velocity	   were	   decreased,	  
whereas	  relenghtening	  time	  was	   increased.	  All	   these	  modifications	  were	  accompanied	  by	  
interstitial	  fibrosis.113,114	  
Diabetic	   and	   obese	   hearts	   show	   increases	   in	   fatty	   acid	   uptake	   and	   oxidation,	  
intramyocardial	  triacylglycerol,	  while	  glucose	  uptake	  and	  oxidation	  as	  well	  as	  malonyl-­‐CoA	  
are	  decreased	  due	  to	  the	  activation	  of	  malonyl-­‐CoA	  decarboxylase	  (MCD).179	  This	  leads	  to	  a	  
decreased	  cardiac	  efficiency	  that	  could	  be	   linked	  to	  the	   low	  oxygen-­‐efficiency	  of	  FAO	  and	  
increased	  mitochondrial	  uncoupling	  as	  a	  consequence	  of	  increased	  FA	  use.	  Eventually,	  this	  
results	   in	   a	   reduction	   of	   ATP	   production	   despite	   energy	   substrate	   oxidation.180,181	  
Therefore,	  the	  delivery	  of	  reducing	  equivalents	  produced	  from	  FAO	  is	   increased	  while	  the	  
oxidative	   phosphorylation	   ability	   of	   the	   respiratory	   chain	   is	   decreased	   leading	   to	   higher	  
ROS	   production.	   Mitochondrial	   uncoupling	   in	   the	   long	   term	   contributes	   to	   the	   energy	  
deficit	  as	   the	   ratio	  PCr/ATP	   is	   reduced	   in	  diabetic	  hearts.182	   In	  obese	  mice,	  mitochondrial	  
respiration	   with	   palmitate	   as	   a	   substrate	   is	   preserved,	   while	   PDH	   activity	   is	   decreased	  
together	  with	  the	  oxidation	  of	  pyruvate	  in	  a	  similar	  manner	  as	  what	  has	  been	  described	  in	  
diabetes.183	   It	  was	  observed	   that	   gene	  expression	  of	   the	   sarcoplasmic	   reticulum	  calcium-­‐
ATPase	  2	  (SERCA2),	  the	  protein	  responsible	  for	  calcium	  (Ca2+)	  reuptake	  permitting	  cardiac	  
relaxation,	  is	  decreased	  in	  the	  diabetic	  heart184,185,186  and	  this	  change	  might	  be	  implicated	  
in	  diastolic	  dysfunction	  in	  diabetic	  cardiomyopathy.	  	  
	  
At	   a	  more	  advanced	   stage	  of	   diabetes,	   cardiac	  dysfunction	   is	   related	   to	   several	   changes:	  
altered	   metabolism,	   reduced	   contractility,	   modified	   calcium	   handling,	   dysfunctional	  
mitochondria,	   ER	   stress,	   lipo-­‐	   and	   glucotoxicity,	   necrosis,	   apoptosis,	   autophagy,	   and	  
fibrosis.179,187-­‐189	   At	   the	   origin	   of	   these	   changes,	   cellular	   mechanisms	   are	   thought	   to	   be	  
involved	  such	  as	  protein	  kinases,	  calcium,	  ROS	  and	  ceramide	  production,	  hexosamines	  and	  
advanced	  glycation	  end-­‐products	  (AGEs).190	  
1.3.2 Cardiac	  stress	  markers	  
Under	   stress	   conditions,	   the	  adult	  heart	   starts	   to	   re-­‐express	   fetal	   genes	   that	   are	  used	   to	  
evaluate	   stress	   and	  hypertrophy.	   For	  example,	   sarcomeric	  proteins	   such	  as	  myosin,	   actin	  
and	   titin	   are	   changing	   to	   their	   fetal	   isoform	   and	   can	   be	   used	   as	   markers	   of	   stress	   and	  
hypertrophy.	  Myosin	  filaments	  are	  formed	  by	  α	  and	  β	  subunits.	  Three	  different	  isoforms	  of	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myosin	  exist	  in	  rodents:	  α-­‐myosin	  heavy	  chain	  (α-­‐MHC),	  which	  detains	  the	  highest	  ATPase	  
activity	  and	  contractile	  velocity;	   the	  α/β-­‐MHC	  and	   the	  β-­‐MHC	   form	  which	  has	   the	   lowest	  
contractile	  ability.191	  During	  fetal	  development	  of	  rodents,	  the	  β	  isoform	  is	  replaced	  by	  the	  
α	  isoform,	  which	  becomes	  the	  dominant	  form	  at	  the	  adult	  stage.192	  Therefore,	  a	  decrease	  
in	  the	  α/β	  ratio	  is	  linked	  to	  cardiac	  hypertrophy	  in	  rodents.193	  Inversely,	  in	  the	  human	  adult	  
the	  β	  isoform	  is	  predominant.	  Skeletal	  α-­‐actin	  is	  highly	  expressed	  in	  the	  fetal	  heart	  whereas	  
the	  adult	  heart	  expresses	  cardiac	  α-­‐actin,	  which	  makes	  the	  fetal	  skeletal	  α-­‐actin	  a	  marker	  
used	   for	   cardiac	   dysfunction	   characterization.	   Finally,	   the	   protein	   titin	   also	   undergoes	   a	  
switch	   from	   the	   long	   form	   N2BA	   isoform	   expressed	   in	   the	   embryonic	   heart	   towards	   a	  
higher	   expression	   of	   the	   shorter	   N2B	   isoform	   in	   perinatal	   and	   adult	   hearts.194	   Thus	   an	  
increase	  of	  the	  N2BA	  isoform	  is	  used	  as	  cardiac	  stress	  marker.	  
	  
Peptides	  hormones	  are	  also	  commonly	  used	  in	  detecting	  cardiac	  stress.	  The	  atrial	  and	  brain	  
natriuretic	   peptides,	   ANP	   and	   BNP	   respectively,	   are	   released	   by	   the	   atria	   in	   response	   to	  
cardiac	  wall	  strain.195	  ANP	  expression	  is	  activated	  by	  the	  fetal	  cardiac	  transcription	  factors	  
GATA4	   and	   NKX2-­‐5.	   Their	   main	   effects	   on	   the	   heart	   are	   indirect	   through	   regulation	   of	  
natriuresis	   and	   reduction	   of	   blood	   pressure.	   It	   also	   has	   been	   shown	   that	   both	   inhibit	  
cardiac	   hypertrophy,	   fibrosis	   and	   activate	   lipolysis.196-­‐198	   As	   mentioned	   above,	   some	  
transcription	   factors	   control	   the	   formation	  of	   the	   fetal	   heart,	  with	   the	   fetal	   transcription	  
factor	  GATA4	  being	  one	  of	  these.	  GATA4	  is	  essential	  for	  valvular	  development	  and	  activates	  
cardiac	  genes	   such	  as	  ANP	  and	  α-­‐MHC,	  and	   is	  able	   to	   induce	  an	   increase	   in	  β-­‐MHC	  after	  
pathological	  hypertrophy.	  Expression	  of	  NKX2-­‐5	  protein	  is	  exclusively	  present	  in	  the	  heart,	  
its	   activation	   in	   adult	   heart	   is	   also	   considered	   as	   fetal	   gene	   reactivation	   and	   has	   been	  
associated	  with	  congestive	  heart	  failure.198	  
1.3.3 Inflammation	  and	  fibrosis	  
Hyperglycemia	  and	  fatty	  acids	   induce	  metabolic	  disorder	  entailing	  by	  a	   low-­‐grade	  chronic	  
inflammation	  in	  metabolically	  active	  tissues	  such	  as	  liver,	  adipocytes	  and	  skeletal	  muscle.199	  
Patients	   suffering	   from	   insulin	   resistance	   and	   T2DM	   have	   elevated	   pro-­‐inflammatory	  
cytokines	   such	   as	   IL-­‐6,	   TNFα	  and	  C-­‐reactive	  protein	   (CRP).200	   Inflammation	   affects	   insulin	  
signaling	   and	   sensitivity.	   The	   nuclear	   factor-­‐kB	   (NF-­‐κB)	   is	   a	   major	   regulator	   of	   the	  
inflammation	  process,	  in	  the	  heart	  it	  induces	  the	  expression	  of	  pro-­‐inflammatory	  cytokines	  
such	   as	   TNFα,	   IL-­‐6,	   IL-­‐1β	   and	   IL-­‐18.169	   Moreover,	   NF-­‐κB	   was	   activated	   after	   FA	   or	   high	  
glucose	   exposure	   in	   cardiomyocytes.201,202	   NF-­‐κB	   is	   a	   dimeric	   complex	   comprised	   of	   p65	  
and	   p50	   subunits,	   bound	   to	   the	   inhibitor	   protein	   IκB,	   NF-­‐κB	   is	   sequestrated	   in	   the	  
cytoplasm	  and	  is	  inactive.	  Upon	  stimulation	  by	  cytokines	  (TNFα,	  IL-­‐1β)	  or	  TLR	  activation	  (by	  
LPS),	   IκBα	   undergoes	   a	   phosphorylation-­‐dependent	   degradation	   mediated	   by	   the	   IκBα	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kinase	   complex	   (IKK),	   IKK-­‐α,	   -­‐β,	   and	   -­‐γ.	   The	   loss	   of	   IκBα	   exposes	   the	   nuclear	   localization	  
motif	   on	   the	   p65	   NF-­‐κB	   subunit	   allowing	   its	   phosphorylation	   and	   nuclear	   translocation	  
where	   it	   mediates	   gene	   transcription	   of	   targets	   such	   as	   IFNγ,	   IL-­‐6	   or	   TNFα	   leading	   to	  
inflammatory	   responses,	   cell	   growth	   and	   cell	   survival.	   In	   the	   heart,	   NF-­‐κB	   has	   also	   been	  
described	  as	  a	  player	  in	  hypertrophic	  responses	  in	  cardiomyocytes203,204	  and	  in	  vivo205	  and	  
involves	  mTOR.206	  
	  
In	  a	  mouse	  model	   fed	  with	  HFD,	  cardiac	  hypertrophy,	   inflammation	  (upregulation	  of	   IL-­‐6,	  
TNFα,	  MCP-­‐1,	  and	  NF-­‐κB	  p65	  mRNA	   levels),	  ROS	  production	  and	  AGE	  accumulation	  were	  
observed.207	   Additionally,	   TNFα,	   IL-­‐6	   and	   FFAs	   can	   activate	   kinases,	  which	   phosphorylate	  
IRS-­‐1	  with,	   as	   a	   consequence,	   the	   inhibition	   of	   insulin	   signaling	   and	   insulin	   resistance.208	  
Moreover,	  free	  fatty	  acids	  are	  able	  to	  activate	  the	  TLR4	  signaling	  pathway	  leading	  to	  NF-­‐κB	  
and	  JNK	  activation209	  in	  adipocytes	  and	  macrophages.	  
	  
Cardiac	  low-­‐grade	  inflammation	  is	  secondary	  to	  systemic	  pro-­‐inflammatory	  status	  induced	  
by	  inflammation	  in	  adipocytes	  and	  macrophages	  from	  adipose	  tissue	  and	  liver.169,210-­‐212	  The	  
cardiac	   defects	   observed	   in	   obesity-­‐related	   HFpEF	   may	   be	   induced	   by	   alterations	   of	  
homeostatic,	  neurohumoral	  and	  pro-­‐inflammatory	   immune	   responses.213,214	  Diabetes	  and	  
obesity	  trigger	  the	  secretion	  of	  adipokines,	  which	  play	  a	  role	  in	  insulin	  sensitivity.	  Palnivel	  
et	  al.	  reported	  that	   in	  cardiomyocytes,	  adiponectin	  acutely	  stimulates	  glucose	  uptake	  and	  
oxidation,	  whereas	  at	  long	  term	  it	  increases	  FA	  uptake	  and	  oxidation	  and	  decreases	  glucose	  
oxidation.215	   Leptin's	   effect	   was	   different	   since	   glucose	   uptake	   and	   oxidation	   as	   well	   as	  
insulin	  signaling	  were	  not	  altered,	  while	  fatty	  acid	  uptake	  was	  increased.	  However,	  at	  short	  
term	  leptin	  decreased	  FAO	  and	  resulted	  in	  an	  accumulation	  of	  lipids.216	  They	  also	  showed	  
that	  conditioned	  medium	  derived	  from	  adipocytes	  of	  wild	  type	  rats	  increases	  glucose	  and	  
FA	   uptake	   and	   oxidation	   in	   cardiomyocytes,	   whereas	   medium	   from	   adipocytes	   of	  
streptozotocine	   (STZ)-­‐induced	   diabetic	   rats	   stimulates	   non-­‐oxidative	   glucose	   metabolism	  
and	  abolishes	  FA	  oxidation.	  These	  differences	  were	  observed	  along	  with	  a	  different	  level	  of	  
adiponectin	   and	   leptin	   secretion	   from	   the	   adipocytes.217	   Together,	   these	   results	   support	  
the	  theory	  that	  adipokines	  have	  deleterious	  effects	  on	  the	  heart.	  	  
	  
Estrogen	  is	  implicated	  in	  inflammatory	  responses	  and	  might	  decrease	  the	  expression	  of	  CRP	  
following	   vascular	   injury	   in	   human	   endothelial	   cells	   via	   activation	   of	   the	   ERα	   and	  
upregulation	  of	  eNOS.218	  Estrogen	  also	  prevents	  upregulation	  of	  intracellular	  cell	  adhesion	  
molecule-­‐1	  (ICAM-­‐1)	   induced	  by	  angiotensin	   II.219	  Estrogen	  receptors	  (ERs)	  cross-­‐talk	  with	  
several	  intracellular	  inflammatory	  signaling	  pathways	  by	  activating	  TLRs	  and	  interleukins.220	  
It	  has	  been	  reported	  that	  estrogen	  inhibits	  NF-­‐κB	  signaling	  via	  ERα	  and	  ERβ.221	  Therefore,	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estrogen	   could	   be	   a	   good	   candidate	   to	   modulate	   inflammatory	   responses.	   However,	   its	  
effects	  depend	  on	  different	  factors	  such	  as	  the	  amount,	  composition,	  type	  of	  stimulus,	  type	  
of	  cells	  and	  the	  presence	  of	  its	  receptor.221,222	  
1.3.4 Regulators	  of	  cardiac	  contractility	  	  
Calcium	  is	  a	  key	  player	  of	  the	  excitation-­‐contraction	  coupling	  in	  muscle.	  Upon	  stimulatory	  
depolarization,	   Ca2+	   enters	   the	   cell	   and	   promotes	   the	   release	   of	   more	   Ca2+	   from	   the	  
sarcoplasmic	   reticulum	   (SR).	  A	  mechanism	  specific	   to	   the	  heart	  exists,	   it	   is	   called	  calcium	  
induced	   calcium	   release,	  whereby	   the	   initial	   entry	  of	   calcium	  via	   the	   L-­‐type	  Ca2+	   channel	  
induces	  a	  further	  calcium	  release	  from	  the	  SR.223,224	  The	  intracellular	  Ca2+	  concentration	  is	  
then	  10-­‐fold	  higher	  and	  binds	   to	   troponin	  C	  which	  allows	   the	   change	   in	   conformation	  of	  
tropomyosin,	  that	  rotates	  and	  exposes	  the	  myosin-­‐actin	  binding	  site.223	  Thereby,	  actin	  and	  
myosin	   can	   bind	   and	   interact	   to	   trigger	   cross-­‐bridge	   cycling	  where	   the	   hydrolysis	   of	   ATP	  
induces	   movements	   of	   the	   myosin	   along	   the	   actin	   filament	   through	   a	   series	   of	  
conformational	  changes.225	  
	  
SERCA	  is	  an	  important	  regulator	  of	  cardiac	  function,	  it	  is	  a	  pump	  that	  belongs	  to	  the	  P-­‐type	  
ATPase	  family	  and	  is	  able	  to	  transport	  two	  Ca2+	  ions	  into	  the	  SR	  in	  exchange	  of	  proton.226,227	  
Ten	  different	  SERCA	  isoforms	  exist,	  SERCA2a	  is	  the	  form	  expressed	  in	  the	  heart.	  The	  various	  
SERCA	   isoforms	   are	   encoded	   by	   one	   of	   the	   three	   SERCA	   genes:	   ATP2A1,	   ATP2A2	   and	  
ATP2A3.	   In	   human,	   the	   ATP2A	   gene	   encodes	   for	   SERCA2a-­‐c	   isoforms.228	   Its	   role	   is	   to	  
reuptake	   Ca2+	   after	   contraction	   to	   allow	   cardiac	   relaxation	   and	   therefore	   it	   is	   a	   critical	  
protein	   for	  determining	   relaxation	   time	  and	   inotropy	  of	   contraction.229	  Actually,	   SERCA	   is	  
the	  main	  responsible	  protein	  for	  calcium	  uptake	  following	  contraction,	  but	  other	  molecules	  
are	  also	  involved:	  the	  sarcolemmal	  calcium	  ATPase,	  the	  mitochondrial	  calcium	  uniport,	  and	  
the	  Na+/Ca2+	   exchanger.230	   In	   the	  mammalian	  heart,	   SERCA2a	   is	   the	  primary	  protein	   that	  
transport	   Ca2+	   to	   the	   SR.230	   The	   percentage	   of	   calcium	   removal	   done	   by	   SERCA2a	   vary	  
between	   species:	   92%,	   75%	   and	   70%	   removal,	   in	   the	   rat,	   rabbit	   and	   human	   heart	  
respectively.	  
	  
SERCA2a	   is	   regulated	   by	   different	   mechanisms:	   transcriptional,	   protein,	   hormonal,	   and	  
post-­‐translational	  modification.	  ATP2A2	  is	  regulated	  by	  mitochondrial	  transcription	  factor	  A	  
(TFAM)	  and	  B2	   (TFB2M).231	  Overexpression	  of	   these	   factors	   in	   a	   rat	  model	  of	  myocardial	  
infarction	   increased	   SERCA2a	   transcription	   and	   prevented	   the	   decrease	   of	   SERCA2a	  
mRNA.231	   Inversely,	   in	   the	  diabetic	  heart	   and	   in	   a	  heart	   failure	  model,	   TFAM	  and	  TFB2M	  
were	   found	   reduced.	   Another	   important	   transcription	   factor	   important	   for	   SERCA	  
transcription	   is	   specificity	  protein	  1	   (SP1),	  which	  can	  mediate	  an	   increase232,233	  but	  also	  a	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decrease	  of	  SERCA	  transcription	   in	  a	  pressure	  overload	  model.234	  The	  myocyte	  enhancing	  
factor-­‐2	   (MEF2)	   upregulates	   SERCA	   transcription	   in	   hypertrophy.235,236	   Diabetic	   patients	  
with	  heart	  failure	  display	  decreased	  MEF2C	  and	  SERCA2a	  protein	  levels	  compared	  to	  heart	  
failure	  patients	  without	  diabetes.237	  	  
	  
An	  alteration	  of	  SERCA2a	  function	  due	  to	  reduced	  mRNA,	  protein	  expression	  or	  activity	   is	  
associated	  with	  defects	   in	   calcium	  handling	  with	  a	  decreased	   calcium	  uptake	   into	   the	  SR	  
and	  inefficient	  energy	  use.228,238-­‐240	  These	  features	  are	  found	  in	  patients	  with	  heart	  failure	  
and	   lead	   to	   systolic	   and	  diastolic	   dysfunction.228,240,241	  Up	   to	   a	   60%	  decrease	  of	   SERCA2a	  
mRNA	  has	  been	  observed	   in	  heart	  failure	  patients.242	   In	  the	  RV	  of	  failing	  hearts,	  SERCA2a	  
activity	   was	   also	   found	   to	   be	   affected,	   since	   a	   50%	   decrease	   in	   calcium	   reuptake	   was	  
noticed.238	  In	  the	  same	  manner,	  diabetic	  hearts	  also	  exhibit	  decreased	  SERCA2a	  expression	  
and	  activity.	  In	  a	  diabetic	  mouse	  model,	  SERCA2a	  protein	  expression	  and	  maximal	  activity	  
were	   decreased	   by	   21%	   and	   32%	   respectively,	   conjointly	   with	   diastolic	   function	  
impairment.243	  In	  another	  study,	  SERCA2a	  protein	  and	  activity	  were	  also	  decreased,	  but	  in	  
contrast	   the	   PLN/SERCA2a	   ratio	   was	   increased	   in	   diabetic	   hearts.244	   The	   reason	   for	  
decreased	  SERCA2a	  in	  diabetic	  hearts	  is	  not	  clear,	  but	  it	  is	  thought	  that	  decreased	  activity	  
of	   silent	   information	   regulation	   (SIRT)1	   might	   be	   involved	   as	   the	   activation	   of	   SIRT1	  
increased	  SERCA2	  to	  normal	  values	  and	  improved	  cardiac	  functional	  parameters.245	  	  
	  
In	   this	   context,	   reestablishing	   SERCA2a	   expression	   could	   be	   promising	   to	   treat	   cardiac	  
dysfunction	   in	  metabolic	   cardiac	  disease	   and	  heart	   failure.	   In	   a	  mouse	  model	   of	   diabetic	  
cardiomyopathy,	  conditional	  expression	  of	  SERCA2a	  was	  able	  to	  restore	  cardiac	  function.246	  
In	   clinical	   trials,	   SERCA2a	   therapy	   was	   beneficial,	   since	   overexpression	   of	   SERCA2a	   by	  
adenoviral	   gene	   transferrin	   in	   cardiomyocytes	   improved	   the	   contraction	   velocity	   and	  
cardiac	  relaxation.247	  Similarly,	  another	  clinical	  trial	  (CUPID	  trial)	  observed	  that	  heart	  failure	  
patients	  that	  received	  intracoronary	  infusion	  of	  SERCA2a	  had	  88%	  risk	  reduction	  in	  adverse	  
effect	  occurrence	  such	  as	  LV	  assistive	  device	  implant,	  heart	  transplant	  and	  death	  than	  the	  
ones	  which	  did	  not	  receive	  SERCA2a	  infusion.248	  
	  
Phospholamban	  (PLN)	  and	  sarcolipin	  regulate	  SERCA	  activity.	  PLN	  is	  predominantly	  present	  
in	  cardiac	  muscle,	  while	  SLN	  is	  abundant	  in	  skeletal	  muscle.	  PKA	  can	  phosphorylate	  PLN	  at	  
Ser16	  whereas	  Ca2+-­‐CAMKII	  phosphorylates	  it	  at	  Thr17,	  both	  effects	  reduce	  PLN	  inhibition	  
of	  SERCA2,	  which	  thereby	  becomes	  more	  active	  and	  obtains	  higher	  affinity	  for	  calcium.249	  
Mouse	  models	   with	   reduced	   or	   ablated	   PLN	   showed	   that	   PLN	   is	   actually	   an	   inhibitor	   of	  
SERCA	   affinity	   for	   calcium	   and	   that	   PLN	   inhibition	   is	   relieved	   during	   beta-­‐adrenergic	  
stimulation.250	   Inversely,	   overexpression	   of	   PLN	   induced	   SERCA2a	   inhibition	   and	   altered	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contractility.251	  In	  human	  and	  experimental	  heart	  failure,	  SERCA	  was	  reduced	  whereas	  PLN	  
was	   not	   changed	   while	   its	   phosphorylation	   was	   decreased.252	   Targeting	   PLN	   in	   heart	  
disease	   appeared	   appealing	   as	   some	   studies	   showed	   that	   PLN	   ablation	   had	   beneficial	  
effects	  on	  cardiac	  function	  and	  remodeling	  by	  improving	  SR	  calcium	  cycling.	  Indeed	  use	  of	  
RNA	  interference	  of	  PLN	  rescued	  cardiac	  function	  in	  rat	  model	  of	  heart	  failure.253	  However,	  
others	   demonstrated	   that	   the	   resulting	   normalization	   of	  myocyte	   calcium	   handling	   after	  
PLN	   ablation	   may	   not	   improve	   cardiac	   function	   in	   vivo	   or	   reverse	   cardiac	   remodeling.	  
Another	  level	  of	  complexity	  of	  PLN	  is	  added	  as	  it	  can	  interact	  with	  several	  partners	  to	  form	  
multimeric	   complex.254	   Thus	   PLN	   can	   interact	   with	   the	   anti-­‐apoptotic	   protein	   HAX-­‐1	   to	  
increase	  the	  SERCA	  inhibition,	  additionally	  HAX-­‐1	   is	  able	  to	  recruit	  the	  heat	  shock	  protein	  
(Hsp)90	   from	   the	   ER	   to	   the	   PLN/SERCA2	   complex	   proposing	   a	   link	   between	   ER	   stress	  
signaling	  and	  calcium	  homeostasis.	  PLN	  is	  also	  able	  to	  bind	  the	  protein	  phosphatase-­‐1	  (PP1)	  
that	  de-­‐phosphorylates	  it	  to	  increase	  its	  inhibition	  on	  SERCA2	  when	  the	  cytosolic	  calcium	  is	  
low.255	  PKA	  modulates	  PLN	  phosphorylation	  level	  and	  consequently	  SERCA	  activity	  through	  
PLN	  inhibition	  by	  phosphorylation	  during	  adrenergic	  activation.	  
	  
The	  understanding	  of	  PLN	   in	  cardiac	  disease	   is	  becoming	  challenging	  as	   two	  human	  PLN-­‐
null	   mutations	   were	   found	   in	   heart	   failure	   patients	   and	   were	   associated	   with	   opposite	  
subcellular	   mechanisms	   or	   PLN	   actions.	   The	   R9C	  mutation	   induced	   chronic	   inhibition	   of	  
SERCA2a	  and	  early	  death	  in	  heterozygous	  carriers,256	  whereas	  the	  other	  mutation,	  L39stop,	  
which	   is	   associated	  with	   a	   loss	   of	   PLN	   function,	   resulted	   in	   dilated	   cardiomyopathy	   and	  
premature	   death	   in	   homozygous	   patients.257	   These	   effects	   observed	   in	   human	   did	   not	  
match	   what	   was	   observed	   after	   PLN	   ablation	   in	   mice,	   which	   resulted	   in	   hyper-­‐dynamic	  
cardiac	  function	  highlighting	  the	  difference	  between	  mouse	  and	  human	  hearts.	  This	  might	  
be	  due	  to	  a	  different	  role	  of	  PLN,	  or	  different	  consequences	  of	  PLN	  mutations	   in	  the	  two	  
species.	  One	  other	  hypothesis	  suggested	  that	  these	  PLN	  mutations	  generate	  modified	  PLNs	  
that	  traffic	  abnormally,	  cause	  cellular	  damage	  and	  associate	  incorrectly	  with	  other	  proteins	  
in	   cardiomyocytes.	   Recently,	   other	   PLN	   mutations	   have	   been	   discovered	   and	   were	  
associated	  with	  arrhythmogenic	  cardiomyopathy,	  although	  the	  underlying	  mechanisms	  are	  
poorly	  understood.	  	  
	  
1.3.5 Protein	  degradation	  by	  autophagy	  
Autophagy	  and	  apoptosis	  participate	  in	  the	  regulation	  of	  cell	  homeostasis,	  and	  autophagy	  
accounts	   for	   a	   larger	   part	   of	   this	   role.	   In	   tissues	   from	  heart	   failure	   patients,	  much	  more	  
cardiomyocytes	   showed	  signs	  of	  enhanced	  autophagy	   than	  of	  apoptosis,258	   suggesting	   its	  
importance	   and	   the	   relevance	   of	   studying	   autophagy	   in	   cardiac	   disease.	   Eukaryotic	   cells	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have	  to	  maintain	  a	  fine	  equilibrium	  between	  protein	  synthesis	  and	  protein	  degradation	  to	  
ensure	   their	   homeostasis.	   Autophagy	   adapts	   rapidly	   in	   response	   to	   nutrient	   and	   growth	  
factor	   availability	   and	   is	   responsible	   for	   degradation	   of	   intracellular	   organelles	   and	  
misfolded	   protein.	   This	   makes	   autophagy	   essential	   for	   protein	   quality	   control.	   Protein	  
degradation	   also	   happens	   via	   the	   ubiquitin-­‐proteasome	   system,	   but	   currently	   the	  
autophagy	  lysosome	  pathway	  is	  perceived	  as	  the	  most	  important	  in	  the	  heart.	  	  
	  
Autophagy	   involves	   degradation	   of	   misfolded	   proteins,	   large	   damaged	   organelles	   or	  
intracellular	   pathogens	   that	   cannot	   be	   degraded	   by	   the	   ubiquitin-­‐proteasome	   system.	  
Protein	  degradation	  is	  defined	  to	  be	  the	  key	  player	  to	  the	  self-­‐renewal	  of	  cells	  by	  degrading	  
long-­‐lived	   protein	   and	   organelles.	   This	   process	   is	   essential	   during	   all	   stages	   of	   life	   and	   is	  
particularly	  important	  during	  stress	  periods	  where	  its	  rapid	  activation	  or	  inhibition	  is	  critical	  
for	  the	  maintenance	  of	  cell	  survival.	  Three	  different	  types	  of	  autophagy	  exist	  according	  to	  
the	  cargo	  delivery	  way	  and	  the	  selectivity.	  The	  chaperone-­‐mediated	  autophagy	  is	  specific	  to	  
the	   degradation	   of	   soluble	   protein.	   Microautophagy	   and	   macroautophagy,	   which	  
commonly	  refers	  to	  autophagy,	  are	  meant	  to	  degrade	   large	  structures.	  Depending	  on	  the	  
selectivity	   of	   the	   cargo,	   others	   terms	   can	   be	   used:	   mitophagy	   for	   degradation	   of	  
mitochondria,	   ribophagy	   (ribosomes),	   pexophagy	   (peroxisomes),	   lipophagy	   (lipids),	   and	  
reticulopathy	  (endoplasmic	  reticulum).259	  
	  
Different	   steps	   leading	   to	   degradation	   of	   the	   components	   are	   needed.	   First	   of	   all,	   a	  
membrane	   supposedly	   coming	   from	   the	   endoplasmic	   reticulum	   is	   isolated	   to	   form	   a	  
phagophore.	   Then,	   this	   membrane	   starts	   to	   elongate	   thanks	   to	   Atg	   (autophagy	   related	  
genes)	  proteins.	  Proteins	  and	  organelles	  to	  degrade	  are	  sequestrated	  into	  this	  membrane	  
undergoing	  elongation	  to	  create	  a	  structure	  called	  the	  autophagosome.	  The	  next	  step	  is	  the	  
recruitment	   of	   a	   lysosome	   containing	   lysosomal	   proteases	   and	   its	   fusion	   with	   the	  
autophagosome,	  resulting	  in	  the	  formation	  of	  an	  autolysosome.	  Finally	  the	  content	  of	  the	  
autolysosome	  is	  degraded,	  amino	  acids,	  fatty	  acids	  and	  other	  components	  are	  released	  and	  
can	  be	  reused	  by	  the	  cells	   in	  particular	  during	  stress	  periods	  such	  as	  starvation.	  All	   these	  
processes	   need	   several	   molecular	   players.	   Beclin-­‐1,	   VPS34	   and	   VPS15	   are	   essential	   for	  
phagophore	   nucleation,	   while	   the	   autophagy	   proteins	   Atg-­‐5,	   -­‐12,	   and	   -­‐16	   and	   the	  
microtubule-­‐associated	  protein	  1	  light	  chain	  3	  beta	  (LC3B)	  play	  a	  role	  in	  its	  elongation.	  LC3B	  
exists	   in	   two	   forms:	   LC3BI	   is	   the	   cytosolic	   form,	  which	   is	   converted	   to	   LC3BII	   during	   the	  
formation	   of	   autophagosomes.	   LC3BII	   is	   specifically	   recruited	   to	   expanding	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Many	  proteins	   regulate	  autophagy.	  The	  Bcl-­‐2	   family	  proteins	  have	  an	   inhibitory	  effect	  on	  
autophagy	   since	   these	   proteins	   can	   interact	   with	   and	   alter	   the	   formation	   of	   class	   III	  
phosphatidylinositol	   3-­‐kinase	   (PI3K)	   family	   complex	   (Beclin1,	   VPS34,	   VPS15)	   which	   are	  
responsible	  for	  phagophore	  formation.	  The	  mTOR	  pathway	  inhibits	  autophagy	  via	  inhibition	  
of	  ULK1,	  an	  Atg	  protein	  important	  for	  autophagosome	  formation	  via	  its	  action	  on	  Beclin1.	  
AMPKα	  is	  a	  primordial	  player	  in	  cell	  homeostasis	  as	  an	  ultimate	  energetic	  sensor	  of	  the	  cell.	  
When	  the	  energetic	  status	  is	  low,	  AMPKα	  phosphorylates	  ULK1,	  Beclin1	  and	  JNK	  to	  activate	  
autophagy.	   It	   also	   activates	   FOXO1/3,	   which	   is	   responsible	   for	   the	   transcription	   of	  
autophagy	  genes	  such	  as	  LC3B.	  Next	  to	  AMPKα,	  mTORC2	  is	  also	  able	  to	  inhibit	  FOXO1/3	  via	  
phosphorylation	  of	  Akt	  at	  S473	  and	  thus	  may	  inhibit	  autophagy.	  
	  
Autophagy	  is	  a	  major	  mechanism	  of	  cardiomyocyte	  survival262,263	  and	  is	  thought	  to	  play	  an	  
important	  role	  in	  cardiac	  remodeling.262	  However,	  excessive	  autophagy	  could	  results	  in	  cell	  
death	   and	   cardiac	   dysfunction.261,262,264	   In	   a	   mouse	   model	   fed	   with	   a	   high	   sucrose	   diet,	  
insulin	  resistance	  was	  associated	  with	  enhanced	  autophagy	  in	  cardiomyocytes,265	  as	  well	  as	  
in	  a	  pig	  model	  where	  HFD	  increased	  autophagy	  and	  apoptosis.266	  However,	  Sciaretta	  et	  al.	  
found	  that	  autophagy	  flux	  was	  reduced	  in	  a	  HFD	  model,	  and	  by	  restoring	  autophagy	  they	  
were	   able	   to	   reduce	   the	   infarct	   size	   after	   ischemic	   injury.267	   Furthermore,	   by	   inhibiting	  
mTOR	  with	  rapamycin,	   the	   infarct	  size	  after	   ischemia	  was	  reduced,	  beclin-­‐1	  heterozygous	  
knock-­‐out	  mice	   suppressed	   the	   protective	   effect	   of	   rapamycin	   proving	   that	   beclin-­‐1	   and	  
autophagy	  were	   implicated	   in	   this	   beneficial	   effect.267	   Upregulation	   of	   autophagy	   during	  
acute	  events	  such	  as	  myocardial	  infarction	  is	  cardioprotective,	  whereas	  its	  downregulation	  
in	  mouse	  models	  of	  chronic	  disease	  such	  as	  obesity,	  diabetes	  and	  metabolic	   syndrome	   is	  
deleterious	   and	   contributes	   to	   heart	   failure	   development.	   Indeed,	   prolonged	  
hyperglycemia	   downregulates	   autophagy	   and	   thereby	   leads	   to	   an	   accumulation	   of	  
misfolded	  proteins	  and	  dysfunctional	  organelles	  such	  as	  mitochondria,	  which	  is	  responsible	  
for	   the	   release	  of	  death-­‐promoting	   factors	   and	   results	   in	   cardiomyocyte	  apoptosis.	   Thus,	  
restoring	   autophagy	   can	   rescue	   cardiac	   function	   in	   this	   situation.	   However,	   as	   already	  
mentioned	  before,	  many	  discrepancies	  appear	  concerning	  its	  role	  in	  pathologic	  conditions.	  
Indeed	  some	  studies	  using	  animal	  models	  showed	  that	  autophagy	  was	  either	  unaffected,268	  
decreased,266	  or	  disrupted.114	  These	  contradictory	  results	  could	  be	  explained	  by	  the	  animal	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 1.4 Estrogen	  
1.4.1 Sex	  hormones	  
The	  initiation	  of	  sex	  hormone	  synthesis	  is	  triggered	  by	  the	  gonadotropin-­‐releasing	  hormone	  
(GnRH)	   released	   by	   the	   hypothalamus.	   This	   hormone	   will	   stimulate	   the	   release	   of	  
luteinizing	   hormone	   (LH)	   and	   follicle-­‐stimulating	   hormone	   (FSH)	   from	   the	   pituitary	   gland	  
into	   the	   blood	   stream.	   LH	   will	   be	   targeting	   Leydig	   cells	   (testis)	   in	  males	   and	   theca	   cells	  
(ovaries)	  in	  females.	  This	  binding	  induces	  an	  increase	  of	  stereoidenogenic	  acute	  regulatory	  
protein	  (StAR),	  which	  initiates	  steroidogenesis	  in	  the	  inner	  mitochondrial	  membrane	  via	  the	  
uptake	  of	   cholesterol.	  Cholesterol	  will	   then	  be	  converted	   to	  pregnenolone	   leading	   to	   the	  
synthesis	   of	   estrogen,	   progesterone	   and	   testosterone	   through	   different	   enzymatic	  
pathways.	   Estrogen	   and	  progesterone	   are	   the	   two	  main	   female	   hormones.	   Progesterone	  
synthesis	  initiation	  takes	  place	  in	  the	  theca	  cells	  and	  corpus	  luteum,	  where	  LH	  is	  stimulating	  
the	  conversion	  of	  pregnenolone	  to	  progesterone.	  Testosterone	  represents	  the	  major	  male	  
hormone.	  Its	  synthesis	  will	  go	  through	  different	  steps	  involving	  several	  enzymatic	  reactions.	  
Pregnenolone	   is	   first	   converted	   to	   dehydroepiandrosterone	   (DHEA),	   followed	   by	  
androstenedione,	   then	   testosterone.	   In	   peripheral	   tissues	   (skin,	   prostate,	   epididymis),	  
testosterone	  is	  converted	  to	  dihydrotestosterone	  (DHT),	  which	   is	  much	  more	  potent	  than	  
testosterone	  despite	  its	  lesser	  abundance.	  
	  
Three	   different	   estrogen	   forms	   exist	   in	   females:	   estrone	   (E1),	   estradiol	   (E2	   or	   17-­‐β-­‐
estradiol)	  and	  estriol	  (E3).269	  E2	  is	  the	  most	  abundant	  and	  the	  most	  potent	  estrogen	  during	  
premenopause,	  whereas	  E1	  is	  the	  most	  important	  after	  menopause	  when	  it	  is	  synthesized	  
in	   adipose	   tissue.	   E3	   is	   the	   least	   potent	   and	   plays	   a	   role	   during	   pregnancy	   when	   the	  
placenta	   produces	   it.	   They	   are	   synthetized	   from	   cholesterol	   in	   the	   gonadal	   organ	  where	  
they	   are	   responsible	   for	   the	   occurrence	   of	   the	   primary	   and	   secondary	   female	   sexual	  
characteristics	  and	  gonadal	  function.	  Estrogen	  has	  also	  an	  important	  role	  in	  extra	  gonadal	  
tissues	  including	  liver,	  heart,	  muscle,	  bone	  and	  brain.	  Together	  with	  progesterone,	  estrogen	  
plays	   a	   role	   in	   the	   menstrual	   cycle,	   inducing	   the	   development	   of	   the	   uterus	   mucous.	  
Progesterone	  is	  released	  after	  ovulation	  to	  prepare	  the	  uterus	  to	  an	  eventual	  fertilization.	  
Over	  90%	  of	  the	  estradiol	   is	  produced	  in	  the	  granulosa	  of	  the	  ovaries.	  The	  remaining	  10%	  
are	  produced	  in	  peripheral	  tissues	  (brain,	  breast,	  skin,	  blood	  vessel,	  muscle)	  where	  FSH	  can	  
convert	  it	  to	  estradiol.	  	  
	  
The	   circulating	   level	   of	   estrogen	   is	   kept	   by	   the	   balance	   between	   estrogen	   synthesis	   and	  
deactivation.	  E2	  deactivation	  occurs	  through	  estrogen	  metabolism	  including	  the	  conversion	  
from	  E2	   to	   the	   less	   active	   form	  E1	  or	   E3270	   or	   the	   formation	  of	   E2	   sulfation	  by	   estrogen	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sulfotransferase	   to	   form	   17-­‐beta-­‐estra-­‐1,3,5-­‐trien-­‐3,17-­‐diol	   3-­‐sulfate	   that	   cannot	   interact	  
with	   the	   ERs	   anymore.271	   Studies	   in	   female	   mice	   described	   another	   way	   of	   estrogen	  
synthesis	   regulation	   implicating	   lipocalin	   2,	   a	   novel	   adipose-­‐derived	   cytokine	   which	   can	  
inhibit	  E2	  synthesis	  through	  downregulation	  of	  aromatase	  in	  adipose	  tissue.272	  The	  enzyme	  
aromatase	   is	   responsible	   of	   the	   last	   step	   in	   E2	   synthesis,	   this	   enzyme	   belongs	   to	   the	  
cytochrome	  P450	  superfamily	  and	  is	  widely	  expressed	  in	  many	  tissues:	  brain,	  gonads,	  blood	  
vessels,	  liver,	  bone,	  skin,	  adipose	  tissue	  and	  endometrium.273	  Thus,	  aromatase	  is	  expressed	  
in	   a	   tissue-­‐specific	   manner,	   which	   depends	   on	   three	   major	   mechanisms:	   alternative	  
splicing,	   tissue-­‐specific	   promoter	   and	   different	   transcription	   factors.	   The	   different	  
aromatase	   promoters	   are	   specifically	   regulated	   in	   tissues	   by	   distinct	   sets	   of	   hormones,	  
cytokines,	  second	  messenger	  signaling	  pathways	  and	  other	  factors.	  Aromatase	  is	  present	  in	  
gonads	  of	  both	  gender,	  it	  is	  found	  only	  in	  the	  granulosa	  and	  luteal	  cells	  in	  the	  female	  and	  in	  
the	  testis	  and	  accessory	  glands	  in	  the	  male	  where	  it	  plays	  a	  crucial	  role	  for	  maintaining	  high	  
level	  of	  E2	  necessary	  for	  normal	  spermiogenesis,	  sperm	  maturation	  and	  sperm	  motility.274	  
	  
Estrogen	  synthesis	  is	  different	  between	  reproductive	  and	  non-­‐reproductive	  women.	  In	  non-­‐
reproductive	  women	  (young	  females	  and	  menopausal	  women),	  the	  extra	  gonadal	  sites	  are	  
the	  main	   source	  of	  estrogen	  and	   include	  kidney,	   adipose	   tissue,	   skin	  and	  brain,	   estrogen	  
acts	  locally	  at	  the	  site	  of	  synthesis	  and	  functions	  as	  a	  paracrine/intracrine	  factor	  to	  maintain	  
the	   function	   of	   the	   tissue.	   275	   In	   contrast,	   in	   reproductive	  women,	   estrogen	   is	   produced	  
mostly	   in	   the	   ovaries,	   which	   will	   be	  mainly	   released	   into	   the	   bloodstream.	   In	   the	  male,	  
estrogen	   is	   produced	   in	   the	   testis	   and	   acts	   locally	   to	   regulate	   normal	   male	   gonadal	  
development	   and	   spermatogenesis,	   particularly	   spermiogenesis.276	   E2	   is	   also	   produced	  
locally	   in	   both	   genders	   through	   the	   conversion	   of	   testosterone	   by	   aromatase,277	   the	  
adipose	  tissue	  is	  the	  major	  source	  of	  circulating	  E2.278	  
	  
Estrogen	   binds	   to	   nuclear	   receptors	   known	   as	   estrogen	   receptor	   α	   (ERα)	   and	   estrogen	  
receptor	  beta	   (ERβ),	   encoded	  by	   ESR1	  and	  ESR2	   respectively.	   They	  belong	   to	   the	   steroid	  
receptor	  superfamily	  and	  are	  able	  to	  influence	  transcriptional	  processes	  of	  target	  genes	  via	  
binding	   to	   the	   ERE	   and	   recruiting	   co-­‐activators.	   Thus,	   estrogen	   is	   implicated	   in	   the	  
regulation	   of	   various	   genes	   involved	   in	   mitochondrial	   function,	   redox	   homeostasis,	  
carbohydrate	   metabolism,	   lipogenesis	   and	   extracellular	   matrix	   integrity.279,280	   Estrogen	  
receptors	  (ERs)	  are	  also	  found	  at	  the	  cytosolic	  and	  cell	  membrane	  level	  where	  they	  exert	  a	  
rapid	   non-­‐genomic	   action,281	   as	   well	   as	   in	   the	   nucleus.	   These	   receptors	   are	   not	   equally	  
distributed	   in	   the	  body,	   the	  heart	   for	  example	  disposes	  of	  both	  receptors	  whereas	   in	   the	  
liver	  only	  the	  ERα	   is	  present.282	   In	  the	  mid-­‐1990s	  a	  new	  receptor	  has	  been	   identified	  and	  
cloned	   from	  vascular	  endothelial	   cells.	   This	   receptor	   is	   called	  G	  protein-­‐coupled	  estrogen	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receptor	   (GPER)30	   and	   is	   a	   7-­‐transmembrane	   receptor	   involved	   in	   rapid	   non-­‐genomic	  
estrogen	  responses	  together	  with	  the	  membrane-­‐associated	  subgroups	  of	  ERα	  and	  ERβ.283	  
GPER	  has	  also	  been	  localized	  to	  the	  endoplasmic	  reticulum.284,285	  The	  first	  GPER	  knockout	  
mice	   appeared	   in	   2008,	   in	   this	   study	   the	   authors	   identified	   GPER	   as	   a	   player	   in	   thymic	  
atrophy.	   GPER	   is	   present	   on	   the	   vasculature286	   and	   is	   also	   highly	   expressed	   in	   cardiac	  
tissue.287	  	  
1.4.2 Estrogen	  in	  the	  heart:	  introduction	  
Cardiovascular	  disease	  is	  the	  leading	  cause	  of	  death	  in	  both	  female	  and	  male.	  Interestingly	  
it	   was	   described	   that	   the	   incidence	   of	   CVD	   is	   lower	   in	   premenopausal	   female	   than	   age-­‐
matched	  male.	  However,	  this	  female	  advantage	  gradually	  disappears	  after	  menopause	  and	  
leads	   to	   a	   CVD	   risk	   that	   is	   higher	   in	   postmenopausal	   women	   than	   age-­‐matched	  men.288	  
Many	   preclinical	   studies	   demonstrated	   beneficial	   effects	   of	   estrogen	   on	   CVD,	   however,	  
data	  from	  the	  clinical	  study	  Heart	  and	  Estrogen/Progestin	  Replacement	  Study	  (HERS-­‐I)	  and	  
the	  follow-­‐up	  HERS-­‐II	  failed	  to	  prove	  the	  cardioprotective	  effect	  of	  estrogen.289	  Surprisingly,	  
the	   Women’s	   Health	   Initiative	   (WHI)	   combined	   estrogen-­‐progestin	   trial	   described	   an	  
increase	  in	  risk	  for	  coronary	  heart	  disease	  in	  patients	  receiving	  estrogen	  supplements.5	  This	  
finding	  could	  be	  explained	  by	  estrogen	  formulation,	  dosing,	  and	  administration	  routes	  used	  
in	  these	  studies.	  	  
	  
Recent	  evidence	  proved	  that	   the	  aromatase	  enzyme	   is	  present	   in	   the	  heart	   implying	  that	  
estrogen	   is	   produced	   locally	   in	   the	   myocardium.290,291	   In	   the	   heart,	   E2	   is	   synthetized	  
endogenously	  from	  testosterone	  by	  the	  aromatase	  enzyme.	  This	  presence	  of	  testosterone	  
may	  be	  the	  major	  source	  of	  estrogen	  in	  postmenopausal	  women.	  It	  was	  recently	  reported	  
that	   a	   correlation	   exists	   between	   aromatase	   gene	   polymorphism	   and	   gender-­‐differential	  
mortality	  risk	  among	  patients	  diagnosed	  with	  acute	  coronary	  syndromes	  and	  patients	  with	  
stable	  CVD.292	  Indeed	  the	  aromatase	  variant	  allele	  CYP19A1-­‐81371C>T	  was	  associated	  with	  
increase	  adverse	  outcomes	  in	  men	  and	  decreased	  risk	  of	  outcomes	  in	  women,	  suggesting	  a	  
role	  of	  cardiac	  aromatase	  in	  estrogen-­‐mediated	  cardioprotection.292	  
1.4.3 Estrogen	  in	  the	  heart:	  role	  and	  mechanisms	  
The	  three	  estrogen	  receptors	  ERα,	  ERβ293	  and	  GPER	  are	  present	  in	  the	  adult	  and	  neonatal	  
heart	  and	  have	  also	  been	  found	  in	  ventricular	  and	  atrial	  cells	  in	  both	  genders	  in	  mice.294	  In	  
the	  heart,	  ERs	  regulate	  gene	  expression	  and	  posttranslational	  modifications	  through	  both	  
genomic	   and	   non-­‐genomic	   mechanisms.295	   Several	   studies	   demonstrated	   that	   the	   ERs	  
induce	   anti-­‐apoptotic,	   anti-­‐inflammatory,	   anti-­‐atherosclerotic,	   vasodilatory,	   pro-­‐
hypertrophic	   and	   angiogenic	   effects	   on	   the	   cardiovascular	   system.221,295-­‐297	   These	  
cardioprotective	   effects	   have	   been	   associated	   with	   direct	   actions	   on	   vascular	   tone	   in	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cardiac	  tissue,	  cell	  growth,	  and	  risks	  factors	  such	  as	  obesity	  and	  hypertension298	  and	  involve	  
both	   classical	   estrogen	   receptors	   as	   well	   as	   the	   GPER.284,299	   Estrogen	   is	   cardioprotective	  
during	   ischemia-­‐reperfusion	   (IR),	   since	   an	   acute	   administration	   of	   estrogen	   just	   before	  
ischemia	   reduces	   infarct	   size.300	   Interestingly,	   these	   protective	   effects	   disappeared	  when	  
women	  reach	  menopause.301-­‐303	  Female	  show	  also	  a	  reduced	  infarct	  size	  after	  IR	  compared	  
to	  males.304-­‐306	   A	   decline	   in	   E2	   in	   postmenopausal	   female	  may	   result	   in	   dysregulation	   of	  
lipid	  and	  glucose	  metabolism	  and	  an	  increased	  risk	  to	  develop	  CVD.	  	  
	  
The	  effects	  of	  E2	  on	  cellular	  mechanisms	   imply	  activation	  of	  PI3K/Akt	  pathway	  which	  can	  
lead	   to	   the	   phosphorylation	   and	   activation	   of	   eNOS	   to	   increase	   nitric	   oxide.	   E2	   can	   also	  
intervene	  in	  the	  expression	  and	  activity	  of	  ion	  channels,	  as	  it	  decreases	  the	  mRNA	  level	  of	  
potassium	  channel	  component	  Kv4.3	  and	  Kv1.5.307	  In	  another	  study,	  E2	  has	  been	  related	  to	  
a	   decrease	   in	   ether-­‐a-­‐go-­‐go-­‐related	   channel	   that	   is	   linked	   to	  QT	   prolongation	   syndrome,	  
which	  is	  affecting	  more	  women.308	  Thus	  E2	  affects	  cardiac	  contractility,	  repolarization	  and	  
can	  play	  a	  role	  in	  arrhythmias.	  A	  study	  performed	  on	  monkeys	  proved	  that	  E2	  is	  responsible	  
for	   the	   reduction	   of	   atherosclerosis.309	   Estrogen	   has	   many	   other	   effects,	   including	   the	  
decrease	   of	   hypertrophy	   in	   female	   mice	   after	   aortic	   constriction-­‐induced	   pressure	  
overload.310	  	  
	  
Some	  studies	  highlight	  that	  E2	  deficiency	  may	  be	  the	  trigger	  for	  obesity	  development	  and	  
result	   in	   T2DM,	   metabolic	   syndrome	   and	   CVD.311-­‐313	   Estrogen	   plays	   a	   primordial	   role	   in	  
several	  metabolic	  pathways.	  Indeed,	  estrogens	  are	  implicated	  in	  adipocyte	  activity	  and	  fat	  
distribution.	   The	  deletion	  of	   ERα	   in	   female	   and	  male	  mice	   causes	   central	   obesity,	   insulin	  
resistance	  and	  diabetes.314-­‐316	  A	  mouse	  model	  of	  ovariectomized	  mice	  fed	  with	  high	  fat	  diet	  
has	  demonstrated	  that	  E2	  replacement	  improved	  glucose	  and	  insulin	  sensitivity	  in	  skeletal	  
muscle	   of	   wild-­‐type	   mice	   but	   not	   in	   knock-­‐out	   ERα	   mice,	   confirming	   that	   ERα	   has	   an	  
important	   role	   in	   preventing	   from	   diet-­‐induced	   obesity	   adverse	   effects	   and	   could	   be	   a	  
potential	  target	  in	  the	  treatment	  of	  obesity.317-­‐319	  	  
	  
Devanathan	  et	  al,	  developed	  a	  mouse	  model	  of	  cardiomyocyte-­‐specific	  deletion	  of	  ERα	  to	  
distinguish	   the	   systemic	   effects	   from	   cardiac	   effects	   induced	   by	   estrogen.280	   They	  
characterized	   the	   genomic	   changes	   by	   microarray	   and	   discovered	   that	   208	   genes	   were	  
modified	   compared	   to	   the	   wild	   type	   mice.	   Recently,	   studies	   were	   conducted	   to	   better	  
understand	  the	  role	  of	  E2	  in	  cardiac	  metabolism.	  It	  has	  been	  shown	  that	  administration	  of	  
estrogen	   improved	   myocardial	   ATP	   levels	   and	   mitochondrial	   function	   in	   the	   heart.320	  
Additionally,	  ERα	  and	  its	  specific	  agonist	  were	  necessary	  to	  maintain	  glucose	  uptake	  in	  the	  
mouse	   heart.321	   The	   use	   of	  GPER	   knockout	  mice	   allowed	   determining	   the	   importance	   of	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GPER.	   These	   mice	   exhibit	   an	   altered	   metabolism,322	   an	   increase	   in	   visceral	   adiposity,323	  
obesity11	   and	  osteoporosis.322	   Indeed,	   female	  but	  not	  male	  GPER	  knockout	  mice	  become	  
glucose	  intolerant	  at	  6	  months	  of	  age.322	  In	  another	  study	  it	  has	  been	  highlighted	  that	  male	  
GPER	  knockout	  mice	  are	  insulin	  resistant	  at	  6	  months	  of	  age	  and	  become	  glucose	  intolerant	  
at	   a	   later	   life	   stage.324	   This	   fact	   is	   connected	   to	   the	   observation	   that	   GPER	   is	   able	   to	  
improve	   glucose	   intolerance	   and	   diabetes	   in	   female	  mice	   by	   activating	   insulin	   secretion	  
from	   pancreatic	   β-­‐cells.325	   In	   addition,	   administration	   of	   the	   GPER	   agonist	   G-­‐1	   causes	   a	  
decrease	   in	   fatty	   acid	   synthesis	   and	   triglyceride	   accumulation	   in	   human	   and	   rodent	  
pancreatic	  β-­‐cells.326	  
	  
Estrogen	  is	  known	  to	  regulate	  adiposity.327	  In	  rodents,	  it	  has	  been	  shown	  that	  the	  absence	  
of	   ovarian	  hormones	   increases	   adiposity328	   and	   that	   this	   is	   prevented	  by	   implantation	  of	  
subcutaneous	   pellet	   of	   E2.	   The	   different	   fat	   tissues	   present	   in	   the	   body	   exert	   different	  
functions.	   Indeed,	   it	   is	   thought	   that	   abdominal	   adipose	   tissue	   is	   metabolically	   and	  
functionally	  different	  than	  the	  other	  fat	  tissues.	  Removal	  of	  abdominal	  tissue	  is	  associated	  
with	   reduced	   insulin	   and	   glucose	   levels	   in	   human329	   and	   prevent	   insulin	   resistance	   and	  
glucose	   intolerance	   in	  male	  rodents	  whereas	  the	  removal	  of	  subcutaneous	  adipose	  tissue	  
do	  not	  show	  the	  same	  effects.330	  Moreover,	   the	  transplantation	  of	  subcutaneous	  adipose	  
tissue	   into	   the	   visceral	   region	  of	   a	   recipient	  mouse	   reduced	   the	   total	   amount	   of	   fat	   and	  
ameliorates	  the	  glucose	  homeostasis.331	  	  
	  
Figure	   10	   shows	   the	   interaction	   between	   Akt	   and	   estrogen	   signaling	   in	   the	   heart.	   Upon	  
insulin	  binding	  to	   its	  membrane	  receptor,	  activation	  of	   IRS-­‐1,	  PI3K	  and	  PDK1	  result	   in	  the	  
phosphorylation	   of	   Akt	   at	   T308,	   which	   in	   turn	   will	   activate	  multiple	   signaling	   pathways.	  
Among	   them	   the	   mTOR	   pathway	   is	   activated	   to	   modulate	   cardiac	   modeling	   and	  
performance.	   In	   the	   same	  way,	   estrogen	   can	  modulate	   cardiac	   function	   and	  morphology	  
via	  the	  regulation	  of	  Akt	  signaling	  and	  also	  via	  nuclear	  actions	  opening	  to	  an	  adjustment	  of	  
different	   channel	   transcription	   and	   expression	   (calcium,	   potassium	   channels).	   Estrogen	  
signaling	  is	  complex	  because	  of	  various	  factors.	  It	  has	  been	  proven	  that	  estrogen	  receptor	  
expression	   is	   differently	   regulated	   in	   a	   tissue-­‐specific	  manner	   and	  more	   importantly	   the	  
three	   receptors	   can	   exhibit	   different	   effects,	   which	   can	   be	   opposed,	   synergistic	   or	  
completely	  independent	  according	  to	  the	  tissue	  and	  time.	  
	  
Upon	  stimulation	  of	   the	  estrogen	  receptor,	   its	   translocation	   into	   the	  nucleus	  and	  binding	  
on	   the	   ERE	   will	   regulate	   transcription	   of	   genes	   according	   to	   the	   co-­‐regulator	   recruited,	  
which	   are	   tissue-­‐	   and	   gender-­‐specific.	   Moreover,	   the	   ERs	   can	   indirectly	   bind	   DNA	   via	  
transcription	   factors	  and	  can	  be	  activated	   in	  a	   ligand-­‐independent	  way	  by	  growth	   factors	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for	   example,	   leading	   to	   ER	   phosphorylation	   and	   translocation	   into	   the	   nucleus	   to	   trigger	  
gene	   transcription.332,333	   Besides	   these	   genomic	   effects,	   a	   non-­‐genomic	   effect	   of	   ER	  
activation	  exists,	  indeed	  ERs	  are	  also	  present	  in	  the	  plasma	  membrane	  and	  can	  trigger	  rapid	  
actions	  such	  as	  activation	  of	  Src,	  PI3K,	  Akt	  and	  MAPK.	  To	  add	  another	  level	  of	  complexity,	  
the	   two	   estrogen	   signaling	  mechanisms,	   genomic	   and	   non-­‐genomic,	   are	   able	   to	   interact	  
with	  each	  other	   in	  synergy.334	  This	   reflects	   the	  difficulty	   to	  understand	  estrogen	  signaling	  
and	  highlights	  the	  need	  of	  studies	  to	  describe	  the	  role	  of	  estrogen	  in	  particular	  in	  the	  heart,	  
where	   it	   appears	   to	   be	   cardioprotective	   in	   conditions	   such	   as	   ischemia-­‐reperfusion,	  
myocardial	   infarction,	  or	   chronic	  heart	   failure.	   It	  was	  only	   in	   the	  60s	   that	   the	  membrane	  
delimited	   action	  of	   estrogen	  was	   first	   described.335	   Today	   it	   is	  well	   accepted	   that	   E2	  not	  
only	   acts	   at	   the	   genomic	   level,	   but	   also	   induces	   rapid	   cellular	   responses	   via	   its	   plasma	  
membrane	  localization.336,337	  Estrogen	  receptors	  have	  also	  been	  localized	  in	  organelles	  such	  
as	  mitochondria	  and	  the	  reticulum	  endoplasmic.338,339	  More	  and	  more	  studies	  are	  going	  to	  





















Figure	  10:	  Insulin-­‐estrogen	  signaling	  crosstalk	  in	  the	  heart.	  
Estrogen	  can	  bind	  the	  3	  different	  estrogen	  receptors	  (ER)	  ERα,	  ERβ	  and	  GPER,	  to	  induce	  the	  various	  
physiological	  responses.	  Three	  different	  ways	  of	  binding	  are	  known.	  The	  classical	  genomic	  estrogen	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cytosol	  to	  the	  nucleus	  where	  it	  binds	  directly	  to	  consensus	  estrogen	  response	  elements	  (ERE)	  in	  the	  
chromosomal	   DNA,	   to	   initiate	   changes	   in	   gene	   expression.	   Co-­‐activators	   or	   co-­‐inhibitors	   are	  
recruited	  to	  activate	  or	  inhibit	  genes.	  ER	  can	  also	  attach	  indirectly	  to	  the	  DNA	  via	  other	  transcription	  
factors	   (e.g.	   API,	   Sp1).	   Another	  way	   of	   estrogen	   signaling	   activation	   is	   called	   ligand	   independent	  
activation.	   In	   this	   case	   ERs	   are	   phosphorylated	   by	   kinases	   such	   as	   p38,	   ERK	   or	   Akt,	   which	   are	  
activated	  by	  ERs	  at	   the	  membrane,	  and	   leads	   to	  DNA	  binding	  and	  gene	  transcription.	  The	  activity	  
and	  localization	  of	  both	  ER	  can	  be	  influenced	  by	  posttranslational	  modifications.	  
1.4.4 Estrogen	  in	  the	  heart:	  gender-­‐specificity	  
It	  is	  clear	  that	  menopause	  is	  associated	  with	  increased	  obesity,	  insulin	  resistance,	  diabetes	  
and	  osteoporosis,340	   and	   this	   is	  explained	  by	   the	   important	   role	  of	  estrogen	   in	  metabolic	  
effects	  such	  as	  regulation	  of	  lipid	  and	  glucose	  metabolism,	  adiposity,	  body	  fat	  distribution	  
and	   obesity.	   Indeed,	   the	   estrogen	   decline	   in	   postmenopausal	   female	   may	   result	   in	  
dysregulation	  of	  lipid	  and	  glucose	  metabolism	  and	  an	  increase	  in	  the	  risk	  to	  develop	  CVD.	  
This	   is	   due	   to	   several	  metabolic	   changes:	   an	   atherogenic	   lipid	  profile	  with	   an	   increase	   in	  
FFA,	  small	  dense	  low-­‐density	  lipoprotein	  particles,	  triglycerides,	  lipoprotein	  and	  a	  decrease	  
in	   HDL2	   particles,	   which	   are	   the	   most	   cardioprotective.312	   Moreover,	   this	   period	   is	   also	  
propitious	  to	  development	  of	  CVD	  hallmarks	  such	  as	  insulin	  resistance,	  disturbed	  peripheral	  
glucose	   clearance,	   increased	   gluconeogenesis	   and	   glucose	   output	   of	   the	   liver,	   increased	  
inflammatory	  markers	  and	  decreased	  fibrinolytic	  capacity.	  	  
	  
Men	  are	  at	  higher	  risk	  to	  develop	  obesity	  and	  cardiovascular	  disease	  including	  hypertension	  
than	  women.	  However,	   this	   tendency	   is	   inversed	   in	  postmenopausal	  population	  meaning	  
that	  at	  this	  stage,	  women	  lost	  their	  advantage	  while	  ovarian	  hormone	  levels	  decrease.165,166	  
This	   observation	   is	   today	   accepted	   but	   the	   reasons	   why	   menopausal	   women	   are	   more	  
susceptible	  to	  obesity	  and	  so	  CVD	  remain	  unclear,	  however	  ovarian	  hormones	  appear	  to	  be	  
the	   ideal	   player	   involved.	   It	   has	  been	  described	   that	  premenopausal	   females	   affected	  by	  
diabetes	   are	   also	   at	   higher	   risk	   to	   develop	   cardiovascular	   disease	   compared	   with	   age-­‐
matched	  males.	   Insulin	   sensitivity	   has	   also	   been	   described	   to	   be	   involved	   in	   the	   gender-­‐
differences	  observed	  in	  insulin	  signaling.	  A	  clinical	  study	  suggested	  that	  females	  were	  less	  
insulin	   sensitive	   than	   males.287	   This	   was	   consistent	   with	   an	   experimental	   study	   where	  
hearts	  from	  female	  rats	  were	  less	  sensitive	  to	  insulin	  compared	  to	  those	  from	  male	  rats.340	  
Interestingly	   however,	   ovariectomy	   (OVX)	   did	   not	   alter	   insulin	   sensitivity,341	   showing	   the	  
complexity	  of	  the	  regulation	  of	  insulin	  sensitivity.	  
	  
 1.5 	  Aim	  of	  the	  study	  	  
Cardiovascular	   diseases	   are	   the	   major	   cause	   of	   death	   in	   industrialized	   countries	   and	  
postmenopausal	  women	  are	  more	  affected	  than	  their	  counter	  part	  men.	  Moreover,	  it	  has	  
been	  described	  that	  premenopausal	  females	  affected	  by	  diabetes	  are	  also	  at	  higher	  risk	  to	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develop	   cardiovascular	   disease	   compared	   with	   age-­‐matched	   males.	   Hence,	   we	   found	   it	  
relevant	   to	   study	  gender-­‐specific	  effects	  and	   the	   role	  of	  ovarian	  hormones	   in	  a	  model	  of	  
metabolic	  disease	  induced	  by	  HFD.	  
	  
High	   fat	   diet	   feeding	   is	   an	   important	   risk	   factor	   for	  metabolic	   syndrome	   occurrence	   and	  
results	   in	   structural	   and	   functional	   cardiac	   alterations.	   One	   hallmark	   of	   the	   metabolic	  
syndrome	  is	  obesity,	  and	  according	  to	  the	  WHO	  estimates,	  more	  women	  (14.9%)	  than	  men	  
(10.8%)	  were	   obese	   in	   2014.	   However,	  women	   are	   less	   prone	   to	   develop	   cardiovascular	  
diseases166	  until	  menopause	  when	  this	   female-­‐advantage	  disappears,	   suggesting	  a	   role	  of	  
estrogen	  hormones.	  Estrogen	  has	  multiple	  roles	  in	  glucose	  and	  energy	  metabolism	  and	  has	  
been	   reported	   to	  be	   involved	   in	   the	   cardiovascular	   system,	  as	  E2	  modulates	   vasculature,	  
inflammatory	   responses	   and	   insulin	   sensitivity.	   For	   example,	   estrogen	   administration	   is	  
able	  to	  reduce	  cardiac	  infarct	  size	  after	  ischemia-­‐reperfusion.	  	  
	  
The	  number	  of	  studies	  on	  estrogen	  signaling	  is	  constantly	  growing	  but	  nevertheless,	  a	  lot	  is	  
still	   not	   discovered	  or	   understood.	   In	   this	   regard,	  many	   studies	   have	   been	  performed	   to	  
evaluate	  the	  role	  of	  E2	  in	  regulating	  gene	  expression	  and	  only	  few	  have	  addressed	  protein	  
expression.	   It	   is	   well	   known	   that	   changes	   in	   gene	   expression	   do	   not	   always	   reflect	   the	  
changes	  observed	  at	  the	  protein	  level.	  This	  is	  why	  in	  this	  study	  I	  aim	  to	  reveal	  potential	  sex-­‐
differences	   in	   protein	   expression	   by	   studying	   male,	   female,	   and	   female	   mice	   lacking	  
estrogen.	   Besides,	   by	   mimicking	   the	   postmenopausal	   situation	   in	   female,	   the	   results	  
obtained	   with	   my	   model	   could	   be	   important	   for	   other	   pathologies	   such	   as	   polycystic	  
ovaries	  where	  a	  defect	  in	  ovaries	  leads	  to	  decreased	  estrogen.	  	  
	  
The	  aims	  of	  my	  study	  are:	  	  
1.	   to	   investigate	   gender-­‐specific	   effects	   and	   the	   role	   of	   ovarian	   hormones	   on	   cardiac	  
function,	  geometry	  and	  cellular	  mechanisms	  in	  a	  model	  of	  obese	  mice	  
2.	  to	  better	  understand	  the	  cardioprotective	  effect	  of	  female	  hormones	  in	  mice	  
	  
It	   has	   been	   shown	   that	   after	   2	  wks	   of	  western	   diet,	   glucose	   oxidation	   and	   glycolysis	   are	  
reduced	  while	  FA	  oxidation	  and	  oxygen	  consumption	  are	  increased	  in	  a	  mouse	  model,133	  in	  
part	   due	   to	   altered	   insulin	   signaling.342,343	   Cardiac	   dysfunction	   similar	   to	   diabetic	  
cardiomyopathy	   was	   observed	   at	   a	   later	   stage,	   after	   20	   wks	   of	   diet.133,344	   Hence,	   the	  
timeline	   chosen	   in	   our	   study,	   which	   also	   depended	   on	   the	   observation	   of	   changes	   in	  
diastolic	   function	   by	   echocardiography.	   Hallmarks	   analyzed	   include	   glucose	   tolerance,	  
blood	   pressure,	   cardiac	   dimension	   and	   hemodynamic	   function,	   insulin	   pathway,	  
inflammation,	  and	  autophagy.	  We	  performed	  these	  analyses	  on	  male	  as	  well	  as	  sham-­‐	  and	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OVX-­‐operated	  female	  mice	  before,	  during	  and	  after	  feeding	  for	  22	  wks	  with	  a	  control	  (CTD)	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 2.1 Protocol	  and	  mouse	  model	  
Female	  and	  male	  C57Bl/6N	  mice	  were	  used	  in	  this	  study.	  Ovariectomy	  and	  different	  tests	  
were	  performed	  according	  to	  the	  precise	  timeline	  shown	  in	  Figure	  11.	  The	  mice	  were	  put	  
on	  two	  different	  diets:	  a	  regular	  chow	  diet	  referred	  to	  as	  control	  diet	  (CTD,	  Kliba	  Nafag)	  and	  
a	   high	   fat	   diet	   (HFD,	   Ssniff)	   containing	   45%	   calories	   derived	   from	   saturated	   fat	   and	   17%	  
from	  sucrose.	  By	  choosing	  this	  diet	  rich	  in	  fat	  and	  sucrose	  we	  aimed	  to	  mimic	  the	  diet	  used	  
in	  western	   countries,	  which	   contains	   a	   lot	  of	   saturated	   fat	   and	   carbohydrates.	   The	   study	  
was	  approved	  by	  the	  Veterinary	  Office	  of	  Canton	  Basel-­‐Stadt.	  The	  mice	  that	  suffered	  from	  
ulcerative	   dermatitis345	   were	   excluded	   from	   the	   study	   and	   in	   severe	   cases	   mice	   were	  























Figure	  11:	  Experimental	  design	  of	  our	  study.	  
At	   8	   weeks	   of	   age,	   all	   mice	   underwent	   ovariectomy	   or	   sham	   surgery.	   Their	   blood	   pressure	   and	  
cardiac	   function	   were	   assessed	   by	   tail-­‐cuff	   and	   echocardiography	   prior	   to	   and	   at	   different	  
timepoints	   after	   start	   of	   the	   diet,	   as	   indicated	   in	   the	   figure.	   Additionally,	   glucose	   tolerance	   tests	  
were	  realized	  at	  9	  and	  20	  weeks	  of	  diet.	  At	  22	  wks	  of	  diet,	  cardiac	  hemodynamics	  were	  measured	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 2.2 Ovariectomy-­‐	  and	  sham-­‐surgery	  
Female	  and	  male	  mice	  were	  anesthetized	  with	  isoflurane,	  the	  surface	  of	  interest	  of	  the	  skin	  
was	  shaved	  and	  cleaned	  with	  antiseptic	  agent	  before	  a	  3	  mm	  incision	  was	  made	  at	  the	  back	  
of	  the	  mouse,	  next	  to	  the	  spine	  0.5	  cm	  below	  the	  rips.	  The	  ovaries	  were	  localized	  and	  either	  
ligated	  and	  extracted	   for	   the	  ovariectomized	   (OVX)	  mice	  or	  not	   ligated	  and	   left	   intact	   for	  
the	  sham-­‐female	  and	  male	  mice.	  The	  OVX	  rodent	  model	   is	  commonly	  used	  in	  research	  to	  
study	  the	  role	  of	  E2	  in	  cardiac	  function,	  indeed	  this	  model	  closely	  mimics	  the	  sex	  hormone	  
level	  of	  surgical	  and	  natural	  menopause	  in	  women.346	  	  
	  
 2.3 Tail-­‐cuff	  blood	  pressure	  measurement	  
Blood	  pressures	  were	  measured	  using	  a	  non-­‐invasive	  method,	  which	  consists	  of	  placing	  a	  
cuff	  around	  the	  animal’s	  tail	  to	  occlude	  the	  blood	  flow.	  As	  the	  cuff	  inflates	  and	  deflates,	  a	  
sensitive	  sensor	  placed	  distally	  to	  the	  occlusion	  cuff	  monitors	  the	  blood	  pressure.	  To	  assess	  
blood	   pressure	   and	   pulse,	  we	   used	   the	   BP-­‐2000	   Series	   II	   blood	   pressure	   analysis	   system	  
(Visitech	   Systems,	   Apex,	   NC,	   USA),	   which	   relies	   on	   photoplethysmography,	   a	   light-­‐based	  
technology.	   Diastolic	   and	   systolic	   blood	   pressures	   as	   well	   as	   pulse	   were	   measured	   at	  
baseline	  (before	  the	  beginning	  of	  the	  diet)	  and	  at	  8	  and	  19	  wks	  of	  diet.	  The	  measurements	  
were	  performed	   in	  a	  quiet	  room	  during	  the	  afternoon	  at	  a	  regular	  hour	  and	  by	  the	  same	  
investigator.	  The	  mice	  were	  first	  trained	  for	  5	  days	  to	  allow	  acclimation	  to	  the	  procedure	  
until	   reproducible	  baseline	  measurements	   are	  obtained	  before	   to	  use	   the	  data.	   To	  avoid	  
any	  systematic	  errors,	  the	  blood	  pressure	  measurement	  of	  each	  mouse	  was	  performed	  on	  
different	  channels	  during	  the	  week.	  
	  
 2.4 Glucose	  tolerance	  test	  and	  plasma	  insulin	  levels	  
The	  glucose	  tolerance	  test	  (GTT)	   is	  a	  widely	  used	  and	  easy	  procedure	  important	  to	  assess	  
the	   ability	   of	   the	   body	   to	   clear	   glucose	   over	   time,	   it	   is	   susceptible	   to	   uncover	   glucose	  
intolerance.	  After	   6h	  of	   fasting,	  mice	  were	   injected	   intraperitoneally	   (i.p.)	  with	   a	   glucose	  
solution	   (2	   mg	   D-­‐glucose/g	   BW).	   Blood	   glucose	   concentrations	   were	   determined	   before	  
injection	   and	   15,	   30,	   60,	   90,	   120	  min	   after	   injection	   using	   the	   Freestyle	   Lite	   glucometer	  
(Abbott,	  Chicago,	  IL,	  USA),	  to	  observe	  glucose	  clearance	  from	  the	  blood.	  Each	  measurement	  
was	  recorded	  in	  duplicate,	  if	  the	  values	  were	  too	  far	  apart	  (more	  than	  1	  mmol/l),	  a	  third	  or	  
a	   fourth	   measure	   was	   taken.	   Insulin	   was	   measured	   in	   plasma	   collected	   during	   sacrifice	  
using	   the	   Multi-­‐array	   Assay	   System	   Mouse/Rat	   Insulin	   Kit	   from	   Meso	   Scale	   Discovery	  
(Rockville,	  Maryland,	  USA).	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 2.5 Echocardiography	  and	  pressure-­‐volume	  loop	  
Cardiac	  geometry	  and	  function	  were	  analyzed	  by	  ultrasound	  under	  isoflurane	  anesthesia.154	  
Next	   to	   routine	   echo	   parameters,154	  M-­‐mode	   imaging	  was	   used	   to	   evaluate	   systolic	   and	  
diastolic	   dimensions,	   posterior	   and	   anterior	   wall	   thickness,	   fractional	   shortening	   and	  
ejection	  fraction.	  Pulsed-­‐waved	  Doppler	  images	  in	  the	  apical	  4-­‐chamber	  view	  were	  used	  to	  
measure	   peak	   early	   (E)	   and	   late	   (A)	  mitral	   valve	   inflow	   velocities	   as	   a	   first	   evaluation	   of	  
diastolic	   function.	   Echocardiography	   was	   performed	   at	   baseline	   (before	   the	   start	   of	   the	  
diet),	  at	  5,	  10,	  15	  wks	  of	  diet	  and	  before	  sacrifice,	  using	  the	  Vevo®	  2100	  System	  from	  Visual	  
Sonics.	   In	   parallel,	   one	   batch	   of	   animals	   was	   dedicated	   to	   pressure-­‐volume	   loop	  
experiments	   for	   real-­‐time	   cardiac	   function	   assessment.	   To	   induce	   an	   additional	   cardiac	  
stress,	  and	  because	  LV	  dysfunction	  in	  HFpEF	  may	  be	  revealed	  better	  during	  exercise	  than	  in	  
the	  resting	  state,	  the	  β-­‐adrenergic	  stimulator	  dobutamine	  was	  infused.	  
	  
For	   the	   realization	   of	   the	   PVL	   experiment,	  mice	  were	   anesthetized	  with	   a	  mixture	   of	   α-­‐
chloralose	   (50	  mg/kg)	  and	  urethane	   (1200	  mg/kg),	   intubated	  with	  a	  ventilator	   to	  provide	  
oxygen	  (MiniVent	  845,	  Hugo	  Sachs/Harvard	  Apparatus)	  at	  a	  rate	  of	  130	  strokes/mi,	  7	  µL/g	  
BW	   tidal	   volume).	   The	   body	   temperature	   was	  maintained	   at	   37°C.	  Mice	   also	   received	   a	  
dose	   of	   pancuronium	   bromide,	   a	   neuromuscular	   blocking	   agent,	   which	   will	   inhibit	  
spontaneous	   breathing.	   While	   recording	   the	   data,	   the	   ventilator	   was	   briefly	   stopped	  
preventing	  the	  breathing	  movement	  that	  influences	  the	  cardiac	  cycle	  loops.	  	  
	  
Briefly,	   after	   calibration	   a	   pressure-­‐conductance	   transducer	   (1.4	   Fr	   pressure	   transducer,	  
Mikro-­‐Tip®	  ultra-­‐miniature,	  model	  SPR839,	  Millar,	  Houston,	  TX,	  USA)	  was	  inserted	  into	  the	  
right	  carotid	  artery	  and	  the	  catheter	   tip	  was	  manipulated	  across	   the	  aortic	  valve	   into	  the	  
left	  ventricle.	  After	  catheter	  stabilization,	  hemodynamic	  parameters	  were	  recorded	  before	  
and	   after	   dobutamine	   infusion	   through	   the	   jugular	   vein	   stepwise	   at	   different	  
concentrations:	  0.3,	  1,	  3,	  and	  10	  µg/ml/kg	  for	  2	  min	  each.	  To	  measure	  LV	  compliance	  and	  
elasticity,	   preload	   was	   decreased	   by	   occlusion	   of	   the	   inferior	   vena	   cava	   for	   5-­‐10	   sec	   to	  
obtain	   load-­‐independent	  measurements.	   The	   calculated	   Tau	   is	   using	   the	  Weiss	   formula.	  
The	   conductance	   was	   converted	   into	   volume	   by	   using	   a	   cuvette	   calibration	   containing	  
several	   small	   cylinders	   with	   known	   volumes.	   The	   catheter	   was	   placed	   in	   each	   of	   the	  
cylinders	  and	  the	  conductivity	  of	   the	  blood	  was	  translated	   into	  volume	  using	  the	  formula	  
described	  under	  1.1.5.	  A	  calibration	  curve	  was	   thus	  obtained,	  which	   served	   for	  obtaining	  
the	  final	  volumes.	  
	  
Data	   were	   acquired	   with	   ADinstruments	   PowerLab	   8	   and	   processed	   with	   LabChart	   Pro	  
software	   (ADInstruments,	   Dunedin,	   New	   Zealand).	   During	   this	   procedure,	   different	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hemodynamic	   parameters	   were	   recorded	   in	   the	   LV	   as	   well	   as	   the	   aorta,	   which	   is	   also	  
relevant	  to	  detect	  eventual	  abnormalities.	  	  
	  
 2.6 Sacrifice	  and	  tissue	  analysis	  
Mice	   from	   the	   PVL	   experiment	   were	   sacrificed	   immediately	   after	   the	   β-­‐adrenergic	  
challenge	  and	  used	  for	  microscopy	  analysis.	  To	  proceed,	  hearts	  were	  harvested	  and	  sliced	  
into	  3	  distinct	  parts:	  base,	  middle	  and	  apex,	  placed	  into	  OCT	  embedding	  matrix	  (Cell	  Path,	  
UK),	  and	  frozen	  into	  isopentane/liquid	  nitrogen	  for	  later	  histology	  analysis.	  	  
	  
In	  addition,	  another	  cohort	  of	  mice	  was	  sacrificed	  to	  study	  molecular	  mechanisms.	  For	  that,	  
mice	  were	   fasted	  6h	  during	   the	  morning	  prior	   sacrifice.	   They	  were	  anesthetized	  with	  3%	  
isoflurane,	   blood	   withdrawn	   from	   the	   heart,	   and	   tissues	   (heart,	   liver,	   gastrocnemius	  
muscle,	  visceral	  fat)	  were	  dissected,	  weighed	  and	  snapfrozen	  in	  liquid	  nitrogen	  for	  further	  
Western	   blot	   and	   RNA	   analysis.	   The	   fat	   harvested	   consisted	   of	   mesenteric/epididymal	  
depots	  of	  white	  adipose	  tissue,	  and	  will	  later	  be	  referred	  to	  as	  visceral	  fat.	  The	  uterus	  was	  
also	   weighed	   and	   served	   as	   a	   readout	   for	   successful	   ovariectomy.	   Tissue	   weights	   were	  
normalized	  to	  tibia	   length.	  Plasmas	  were	  collected	  to	  analyze	   insulin	  concentration	   in	  the	  
different	  groups,	  and	  all	  tissues	  collected	  were	  stored	  at	  -­‐80°C.	  	  
	  
 2.7 Protein	  analysis	  
Total	  proteins	  were	  extracted	  in	  RIPA	  buffer	  (50	  mmol/l	  Tris-­‐HCl,	  pH=7.4,	  150	  mmol/l	  NaCl,	  
1%	   (v/v)	   NP40,	   0.25%	   (v/v)	   Na+-­‐deoxycholate,	   5	   mmol/l	   EDTA,	   10	   mmol/l	   Na+-­‐
pyrophosphate,	   10	  mmol/l	   glycerophosphate,	   0.5%	   (v/v)	   phosphatase	   inhibitor	   cocktail	   1	  
and	  2	  (Sigma),	  1%	  protease	  inhibitor	  cocktail	  (Sigma)	  using	  a	  Polytron	  homogenizer.	  Equal	  
amounts	  of	  protein	  were	  separated	  by	  SDS-­‐PAGE	  and	  transferred	  onto	  a	  PVDF	  membrane	  
(0.2µm,	   GE	   healthcare).	   After	   1h	   of	   blocking	   with	   5%	   BSA	   to	   mask	   non-­‐specific	   sites,	  
membranes	   were	   incubated	   with	   the	   primary	   antibody	   overnight	   at	   4°C	   on	   a	   shaking	  
platform.	  The	  membranes	  were	  then	  washed	  3x20	  min	  with	  TBS-­‐Tween20	  0.1%	  to	  remove	  
unbound	  primary	  antibodies,	  and	  blocked	  again	  with	  5%	  BSA	  for	  30	  min	  prior	  to	  incubation	  
with	  a	  HRP-­‐labeled	  secondary	  antibody	  (Jackson	  Laboratories)	  for	  1h	  at	  RT.	  After	  3x20	  min	  
of	   washing,	   the	   signal	   was	   detected	   using	   SuperSignal	   West	   Pico	   Chemiluminescent	  
substrate	  (Thermo	  Scientific)	  and	  pictures	  were	  acquired	  with	  the	  Chemi-­‐Doc	  (Bio	  Rad)	  and	  
analyzed	  with	  the	  Image	  Lab	  software	  (Bio	  Rad).	  Antibodies	  were	  purchased	  from	  different	  
companies	  (Supplement,	  Table	  SI).	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 2.8 RNA	  analysis	  
Tissues	  were	  homogenized	  in	  Tri-­‐Reagent	  (Sigma)	  using	  a	  Polytron.	  RNA	  was	  first	  separated	  
from	  DNA	  and	  proteins	  using	  chloroform.	  After	  centrifugation,	  three	  phases	  were	  obtained,	  
an	  aqueous	  phase	  containing	  the	  RNA,	  an	  interphase	  containing	  DNA	  and	  a	  phenolic	  phase	  
containing	   proteins.	   The	   aqueous	   phase	   containing	   RNA	   was	   then	   transferred	   into	  
microtubes	   and	   precipitated	   with	   isopropanol.	   After	   centrigugation,	   the	   obtained	   pellet	  
was	   washed	   with	   70%	   ethanol,	   dried,	   and	   dissolved	   in	   water.	   It	   then	   received	   DNAse	  
treatment	   using	   the	   DNA-­‐free	   kit	   (Ambion)	   to	   eliminate	   any	   potential	   genomic	   DNA	  
contamination.	  The	  RNA	  was	  then	  quantified	  with	  a	  spectrophotometer	  (OD	  260	  nm),	  and	  
the	   purity	   evaluated	   by	   using	   the	   ratio	  OD260/OD280,	   and	   stored	   at	   –80°C.	   To	   check	   RNA	  
integrity,	   electrophoresis	   on	   an	   agarose	   gel	   was	   performed:	   two	   intact	   bands	   should	   be	  
visible	  corresponding	  to	  the	  subunit	  28s	  and	  18s	  of	  the	  ribosomal	  RNA.	  	  
	  
The	   reverse	   transcription	   process	   started	  with	   denaturation	  of	   the	  RNA,	  which	  was	   then	  
transcribed	  into	  cDNA	  using	  the	  High	  Capacity	  cDNA	  Reverse	  Transcription	  kit	  from	  Applied	  
Biosystems.	  cDNA	  was	  stored	  at	  –20°C.	  Quantitative	  real-­‐time	  PCR	  was	  performed	  with	  the	  
GoTaq	  qPCR	  Master	  Mix	  kit	  from	  Promega.	  Briefly,	  forward	  and	  reverse	  specific	  primers	  (5	  
µM)	   and	   an	   equal	   quantity	   of	   cDNA	   were	   added	   to	   the	   Master	   Mix.	   Each	   sample	   was	  
measured	  in	  triplicate	  and	  a	  standard	  curve	  was	  made	  to	  allow	  RNA	  quantification.	  All	  PCR	  
primers	  were	  bought	  from	  Microsynth,	  (see	  Supplement,	  Table	  SII	  for	  primers	  sequences).	  
To	  normalize	  our	  data	  different	  housekeeping	  genes	  were	  tested:	  GAPDH,	  myoglobin	  and	  
lamin	  B1,	  all	  these	  genes	  were	  regulated	  in	  our	  experimental	  groups.	  This	  is	  why	  our	  results	  
were	  normalized	  with	  the	  only	  gene	  that	  was	  not	  regulated,	  the	  GLUT4	  gene	  (Supplement,	  
Figure	  S	  VIIC).	  
	  
 2.9 Microscopy	  
Frozen	  hearts	  were	  sectioned	  at	  12	  µm	  thickness	  with	  a	  Leica	  Cryostat	  and	  stored	  at	  -­‐80°C.	  
Cryosections	   were	   processed	   for	   Picrosirius	   red	   (PSR)	   and	   Oil	   Red	   O	   (ORO)	   staining	   to	  
visualize	   fibrosis	  and	  neutral	   lipids,	   respectively.	  For	   the	  PSR	  staining,	  sections	  were	   fixed	  
with	  MetOH	  at	   -­‐20°C	   for	  10	  min,	   incubated	  with	  hematoxylin	   to	  color	   the	  nuclei,	   stained	  
with	  Sirius	  Red	  F3BA	  (Polysciences	  kit)	  and	  rinsed	  with	  0.01N	  HCl.	  Slides	  were	  mounted	  in	  
an	  anhydrous	  mounting	  medium.	  	  
	  
For	  the	  ORO	  staining,	  sections	  were	  allowed	  to	  equilibrate	  at	  room	  temperature	  (RT)	  for	  10	  
min	  and	  were	  then	  incubated	  with	  the	  ORO	  working	  solution,	  containing	  Oil	  Red	  O	  (Sigma)	  
dissolved	   in	   isopropyl	   alcohol,	   for	   5	   min.	   Sections	   were	   counterstained	   with	   Mayer’s	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hematoxylin,	  washed	  and	  mounted	  in	  a	  water-­‐soluble	  mounting	  medium.	  For	  both	  stains,	  
Pictures	  were	  acquired	  using	  bright-­‐field	  on	  an	  Olympus	  BX63	  microscope.	  	  
	  
Wheat	   germ	   agglutinin	   (WGA)	   staining,	   caspase-­‐3,	   Mac-­‐2,	   and	   TGF-­‐βI	   labelling	   were	  
detected	  by	  immunofluorescence.	  Cryosections	  were	  fixed	  with	  4%	  paraformaldehyde	  and	  
permeabilized	   with	   Triton	   X-­‐100	   0.3%.	   After	   2	   washings	   with	   PBS-­‐glycine,	   sections	   were	  
treated	   with	   NaBH4	   to	   reduce	   the	   background.	   For	   2x15	   min	   a	   solution	   containing	  
PBS+0.2%	   gelatin+3%	   BSA	   was	   used	   to	   block	   non-­‐specific	   sites.	   Finally,	   sections	   were	  
incubated	   overnight	   at	   4°C	  with	   the	   primary	   antibody,	   one	   section	   served	   as	   a	   negative	  
control.	  The	  second	  day,	  the	  sections	  were	  washed	  with	  PBS-­‐gelatin	  and	  incubated	  with	  a	  
secondary	  antibody	   (Alexa	  Fluor-­‐conjugated,	   Jackson,	  Molecular	  Probes)	   for	  1h	  at	  RT	   in	  a	  
humid	   chamber.	   Consecutive	   to	   washing,	   the	   sections	   were	   mounted	   with	   a	   minimal	  
amount	   of	   homemade	  mounting	   medium.	   Pictures	   were	   acquired	   with	   fluorescent	   light	  
using	  an	  Olympus	  BX63	  microscope.	  	  
	  
For	  Transmission	  Electron	  Microscopy,	  mice	  were	  perfuse-­‐fixed	  with	  2.5%	  glutaraldehyde	  
in	   0.1	  mol/l	   sodium	   phosphate	   for	   10-­‐15	  min.	   The	   heart	   was	   isolated	   and	   immerged	   in	  
glutaraldehyde.	  A	  small	  part	  of	  the	  LV	  free	  wall	  was	  taken	  out	  and	  transferred	   into	  tubes	  
containing	   glutaraldehyde	   for	   overnight	   post-­‐fixation	   at	   4°C	   on	   a	   rotator.	   Samples	   were	  
then	   processed	   by	   the	   Bio-­‐EM	   lab	   at	   the	   Center	   for	   Cellular	   Imaging	   and	   NanoAnalytics	  
from	  the	  Biocenter,	  University	  of	  Basel.	  
	  
 2.10 Statistical	  analysis	  
Data	  are	  presented	  using	  a	  box	  plot	  representing	  the	  interquartile	  range	  and	  showing	  the	  
highest	  and	  the	  lowest	  values	  as	  well	  as	  the	  median.	  Differences	  in	  means	  were	  evaluated	  
with	  two-­‐way	  ANOVA	  (P-­‐values	  in	  text),	  followed	  by	  Sidak’s	  multiple	  comparisons	  tests	  (P-­‐
values	   in	   figures).	   To	   discriminate	   gender-­‐specific	   effects	   from	   effects	   due	   to	   the	   OVX	  
surgery,	  data	  were	  analyzed	  into	  2	  different	  sets:	  male	  vs	  sham-­‐female	  and	  OVX-­‐	  vs	  sham-­‐
female	   mice.	   For	   multiple	   measurements	   of	   the	   same	  mice,	   repeated-­‐measures	   ANOVA	  
was	   used.	   All	   statistics	   were	   performed	   with	   GraphPad	   Prism	   7.0.	   P-­‐values	   <0.05	   were	  
considered	   statistically	   significant.	   Three	   different	   symbols	   were	   used	   to	   compare	   the	  
conditions:	   *refers	   to	   differences	   between	   HFD	   and	   CTD,	   $	   refers	   to	   male	   vs	   female	  
differences	  and	  #	  to	  the	  effects	  of	  ovarian	  hormones	  ablation.	  The	  p-­‐values	  correspond	  to	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Figure	  12:	  Body	  weights	  of	  female	  and	  male	  mice	  prior	  to	  and	  after	  feeding	  with	  CTD	  and	  
HFD.	  
A:	  OVX	  or	  sham	  surgery	  was	  performed	  at	  8	  wks	  of	  age	  and	  body	  weights	  measured	  at	  4	  wks	  after	  
this	  surgery	  (N=82-­‐110);	  B:	  diet	  feeding	  was	  started	  at	  4	  weeks	  after	  OVX/sham	  surgery	  and	  body	  
weights	  were	  measured	  at	  multiple	  time	  points	  afterwards	  as	  indicated	  (N=18-­‐25);	  C:	  body	  weight	  
gain	  was	   calculated	  by	   subtracting	  body	  weight	  at	  0	  wks	   from	  body	  weight	  at	   the	   indicated	   time	  
point	  (N=18-­‐25).	  Results	  are	  presented	  with	  the	  median,	  whiskers	  show	  the	  min	  and	  max	  values	  (A),	  
and	  mean	   ±	   SEM	   (B+C).	   *	   symbol	   corresponds	   to	   CTD	   vs	   HFD,	   #	   symbol	   corresponds	   to	   OVX	   vs	  


















  Female       OVXMale
####













































































	   70	  
 3.1 Analysis	  of	  body	  weight	  over	  time	  
Female	  mice	  underwent	  OVX-­‐	  or	  sham-­‐surgery	  at	  8	  wks	  of	  age	  and	  feeding	  with	  control	  or	  
high	  fat	  diet	  was	  started	  4	  wks	  later,	  at	  12	  wks	  of	  age.	  Male	  mice	  underwent	  sham	  surgery	  
and	   diet	   feeding	   was	   started	   at	   12	   wks	   in	   parallel	   to	   the	   female	   groups.	   To	   evaluate	  
potential	   differences	   in	   weight	   gain	   between	   male,	   female,	   and	   OVX-­‐female	   mice	   after	  
feeding	  with	  CTD	  or	  HFD,	  body	  weight	  was	  measured	  on	  a	  weekly	  basis.	  Body	  weights	  were	  
also	  measured	  prior	   to	  sham/OVX	  surgery	  and	  at	  start	  of	   the	  diet	   feeding	   (referred	  to	  as	  
baseline	  hereafter)	  to	  assess	  the	  acute	  effects	  of	  OVX	  on	  body	  weight	  (Figure	  12).	  
	  
First	  of	  all,	  Figure	  12A	  shows	  that	  during	  the	  4	  wks	  after	  surgery	  prior	  to	  the	  begin	  of	  HFD-­‐	  
or	   CTD-­‐feeding,	   the	   OVX	   mice	   (n=111)	   gained	   1.7	   grams	   more	   weight	   than	   the	   sham-­‐
operated	   female	  mice	   (n=83,	  p<0.0001).	  As	  a	   consequence,	   the	  body	  weight	  of	   the	  OVX-­‐
HFD-­‐group	  was	   already	  15%	  higher	   than	   that	  of	   the	   sham-­‐female-­‐HFD-­‐group	  at	   the	   time	  
that	  diet	  feeding	  was	  started	  (Figure	  12B).	  After	  10	  wks	  of	  HFD	  feeding,	  a	  difference	  of	  15%	  
was	   still	   observed	   between	   OVX-­‐	   and	   sham-­‐female	   mice,	   whereas	   at	   20	   wks	   this	   value	  
dropped	   to	   10%,	   showing	   that	   overtime	   the	   difference	   between	   OVX	   and	   sham-­‐female	  
mice	   became	   less	   (Figure	   12B).	   In	   fact,	   the	   body	  weight	   curves	   of	   the	  OVX-­‐HFD	   and	   the	  
sham-­‐HFD	  groups	  diverged	  up	  to	  5	  wks	  of	  feeding,	  then	  started	  to	  run	  parallel,	  and	  finally	  
during	  the	  last	  weeks	  of	  feeding	  the	  difference	  in	  weight	  became	  less	  (Figure	  12B).	  	  
	  
Since	  baseline	  body	  weights	  were	  different	  between	  the	  groups	  due	  to	  gender	  (males	  had	  
higher	  body	  weights	  than	  age-­‐matched	  females)	  and	  OVX,	  we	  calculated	  the	  body	  weight	  
gain	  compared	  to	  baseline	  for	  each	  mouse	  to	  evaluate	  the	  effects	  of	  HFD	  feeding	  for	  the	  
male,	  sham-­‐	  and	  OVX-­‐female	  groups	  (Figure	  12C).	  First	  of	  all,	  and	  as	  expected,	  HFD	  feeding	  
significantly	   increased	   body	  weight	   gain	   compared	   to	   CTD	   feeding	   for	   the	   three	   groups.	  
Overall,	   the	  male-­‐HFD	  group	  gained	  most	  weight	   followed	  by	   the	  OVX-­‐	  and	  sham-­‐female	  
mice.	   However,	  when	   the	   increase	   is	   calculated	   as	   percentage	   of	   total	   body	  weight,	   the	  
sham-­‐female	  group	  gained	  most	  weight	  over	  time	  with	  a	  64%	  increase	  measured	  at	  20	  wks	  
compared	   to	   baseline	   at	   the	   beginning	   of	   the	   feeding.	   The	   OVX	   and	   male	   HFD	   groups	  
gained	  59%	  body	  weight	  over	  the	  same	  time	  period.	  As	  for	  the	  CTD	  groups,	  during	  the	  20	  
wks	   of	   feeding,	   the	   OVX-­‐group	   gained	   somewhat	   more	   weight	   over	   time,	   but	   the	  
differences	  between	  the	  groups	  were	  small	  and	  not	  significant.	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Figure	   13:	   Post-­‐mortem	  organ	  weights	   of	  male,	   female	   and	  OVX	  mice	   fed	  with	   CTD	  or	  
HFD	  for	  22	  wks.	  
Organs	  were	  weighed	  after	  sacrifice	  and	  normalized	  to	  tibia	  length	  (TL:	  C,	  E,	  G	  and	  I)	  or	  body	  weight	  
(BW:	  D,	   F,	   H	   and	   J).	   LW,	   Liver	  weight;	   GW,	   gastrocnemius	  weight;	   VFW,	   visceral	   fat	  weight;	   VW,	  
ventricle	  weight.	  Results	  are	  presented	  with	   the	  median,	  whiskers	   show	  the	  min	  and	  max	  values.	  
*symbol	  corresponds	  to	  CTD	  vs	  HFD,	  #	  symbol	  corresponds	  to	  OVX	  vs	  sham,	  $	  symbol	  corresponds	  


































































































































































































	   72	  
 3.2 Analysis	  of	  organ	  weights	  	  
Body	  weight	  measurements	  done	  at	  the	  day	  of	  sacrifice	  after	  22-­‐23	  wks	  of	  diet	  gave	  results	  
similar	   to	   those	   described	   above	   under	   3.1.	   For	   all	   three	   groups	   (sham-­‐females,	   OVX-­‐
females	  and	  males),	  the	  HFD-­‐fed	  mice	  had	  significantly	  higher	  body	  weights	  than	  CTD-­‐fed	  
mice.	  The	  males	  had	  higher	  body	  weights	  than	  the	  females	  irrespective	  of	  the	  diet	  that	  was	  
fed,	  and	  no	  differences	  were	  observed	  between	  the	  sham-­‐	  and	  OVX-­‐females	  (Figure	  13A).	  
Notably,	   the	   OVX	  mice	   had	   a	   decreased	   uterus	   weight	   compared	  with	   the	   sham-­‐female	  
mice,	  confirming	  the	  successfulness	  of	  ovary	  ablation	  and	  the	  decreased	  level	  of	  estrogen	  
(Figure	  13B).	  
	  
In	   females	   as	   well	   as	  males,	   the	   HFD	   increased	   liver	   weight,	   but	   not	   the	   gastrocnemius	  
weight	  (Figure	  13C-­‐F).	  Moreover,	  paralleling	  the	  higher	  body	  weights	  of	  males	  compared	  to	  
females,	  the	  liver	  and	  gastrocnemius	  were	  heavier	  in	  males	  than	  in	  females	  (Figure	  13C,	  E).	  
In	  the	  CTD-­‐fed	  mice,	   the	  gender-­‐related	  difference	   in	   liver	  and	  gastrocnemius	  weight	   lost	  
significance	  after	  normalization	  to	  body	  weight,	  meaning	  that	  the	  liver	  and	  gastrocnemius	  
weight	  were	   in	  proportion	   to	   the	  body	  weight	   (Figure	  13D,	  F).	  However,	   for	   the	  HFD-­‐fed	  
mice,	  normalization	  of	  liver	  weight	  to	  body	  weight	  resulted	  in	  higher	  values	  for	  males	  than	  
sham-­‐females,	  indicating	  a	  gender-­‐difference	  in	  the	  liver's	  response	  to	  HFD	  feeding	  (Figure	  
13D).	  On	  the	  other	  hand,	  the	  CTD-­‐fed	  OVX	  mice	  had	  slightly	  lower	  liver/BW	  ratios	  than	  the	  
sham-­‐females,	   whereas	   HFD-­‐fed	   OVX	  mice	   had	   an	   increased	   ratio	   compared	   to	   CTD-­‐fed	  
mice	   (Figure	   13D).	   Thus,	   compared	   to	   CTD,	   HFD	   feeding	   causes	   an	   over-­‐proportional	  
increase	  in	  liver	  weight	  in	  OVX-­‐females	  and	  males,	  but	  not	  in	  sham-­‐females.	  These	  findings	  
suggest	  that	  liver	  hypertrophy	  develops	  in	  a	  gender-­‐specific	  manner	  after	  HFD	  feeding.	  Our	  
data	  also	  suggest	  a	  role	  for	  the	  ovarian	  hormones	  in	  determining	  liver	  weight	  at	  least	  under	  
CTD	  conditions.	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Figure	  14:	  Oil	  Red	  O	  staining	  to	  detect	  neutral	  lipids	  in	  liver	  sections.	  
Liver	  cryosections	  of	  male,	  female	  and	  OVX	  mice	  (sacrificed	  at	  22	  wks)	  were	  stained	  with	  Oil	  red	  O	  
to	   detect	   neutral	   lipids	   (red)	   and	   counterstained	   with	   hematoxylin	   to	   reveal	   nuclei	   (blue).	  
Magnification	  x20.	  
	  
To	  evaluate	  if	  the	  liver	  from	  males	  had	  a	  different	  composition	  or	  appearance	  than	  the	  liver	  
from	   sham-­‐females,	   liver	   sections	   were	   stained	   with	   Oil	   Red	   O	   to	   detect	   neutral	   lipids	  
(Figure	  14).	  The	  HFD	  feeding	  was	  responsible	  for	  an	  important	  accumulation	  of	  lipids	  in	  all	  
groups	  but	  the	  effect	  was	  much	  more	  pronounced	  in	  the	  OVX-­‐female	  followed	  by	  the	  male	  
mice.	  This	  observation	  could	  explain	   the	   fact	   that	   the	   livers	   from	  these	   two	  groups	  were	  
heavier	   after	  HFD.	   In	   the	   sham-­‐female	   group,	   the	  HFD	   feeding	   had	   a	   smaller	   effect.	   The	  
observed	   low	   accumulation	   of	   lipids	   after	   HFD	   feeding	   is	   in	   line	   with	   the	   fact	   that	   liver	  
weight	  was	  not	  increased	  in	  this	  group.	  In	  the	  CTD-­‐fed	  groups,	  the	  OVX-­‐female	  mice	  seem	  
to	   have	   bigger	   lipids	   droplets	   than	   the	   sham-­‐female.	   It	   also	   appeared	   that	   in	  males	   the	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The	   gender-­‐specific	   differences	   in	  weight	   applied	   to	   the	   liver	  but	  not	   the	   gastrocnemius.	  
The	  latter	  was	  heavier	  in	  males	  than	  in	  females,	  with	  no	  difference	  between	  the	  OVX-­‐	  and	  
sham-­‐female	   groups	   (Figure	   13E).	   No	   effects	   of	   HFD	   on	   gastrocnemius	   weight	   were	  
observed	   for	   any	   of	   the	   groups	   after	   normalization	   to	   tibia	   length	   (Figure	   13E).	  
Normalization	   to	  body	  weight	   resulted	   in	   reduced	  GW/BW	   ratios	   in	   response	   to	  HFD	   for	  
males,	   females,	   and	   OVX-­‐females	   alike	   (Figure	   13F).	   These	   results	   are	   explained	   by	   a	  
change	  in	  body	  composition	  after	  HFD.	  Muscle	  mass	  was	  stable	  after	  the	  HFD	  feeding,	  but	  
fat	   and	   liver	   weight	   increased	   and	   are	   together	   responsible	   for	   the	   overall	   body	   weight	  
increase,	  consistent	  with	  the	  GW/BW	  decrease.	  
	  
Interestingly,	  the	  visceral	  fat	  weight	  showed	  OVX-­‐related	  differences	  (Figure	  13G,	  H).	  First	  
of	  all,	  and	  as	  expected,	  HFD	  caused	  an	  increase	  in	  fat	  weight	  for	  all	  three	  groups.	  Moreover,	  
OVX	   increased	  visceral	   fat	  weight	  after	  CTD	  feeding,	  but	  no	  effect	  of	  OVX	  was	  noticeable	  
after	  HFD	   feeding	  most	   likely	  because	   the	  HFD	  by	   itself	  had	  already	  maximally	   increased	  
the	  fat	  weight.	   In	  other	  words,	  HFD	   increased	  fat	  mass	   in	  sham-­‐females	  and	  OVX	  did	  not	  
increase	   this	   any	   further.	   These	   effects	   on	   fat	   mass	   remained	   significant	   also	   after	  
normalization	   to	   body	   weight,	   indicating	   an	   over-­‐proportional	   increase	   in	   body	   fat.	  
Interestingly,	  despite	  the	  higher	  BW	  of	  the	  males,	   fat	  mass	  after	  HFD	  was	   lower	   in	  males	  
than	  in	  females.	  Thus,	  HFD-­‐fed	  males	  had	  less	  fat	  than	  the	  females	  for	  a	  given	  body	  weight	  
(Figure	  13H).	  
	  
Immediately	  after	  sacrifice	  by	  cardiectomy,	  the	  hearts	  were	  dissected	  for	  further	  analysis.	  
Atria	   were	   removed	   and	   the	   ventricles	   weighed.	   HFD	   feeding	   increased	   the	   ventricular	  
weight	   only	   in	   the	   female	   and	   not	   in	   the	   male	   mice	   (Supplement,	   Figure	   S	   ID).	   After	  
normalizing	  for	  tibia	  length,	  the	  HFD	  feeding	  increased	  the	  ventricular	  weight	  in	  the	  sham-­‐
females	  but	  not	  in	  the	  males,	  highlighting	  the	  presence	  of	  a	  gender	  difference	  (Figure	  13I).	  
A	  small	  increase	  observed	  in	  the	  OVX-­‐females	  was	  not	  significant	  (p=0.079),	  so	  more	  mice	  
are	  needed	  to	  draw	  a	  conclusion	  about	  the	  role	  of	  ovarian	  hormones	  on	  ventricular	  weight.	  
As	  expected,	  the	  ventricular	  weights	  of	  males	  were	  higher	  than	  those	  of	  females.	  This	  was	  
still	   true	  after	  normalizing	   to	  body	  weight.	  Thus,	  males	  have	  heavier	  hearts	   than	   females	  
and	  HFD	  increases	  ventricular	  weight	  in	  sham-­‐females	  after	  22	  wks	  of	  feeding.	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Figure	  15:	  Systemic	  glucose	  clearance	  assessed	  by	  glucose	  tolerance	  tests	  at	  9	  and	  20	  wks	  
of	  diet	  in	  male,	  female	  and	  OVX	  mice.	  
A,	  B:	  glucose	   tolerance	   tests	  were	  performed	  after	  6h	  of	   fasting.	  Glucose	  clearance	  was	   followed	  
prior	  and	  120	  min	  after	  i.p.	  glucose	  injection;	  C,	  D:	  the	  "area	  under	  the	  curve"	  (AUC)	  of	  A	  and	  B	  was	  
calculated	  using	  the	  trapezoid	  method;	  E:	  plasma	  insulin	  was	  measured	  as	  described	  in	  the	  methods	  
section.	  Results	  are	  presented	  with	   the	  median,	  whiskers	   show	  the	  min	  and	  max	  values	   (C,	  D,	  E),	  
and	  mean	  ±	  SEM	  (A,B).	  *	  symbol	  corresponds	  to	  CTD	  vs	  HFD,	  #	  symbol	  corresponds	  to	  OVX	  vs	  sham,	  
$	  symbol	  corresponds	  to	  male	  vs	  female;	  N=18-­‐25.	  
	  
 3.3 Analysis	  of	  glucose	  tolerance	  and	  plasma	  insulin	  levels	  
At	  9	  and	  20	  wks	  of	  CTD-­‐	  or	  HFD-­‐feeding,	  we	  performed	  the	  glucose	  tolerance	  test	  (GTT)	  to	  
assess	  the	  efficiency	  of	  systemic	  glucose	  clearance	  in	  the	  different	  groups	  (Figure	  15).	  The	  
GTT	   evaluates	   the	   body’s	   capability	   to	  metabolize	   glucose	   and	   the	   ability	   of	   the	   liver	   to	  
store	   excess	   glucose	   as	   glycogen.	   After	   i.p.	   injection	   of	   glucose,	   its	   concentration	   was	  
measured	  at	  multiple	  timepoints	  (Figure	  15A,	  B).	  The	  resulting	  curve	  shows	  the	  relationship	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between	   glucose	   concentration	   and	   time	   and	   is	   used	   to	   calculate	   the	   "area	   under	   the	  
curve"	   (AUC)	  as	  a	  measure	  of	  glucose	  clearance	   (Figure	  15C,	  D).	  At	  9	  wks,	  HFD	   increased	  
the	  AUC	  values	  in	  all	  groups	  (Figure	  15C),	  indicating	  decreased	  glucose	  tolerance	  compared	  
to	  CTD,	  and	  this	  effect	  was	  similar	  at	  20	  wks	  (Figure	  15D).	  The	  effect	  of	  HFD	  feeding	  was	  
stronger	   in	  OVX-­‐females	   (1.54-­‐fold	  at	  9	  and	  20	  wks)	   than	   in	   sham-­‐females	   (1.34-­‐fold	  and	  
1.38-­‐fold	   at	   9	   and	   20	   wks,	   respectively).	   Consistently,	   the	   AUC	   was	   1.44-­‐	   and	   1.24-­‐fold	  
higher	   in	   OVX-­‐	   than	   in	   sham-­‐females	   after	   HFD	   at	   9	   wks	   (p<0.0001)	   and	   20	   wks	   and	  
(p=0.034)	  respectively,	  indicating	  a	  role	  for	  the	  ovarian	  hormones.	  The	  effect	  of	  OVX	  after	  
CTD	  was	  smaller	  compared	  with	  the	  HFD	  feeding.	  Thus,	  at	  9	  wks	  of	  diet	  the	  OVX-­‐females	  
had	  a	  slightly	  higher	  AUC	  than	  the	  sham-­‐females	  (p=0.07),	  whereas	  at	  20	  wks	  there	  was	  no	  
effect.	  No	  differences	  were	  observed	  between	   the	   sham-­‐female	   and	   the	  male	  mice.	   The	  
glucose	  tolerance	  was	  reduced	  by	  OVX	  despite	  equal	  amounts	  of	  adipose	  tissue	  in	  the	  OVX-­‐	  
and	   sham-­‐female	   mice.	   As	   it	   is	   thought	   that	   inflammatory	   cytokines	   released	   from	   fat	  
(adipokines)	  may	  participate	   in	   the	  onset	  of	   glucose	   intolerance,	   these	  data	   suggest	   that	  
the	  glucose	  intolerance	  observed	  in	  the	  OVX-­‐HFD	  mice	  may	  be	  independent	  of	  adipokines.	  
Inversely,	   when	   the	   mice	   are	   fed	   with	   CTD,	   the	   OVX	  mice	   do	   not	   exhibit	   a	   higher	   AUC	  
despite	  an	  increased	  fat	  mass,	  strengthening	  the	  fact	  that	  there	  is	  no	  correlation	  between	  
visceral	  fat	  mass	  and	  glucose	  tolerance	  measured	  with	  the	  GTT	  method.	  In	  conclusion,	  our	  
data	  demonstrate	  that	  OVX	  decreases	  glucose	  tolerance	   in	  HFD-­‐fed	  female	  mice	  and	  that	  
this	  effect	  is	  most	  likely	  independent	  of	  the	  amount	  of	  adipose	  tissue.	  In	  our	  earlier	  work,	  
we	  observed	  similar	  effects	  of	  OVX	  already	  at	  3	  wks	  of	  feeding	  (data	  not	  shown).	  
	  
Fasting	   glucose	   concentrations	   were	   not	   changed	   by	   HFD	   in	   any	   of	   our	   experimental	  
groups,	  proving	  that	  our	  mice	  were	  not	  yet	  diabetic	  at	  this	  stage.	  The	  difference	  appeared	  
only	  at	  the	  glucose	  clearance	  level	  after	  a	  glucose	  load,	  suggesting	  that	  after	  20	  wks	  of	  diet	  
the	  HFD-­‐fed	  mice	   and	   in	  particular	   the	  OVX	  mice	   are	  pre-­‐diabetic.	   To	   further	   investigate	  
this,	  we	  analyzed	  plasma	   insulin	   levels.	  At	  22	  wks,	   the	  mice	  were	   sacrificed	   in	   the	   fasted	  
state	   and	   blood	   was	   collected	   to	   measure	   insulin	   by	   ELISA	   (Figure	   15E).	   Female,	   OVX-­‐
female	   and	   male	   mice	   were	   not	   different	   after	   CTD	   feeding.	   However,	   HFD	   strongly	  
increased	   the	   insulin	   concentration	   in	   the	   male	   group,	   indeed,	   a	   5-­‐fold	   increase	   was	  
measured	  compared	  to	  CTD	  (p<0.0001).	  After	  HFD,	  the	  male	  mice	  had	  much	  higher	  insulin	  
levels	  than	  the	  sham-­‐female	  mice.	  HFD	  also	  increased	  plasma	  insulin	  in	  the	  sham-­‐females,	  
but	  the	  effect	  (2.9-­‐fold	  increase)	  was	  much	  smaller	  than	  in	  the	  males.	  In	  contrast,	  no	  effect	  
of	  HFD	  was	  visible	   in	   the	  OVX	  group.	   In	   conclusion,	  22	  wks	  of	  HFD	   feeding	   rendered	   the	  
male	  mice	  highly	  hyperinsulemic	  to	  attempt	  to	  compensate	  for	  their	  insulin	  resistance.	  The	  
effect	  was	  much	  weaker	   in	  the	  sham-­‐females	  and	  completely	  absent	   in	  the	  OVX-­‐females,	  
suggesting	  that	  these	  groups	  are	  less	  and	  not	  insulin-­‐resistant	  at	  all,	  respectively.	  
Results	  
	  






























Figure	  16:	  Blood	  pressure	  and	  heart	  pulse	  measurements	  using	  the	  tail-­‐cuff	  method	  at	  8	  
and	  19	  wks	  of	  diet	  in	  male,	  female	  and	  OVX	  mice.	  
A,	   B:	   systolic	   blood	   pressure	   (BP);	   C,	   D:	   diastolic	   blood	   pressure;	   E,	   F:	   heart	   pulse.	   Results	   are	  
presented	  with	  the	  median,	  whiskers	  show	  the	  min	  and	  max	  values.	  *	  symbol	  corresponds	  to	  CTD	  
vs	  HFD,	  #	  symbol	  corresponds	  to	  OVX	  vs	  sham,	  $	  symbol	  corresponds	  to	  male	  vs	  female.	  N=14-­‐26	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 3.4 Blood	  pressure	  and	  pulse	  measurements	  
In	   human,	   estrogen	   is	   known	   to	   regulate	   blood	   pressure	   via	   endothelial347	   and	   vascular	  
smooth	  muscle	  cells.348	  However,	  in	  rodent	  models,	  blood	  pressure	  changes	  have	  not	  been	  
observed	   in	   estrogen-­‐deficient	   states.349-­‐352	   Since	   blood	   pressure	   may	   influence	   cardiac	  
functional	  parameters	  and	  hypertrophy,	  we	  verified	  blood	  pressures	  at	  baseline,	  8	  and	  19	  
wks	   of	   feeding,	   using	   the	   non-­‐invasive	   tail-­‐cuff	  method.	   At	   8	  wks	   of	   CTD,	  OVX	  mice	   had	  
lower	  systolic	  blood	  pressures	  (SBP)	  than	  sham-­‐female	  mice.	  At	  19	  wks,	  HFD	  decreased	  the	  
SBP	  compared	  with	  CTD,	  an	  effect	  that	  was	  observed	  only	  in	  the	  OVX	  mice	  (Figure	  16A,	  B).	  
Additionally,	  HFD	  reduced	  diastolic	  blood	  pressures	  (DBP)	  in	  male	  mice	  at	  both	  time	  points	  
and	  in	  OVX-­‐female	  mice	  at	  8	  wks	  of	  diet	  (Figure	  16C,	  D).	  The	  CTD-­‐fed	  males	  had	  a	  higher	  
DBP	   than	   the	   diet-­‐matched	   sham-­‐females	   at	   8	   wks.	   HFD	   increased	   the	   pulse	   rate	   in	   all	  
groups	  at	  both	   timepoints	   (Figure	  16E,	  F).	  Moreover,	   the	  male	   fed	  with	  CTD	  had	  a	   lower	  
pulse	  rate	  than	  the	  sham-­‐female	  at	  later	  stage.	  Therefore,	  HFD	  increased	  the	  heart	  rate	  in	  
all	   groups,	   whereas	   it	   decreased	   the	   diastolic	   blood	   pressure	   in	   the	   male	   mice	   only,	  
identifying	  a	  gender-­‐specific	  effect.	  	  
	  
 3.5 Echocardiography	  
We	   used	   echocardiography	   as	   non-­‐invasive	   method	   to	   assess	   cardiac	   geometry	   and	  
function.	  Images	  were	  acquired	  in	  the	  parasternal	  long	  and	  short	  axis	  view	  in	  B-­‐mode	  and	  
M-­‐mode.	   Mitral	   annulus	   velocity	   and	   mitral	   valve	   blood	   flow	   were	   assessed	   by	   tissue	  
Doppler	   and	   pulsed-­‐wave	   Doppler,	   respectively.	   At	   baseline,	   none	   of	   the	   parameters	  
obtained	   by	   echocardiography	   were	   different	   between	   the	   experimental	   groups	  
(Supplement,	  Table	  SIII).	  Table	  I	  (p.86)	  shows	  the	  data	  recorded	  after	  21	  wks	  of	  diet.	  The	  LV	  
free	  wall	   thickness,	  LV	   internal	  diameter,	  LV	  mass,	  FS	  and	  E/E’	  ratio	  were	  not	  affected	  by	  
gender,	  OVX	  or	  diet.	  Also,	  the	  ejection	  fraction	  (EF),	  which	  is	  the	  percentage	  of	  total	  blood	  
pumped	  out	  of	  the	  left	  ventricle	  during	  each	  cardiac	  cycle,	  stayed	  unchanged	  between	  the	  
experimental	  groups.	  	  
	  
The	   parameters	   that	   showed	   significant	   changes	   are	   shown	   in	   Figure	   17.	   Importantly,	  
cardiac	  geometry	  was	  altered	  in	  some	  groups.	  Notably,	  in	  the	  sham-­‐female	  group,	  the	  HFD	  
increased	  the	  relative	  wall	  thickness	  during	  diastole	  (+9.3%)	  compared	  with	  the	  CTD	  group	  
(Figure	   17A).	   The	   LV	   posterior	   wall	   was	   also	   slightly	   increased	   by	   the	   HFD	   in	   the	   sham-­‐
female	  group	  (2-­‐way	  ANOVA	  p=0.02,	  post-­‐hoc	  p=0.06)	  (Figure	  17B).	  These	  results	  suggest	  
that	   the	   sham-­‐female	   mice	   start	   to	   develop	   cardiac	   remodeling.	   Moreover,	   the	   HFD	  





























Figure	  17:	  Echocardiographic	  parameters	  of	  male,	  female	  and	  OVX	  mice	  evaluated	  after	  
21	  wks	  of	  diet.	  
A:	   relative	   wall	   thickness	   during	   diastole;	   B:	   left	   ventricle	   anterior	   wall	   (LVAW)	   thickness	   during	  
diastole;	  C:	   left	  ventricle	  posterior	  wall	   (LVPW)	  during	  diastole;	  D:	   left	  ventricle	  volume	  (LV	  vol,	  d)	  
during	  diastole;	  E:	  E/A	  ratio,	  E	  represents	  the	  velocity	  of	  the	  mitral	  blood	  flow	  at	  early	  stage	  and	  A	  
at	  late	  stage;	  F:	  cardiac	  output.	  Results	  are	  presented	  with	  the	  median,	  whiskers	  show	  the	  min	  and	  
max	  values.	  *	  symbol	  corresponds	  to	  CTD	  vs	  HFD,	  #	  symbol	  corresponds	  to	  OVX	  vs	  sham,	  $	  symbol	  
corresponds	  to	  male	  vs	  female.	  N=22-­‐32.	  
	  
	  
of	  HFD	  was	  clearly	  more	  pronounced	  than	   in	  the	  other	  groups	  (Figure	  17C).	  The	  HFD	  had	  
another	  effect	  specific	  to	  the	  male	  mice.	  Indeed,	  the	  LV	  volume	  at	  diastole	  is	  lower	  in	  the	  
male	  group	  after	  HFD	  feeding	  (Figure	  17D).	  Thus,	  the	  LV	  of	  the	  HFD-­‐fed	  males	  is	  not	  able	  to	  
fill	  with	  the	  same	  volume	  of	  blood	  as	  in	  the	  CTD-­‐fed	  males.	  This	  observation	  suggests	  that	  
the	   hearts	   of	   the	   HFD-­‐fed	   male	   mice	   present	   a	   reduced	   capability	   to	   distend	   during	  
diastole,	   which	   could	   be	   linked	   to	   a	   less	   compliant	   LV	   or	   alternatively,	   could	   be	   the	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Interestingly,	  HFD	  feeding	  caused	  a	  decrease	  in	  the	  E/A	  ratio	  in	  the	  sham	  and	  OVX-­‐female	  
mice	  (Figure	  17E).	  The	  E	  in	  the	  E/A	  ratio	  corresponds	  to	  the	  E-­‐wave	  measured	  by	  Doppler,	  
which	   is	   the	   peaking	   of	   blood	   velocity	   in	   early	   diastole	   during	   the	   initial	   filling	   of	   the	   LV	  
after	   the	  mitral	   valve	   opens.	   At	   the	   end-­‐diastole,	   the	   atrium	   contracts	   creating	   the	   final	  
filling	  stage	  of	  the	  LV,	  this	  is	  the	  late	  filling	  A-­‐wave.	  The	  E/A	  ratio	  is	  therefore	  used	  to	  assess	  
diastolic	  function.	  A	  stiffer	  LV	  could	  be	  at	  the	  origin	  of	  a	  decreased	  E/A	  ratio	  since	  the	  LV	  
pressure	  at	   the	  end	  diastole	  would	   increase,	   slowing	  down	  the	  early	   filling.	  On	   the	  other	  
hand,	  the	  late	  filling	  A	  could	  also	  be	  impaired	  and	  increased	  as	  a	  consequence	  of	  a	  stiffer	  LV	  
walls.	  A	  decrease	  in	  the	  E/A	  ratio	  can	  be	  translated	  as	  a	  decrease	  of	  the	  blood	  flow	  velocity	  
during	   the	  early	   filling	  due	   to	   a	   stiffer	   heart,	  which	   induces	   an	   increase	  of	   pressure.	  Our	  
data	  therefore	  suggest	  a	  defect	  in	  diastolic	  function	  in	  the	  female	  mice	  when	  fed	  with	  HFD	  
whereas	  the	  males	  are	  not	  affected,	  pointing	  to	  the	  presence	  of	  a	  gender-­‐specific	  effect.	  
	  
Finally,	  our	  echocardiographic	  analysis	  also	  revealed	  that	  the	  cardiac	  output	  was	  increased	  
after	   HFD	   in	   the	   OVX-­‐female	   compared	   with	   the	   sham-­‐female	   mice	   (Figure	   17F).	   The	  
cardiac	  output	  is	  the	  volume	  of	  blood	  ejected	  by	  the	  heart	  per	  minute. Although	  this	  effect	  
was	  small,	  our	  results	   indicate	  that	  hearts	  from	  OVX	  mice	  expel	  a	  higher	  volume	  of	  blood	  
per	  minute	  than	  the	  sham-­‐female	  mice	  despite	  a	  similar	  body	  weight.	  Moreover,	  the	  male	  
mice	   have	   a	   higher	   CO	   than	   the	   female,	   as	   the	   ejected	   volume	   necessary	   to	   properly	  
perfuse	  the	  organs	  is	  higher.	  	  
	  
 3.6 Pressure-­‐volume	  loop	  analysis	  
Very	   few	   studies	   evaluated	   gender	   differences	   in	   cardiac	   hemodynamics	   after	   high	   fat	  
feeding	  and	  described	  the	  effect	  of	  ovariectomy	  in	  this	  context.	  In	  our	  study,	  we	  analyzed	  
the	   influence	  of	  diet,	  gender	  and	  ovarian	  hormones	  on	  cardiac	  hemodynamic	  function	  by	  
the	  pressure-­‐volume	  loop	  (PVL)	  technique.	  The	  PVL	  technique	  is	  the	  gold	  standard	  method	  
to	   accurately	   measure	   real-­‐time	   pressure	   and	   volume	   in	   the	   ventricle.	   To	   induce	   an	  
additional	   stress	   to	   the	   heart,	   we	   infused	   the	   β-­‐adrenergic	   agonist	   dobutamine,	   which	  
normally	   increases	   contractility	   and	   heart	   rate	   enhancing	   the	   energy	   demand	   thereby	  
mimicking	   physical	   exercise.	   Table	   II	   (p.90)	   shows	   the	   results	   at	   baseline	   without	  
dobutamine	   infusion,	   whereas	   Table	   S	   IV	   shows	   the	   results	   at	   the	   highest	   dobutamine	  
concentration.	  Most	  hemodynamic	  parameters	  were	  neither	  influenced	  by	  the	  diet,	  nor	  by	  
the	   gender	   or	   ovariectomy.	   Concretely,	   the	   minimal	   and	   maximal	   pressure,	   end-­‐systolic	  
pressure,	   the	   relaxation	  constant	  Tau,	  and	   the	   rate	  of	  pressure	  development	  and	  decline	  
(dP/dt	  max	  and	  dP/dt	  min,	  respectively)	  were	  not	  changed.	  Some	  significant	  changes	  were	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Table	   I:	   Echocardiographic	   parameters	   of	  male,	   female	   and	  OVX	  mice	   fed	  with	   CTD	   or	  































*	  Symbol	  corresponds	  to	  CTD	  vs	  HFD,	  #	  symbol	  corresponds	  to	  OVX	  vs	  sham,	  $	  symbol	  corresponds	  
to	  male	  vs	  female.	  
	   	  
	 MALE	 FEMALE	 OVX	
Echocardiography,	
	21	wks	of	diet	
CTD	(n	=28)	 HFD	(n	=28)	 CTD	(n	=27)	 HFD	(n	=22)	 CTD	(n	=27)	 HFD	(n	=	32)	




	 	 	 	 	 	
						diastole	 0.87±0.09	 0.90±0.07	 0.77±0.07	 0.80±0.07	 0.74±0.07	 0.81±0.09*	
						systole	 1.24±0.16	 1.27±0.11	 1.10±0.13	 1.11±0.12	 1.06±0.12	 1.14±0.14	
Left	ventricular	free	wall	
thickness	(mm)	
	 	 	 	 	 	
						diastole	 0.74±0.08	 0.77±0.08	 0.66±0.07	 0.72±0.09	 0.66±0.07	 0.68±0.1	
						systole	 1.04±0.13	 1.08±0.16	 0.95±0.14	 1±0.16	 0.97±0.15	 1.01±0.15	
Left	ventricular	internal	
diameter	(mm)	
	 	 	 	 	 	
						diastole	 4.65±0.36	 4.47±0.32	 4.15±0.26	 4.03±0.27	 4.10±0.29	 4.11±0.33	
						systole	 3.53±0.38	 3.33±0.34	 3.12±0.34	 3.01±0.37	 3.04±0.31	 3.01±0.42	
Heart	rate	(beats/min)	 518±50	 529±63	 495±40	 498±37	 502±57	 507±42	
Left	ventricular	
anteroseptal	wall	
	 	 	 	 	 	
	 MALE	 FEMALE	 OVX	
Echocardiography,	
	21	wks	of	diet	
CTD	(n	=28)	 HFD	(n	=28)	 CTD	(n	=27)	 HFD	(n	=22)	 CTD	(n	=27)	 HFD	(n	=	32)	
Relative	wall	thickness,	d	
	 	 	 	 	 	
						diastole	 0.32±0.04	 0.34±0.04	 0.32±0.05	 0.359±0.06*	 0.32±0.03	 0.33±0.06	
						systole	 0.59±0.12	 0.66±0.15	 0.62±0.15	 0.68±0.18	 0.64±0.14	 0.69±0.18	
Ejection	fraction	(%)	 47.9±7.11	 50±6.72	 49.45±8.47	 50.5±8.72	 50.6±8.97	 52.8±8.58	
Fraction	of	shortening	(%)	 24.2±4.34	 25.4±4.27	 24.97±5.22	 25.6±5.37	 25.6±5.48	 27.05±5.51	
Cardiac	Output	(ml/min)	 25.4±1.15	 24.7±1.03	 18.32±0.62	 17.67±0.544	 18.956±1.083	 20.15±0.58#	
Left	ventricular	Volume	
(µl)	
	 	 	 	 	 	
						diastole	 101±0.09	 91.7±3.04*	 77.05±2.28	 72.04±2.46	 74.83±2.45	 75.7±2.59	
						systole	 53±2.51	 46.1±2.07	 29.28±2	 36.22±2.34	 36.95±1.80	 36.47±2.13	
E/A	 1.36±0.26	 1.34±0.24	 1.48±0.24	 1.35±0.18	 1.48±0.19	 1.34±0.14*	
E/E’	 20±1.38	 19.5±1.17	 19.3±1.14	 19.32±1.32	 21.37±1.32	 18.71±0.82	
Deceleration	(mm/s2)	 -27192±1262	 -23307±902	 -31155±2077	 -23858±1484**	 -26765±1208	 -26387±1074	
	 MALE	 FEMALE	 OVX	
Echocardiography,	
	21	wks	of	diet	
CTD	(n	=28)	 HFD	(n	=28)	 CTD	(n	=27)	 HFD	(n	=22)	 CTD	(n	=27)	 HFD	(n	=	32)	
E/A	 1.36±0. 	 1. 4±0.24	 .48±0.24	 1.35 0.18	 1.48±0.19	 1. 4±0.14*	
Body	weight	(g)	 33.1±2.84*	 47.1±4.1*	 26.2±5.52*	 33.9±5.8*	 27.57±4*	 39.43±5.34*#	
E/E’	 20±1.38	 19.5±1.17	 19.3±1.14	 19.32±1.32	 21.37±1.32	 18.71±0.82	
Deceleration	(mm/s2)	 -27192±1262	 -23307±902	 -31155±2077	 -23858±1484**	 -26765±1208	 -26387±1074	
Tei	index	 0.42±0.02	 0.54±0.03**	 0.46±0.02	 0.55±0.02	 0.449±0.028	 0.53±0.02	
LV	mass	(g)	 124±22.2	 120±17.91****	 87.1±7.94	 89.63±11.3****	 83.6±15.1	 90.9±16.5****	
						diastole	 0.74±0.08	 0.77±0.08	 0.66±0.07	 0.72±0.09	 0.66±0.07	 0.68±0.1	
						systole	 1.04±0.13	 1.08±0.16	 0.95±0.14	 1±0.16	 0.97±0.15	 1.01±0.15	
Left	ventricular	internal	
diameter	(mm)	
	 	 	 	 	 	
						diastole	 4.65±0.36	 4.47±0.32	 4.15±0.26	 4.03±0.27	 4.10±0.29	 4.11±0.33	
						systole	 3.53±0.38	 3.33±0.34	 3.12±0.34	 3.01±0.37	 3.04±0.31	 3.01±0.42	
Relative	wall	thickness,	d	 	 	 	 	 	 	
	
						diastole	 0.32±0.04	 0.34±0.04	 0.32±0.05	 0.359±0.06*	 0.32±0.03	 0.33±0.06	
						systole	 0.59±0.12	 0.66±0.15	 0.62±0.15	 0.68±0.18	 0.64±0.14	 0.69±0.18	
Ejection	fraction	(%)	 47.9±7.11	 50±6.72	 49.45±8.47	 50.5±8.72	 50.6±8.97	 52.8±8.58	
Fraction	of	shortening	(%)	 24.2±4.34	 25.4±4.27	 24.97±5.22	 25.6±5.37	 25.6±5.48	 27.05±5.51	
Cardiac	Output	(ml/min)	 25.4±1.15	 24.7±1.03	 18.32±0.62	 17.67±0.544	 18.956±1.083	 20.15±0.58#	
Left	ventricular	Volume	
(µl)	
	 	 	 	 	 	
						diastole	 101±0.09	 91.7±3.04*	 77.05±2.28	 72.04±2.46	 74.83±2.45	 75.7±2.59	
						systole	 53±2.51	 46.1±2.07	 29.28±2	 36.22±2.34	 36.95±1.80	 36.47±2.13	
E/A	 1.36±0.26	 1.34±0.24	 1.4 ±0.24	 1.35±0.18	 1.48±0.19	 1.34±0.14*	
E/E’	 20±1.38	 9.5 .17 1 .3±1.14	 19.32±1.3 	 21.37± 32	 18.71 .82	
Body	weight	(g)	 33.1±2.84*	 47.1±4.1*	 26.2±5.52*	 33.9±5.8*	 27.57±4*	 39.43±5.34*#	
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First	   of	   all,	   heart	   rates	  were	   somewhat	   different	   between	   the	   groups	   at	   baseline	   (p=ns).	  
Heart	   rates	  were	   increased	  upon	  administration	  of	   increasing	  doses	  of	  dobutamine	   in	  all	  
groups	  independently	  from	  the	  diet,	  as	  expected	  (Supplement,	  Figure	  S	  II).	  
	  
The	   end-­‐diastolic	   pressure	   (Ped)	   was	   affected	   by	   the	   HFD	   in	   the	   sham-­‐female	   group.	  
Indeed,	   the	   HFD-­‐fed	   sham-­‐female	   mice	   had	   lower	   end-­‐diastolic	   pressures	   than	   the	  
corresponding	  CTD-­‐fed	  mice	  at	  baseline	  (Figure	  18A)	  and	  at	  all	  dobutamine	  concentrations	  
(Figure	  19A	  shows	  the	  highest	  concentration).	  In	  contrast,	  the	  OVX-­‐female	  as	  well	  as	  male	  
mice	  exhibited	  similar	  pressures	  when	  fed	  with	  CTD	  or	  HFD	  (Figure	  18A).	  Interestingly,	  the	  
sham-­‐female	  mice	  presented	  slightly	  higher	  Ped	  values	  than	  the	  OVX-­‐females	  when	  fed	  the	  
CTD	   (p=0.1).	   As	   at	   the	   highest	   dose	   of	   dobutamine	   the	   sham-­‐female	   but	   not	   the	   OVX-­‐
female	   mice	   decreased	   their	   Ped	   in	   response	   to	   HFD,	   the	   sham-­‐female	   mice	   had	  
significantly	  lower	  pressures	  than	  the	  OVX	  mice	  under	  these	  stress	  conditions	  (Figure	  19A).	  
	  
Other	  hemodynamic	  parameters	  affected	  were	  the	  peak	  emptying	  and	  filling	  rates,	  dV/dt	  
min	  and	  dV/dt	  max,	  respectively.	  Both	  were	  decreased	  in	  the	  male	  after	  HFD	  compared	  to	  
CTD	   at	   baseline	   (Figure	   18B,	   C)	   and	   at	   the	   highest	   dose	   of	   dobutamine	   (Figure	   19B,	   C).	  
These	  effects	   of	  HFD	  were	  not	  observed	   in	   the	   females	  with	  or	  without	  OVX.	  Moreover,	  
these	  parameters	  were	  lower	  in	  female	  mice	  compared	  with	  male	  mice	  after	  CTD	  feeding,	  
indicating	   a	   gender	   difference.	   The	   peak-­‐filling	   rate	   is	   normally	   reached	   shortly	   after	  
opening	   of	   the	   mitral valves	   whereas	   the	   peak-­‐emptying	   rate	   happens	   when	   the	   LV	  
contracts	   actively.	   This	   observation	   therefore	   suggests	   that	   HFD	   reduces	   the	   contraction	  
and	  relaxation	  velocity	  in	  the	  male	  group.	  
	  
The	  end-­‐systolic	  pressure-­‐volume	  relationship	   (ESPVR)	   is	   the	   relationship	  between	  the	  LV	  
pressure	  and	  the	  volume	  when	  the	  heart	  reaches	  its	  maximum	  contraction.	  This	  parameter	  
gives	  an	  estimation	  of	  cardiac	  contractility	  capability	  as	  it	  describes	  how	  much	  pressure	  is	  
developed	  for	  a	  certain	  volume	  to	  be	  ejected.	  For	  example,	  when	  the	  ESPVR	   is	   increased	  
(steeper	  slope)	  the	  heart	  builds	  more	  pressure	  to	  pump	  out	  a	  certain	  amount	  of	  blood,	  and	  
this	   indicates	   an	   increased	   contractility.	   	   This	   value	  was	  not	   altered	  by	  diet	   or	   gender	   at	  
baseline	  and	  at	  the	  maximal	  infusion	  of	  dobutamine	  (Figure	  18D	  and	  19D).	  A	  small	  gender	  
difference	  was	  observed	  in	  the	  hearts	  from	  HFD-­‐fed	  mice,	  with	  the	  females	  having	  higher	  
values	  that	  the	  males	  (p=0.059)	  at	  high	  dobutamine	  concentrations.	  As	  for	  the	  end-­‐diastolic	  
pressure-­‐volume	  relationship	  (EDPVR),	  which	  characterizes	  the	  compliance	  of	  the	  heart:	  at	  
baseline	  the	  HFD	  tended	  to	  increase	  it	  in	  the	  OVX	  group	  (Figure	  18E,	  p=0.08),	  suggestive	  of	  
a	   less	   stiff	   or	   a	   more	   dilated	   heart.	   On	   the	   other	   hand,	   after	   dobutamine	   infusion	   the	  
compliance	   was	   not	   affected	   by	   gender,	   OVX	   or	   diet	   (Figure	   19E).	   To	   summarize,	   HFD	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decreases	  emptying	  and	   filling	  peak	   rates	  only	   in	  male	  mice,	   suggesting	   that	  male	  hearts	  
need	  more	  time	  to	  relax	  and	  contract	  and	  are	  more	  susceptible	  to	  this	  diet-­‐induced	  effect	  
than	   female	   hearts.	   On	   the	   other	   hand,	   HFD	   decreases	   end-­‐diastolic	   pressures	   in	   sham-­‐
female	   and	   not	   in	   the	   OVX-­‐female	  mice,	   whereas	   after	   dobutamine	   stress	   HFD-­‐fed	   OVX	  


























Figure	   18:	   Baseline	   LV	   hemodynamic	   parameters	   recorded	   with	   PVL	   method	   in	   male,	  
female	  and	  OVX	  mice	  fed	  with	  CTD	  or	  HFD	  for	  22	  wks.	  
A:	  end-­‐diastolic	  pressure	  (Ped);	  B:	  dV/dt	  min	   is	  the	  emptying	  peak	  rate;	  C:	  dV/dt	  max	   is	  the	  filling	  
peak	   rate;	   D:	   the	   slope	   of	   the	   end-­‐systolic	   pressure-­‐volume	   relationship	   (ESPVR)	   is	   a	  measure	   of	  
contractility;	   E:	   the	   1/slope	   end-­‐diastolic	   pressure-­‐volume	   relationship	   (EDPVR)	   is	   a	   measure	   of	  
compliance.	   Results	   are	   presented	   with	   the	   median,	   whiskers	   show	   the	   min	   and	   max	   values.	   *	  
symbol	  corresponds	  to	  CTD	  vs	  HFD,	  #	  symbol	  corresponds	  to	  OVX	  vs	  sham,	  $	  symbol	  corresponds	  to	  




























































































































Figure	  19:	  Hemodynamic	  parameters	  of	  male,	   female	   and	  OVX	  mice	   recorded	  with	   the	  
PVL	  method	  after	  21	  wks	  of	  diet	  with	  maximal	  dobutamine	  infusion.	  
A:	  end-­‐diastolic	  pressure	   (Ped);	  B:	  dV/dt	  min	   is	   the	  emptying	  peak	   rate;	  C:dV/dt	  max	   is	   the	   filling	  
peak	   rate;	   D:	   the	   slope	   end-­‐systolic	   pressure-­‐volume	   relationship	   (ESPVR)	   is	   a	   measure	   of	  
contractility;	   E:	   the	   1/slope	   end-­‐diastolic	   pressure-­‐volume	   relationship	   (EDPVR)	   is	   a	   measure	   of	  
compliance.	   Results	   are	   presented	   with	   the	   median,	   whiskers	   show	   the	   min	   and	   max	   values.	   *	  
symbol	  corresponds	  to	  CTD	  vs	  HFD,	  #	  symbol	  corresponds	  to	  OVX	  vs	  sham,	  $	  symbol	  corresponds	  to	  
male	  vs	  female.	  N=7-­‐11.	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Table	  II:	  Baseline	  LV	  hemodynamic	  parameters	  of	  male,	  female,	  and	  OVX	  mice	  recorded	  
with	  the	  PV	  loop	  method	  after	  21	  wks	  of	  diet	  of	  CTD	  and	  HFD.	  
	  
	  
*	  symbol	  corresponds	  to	  CTD	  vs	  HFD,	  $	  symbol	  corresponds	  to	  male	  vs	  female.	  
	  
	   	  
	 Male	 Female		 OVX	
LV	Hemodynamics,	Baseline	 CTD	(n	=8)	 HFD	(n	=8)	 CTD	(n	=8)	 HFD	(n	=7)	 CTD	(n	=8)	 HFD	(n	=	9)	
Rate	of	pressure	(mmHg/sec)	 	 	 	 	 	 	
						Development,	dP/dt	max	 7553±738	 6724±946	 5580±790	 6006±708	 7932±1216	 6986±670	








40.1±7.06	 60.7±17.5	 68.4±17.9	 65.2±12.7	 52.6±48.4	 148±43.7	
End-systolic	pressure-volume	
relationship	(ESPVR),	slope	
7.24±1.14	 5.83±1.39	 5.34±1.08	 6.34±1.2	 4.47±0.62	 5.92±0.94	
Rate	of	pressure	(mmHg/sec)	 	 	 	 	 	 	
						Development,	dP/dt	max	 7553±738	 6724±946	 5580±790	 6006±708	 7932±1216	 6986±670	








40.1±7.06	 60.7±17.5	 68.4±17.9	 65.2±12.7	 52.6±48.4	 148±43.7	
Peak	rate	(µL/sec)	 	 	 	 	 	 	
	
						diastole	 0.32±0.04	 0.34±0.04	 0.32±0.05	 0.359±0.06*	 0.32±0.03	 0.33±0.06	
						systole	 0.59±0.12	 0.66±0.15	 0.62±0.15	 0.68±0.18	 0.64±0.14	 0.69±0.18	
Ejection	fraction	(%)	 47.9±7.11	 50±6.72	 49.45±8.47	 50.5±8.72	 50.6±8.97	 52.8±8.58	
Fraction	of	shortening	(%)	 24.2±4.34	 25.4±4.27	 24.97±5.22	 25.6±5.37	 25.6±5.48	 27.05±5.51	
Cardiac	Output	(ml/min)	 25.4±1.15	 24.7±1.03	 18.32±0.62	 17.67±0.544	 18.956±1.083	 20.15±0.58#	
Left	ve tricular	Volume	
(µl)	
	 	 	 	 	 	
						diastole	 101±0.09	 91.7±3.04*	 77.05±2.28	 72.04±2.46	 74.83±2.45	 75.7±2.59	
						systole	 53±2.51	 46.1±2.07	 29.28±2	 36.22±2.34	 36.95±1.80	 36.47±2.13	
E/A	 1.36±0.26	 1.34±0.24	 1.48±0.24	 1.35±0.18	 1.48±0.19	 1.34±0.1 *	
E/E’	 20±1.38	 19.5±1.17	 19.3±1.14	 19.32±1.32	 21.37±1.32	 18.71±0.82	
Body	weight	(g)	 33.1±2.84*	 47.1±4.1*	 26.2±5.52*	 33.9±5.8*	 27.57±4*	 39.43±5.34*#	
! Male% Female%% OVX%
LV%Hemodynamics,%Baseline% CTD!(n!=8)! HFD!(n!=8)! CTD!(n!=8)! HFD!(n!=7)! CTD!(n!=8)! HFD!(n!=!9)!
Heart!rate!(beats/min)! 527±13! 478±19! 438±24! 485±17! 468±21! 480±7!
Volume%(µl)% ! ! ! ! ! !
!!!!!End@diastole,!Ved! 19.5±2.14! 15.9±2.43! 16.8±2.25! 14±1.96! 14.2±1.98! 14.1±2.5!
!!!!!End@systole,!Ves! 7.98±0.88! 7.78±0.86! 8.79±1.52! 5.41±1.08! 6.51±1.46! 6.16±1.62!
!!!!!Minimum!Volume,!Vmin! 7.55±0.88! 8.9±1.75! 8.78±1.65! 5.07±0.99! 6.12±1.36! 5.83±1.31!
!!!!!Maximal!Volume,!Vmax! 20.2±2.08! 16.9±2.28! 18.2±2.44! 15.3±1.99! 15.5±1.96! 14.6±2.14!
Pressure%(mmHg)% ! ! ! ! ! !
!!!!!!End@diastole,!Ped! 5.07±0.5! 5.67±0.46! 6.04±0.62! 4.56±0.23! 4.85±0.3! 4.82±0.35!
!!!!!!End@systole,!Pes! 71.7±5.07! 71.6±4.36! 65.6±5.02! 60±4.4! 70.8±3.83! 68.5±3.82!
!!!!!!Minimum!Pressure,!Pmin! 2.16±0.6 ! 3.37±1.1! 3.85±0.54! 2.41±0.28! 2.12±0.51! 2.26±0.31!
!!!!!!Maximum!Pressure,!Pmax! 79.4±4.94! 78.6±4.87! 73.3±4.68! 71.2±3.7! 78.6±4.83! 77±3.7!
Peak%rate%(µL/sec)% ! ! ! ! ! !
!!!!!!Filling,!dV/dt!max!! 662±47.5
$% 338±28.2***% 449±47.5! 509±78.46! 516±84.2! 403±44.7!
!!!!!!Emptying,!dV/dt!min! J544±54.2$% J366±35.7*% @354±45.4! @419±49.6! @369±49.4! @339±40.9!
Rate%of%pressure%(mmHg/sec)% ! ! ! ! ! !
!!!!!!Development,!dP/dt!max! 7553±738! 6724±946! 5580±790! 6006±708! 7932±1216! 6986±670!
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Figure	  20:	  Oil	  Red	  O	  staining	  to	  detect	  neutral	  lipids	  on	  heart	  sections.	  
Cryosections	  of	  the	  hearts	  of	  male,	  female	  and	  OVX	  mice	  (sacrificed	  at	  22	  wks)	  were	  stained	  with	  
Oil	  Red	  O	  to	  detect	  neutral	  lipids	  (red)	  and	  counterstained	  with	  hematoxylin	  to	  reveal	  nuclei	  (dark	  
blue).	  A	  representative	  picture	  of	  each	  condition	  is	  shown.	  Magnification	  x40;	  N=3.	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 3.7 Analysis	  of	  cardiac	  lipid	  deposition	  and	  fibrosis	  	  
Long-­‐term	   high	   fat	   diet	   feeding	   may	   lead	   to	   cardiac	   lipid	   accumulation	   and	   lipotoxicity,	  
which	  contributes	  to	  cardiac	  dysfunction.	  To	  evaluate	  the	  impact	  of	  the	  diets	  that	  we	  used	  
on	   cardiac	   lipids,	   Oil	   Red	   O	   staining	   was	   performed	   to	   reveal	   the	   neutral	   lipids	   (in	   red)	  
(Figure	  20).	  Our	  results	  showed	  that	  the	  HFD	  increased	  the	  number	  of	  droplets	  in	  the	  male,	  
sham-­‐	  and	  OVX-­‐female	  mice.	  However,	  this	  increase	  was	  not	  equal	  in	  the	  3	  groups.	  Indeed,	  
the	  accumulation	  of	  lipids	  induced	  by	  HFD	  was	  more	  pronounced	  in	  the	  male	  group	  where	  
the	   droplets	   appeared	   numerous	   and	   of	   bigger	   size	   compared	   to	   the	   female	   groups.	  
Moreover,	   the	  OVX-­‐female	  mice	  have	  a	  higher	  number	  of	  droplets	  than	  the	  sham-­‐female	  
mice	  after	  HFD	  as	  well	  as	  CTD.	  These	  observations	  were	  confirmed	  by	  transmission	  electron	  
microscopy	   (TEM,	   Supplement,	   Figure	   S	   III).	   Thus,	   the	   absence	   of	   ovarian	   hormones	  
increases	  the	  accumulation	  of	  lipid	  droplets	  in	  the	  heart	  of	  females	  irrespective	  of	  the	  diet.	  
In	  contrast,	  the	  males	  have	  larger	  lipid	  droplets	  than	  the	  females	  for	  both	  diets.	  It	  appears	  
that	  under	  CTD	  conditions,	  the	  droplets	  are	  fewer	  in	  the	  male	  mice	  but	  an	  opposite	  effect	  
was	  observed	  when	   fed	  with	  HFD.	  Along	  with	  our	  earlier	  observation	  of	  decreased	   filling	  
and	  emptying	   LV	   rates,	   these	  data	   strengthen	   the	   view	   that	  males	   are	  more	   sensitive	   to	  
HFD-­‐induced	   cardiac	   effects	   than	   females.	   A	   quantification	   of	   the	   lipid	   droplets	   is	   still	  
necessary	   to	  confirm	  the	  differences	  observed	  between	  conditions.	  A	   technical	   limitation	  
for	  proper	  quantification	  is	  that	  the	  pictures	  from	  the	  Oil	  Red	  O	  staining	  present	  some	  dirt	  
particles	  coming	  from	  the	  oil	   red	  O	  powder	  despite	  multiple	  filtrations	  steps.	  These	  small	  
particles	  would	  fake	  the	  quantification,	  as	  they	  would	  be	  counted	  as	  lipid	  droplets.	  
	  
As	  fibrosis	  is	  an	  important	  trigger	  for	  cardiac	  dysfunction	  development,	  we	  analyzed	  gene	  
expression	  of	  collagen	  I	  and	  III	   in	  our	  cardiac	  tissues.	  These	  are	  the	  two	  collagen	  isoforms	  
that	   participate	   in	   cardiac	   fibrosis	   and	   increase	  myocardial	   stiffness	   by	   contributing	   to	   a	  
more	  elastic	  extracellular	  matrix.353,354	  Although	  small	  decreases	  of	  collagen	  I	  and	  III	  mRNA	  
were	   observed	   in	   the	  HFD-­‐fed	  OVX-­‐females	   compared	  with	   the	   CTD	   group	   (Supplement,	  
Figure	  S	  IVA,	  B),	  none	  of	  the	  differences	  reached	  significance.	  Increased	  ratios	  of	  type	  I	  to	  
type	   III	   collagen	  have	  been	   reported	   in	   chronic	   congestive	   heart	   failure355	   and	   end-­‐stage	  
dilated	  cardiomyopathy.356	  This	  ratio	  was	  however	  not	  changed	  in	  our	  mouse	  model;	  only	  a	  
slight	   increase	  was	  visible	   in	   the	  OVX-­‐female	  mice	   (Supplement,	  Figure	  S	   IVC).	  To	   further	  
investigate	  fibrosis,	  we	  performed	  Picrosirius	  Red	  staining	  (Figure	  21).	  The	  results	  did	  not	  
show	  any	  striking	  differences	  between	  the	  three	  groups.	  Nevertheless,	  the	  HFD	  seemed	  to	  
increase	  the	  intensity	  of	  the	  staining	  in	  all	  groups.	  Figure	  21	  visualizes	  that	  the	  OVX-­‐female	  
mice	  have	  higher	  staining	  after	  CTD	  and	  that	   the	  HFD	  feeding	  enhances	  this	  effect.	  Thus,	  
our	   results	   suggest	   that	   HFD	   increases	   the	   collagen	   content	   in	   the	   heart	   and	   that	   the	  
absence	  of	  ovarian	  hormones	  by	   itself	   is	   increasing	   it	  as	  well.	   It	  also	  appeared	  that	  more	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collagen	  fibers	  were	  detected	  in	  the	  male	  mice	  compared	  to	  the	  sham-­‐female	  mice.	  These	  
results	   still	   require	   a	   proper	   quantification	   and	  more	  mice	   need	   to	   be	   analyzed	   to	   draw	  
conclusions.	  The	  Picrosirius	  Red	  pictures	  quantification	  was	  problematic,	  as	  the	  automatic	  
quantification	   planned	  would	   not	   discriminate	   between	   collagen	   surrounding	   the	   vessels	  




























Figure	  21:	  Picrosirius	  Red	  staining	  to	  detect	  collagen	  on	  heart	  sections.	  
Cryosections	  of	  the	  hearts	  of	  male,	  female	  and	  OVX	  mice	  (sacrificed	  at	  22	  wks)	  were	  stained	  with	  
Picrosirius	  Red	  to	  detect	  collagen	  fibers	  (red).	  A	  representative	  picture	  of	  each	  condition	  is	  shown.	  
Magnification	  x10;	  N=3.	  
	  






















































Figure	   22:	  Quantitative	   real-­‐time	   PCR	   and	  Western-­‐blot	   analysis	   of	   genes	   and	   proteins	  
involved	  in	  inflammation.	  
Cardiac	  muscles	  from	  male,	  female	  and	  OVX	  mice	  fed	  with	  CTD	  or	  HFD	  for	  22	  wks	  were	  used	  to	  
extract	  mRNA	  and	  protein	  to	  evaluate	  genes	  and	  proteins	  involved	  in	  inflammation.	  Representative	  
examples	  of	  Western	  blots	  (bottom)	  and	  quantification	  normalized	  to	  the	  corresponding	  control	  
(top)	  are	  shown.	  The	  bands	  visible	  for	  each	  protein	  belong	  to	  the	  same	  membrane.	  A:	  N=5-­‐7;	  B,	  C:	  
N=6-­‐8;	  D,	  E:	  N=8-­‐10.	  	  Results	  are	  presented	  with	  the	  median,	  whiskers	  show	  the	  min	  and	  max	  
values.	  *	  symbol	  corresponds	  to	  CTD	  vs	  HFD,	  #	  symbol	  corresponds	  to	  OVX	  vs	  sham,	  $	  symbol	  
corresponds	  to	  male	  vs	  female.	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 3.8 Inflammatory	  signaling	  molecules	  and	  cytokines	  
Inflammation	   is	  one	  of	   the	   first	  mechanisms	   that	  our	  organism	  sets	  up	   to	  defend	  against	  
pathogens	  or	  other	  stress	  stimuli.	  Chronic	   inflammation	  can	  become	  deleterious	  and	  lead	  
to	  irreversible	  fibrosis.	  The	  onset	  of	  this	  cellular	  mechanism	  is	  characteristic	  of	  hearts	  that	  
in	  the	  long	  term	  may	  fail.	  We	  had	  hypothesized	  that	  chronic	  inflammation	  is	  present	  after	  
HFD	  feeding,	  but	  we	  did	  not	  yet	  find	  any	  detectable	  effects	  on	  cardiac	  fibrosis	  at	  this	  stage.	  
Indeed,	  we	  were	  not	   able	   to	  draw	  a	   strong	   conclusion	  about	   the	  Picrosirius	  Red	   staining	  
(Figure	  21),	  similarly	  collagen	  expression	  was	  not	  modified	  by	  the	  HFD	  (Supplement,	  Figure	  
S	  IV).	  
	  
To	   further	   evaluate	   whether	   diet,	   gender	   or	   ovarian	   hormones	   had	   any	   effect	   at	   all	   on	  
cardiac	   inflammation,	   we	   analyzed	   relevant	   signaling	   molecules	   and	   pro-­‐inflammatory	  
cytokines	  at	  the	  protein	  or	  RNA	  level,	  including	  NF-­‐κB,	  IκBα,	  TNFα,	  and	  IL-­‐6.	  The	  protein	  NF-­‐
κB	   is	   an	   important	   regulator	   of	   inflammation.	   In	   the	   unstimulated	   state,	   NF-­‐κB	   is	  
sequestered	   in	  the	  cytoplasm	  by	   IκBα	   inhibitory	  proteins.357,358	  Upon	  stimulation	  by	  TNFα	  
or	   other	   inflammatory	   signaling	   molecules,	   the	   kinase	   IKKB	   is	   activated	   and	   will	  
phosphorylate	   IκBα,	   which	   in	   turn	   will	   release	   its	   inhibitory	   effect	   on	   NF-­‐κB	   p65.	   The	  
proteasome/ubiquitin	  pathway	  will	  degrade	   IκBα	  and	  NF-­‐κB	  will	  migrate	   into	   the	  nucleus	  
where	   it	   will	   activate	   the	   transcription	   of	   target	   proteins	   involved	   in	   inflammation,359-­‐361	  
such	  as	  TNFα.	  
	  
Figure	   22A	   shows	   that	   HFD	   decreased	   IκBα	   expression	   in	   the	   sham-­‐female	   group	  
(p=0.0042)	   and	  not	   in	   the	  OVX-­‐female	   and	  male	   groups.	   It	   has	   been	   reported	   that	   upon	  
stimulation	   with	   TNFα,	   NF-­‐κB	   phosphorylation	   on	   the	   p65	   subunit	   at	   S536	   is	   increased	  
resulting	   in	   the	   onset	   of	   the	   inflammation	   process.362,363	  We	   observed	   that	   HFD	   did	   not	  
modify	   NF-­‐κB	   protein	   expression	   although	   a	   slight	   increase	  was	   noticeable	   in	   the	   sham-­‐
female	  mice	   (p=0.08,	   Figure	   22B).	   As	   for	   the	   total	   form	  of	  NF-­‐κB,	   the	   sham-­‐females	   had	  
significantly	   lower	   levels	   than	   the	   males	   when	   fed	   with	   CTD	   (p=0.019),	   whereas	   HFD	  
increased	  NF-­‐κB	  in	  the	  OVX-­‐female	  (p=0.053,	  Figure	  22C).	  	  
	  
We	   also	   evaluated	   the	   cardiac	   mRNA	   content	   of	   IL-­‐6	   and	   TNFα.	   Similar	   to	   NF-­‐κB,	   HFD	  
slightly	  enhanced	   the	   level	  of	   TNFα	   in	   the	   female	  groups	   (p=0.018,	  post-­‐hoc:	  p=0.18	  and	  
p=0.08	  for	  sham	  and	  OVX-­‐female,	  respectively)	  (Figure	  22D).	  IL-­‐6	  mRNA	  expression	  was	  not	  
changed	  in	  our	  groups,	  only	  a	  slight	  increase	  was	  noticeable	  in	  the	  OVX-­‐female	  compared	  
to	   the	   sham-­‐female	   mice	   after	   HFD	   feeding	   (p=0.06)	   (Figure	   22E).	   Together,	   these	  
observations	   indicate	   that	   female	  have	   lower	  expression	  of	   the	   inflammatory	  NF-­‐κB	   than	  
male	   mice	   and	   also	   that	   the	   HFD	   increases	   NF-­‐κB	   and	   TNFα	   in	   the	   OVX-­‐female	   mice,	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suggesting	  that	  the	  absence	  of	  ovarian	  hormones	  could	  accentuate	  the	  inflammatory	  status	  
after	  HFD.	  
	  
Additionally,	   we	   performed	   an	   immunofluorescent	   staining	   of	  macrophages	   using	  Mac-­‐2	  
antibody	  (Supplement,	  Figure	  S	  VI).	  We	  observed	  that	  HFD	  feeding	  increased	  macrophages	  
densities	  in	  all	  groups	  with	  a	  more	  accentuated	  effect	  in	  the	  OVX-­‐female	  and	  male	  group.	  
Under	   CTD	   conditions,	   no	   striking	   differences	   were	   observed	   between	   the	   groups.	   A	  
quantification	  of	  Mac-­‐2	  positive	   cells	   should	   still	  be	  done	   to	   reliably	  evaluate	   this	   sign	  of	  
inflammation	   in	   our	  model.	   To	   further	   test	   potential	   differences	   in	   cardiac	   inflammatory	  
responses,	   we	   stained	   cardiac	   cryosections	   for	   TGF-­‐β1,	   an	   important	   player	   in	  
inflammation,	   fibrosis	   and	   hypertrophy.	   As	   shown	   in	   Figure	   S	   VII,	   the	   TGF-­‐β1	   signal	  was	  






















Figure	  23:	  Quantitative	  real-­‐time	  PCR	  analysis	  of	  genes	  involved	  in	  cardiac	  stress.	  
Cardiac	  muscles	   from	  male,	   female	   and	  OVX	  mice	   fed	  with	  CTD	  or	  HFD	   for	   22	  wks	  were	  used	   to	  
extract	  mRNA	   evaluate	   genes	   involved	   in	   cardiac	   stress.	   Results	   are	   presented	  with	   the	  median,	  
whiskers	  show	  the	  min	  and	  max	  values.	  *	  symbol	  corresponds	  to	  CTD	  vs	  HFD,	  #	  symbol	  corresponds	  
to	  OVX	  vs	  sham,	  $	  symbol	  corresponds	  to	  male	  vs	  female.	  N=8-­‐10.	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 3.9 Stress	  markers	  
In	   a	   failing	   or	   hypertrophied	   heart	   certain	   cellular	   markers	   called	   stress	   markers	   are	  
upregulated.	  For	  instance,	  a	  shift	  from	  the	  adult	  form	  of	  MHC,	  the	  α-­‐MHC,	  toward	  the	  fetal	  
form	   β-­‐MHC,	   as	   well	   as	   increased	   levels	   of	   ANP	   and	   BNP,	   normally	   involved	   in	   arterial	  
pressure	   reduction,	  have	  been	  described	   in	  heart	   failure.	  To	  evaluate	   the	   level	  of	  cardiac	  
stress,	  we	  measured	  gene	  expression	  of	  β-­‐MHC,	  ANP	  and	  BNP.	  Figure	  23A	  shows	  that	  after	  
HFD,	  OVX	  caused	  slightly	  higher	  β-­‐MHC	  expression	  levels	  in	  females	  (p=0.07).	  Interestingly,	  
ANP	  mRNA	  was	  decreased	  in	  both	  female	  groups	  after	  HFD,	  and	  the	  male	  had	  slightly	  lower	  
ANP	   mRNA	   than	   the	   sham-­‐female	   (p=0.09)	   under	   CTD	   conditions	   (Figure	   23B).	  
Furthermore,	  BNP	  mRNA	   showed	  a	  decrease	  due	   to	   the	  HFD	   in	   the	  male	   group	   (p=0.11)	  
whereas	  the	  OVX-­‐	  had	  lower	  BNP	  than	  the	  sham-­‐female	  group	  (p=0.058,	  Figure	  23C).	  We	  
observed	  that	  the	  HFD	  is	  decreasing	  the	  stress	  marker	  ANP	  in	  female	  and	  BNP	  in	  male.	  A	  
question	  that	  must	  to	  be	  asked	  is	  if	  these	  changes	  in	  mRNA	  expression	  are	  direct	  effects	  of	  
the	  HFD	  and	  in	  this	  case	  HFD	  would	  have	  a	  positive	  effect	  by	  reducing	  these	  stress	  markers;	  
or	  if	  these	  effects	  are	  a	  consequence	  of	  long-­‐term	  HFD	  feeding,	  and	  what	  we	  observe	  is	  a	  
compensatory	   effect	   aiming	   to	   decrease	   the	   level	   of	   the	   cardiac	   stress.	   In	   this	   regard,	   it	  
would	  be	  interesting	  to	  test	  stress	  markers	  at	  an	  earlier	  time	  point.	  
	  
 3.10 Insulin/Akt/mTOR	  signaling	  pathways	  
With	   our	   mouse	   model,	   we	   aimed	   to	   mimic	   cardiometabolic	   disease	   and	   indeed,	   we	  
observed	   specific	   alterations	   in	   cardiac	   geometry	   and	   function	   accompanied	   by	   systemic	  
metabolic	   changes.	   The	  metabolic	   changes	  were	   induced	   primarily	   by	   the	   diet,	   and	   to	   a	  
lesser	  extent	  by	  the	  absence	  of	  estrogen.	  The	  next	  question	  we	  wanted	  to	  answer	  is	  which	  
cardiac	  molecular	  mechanisms	  are	  affected	  in	  our	  model.	  Multiple	  pathways	  are	  thought	  to	  
be	   actively	   involved	   in	   the	   pathophysiology	   of	   cardiometabolic	   disease.	   Insulin-­‐induced	  
Akt/mTOR	   signaling	   has	   been	   implicated	   in	   glucose,	   lipid	   and	   protein	   metabolism.	   This	  
pathway	  regulates	  different	  processes	  including	  autophagy,	  inflammation	  and	  fibrosis,	  each	  
of	  which	  may	  contribute	  to	  cardiac	  failure	  in	  the	  long-­‐term.	  
	  
We	  analyzed	  different	  components	  of	  the	  insulin/Akt/mTOR	  pathway.	  IRS-­‐1	  is	  an	  important	  
adapter	   protein	   that	   transmits	   the	   signal	   from	   insulin	   and	   IGF-­‐1	   receptors	   to	   PI3K/Akt.	  
Different	  players	   interact	  with	   IRS-­‐1	  to	  regulate	  downstream	  signal	  transduction	  proteins.	  
We	   found	  effects	  on	   total	   IRS-­‐1	   in	  our	  model	  as	   follows.	  OVX	  mice	  had	   lower	   total	   IRS-­‐1	  
protein	  than	  sham-­‐female	  mice	  when	  fed	  with	  CTD	  and	  HFD	  slightly	  increased	  IRS-­‐1	  protein	  
in	  the	  OVX	  mice	  (Figure	  24B).	  Notably,	  the	  HFD	  feeding	  increased	  IRS-­‐1	  protein	  in	  the	  male,	  
the	  OVX-­‐female,	   but	   not	   in	   the	   sham-­‐female	   group.	   Consistently,	   sham-­‐female	  mice	   had	  
less	  IRS-­‐1	  protein	  than	  male	  after	  HFD	  (Figure	  24B,	  p=0.0002).	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Figure	  24:	  Western-­‐blot	  analysis	  of	  the	  insulin/Akt/mTOR	  pathway	  (1).	  
Cardiac	  proteins	  from	  male,	  female	  and	  OVX	  mice	  fed	  with	  CTD	  or	  HFD	  for	  22	  wks	  were	  subjected	  
to	   SDS-­‐PAGE	   and	   probed	   with	   antibodies	   to	   proteins	   as	   indicated.	   Representative	   examples	   of	  
Western	   blots	   (bottom)	   and	   quantification	   normalized	   to	   the	   corresponding	   control	   (top)	   are	  
shown.	   The	  bands	   visible	   for	   each	  protein	   belong	   to	   the	   same	  membrane.	   Results	   are	   presented	  
with	  the	  median,	  whiskers	  show	  the	  min	  and	  max	  values.	  *	  symbol	  corresponds	  to	  CTD	  vs	  HFD,	  #	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Distinct	  phosphorylation	  sites	  on	  IRS-­‐1	  are	  known	  to	  have	  specific	  effects.	  mTOR/p70-­‐S6K	  
activation	  is	  key	  in	  PI3K/Akt	  signaling	  because	  it	  causes	  phosphorylates	  of	  IRS-­‐1	  at	  S636-­‐639	  
to	   inhibit	   its	   activity	   and	   decrease	   Akt	   signaling	   as	   a	   negative	   feedback	   loop.	   A	   strong	  
gender	   difference	   appeared	   here:	   in	   sham-­‐female	   mice,	   HFD	   feeding	   decreased	   IRS-­‐1	  
phosphorylation,	  whereas	   in	  male	  mice	   HFD	   had	   the	   inverse	   effect	   as	   it	   increased	   IRS-­‐1	  
phosphorylation.	   Consistently,	   HFD-­‐fed	   males	   had	   higher	   IRS-­‐1-­‐pS636-­‐639	   than	   sham-­‐
females.	  On	   the	  other	  hand,	   the	  sham-­‐female	  had	  higher	   IRS-­‐1-­‐pS636-­‐639	   than	   the	  OVX-­‐
female	  mice	  under	  CTD	  conditions	  (Figure	  24A).	  
	  
Association	  of	  IRS-­‐1	  with	  the	  p85α	  domain	  of	  PI3-­‐kinase	  leads,	  through	  PDK1,	  to	  activation	  
of	   Akt.	   Figure	   24C	   shows	   that	   despite	   the	   above-­‐described	   differences	   in	   total	   IRS-­‐1,	  
phosphorylation	  of	  Akt	  at	  T308	  stayed	  unchanged,	  suggesting	  that	  Akt	  activity	  is	  not	  altered	  
in	  our	  experimental	  groups.	  Concerning	  Akt	  phosphorylation	  at	   the	   site	  S473,	   the	   female	  
mice	  had	  higher	  phosphorylation	  of	  this	  site	  than	  the	  male	  mice	  after	  CTD	  feeding	  (Figure	  
24D).	   It	   is	   of	   note	   that	   overall	   the	   HFD	   decreased	   total	   Akt	   protein,	   although	   post-­‐hoc	  
testing	  did	  not	   reveal	   significance	   for	   the	  males	   (p=0.2).	  Moreover,	  male	  mice	  had	   lower	  
Akt	  protein	  levels	  than	  both	  female	  groups	  when	  fed	  with	  CTD	  (p=0.0015)	  (Figure	  24E).	  
	  
To	   analyze	   whether	   the	   observed	   lower	   total	   Akt	   levels	   had	   consequences	   for	   its	  
downstream	   targets	  we	   tested	   GSK3β	   (Supplement,	   Figure	   S	   VIIA	   and	   B).	   This	   protein	   is	  
involved	  in	  apoptosis	  and	  glycogen	  metabolism	  by	  inhibiting	  glycogen	  synthase.	  Akt	  inhibits	  
GSK3β	  activity	  by	  phosphorylating	  it	  at	  S9.	  HFD	  slightly	  increased	  GSK3β-­‐pS9	  in	  the	  female	  
whereas	   no	   effects	   were	   observed	   in	   the	   male	   group.	   Total	   GSK3β	   followed	   the	   same	  
pattern,	   as	   the	   HFD	   slightly	   increased	   it	   in	   both	   female	   groups	   (p=0.12,	   p=0.18	   for	   the	  
sham-­‐	  and	  OVX-­‐female,	  respectively),	  but	  did	  not	  affect	  it	  in	  the	  male	  group.	  Nonetheless,	  
these	   effects	   did	   not	   reach	   statistical	   significance.	   Thus,	   the	   reduced	   Akt	   levels	   that	   we	  
found	   in	   the	   HFD	   groups	   were	   not	   paralleled	   by	   reduced	   GSK3β	   phosphorylation,	  
suggesting	  that	  this	  target	  of	  Akt	  is	  not	  playing	  a	  role	  in	  our	  model.	  
	  
Another	   target	   of	   Akt	   is	   Akt	   substrate	   160	   (AS160).	   Upon	   insulin	   stimulation,	   AS160	   is	  
phosphorylated	  and	  triggers	   the	  translocation	  of	   the	  glucose	  transporter	  GLUT4	   from	  the	  
cytoplasm	  to	  the	  membrane	  to	  allow	  glucose	  entry	   into	  the	  cell	  and	  be	  processed	  during	  
glycolysis.	  Figure	  24F	  shows	  that	  AS160	  phosphorylation	  at	  T642	   is	  not	  affected	   in	  any	  of	  
our	  experimental	  groups.	  In	  contrast,	  HFD	  increased	  total	  AS160	  protein	  in	  the	  OVX-­‐female	  
group	   (Figure	   24G),	   which	   could	   be	   linked	   to	   the	   observation	   that	   these	   mice	   have	  
decreased	  IRS-­‐1	  and	  Akt	  protein,	  which	  both	  participate	  in	  the	  insulin	  pathway	  activity	  and	  
lead	  to	  GLUT4	  translocation	  through	  AS160.	  Our	  results	  suggest	  that	  AS160	  is	  significantly	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Figure	  25:	  Western-­‐blot	  analysis	  of	  the	  insulin/Akt/mTOR	  pathway	  (2).	  
Cardiac	  muscle	  proteins	  hearts	   from	  male,	   female	  and	  OVX	  mice	   fed	  with	  CTD	  or	  HFD	  for	  22	  wks	  
were	  subjected	  to	  SDS-­‐PAGE	  and	  probed	  with	  antibodies	   to	  protein	   involved	   in	   insulin/Akt/mTOR	  
pathway.	  Results	  are	  presented	  with	  the	  median,	  whiskers	  show	  the	  min	  and	  max	  values.	  *	  symbol	  
corresponds	  to	  CTD	  vs	  HFD,	  #	  symbol	  corresponds	  to	  OVX	  vs	  sham,	  $	  symbol	  corresponds	  to	  male	  vs	  
female.	  N=6-­‐8.	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increased	   to	   alleviate	   the	   decreases	   in	   IRS-­‐1	   and	   Akt	   (Figure	   24G).	   However,	   unchanged	  
phosphorylation	   of	   AS160	   suggests	   that	   GLUT4	   translocation	   to	   the	   membrane	   is	   not	  
modified	  by	  OVX	  or	  gender-­‐specific.	  GLUT4	  mRNA	  was	  also	  not	  altered	  by	  HFD,	  gender,	  or	  
estrogen	  (Supplement,	  Figure	  S	  VIIC).	  
	  
mTOR	   is	   another	   protein	   regulated	   by	   Akt.	   It	   has	   an	   essential	   role	   in	   several	   primordial	  
cellular	   mechanisms	   by	   regulating	   protein	   and	   lipid	   synthesis	   as	   well	   as	   autophagy,	  
important	   in	   our	   experimental	   model.	   mTOR	   can	   undergo	   phosphorylation	   at	   different	  
sites,	   Akt	   signaling	   leads	   to	   its	   phosphorylation	   at	   S2448,	   which	   activates	   it.	   The	  
phosphorylation	  of	  this	  site	  appears	   increased	  by	  the	  HFD	  in	  both	  female	  groups	  (p=0.01,	  
post-­‐hoc:	  p=0.15)	  and	  decreased	  in	  the	  male	  (ns)	  (Figure	  24H).	  The	  sham-­‐female	  mice	  have	  
slightly	  higher	  mTOR	  phosphorylation	  than	  the	  male	  after	  HFD	  (p=0.054).	  As	   for	   the	  total	  
form	  of	  mTOR,	   it	   stayed	  unchanged	   (Figure	  24I).	  Another	  phosphorylation	  site	  known	  for	  
mTOR	  is	  S2481.	  In	  our	  experimental	  model,	  it	  was	  not	  affected	  by	  diet,	  hormonal	  status	  or	  
gender	  (data	  not	  shown).	  We	  also	  analyzed	  p70-­‐S6K1	  as	  one	  of	  the	  downstream	  targets	  of	  
mTOR	   implicated	   in	  protein	  synthesis.	  Figure	  25A	  shows	   that	   its	  phosphorylation	  at	  T389	  
was	   increased	   after	   HFD	   (p=0.03	   and	   p=0.08	   in	   2-­‐way	   ANOVA	   for	   female	   and	   male	  
respectively;	   post-­‐hoc:	   ns).	   The	   effect	   was	   the	   strongest	   in	   female	   mice,	   in	   line	   with	  
increased	  mTOR	  activation	   in	  the	  female	  following	  HFD	  feeding.	  However,	   total	  p70-­‐S6K1	  
protein	  remained	  unchanged	  in	  all	  experimental	  groups	  (Figure	  25B).	  
	  
Finally,	  we	  also	  measured	  AMPKα	  as	   important	  regulator	  that	  controls	  cell	  metabolism	  in	  
general.	  This	  essential	  protein	  is	  an	  energy	  sensor	  that	  inhibits	  the	  mTOR	  activation	  when	  
the	  cell	  is	  low	  in	  energy	  (when	  the	  ATP/AMP	  ratio	  decreases).	  In	  other	  circumstances,	  it	  is	  
activated	  by	  LKB1,	  a	  tumor	  suppressor	  that	  phosphorylates	  it	  at	  its	  T172	  site.	  Its	  inhibitory	  
effect	   on	   mTOR	   goes	   through	   the	   activation	   of	   the	   TSC1/TSC2	   complex	   that	   inhibits	  
mTORC1,	   but	   also	   via	   a	   direct	   inhibition	   of	   mTORC1.364	   Additionally,	   AMPKα	   is	   able	   to	  
phosphorylate	   ULK1	   to	   initiate	   its	   activation	   and	   promote	   autophagy.	   Our	   statistical	  
analysis	   shows	   that	   phosphorylation	  of	   T172,	   the	   activity	   site	   of	  AMPKα,	   as	  well	   as	   total	  
AMPKα	   protein	   were	   not	   modified	   by	   HFD,	   OVX	   or	   gender.	   Nevertheless,	   AMPKα	   total	  
protein	  showed	  trends	  toward	  increased	  levels	  in	  the	  HFD-­‐fed	  sham-­‐female	  mice	  compared	  
to	  CTD-­‐fed	  female	  mice	  (p=0.13)	  and	  to	  the	  HFD-­‐fed	  OVX	  mice	  (p=0.16).	  (Figure	  25C,	  D).	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Figure	  26:	  Quantitative	  real-­‐time	  and	  Western-­‐blot	  analysis	  of	  metabolic	  targets	  (1).	  
Cardiac	  muscles	   from	  male,	   female	   and	  OVX	  mice	   fed	  with	  CTD	  or	  HFD	   for	   22	  wks	  were	  used	   to	  
extract	  mRNA	  and	  protein	  to	  evaluate	  genes	  and	  proteins	  involved	  in	  metabolism.	  	  
Representative	   examples	   of	   Western	   blots	   (bottom)	   and	   quantification	   normalized	   to	   the	  
corresponding	   control	   (top)	   are	   shown.	   The	   bands	   visible	   for	   each	   protein	   belong	   to	   the	   same	  
membrane.	  Results	  are	  presented	  with	  the	  median,	  whiskers	  show	  the	  min	  and	  max	  values.	  	  
*	  symbol	  corresponds	  to	  CTD	  vs	  HFD,	  #	  symbol	  corresponds	  to	  OVX	  vs	  sham,	  $	  symbol	  corresponds	  
to	  male	  vs	  female.	  N=6-­‐10.	  
	  
 3.11 Regulators	  of	  glucose	  and	  fatty	  acid	  metabolism	  
We	   hypothesized	   that	   gender	   or	   OVX	   would	   modify	   expression	   of	   genes	   that	   encode	  
proteins	   involved	   in	   glucose	   metabolism	   such	   as	   GAPDH	   and	   PDK4	   in	   response	   to	   HFD	  
feeding.	   Interestingly,	  PDK4	  mRNA	  levels	   increased	  in	  the	  OVX-­‐	  compared	  with	  the	  sham-­‐
female	   and	   the	   male	   under	   CTD	   conditions,	   and	   the	   HFD	   had	   a	   negative	   effect	   on	   its	  
expression	   in	   the	   OVX	  mice	   (Figure	   26A).	   The	   HFD	   feeding	   also	   slightly	   decreased	   PDK4	  





























































































	   98	  
PDK4	   is	   involved	   in	   the	   phosphorylation	   of	   the	   pyruvate	   dehydrogenase	   (PDH)	   complex,	  
another	   important	   player	   in	   glucose	   oxidation	   because	   it	   catalyzes	   the	   conversion	   of	  
pyruvate	   into	   acetyl-­‐CoA	   (see	   1.2.4).	   In	   our	   mouse	   model,	   HFD	   decreased	   the	   S293	  
phosphorylation	  site	  of	  PDH,	  which	   indicates	   its	   inhibition	   level,	   in	   the	  OVX-­‐female	  group	  
(p=0.04)	  (Figure	  26C),	  this	  is	  consistent	  with	  the	  observed	  PDK4	  mRNA	  level	  decrease.	  The	  
sham-­‐female	  mice	  also	  exhibited	  reduced	  PDK4	  mRNA	  and	  PDH	  phosphorylation,	  but	  to	  a	  
much	   lesser	   extent	   (ns,	   Figure	   26A,	   C).	  Moreover,	   the	   OVX-­‐group	   had	   also	   an	   increased	  
level	   of	   PDH	   phosphorylation	   compared	   to	   the	   sham-­‐female	   group	   when	   fed	   with	   CTD	  
(Figure	  26C).	  The	   total	   form	  of	  PDH	   is	   increased	  after	  HFD	   in	  both	   female	  groups,	  and	   in	  
contrast,	   it	  was	  decreased	   in	   the	  male	   group	   in	   response	   to	  HFD.	  Moreover,	  male	  had	  a	  
higher	  protein	  expression	  of	  total	  PDH	  than	  both	  female	  groups	  (Figure	  26D).	  Since	  PDK4	  
and	   PDH	   are	   involved	   in	   glucose	   oxidation,	   our	   results	   suggest	   that	   OVX-­‐female	   have	   a	  
decreased	  glucose	  oxidation	  at	  baseline	   (CTD)	   compared	  with	   the	   sham-­‐female	  mice	  and	  
that	  this	  effect	  is	  blunted	  by	  HFD	  feeding	  as	  they	  present	  less	  inhibited	  PDH	  underlining	  a	  
possible	   higher	   level	   of	   glucose	   oxidation	   than	   the	   sham-­‐female	   mice.	   Overall,	   HFD	  
decreased	   PDH	   phosphorylation,	   and	   together	   with	   the	   increased	   total	   PDH,	   this	   is	  
suggestive	  of	  increased	  glucose	  oxidation	  in	  female	  mice	  mainly.	  	  
	  
Acetyl-­‐CoA-­‐carboxylase	   (ACC)	   is	   a	   mediator	   involved	   in	   lipid	   metabolism.	   ACC	   activity	  
inhibits	  FA	  oxidation;	  indeed,	  this	  enzyme	  is	  responsible	  for	  the	  synthesis	  of	  malonyl-­‐CoA,	  
which	  is	  inhibiting	  the	  mitochondrial	  transporter	  CPT-­‐I	  that	  transfers	  FA	  from	  the	  cytosol	  to	  
the	   mitochondria.	   Activated	   AMPKα	   inhibits	   ACC	   when	   the	   cellular	   energy	   supply	   is	  
decreasing.	  Protein	  analysis	  of	  ACC	  demonstrated	  that	  its	  AMPKα	  phosphorylation	  site	  S79	  
was	  not	  modified	   in	  our	  experimental	  groups	  although	   it	  appeared	  that	  OVX	  mice	  have	  a	  
higher	  expression	  than	  the	  sham-­‐female	  after	  HFD	  (p=0.2)	  (Supplement,	  Figure	  S	  VIID).	  The	  
total	  form	  of	  ACC	  was	  also	  not	  affected	  neither;	  a	  trend	  toward	  an	  increase	  was	  noticeable	  
in	   the	   sham-­‐female	  mice	   compared	  with	   the	  male	  mice	   after	  CTD	   (p=0.16)	   (Supplement,	  
Figure	  S	  VIIE).	  These	  findings	  are	  consistent	  with	  the	  results	  on	  AMPKα	  described	  above.	  	  
	  
As	   part	   of	   glucose	   metabolism	   signaling,	   gene	   expression	   of	   GAPDH	   was	   also	   changed.	  
Indeed,	  it	  was	  decreased	  after	  HFD,	  but	  this	  effect	  was	  significant	  only	  in	  the	  sham-­‐female	  
(p=0.007,	   Figure	   27A).	  Many	   genes	   are	   implicated	   in	  mitochondrion	  metabolism,	   among	  
them	  the	  PGC1α	  and	  the	  PPARs	  genes.	  We	  hypothesized	  that	  these	  metabolic	  genes	  would	  
be	  modified	   in	   our	   study,	   as	   they	   play	   a	  major	   role	   in	   controlling	   glucose	   and	   fatty	   acid	  
oxidation.	  The	  mRNA	   level	  of	  PGC1α	  was	  not	  different	  between	  our	  experimental	  groups	  
(Supplement,	   Figure	   S	   VIIF).	   The	   expression	   of	   PPARα	   mRNA,	   on	   the	   other	   hand,	   was	  
increased	  by	  HFD	  feeding	  of	  the	  male	  mice	  (Figure	  27B).	  Moreover,	  the	  sham-­‐female	  mice	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Figure	  27:	  Quantitative	  real-­‐time	  and	  Western-­‐blot	  analysis	  of	  metabolic	  targets	  (2).	  
Cardiac	  muscles	   from	  male,	   female	   and	  OVX	  mice	   fed	  with	  CTD	  or	  HFD	   for	   22	  wks	  were	  used	   to	  
extract	  mRNA	  and	  protein	  to	  evaluate	  genes	  and	  proteins	  involved	  in	  metabolism.	  	  
Results	   are	   presented	   with	   the	   median,	   whiskers	   show	   the	   min	   and	   max	   values.	   *	   symbol	  
corresponds	  to	  CTD	  vs	  HFD,	  #	  symbol	  corresponds	  to	  OVX	  vs	  sham,	  $	  symbol	  corresponds	  to	  male	  vs	  
female.	  N=6-­‐10.	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had	   higher	   PPARα	  mRNA	   expression	   than	   the	   male	   mice	   under	   CTD	   conditions.	   Protein	  
expression	  of	  PPARα	  was	  slightly	  higher	  in	  male	  mice	  than	  in	  sham-­‐female	  mice	  when	  fed	  
with	  CTD	  (p=0.1)	  (Figure	  27C).	  PPARγ	  is	  another	  member	  of	  the	  PPAR	  family	  and	  its	  role	  in	  
the	   heart	   stays	   unclear	   and	   controversial.	   Our	   analysis	   showed	   that	   HFD	   decreased	   its	  
expression	  in	  the	  sham-­‐	  and	  OVX-­‐female	  but	  not	  in	  the	  male	  group	  (p=0.04,	  post-­‐hoc:	  ns).	  
Interestingly,	  both	  female	  groups	  had	  higher	  protein	  levels	  of	  PPARγ	  than	  the	  male	  group	  
(Figure	   27D).	   Finally,	   HFD	   increased	   mRNA	   levels	   of	   CPT-­‐Iβ,	   a	   transferase	   in	   the	   outer	  
mitochondrial	   membrane	   involved	   in	   lipid	   uptake.	   Post-­‐hoc	   testing	   demonstrated	  
significance	  in	  the	  sham-­‐female	  group	  (p=0.04,	  Figure	  27E).	  
	  
To	   summarize,	   in	   female	   mice	   mRNA	   expression	   of	   GAPDH,	   an	   enzyme	   involved	   in	  
glycolysis	  was	  reduced	  by	  the	  HFD	  and	  PDK4	  protein	  levels	  were	  decreased	  consistent	  with	  
decreased	   phosphorylation	   of	   its	   downstream	   target	   PDH.	   However,	   total	   PDH	   was	  
increased,	  maybe	   to	   increase	  glucose	  oxidation.	  Unlike	   the	  molecules	   involved	   in	  glucose	  
metabolism,	   the	   lipid	   transporter	   CPT-­‐Iβ	   was	   increased.	   Altogether,	   these	   data	   point	  
toward	   decreased	   glycolysis	   and	   increased	   glucose	   oxidation	   and	   lipid	   metabolism.	  
Interestingly,	   in	   the	  male	  group	  only	   the	  PPARα	  mRNA	  was	   significantly	   increased	  by	   the	  
HFD,	  proving	  that	  female	  and	  male	  mice	  diverge	  in	  their	  answer	  to	  HFD.	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Figure	  28:	  Western-­‐blot	  analysis	  of	  proteins	  regulating	  cardiac	  contractility.	  
Cardiac	  muscle	   proteins	   from	  male,	   female	   and	  OVX	  mice	   fed	  with	   CTD	  or	  HFD	   for	   22	  wks	  were	  
subjected	  to	  SDS-­‐PAGE	  and	  probed	  with	  antibodies	  to	  protein	  involved	  in	  the	  regulation	  of	  cardiac	  
contractility.	  Representative	  examples	  of	  Western	  blots	  (bottom)	  and	  quantification	  normalized	  to	  
the	  corresponding	  control	  (top)	  are	  shown.	  The	  bands	  visible	  for	  each	  protein	  belong	  to	  the	  same	  
membrane.	  Results	  are	  presented	  with	  the	  median,	  whiskers	  show	  the	  min	  and	  max	  values.	  	  
*	  symbol	  corresponds	  to	  CTD	  vs	  HFD,	  #	  symbol	  corresponds	  to	  OVX	  vs	  sham,	  $	  symbol	  corresponds	  
to	  male	  vs	  female.	  N=6-­‐8.	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 3.12 Regulators	  of	  cardiac	  contractility	  
SERCA2a	   is	   a	   calcium	  pump	   responsible	   for	   the	   reuptake	  of	   calcium	   into	   the	   SR	   to	   allow	  
cardiac	  relaxation.	  The	  protein	   levels	  of	  SERCA2	  were	  unchanged	  under	  our	  experimental	  
conditions.	   Small	   trends	   toward	  decreased	  SERCA2	   in	   the	  male	   group	  after	  HFD	   (p=0.12)	  
and	   toward	   increased	   SERCA2	   in	   the	   sham-­‐female	   compared	   to	   the	  male	  mice	   (p=0.09)	  
(Figure	  28A)	  were	  visible.	  SERCA2	  is	  regulated	  by	  phospholamban	  (PLN),	  which	  exists	  in	  two	  
forms:	   a	   pentamer	   and	   a	   monomer.	   At	   a	   basal	   state,	   it	   forms	   a	   pentamer	   that	   will	  
dissociate	  upon	  SERCA2a	  interaction.	  As	  a	  monomer,	  this	  protein	   inhibits	  SERCA2a,	  which	  
will	   lead	  to	  a	  reduced	  affinity	  for	  calcium	  thus	  lowering	  the	  calcium	  reuptake	  into	  the	  SR.	  
When	   phosphorylated	   at	   S16,	   PLN	   releases	   its	   inhibitory	   action	   on	   SERCA2a	   and	  
consequently	  enhances	  calcium	  re-­‐entry	  into	  the	  SR.	  
	  
Interestingly,	  the	  phosphorylated	  PLN	  pS16	  pentamer	  was	  increased	  in	  sham-­‐female	  mice	  
(p<0.001),	   slightly	   increased	   in	   OVX	   mice	   (p=0.15),	   and	   unchanged	   or	   even	   slightly	  
decreased	   in	   the	  male	  mice	   (p=0.23)	  after	  HFD	  (Figure	  28B).	  Furthermore,	   the	  male	  mice	  
fed	   with	   CTD	   had	   significantly	   higher	   phosphorylated	   PLN	   pentamer	   compared	   with	   the	  
sham-­‐female	   mice.	   Inversely,	   the	   sham-­‐female	   mice	   had	   a	   significantly	   higher	   level	   of	  
phosphorylated	  protein	  than	  the	  male	  mice	  after	  HFD.	  The	  monomer	  form	  of	  PLN	  was	  not	  
different	   between	   our	   groups	   (Figure	   28C).	   Concerning	   the	   total	   PLN	   protein,	   HFD	  
increased	   its	   expression	   in	   the	  OVX	  mice	  only	   (p<0.001),	  while	  OVX-­‐female	   fed	  with	  CTD	  
had	   a	   slightly	   lower	   PLN	   protein	   expression	   than	   the	   sham-­‐female	  mice	   (p=0.07)	   (Figure	  
28D).	   The	   observation	   that	   the	   monomer	   form	   of	   PLN	   was	   not	   changed	   suggests	   that	  
calcium	  re-­‐uptake	   into	  the	  SR	  was	  not	  altered.	  The	  fact	  that	  HFD	  increased	  the	  pentamer	  
and	  total	  form	  in	  sham-­‐female	  and	  OVX-­‐female	  mice,	  respectively,	  could	  indicate	  that	  PLN	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Figure	  29:	  Western-­‐blot	  analysis	  of	  proteins	  involved	  in	  autophagy.	  	  
Cardiac	  muscle	   proteins	   from	  male,	   female	   and	  OVX	  mice	   fed	  with	   CTD	  or	  HFD	   for	   22	  wks	  were	  
subjected	   to	   SDS-­‐PAGE	   and	   probed	   with	   antibodies	   to	   proteins	   involved	   in	   autophagy.	  
Representative	   examples	   of	   Western	   blots	   (bottom)	   and	   quantification	   normalized	   to	   the	  
corresponding	   control	   (top)	   are	   shown.	   The	   bands	   visible	   for	   each	   protein	   belong	   to	   the	   same	  
membrane.	  A,	  B:	  N=9-­‐13;	  C:	  N=6-­‐8.	  	  Results	  are	  presented	  with	  the	  median,	  whiskers	  show	  the	  min	  
and	  max	  values.	  *	  symbol	  corresponds	  to	  CTD	  vs	  HFD,	  #	  symbol	  corresponds	  to	  OVX	  vs	  sham.	  
	  
 3.13 Autophagy	  and	  apoptosis	  
Kinases	  such	  as	  mTOR	  and	  AMPKα	  tightly	  regulate	  autophagy.	  High	  levels	  of	  glucose	  allow	  
the	  activation	  of	  mTOR,	  which	  in	  turn	  phosphorylates	  the	  protein	  ULK1	  at	  S757	  to	  prevent	  
its	   interaction	   with	   AMPKα	   and	   its	   concomitant	   activation	   to	   induce	   autophagy.	   In	   our	  
model,	  ULK1-­‐pS757	  was	  increased	  in	  the	  OVX-­‐	  compared	  to	  the	  sham-­‐female	  mice	  (Figure	  
29A).	   Interestingly,	   HFD	   had	   different	   effects	   on	   ULK1	   phosphorylation	   in	   the	   OVX-­‐	   and	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(p=0.12),	  the	  sham-­‐female	  and	  male	  mice	  experienced	  a	  small	  decrease	  upon	  HFD	  feeding	  
(p=ns).	  As	  for	  total	  ULK1	  protein,	  its	  level	  stayed	  equal	  between	  feeding	  conditions	  (Figure	  
29B).	   Taken	   together,	   our	   observations	   suggest	   that	   the	   OVX-­‐female	   mice	   have	   lower	  
autophagy	  than	  sham-­‐female	  mice	  after	  HFD	  feeding.	  
	  
Akt	  may	   change	   LC3BI/LC3BII	   expression.	   In	   the	   fed	   state,	   activated	  Akt	  will	   inhibit	   LC3B	  
gene	  transcription	  through	  FOXO	  inhibition,	  to	  eventually	  block	  autophagy.	  LC3BII	  protein	  
expression	   did	   not	   exhibit	   differences	   between	   the	   groups	   (Figure	   29C).	   In	   the	   HFD-­‐fed	  
sham-­‐female	  group,	  LC3BII	  showed	  very	  high	  variability	  with	  a	  few	  animals	  having	  very	  high	  
LC3BII	  levels,	  whereas	  in	  the	  CTD	  group	  all	  animals	  had	  low	  levels	  (Figure	  29C).	  To	  evaluate	  
autophagy,	  the	  ratio	  LC3BII/LC3BI	   is	  essential.	   In	  our	  study,	  the	  ratio	  showed	  the	  same	  as	  
the	   LC3BII	   levels	   by	   itself	   (Figure	   29D).	   Our	   data	   suggest	   increased	   autophagy	   in	   some	  
sham-­‐female	  mice,	  and	  no	  effect	  of	  the	  diet	  in	  male	  and	  OVX-­‐female	  mice.	  We	  would	  need	  
to	  test	  more	  mice	  to	  prove	  significance	  of	  this	  gender	  difference.	  	  
	  
Additionally,	   we	   studied	   autophagy	   by	   TEM	   since	   it	   is	   considered	   as	   “gold-­‐standard”	  
method	   to	   detect	   morphological	   and	   ultrastructural	   changes	   associated	   with	   autophagy	  
activation.365	  We	  obtained	  mitigated	  results,	  as	  it	  was	  difficult	  to	  detect	  with	  certainty	  the	  
presence	   of	   autophagosome	   or	   autolysosome	   (Supplement,	   Figure	   S	   III).	   Given	   this,	   it	  
would	  be	  interesting	  to	  use	  chloroquine,	  an	  autophagic	  flux	  inhibitor,	  to	  better	  evaluate	  the	  
level	  of	  autophagy	   in	  our	  different	  experimental	   conditions.	  We	  also	   stained	   for	   cleaved-­‐
caspase3	   on	   cardiac	   sections	   to	   detect	   apoptosis,	   but	   no	   obvious	   differences	   were	  
observed	   between	   our	   conditions	   (data	   not	   shown).	   Further	   experiments	   are	   needed	   to	  
prove	  that	  no	  changes	  are	  induced,	  for	  instance	  since	  apoptosis	  is	  a	  rare	  event	  more	  mice	  
would	  need	  to	  be	  tested	  and	  multiple	  sections	  at	  different	  levels	  of	  the	  heart	  would	  have	  to	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 4.1 Introduction	  
The	  metabolic	  syndrome	  is	  defined	  by	  a	  combination	  of	  pathologies:	  	  obesity,	  hypertension	  
and	   diabetes,	   and	   is	   associated	   with	   a	   high	   risk	   to	   develop	   CVD.366	   The	   prevalence	   of	  
obesity,	   diabetes	   and	   hypertension	   is	   higher	   in	   postmenopausal	   women	   than	   in	   age-­‐
matched	  men	  and	   is	  associated	  with	   increased	  diastolic	  heart	   failure.170,367-­‐369	  The	  causes	  
for	   this	  unequal	  distribution	   for	   the	  genders	   remain	  unclear.370	  Several	  preclinical	   studies	  
attributed	   to	   estrogen	   a	   beneficial	   effect	   on	   cardiac	   function.	   However,	   hormone	  
replacement	   therapy	   failed	   to	   improve	   cardiac	   function	   in	   advanced	   menopausal	  
women371,372	   highlighting	   the	   complexity	   of	   the	   estrogen	   system	   in	   the	   heart.	   Our	   study	  
therefore	   aimed	   to	   investigate	   the	   impact	   of	   gender	   and	   ovarian	   hormones	   on	   cardiac	  
function	  in	  a	  mouse	  model	  of	  diet-­‐induced	  obesity,	  depicting	  a	  cardiometabolic	  disorder.	  
	  
 4.2 Summary	  of	  the	  effects	  of	  HFD	  in	  male,	  female	  and	  OVX-­‐female	  mice	  
Body	  weight,	  glucose	  tolerance,	  insulin	  levels	  and	  fat	  weight	  	  
1.	  High	  fat	  diet	  decreased	  glucose	  tolerance	  in	  male,	  female	  and	  OVX-­‐female	  mice	  at	  3,	  9	  
and	  22	  wks	  of	  feeding.	  2.	  Male	  mice	  gained	  less	  weight	  than	  female	  mice	  and	  their	  glucose	  
tolerance	  was	  similar	  to	  that	  of	  the	  sham-­‐female.	  HFD	  induced	  a	  much	  stronger	  increase	  of	  
plasma	   insulin	   in	   male	   than	   in	   female	   mice.	   Male	   had	   less	   visceral	   adipose	   tissue	   than	  
female	  mice.	  3.	  OVX-­‐female	  mice	  fed	  with	  HFD	  had	  higher	  body	  weights	  than	  sham-­‐female	  
mice,	  but	   this	  difference	  disappeared	  over	   time	  and	  was	  absent	  after	  22	  wks	  of	   feeding.	  
The	   HFD-­‐fed	   OVX-­‐females	   were	   more	   glucose	   intolerant	   than	   the	   corresponding	   sham-­‐
females.	   Furthermore,	   in	   response	   to	   HFD,	   the	   sham-­‐female	  mice	   had	   slightly	   increased	  
insulin	  levels,	  whereas	  this	  HFD-­‐induced	  increase	  was	  absent	  in	  the	  OVX-­‐female	  mice.	  The	  
ablation	  of	  the	  ovaries	  induced	  an	  increase	  in	  fat	  content	  in	  the	  female	  mice	  fed	  with	  CTD,	  
a	   difference	   that	   disappeared	   when	   the	   female	   mice	   were	   fed	   with	   HFD.	   Since	   glucose	  
uptake	  mainly	   takes	  place	   in	  organs	  such	  as	  skeletal	  muscle,	   liver	  and	  adipose	  tissue,	   the	  
observed	  changes	  in	  glucose	  tolerance	  are	  most	  likely	  related	  to	  these	  organs.	  Whether	  or	  
not	   the	   various	   conditions	   also	   affect	   cardiac	   glucose	  uptake	   remains	   to	  be	   investigated.	  
The	  first	  hints	  came	  from	  our	  analysis	  of	  insulin/Akt-­‐signaling	  in	  cardiac	  tissue,	  which	  points	  
toward	  modest	  effects	  of	  HFD,	  gender	  and	  OVX	  on	  this	  pathway	  that	  amongst	  other	  things	  
regulates	  glucose	  uptake	  in	  the	  heart.	  
	  
Cardiac	  dimensions	  and	  function	  
Firstly,	  our	  analysis	  by	  echocardiography	  demonstrated	   that	  HFD	  had	  distinct	  effects	   in	  a	  
gender-­‐specific	  way.	  1.	   It	  decreased	  the	  E/A	  ratio	   in	  the	  female	  mice	  only.	  2.	  The	  relative	  
wall	  and	  posterior	  wall	  thicknesses	  were	  increased	  in	  the	  sham-­‐female	  mice.	  Notably,	  HFD	  
also	  increased	  the	  ventricle	  weight	  measured	  post-­‐mortem	  solely	  in	  the	  sham-­‐female	  mice.	  	  
Discussion	  
	  
	   107	  
Secondly,	   HFD	   had	   specific	   effects	   linked	   to	   the	   absence	   of	   ovarian	   hormone.	   1.	   The	   LV	  
anterior	  wall	   thickness	  was	   increased	   in	   the	   OVX	   group	   only.	   2.	   The	   cardiac	   output	  was	  
increased	  in	  the	  OVX	  compared	  with	  the	  sham-­‐female	  group.	  
	  
The	  PVL	  method	  showed	   that	  1.	  HFD	  decreased	   the	  emptying	  and	   filling	   rates	  dV/dt	  min	  
and	  dV/dt	  max	  in	  male	  respectively.	  2.	  Female	  had	  a	  lower	  dV/dt	  min	  and	  dV/dt	  max	  values	  
than	  male	  when	  fed	  with	  CTD	  diet	  under	  conditions	  of	  normal	  work	  as	  well	  as	  dobutamine-­‐
induced	  increased	  work.	  3.	  HFD	  caused	  a	  decrease	  in	  end-­‐diastolic	  pressure	  in	  sham-­‐female	  
mice.	   Concerning	   the	   effects	   linked	   to	   estrogen	   deficiency:	   1.	   Following	   dobutamine	  
infusion,	   OVX-­‐female	   had	   a	   lower	   dV/dt	  min	   than	   the	   sham-­‐female	   group	   after	   HFD.	   2.	  
Dobutamine	   infusion	   revealed	   that	   HFD-­‐fed	   OVX-­‐female	   mice	   have	   higher	   end-­‐diastolic	  
pressures	  than	  diet-­‐matched	  sham-­‐female	  mice.	  	  
	  
Cardiac	  steatosis,	  inflammation,	  fibrosis	  and	  stress	  markers	  
Our	  evaluation	  of	   cardiac	   steatosis	   suggests	   that	  HFD	   increased	   lipid	  accumulation	   in	   the	  
heart,	   an	  effect	   that	  was	  more	  pronounced	   in	  male	   and	  OVX-­‐female	  mice	   than	   in	   sham-­‐
female	   mice.	   Additionally,	   cardiac	   signaling	   pathways	   implicated	   in	   inflammation	   were	  
changed:	   1.	   After	   HFD,	   phosphorylation	   of	   NF-­‐κB	   at	   S536	   was	   slightly	   increased	   in	   the	  
sham-­‐female	  group,	  whereas	   IκBα	  was	  decreased	   in	   this	  same	  group.	  2.	  Male	  showed	  an	  
increased	  expression	  of	  NF-­‐κB	  compared	  with	  the	  sham-­‐female	  mice	  under	  CTD	  conditions.	  
3.	  NF-­‐κB	  was	  also	  slightly	   increased	   in	  the	  OVX-­‐female	  group	  after	  HFD.	  Collagen	   I	  and	   III	  
mRNA	  levels	  were	  not	  different	  between	  our	  groups	  at	  the	  timepoint	  of	  analysis.	  This	  was	  
confirmed	   by	   Picrosirius	   Red	   staining	   on	   sections,	   although	   it	   seemed	   that	   in	   the	   OVX-­‐
female	  mice	  the	  staining	  was	  more	  pronounced	  than	  in	  the	  sham-­‐female	  and	  male	  mice.	  	  
	  
To	  assess	  the	  level	  of	  cardiac	  stress	  induced	  by	  HFD	  in	  the	  three	  groups,	  we	  measured	  ANP,	  
BNP	  and	  β-­‐MHC	  mRNA	   levels.	   1.	   The	  HFD	  decreased	  ANP	  gene	  expression	   in	   the	   female	  
mice,	  and	  its	  level	  was	  slightly	  increased	  in	  the	  sham-­‐female	  compared	  with	  the	  male	  group	  
after	   CTD	   feeding.	   2.	   BNP	  was	   slightly	   decreased	   in	   the	  OVX-­‐female	   compared	   to	   sham-­‐
female	  in	  the	  CTD-­‐fed	  group.	  
	  
Cardiac	  signaling:	  insulin/Akt/mTOR	  
Some	  components	  of	  the	  insulin/Akt/mTOR	  pathway	  were	  modified.	  1.	  HFD	  increased	  IRS-­‐
pS636-­‐639	  in	  the	  male	  whereas	  it	  was	  decreased	  in	  the	  sham-­‐female	  mice.	  Male	  mice,	  next	  
to	  having	  more	  phosphorylated	   IRS-­‐1	   than	  sham-­‐female	  mice,	  also	  had	  higher	   total	   IRS-­‐1	  
protein	  amounts.	  2.	  HFD	  strongly	  decreased	  Akt	  protein	   in	  both	  female	  groups	  but	  not	   in	  
the	  male	  group.	  The	  sham-­‐female	  mice	  had	  higher	  Akt	  expression	  than	  the	  male	  when	  fed	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with	   CTD,	   and	   similarly	   the	   Akt	   phosphorylation	   at	   S473	  was	   higher	   in	   the	   sham-­‐female	  
than	   in	   the	  male.	  3.	  AS160	  protein	  expression	  and	  phosphorylation	  were	  not	   importantly	  
altered	  by	  the	  diet	  or	  the	  gender.	  4.	  HFD	  increased	  the	  activation	  site	  S2448	  of	  mTOR	  in	  the	  
female	  groups,	  whereas	  it	  was	  slightly	  decreased	  in	  the	  male	  group.	  As	  a	  consequence	  the	  
female	  had	  higher	  phosphorylated	  mTOR	  than	  the	  male	  mice	  after	  HFD	  feeding.	  	  
	  
Ablation	  of	  ovaries	  induced	  the	  following	  specific	  effects:	  1.	  OVX-­‐female	  had	  lower	  levels	  of	  
phospho-­‐	   and	   total	   IRS-­‐1	   than	   sham-­‐female	  mice	   after	   CTD	   feeding.	   2.	   Total	   AS160	  was	  
increased	  in	  the	  OVX-­‐female	  after	  HFD	  feeding.	  3.	  ULK1	  as	  a	  downstream	  target	  of	  mTOR	  
was	   studied	   to	   evaluate	   autophagy.	   ULK1	   was	   not	   much	   changed,	   only	   phosphorylated	  
ULK1	  was	  increased	  in	  the	  OVX-­‐female	  after	  HFD	  compared	  to	  the	  sham-­‐female	  mice.	  LC3B	  
protein	  expression	  was	  not	  affected	  by	  the	  various	  conditions.	  
	  
Cardiac	  metabolic	  signaling	  
Reduced	  GAPDH	  gene	  expression	  was	  observed	  in	  the	  sham-­‐female	  mice	  after	  HFD	  feeding.	  
Other	   genes	   participating	   in	   glucose	   metabolism	   were	   also	   changed:	   1.	   PDH	   protein	  
expression	  was	  increased	  after	  HFD	  in	  the	  female	  groups,	  and	  the	  sham-­‐female	  had	  a	  lower	  
protein	  level	  than	  the	  male	  mice.	  2.	  HFD	  caused	  an	  overall	  increase	  in	  mRNA	  expression	  of	  
the	  lipid	  transporter	  CPT-­‐Iβ,	  an	  effect	  that	  reached	  significance	  for	  the	  sham-­‐female	  mice.	  
3.	   PPARα	   gene	   expression	   was	   lower	   in	   the	   male	   than	   in	   the	   female	   group	   under	   CTD	  
conditions,	   and	  HFD	   increased	   its	   expression	   in	   the	  male	   group.	   4.	   Protein	   expression	  of	  
PPARγ	  was	  increased	  in	  the	  sham-­‐female	  compared	  to	  the	  male	  under	  CTD	  conditions.	  As	  
for	  the	  ovarian-­‐hormone-­‐related	  effects:	  1.	  PDK4	  gene	  expression	  was	  higher	   in	  the	  OVX-­‐
female	   than	   in	   the	   sham-­‐female	  mice	  under	  CTD	   conditions.	  HFD	  decreased	  PDK4	   in	   the	  
OVX	   group	   back	   to	   levels	   of	   the	   sham	   group.	   2.	   Similar	   to	   PDK4,	   PDH	   protein	  
phosphorylation	   at	   S293	   was	   higher	   in	   the	   OVX	   than	   in	   the	   sham-­‐female,	   and	   HFD	  
decreased	  it	   in	  the	  OVX	  group.	  Table	  III	  shows	  a	  summary	  of	  the	  main	  results	  obtained	  in	  
our	  study.	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Table	  III:	  Summary	  of	  the	  main	  results	  obtained	  in	  our	  study.	  
Differences	  and	  similarities	  between	  groups	  after	  19-­‐22	  wks	  of	  diet.	  	  
Additional	   color	   code:	   grey	   filling:	   no	   changes	   occurred,	   green	   filling:	   higher	   level,	   red	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 4.3 Ovariectomy	  increases	  body	  weight	  gain,	  adiposity	  and	  glucose	  intolerance	  
Postmenopausal	  women	  present	  deteriorated	  metabolism	  resulting	  in	  increased	  abdominal	  
adipose	   tissue	   and	   dyslipidemia.312	   Similarly,	   ovariectomized	   animals	   show	   a	  weight	   gain	  
and	  an	  altered	  metabolic	  state,	  which	  is	  reversed	  by	  estrogen	  replacement.328	  The	  ablation	  
of	  ovaries	   in	  our	  mouse	  model	   triggered	  an	   increase	   in	  body	  weight	  detectable	  already	  4	  
wks	   after	   the	   surgery,	   prior	   to	   the	   start	   of	   CTD	   and	   HFD	   feeding.	   In	   a	   pilot	   study	   we	  
observed	  that	  the	  food	  intake	  between	  the	  sham-­‐	  and	  OVX-­‐female	  mice	  was	  not	  different,	  
excluding	  the	  possibility	  that	  the	  higher	  body	  weight	  measured	  in	  the	  OVX-­‐female	  mice	  was	  
due	  to	  higher	  food	  consumption.	  During	  the	  22	  wks	  of	  regular	  chow	  feeding	  the	  two	  female	  
groups	  maintained	  similar	  body	  weights,	  a	  difference	  remained	  visible	  only	  when	  the	  mice	  
were	  fed	  with	  HFD.	  Indeed,	  the	  OVX	  mice	  kept	  their	  higher	  body	  weights	  up	  to	  15	  wks	  of	  
feeding,	   indicating	   that	   the	  deficiency	  of	  ovarian	  hormones	  has	  more	  pronounced	  effects	  
under	  HFD	  conditions.	  
	  
The	   OVX	  mice	   had	  more	   visceral	   fat	   than	   the	   sham-­‐female	  mice	   after	   5	   and	   22	   wks	   of	  
feeding,	  and	  therefore	  their	  higher	  body	  weights	  may	  be	  explained	  by	  the	  development	  of	  
more	   visceral	   adipose	   tissue.	   Surprisingly,	   we	   observed	   this	   difference	   in	   the	   amount	   of	  
adipose	  tissue	  after	  CTD-­‐,	  but	  not	  after	  HFD-­‐feeding.	  This	  may	  be	  due	  to	  the	  fact	  that	  at	  22	  
wks	   of	   HFD	   feeding	   a	   plateau	   of	   body	   and	   fat	   weight	   was	   reached.	   A	   difference	   in	   fat	  
weight	   between	   sham-­‐	   and	   OVX-­‐females	   may	   have	   been	   present	   at	   earlier	   timepoints,	  
while	   BW	   was	   still	   increasing.	   Our	   results	   are	   consistent	   with	   earlier	   rodents	   studies	   in	  
which	  it	  has	  been	  shown	  that	  the	  absence	  of	  ovarian	  hormones	  increases	  adiposity328	  and	  
that	   this	   is	   prevented	   by	   implantation	   of	   subcutaneous	   pellet	   of	   E2,	   proving	   that	   of	   the	  
different	   ovarian	   hormones	   it	   is	   indeed	   E2	   that	   regulates	   adiposity.327	   Collectively,	   the	  
available	  data	  support	  that	  E2	  modulates	  fat	  mass	  in	  animals	  that	  are	  increasing	  their	  body	  
weight.	  
	  
Is	  E2	  responsible	  for	  gender	  differences	  in	  fat	  mass	  after	  HFD	  feeding?	  Males	  have	  lower	  E2	  
than	  females.	  We	  found	  that	  males	  had	  also	  lower	  fat	  content	  than	  females	  in	  our	  mouse	  
model	  especially	  after	  HFD	  feeding.	  However,	  the	  HFD-­‐fed	  OVX-­‐female	  mice	  had	  the	  same	  
amount	  of	  visceral	  fat	  as	  the	  sham-­‐female	  mice	  despite	  the	  absence	  of	  E2.	  Taken	  together,	  
this	   suggests	   that	   the	   observed	   gender	   difference	   in	   fat	   accumulation	   is	  most	   likely	   not	  
directly	  related	  to	  E2.	  The	  observed	  gender	  difference	  in	  fat	  is	  in	  line	  with	  studies	  showing	  
that	  men	  have	  a	  lower	  amount	  of	  total	  body-­‐fat,	  due	  to	  a	  lower	  fat	  storage	  capacity	  of	  their	  
adipose	   tissue.373	   It	   is	   however	   known	   that	   a	   sexual	   dimorphism	   exists	   related	   to	   fat	  
distribution.	   Men	   have	   increased	   central	   intra-­‐abdominal	   adipose	   tissue	   compared	   with	  
women,	  who	  exhibit	  more	  subcutaneous	  adipose	  tissue.374	  After	  menopause,	  women	  gain	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intra-­‐abdominal	   fat	   thus	   following	  a	  male	  pattern,	  and	   this	   can	  be	   improved	  by	  estrogen	  
replacement	   therapy.375	   Accumulation	  of	   abdominal	   fat	   correlates	  with	   a	   higher	   risk	   and	  
mortality	  caused	  by	  diabetes	  and	  atherosclerosis.376	  	  
	  
Interestingly,	  we	  found	  that	  OVX-­‐female	  mice	  became	  more	  glucose	  intolerant	  after	  HFD-­‐
feeding	  than	  sham-­‐female	  mice	  suggesting	  a	  role	  of	  E2	  in	  glucose	  homeostasis.	  These	  two	  
groups	   had	   similar	   amounts	   of	   visceral	   adipose	   tissue	   at	   22	   wks,	   and	   the	   glucose	  
intolerance	   found	   in	   the	   OVX	  mice	  may	   therefore	   not	   be	   directly	   related	   to	   visceral	   fat	  
content.	  It	   is	  thought	  that	  adipose	  tissue	  participates	  in	  the	  onset	  of	  insulin	  resistance	  via	  
the	  secretion	  of	  adipokines.119-­‐121,377	  In	  our	  study,	  the	  sham	  and	  OVX-­‐female	  mice	  had	  the	  
same	   amount	   of	   fat,	   thus	   comparable	   adipokine	   levels	   are	   expected	   and	   should	   have	  
triggered	  the	  same	  insulin	  resistance	  in	  both	  groups,	  which	  is	  not	  the	  case.	  These	  findings	  
suggest	   that	   the	   lack	   of	   ovarian	   hormones	   modifies	   glucose	   tolerance	   independently	   of	  
potential	  endocrine	  effects	  of	  adipose	  tissue.	   Indeed,	  from	  a	  batch	  of	  mice	  sacrificed	  at	  5	  
wks	  we	  know	  that	  a	  difference	  in	  fat	  mass	  and	  glucose	  tolerance	  between	  sham-­‐	  and	  OVX-­‐
females	  was	  present	  earlier	  during	   the	  HFD-­‐feeding,	  which	  could	  have	  caused	  their	  more	  
severe	  glucose	  intolerance.	  
	  
Furthermore,	  fasting	  glucose	  was	  not	  influenced	  by	  the	  HFD,	  gender	  or	  ovarian	  hormones	  
after	  22	  wks	  of	  diet,	  similarly	  Carbone	  et	  al.,	  did	  not	  find	  any	  increase	  in	  fasting	  glucose	  in	  
male	  and	  female	  mice	  fed	  with	  a	  western-­‐diet	  similar	  to	  ours	  during	  8	  wks.378	  
	  
 4.4 Male	  mice	  have	  higher	  plasma	  insulin	  than	  female	  mice	  after	  HFD	  	  
Diabetes	   is	   a	   progressive	   disease	   that	   takes	   place	   according	   different	   stages.	   A	  
hyperglycemic	   state	   triggers	   an	   overproduction	   of	   insulin	   by	   the	   beta	   pancreatic	   cells	   to	  
alleviate	  this	  increase	  of	  blood	  glucose.	  At	  an	  early	  stage,	  blood	  glucose	  levels	  are	  brought	  
back	   to	   normal	   thanks	   to	   this	   increased	   production	   of	   insulin.	  When	   the	   hyperglycemic	  
state	  is	  sustained,	  it	  ensues	  pancreatic	  failure:	  insulin	  is	  less,	  or	  ultimately	  not	  secreted	  and	  
its	  blood	  concentration	  drops	  characterizing	  more	  advanced	  diabetes.379	  	  Insulin	  resistance	  
is	  defined	  as	  a	  decreased	  capacity	  of	  the	  large	  metabolic	  organs	  to	  respond	  to	  insulin.	  The	  
main	  metabolic	   organs	   (liver,	   adipose	   tissue	   and	   skeletal	  muscle)	   start	   to	   be	   less	   insulin	  
sensitive,	   increasing	   the	   insulin	   demand,	  which	   leads	   to	  hyperinsulinemia.380	  Obesity	   is	   a	  
state	  that	  importantly	  contributes	  to	  the	  development	  of	  insulin-­‐resistance,	  which	  itself	   is	  
part	  of	  diabetic	  pathophysiology.	  
	  
Our	   results	   demonstrate	   that	   22	  wks	   of	  HFD	   feeding	   resulted	   in	   obesity	   and	   induced	   an	  
increase	   in	   fasting	   plasma	   insulin	   levels	   in	   male	   and	   female	   mice.	   This	   increase	   can	   be	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interpreted	   as	   an	   adaptation	   to	   the	   HFD	   feeding,	   which	   is	   known	   to	   affect	   insulin	  
sensitivity.381-­‐383	  The	  increased	  insulin	  would	  be	  important	  in	  the	  context	  of	  our	  HFD	  model,	  
in	  which	  fatty	  acid	  utilization	  is	  enhanced.	  Indeed,	  to	  overcome	  this	  situation,	  the	  increased	  
insulin	  secretion	  would	  be	  beneficial	  since	  it	  would	  activate	  the	  Akt	  pathway	  and	  increase	  
glucose	   uptake	   and	   utilization	   to	   participate	   in	   the	   process	   of	   energy	   production.	   The	  
question	  whether	  this	  insulin	  pathway	  activation	  is	  cardioprotective	  or	  not	  in	  the	  context	  of	  
obesity	  and	  T2DM	  still	   remains	  open,	  but	  activation	  of	   the	  Akt	  pathway	   is	   thought	   to	  be	  
beneficial	  for	  the	  heart	  in	  certain	  conditions	  such	  as	  ischemia-­‐reperfusion.384-­‐386	  	  
	  
Notably,	  we	  observed	  a	   striking	  sexual	  dimorphism	  with	   the	  males	  having	  much	  stronger	  
increases	  in	  insulin	  after	  HFD	  feeding	  than	  the	  females.	  This	  stronger	  increase	  could	  mean	  
that	  males	  are	  more	  insulin	  insensitive	  and	  suggests	  that	  they	  are	  facing	  a	  more	  advanced	  
stage	  of	  insulin	  resistance,	  hence	  the	  overproduction	  of	  insulin	  to	  cope	  with	  the	  decreased	  
insulin	   sensitivity.	   This	   strong	   increase	   in	   insulin	   levels	   could	   suggest	   that	   the	  male	  mice	  
start	  to	  develop	  diabetes	  and	  are	  most	  likely	  in	  a	  pre-­‐diabetic	  phase,	  where	  the	  pancreas	  is	  
still	  able	  to	  cope	  with	  increased	  needs	  of	  insulin	  to	  palliate	  decreased	  insulin	  sensitivity	  in	  
the	   liver,	  adipose	  tissue	  and	  skeletal	  muscle.	  Surprisingly	  however,	  glucose	  tolerance	  was	  
reduced	   to	  a	  similar	  degree	   in	   the	   female	  and	  male	  groups	  after	  HFD.	  This	   indicates	   that	  
male	  mice	  may	   need	   a	   lot	   more	   insulin	   to	   trigger	   the	   same	   glucose	   clearance	   than	   the	  
female	  mice	  after	  HFD.	  One	  could	  hypothesize	  that	  with	  the	  same	  insulin	   level	  as	  female,	  
male	  would	  be	  more	  glucose	  intolerant	  than	  female.	  Alternatively,	  it	  could	  also	  be	  thought	  
that	   the	   males	   exhibit	   a	   higher	   level	   of	   adaptation	   than	   the	   sham-­‐female	   by	   increasing	  
more	  their	  plasma	  insulin	  to	  increase	  glucose	  utilization.	  In	  our	  study,	  no	  major	  differences	  
existed	   between	   male	   and	   female	   regarding	   glucose	   tolerance	   at	   9	   and	   20	   wks	   of	   HFD	  
feeding.	  Only	  a	  trend	  toward	  lower	  glucose	  tolerance	  appeared	  in	  the	  male	  compared	  with	  
the	   sham-­‐female	  after	  9	  wks	  of	  HFD	   (p=0.08),	   suggestive	  of	   reduced	   insulin-­‐sensitivity	   at	  
this	   timepoint.	   Based	   on	   all	   these	   data,	   we	   propose	   that	   the	   males	   started	   to	   develop	  
insulin	  resistance	  earlier	  than	  females.	  	  
	  
Interestingly,	   the	  OVX-­‐female	  mice	   did	   not	   show	   any	   plasma	   insulin	   increase	   at	   all	   after	  
HFD,	   this	   in	   contrast	   to	   the	   sham-­‐female	   and	   the	  male	  mice.	   This	   absence	   of	   increased	  
insulin	   secretion	   is	   in	   line	   with	   the	   observed	   decrease	   in	   glucose	   clearance	   in	   OVX-­‐	  
compared	  to	  sham-­‐female	  mice.	  Thus,	  low	  plasma	  insulin	  level	  in	  the	  OVX	  mice	  may	  cause	  
their	  glucose	  intolerance.	  Moreover,	  the	  main	  difference	  that	  separates	  sham-­‐	  from	  OVX-­‐
female	  mice	  is	  their	  different	  ovarian	  hormone	  level,	  and	  therefore	  our	  result	  suggests	  that	  
ovarian	  hormones	  are	   implicated	  in	   increasing	  plasma	  insulin	   in	  response	  to	  HFD	  feeding.	  
However,	  the	  male	  mice	  that	  have	  no	  ovaries	  and	  only	  low	  levels	  of	  E2	  derived	  from	  other	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tissues	  are	  very	  well	  able	  to	  increase	  insulin	  levels,	  which	  suggests	  that	  this	  strong	  effect	  in	  
the	   males	   is	   due	   to	   some	   E2-­‐independent	   mechanisms,	   possibly	   the	   male	   hormones	   or	  
other	   features	   that	  distinguish	  males	   from	   females.	  Dandona	  et	   al.	   recently	   showed	   that	  
testosterone	   increases	   insulin	   sensitivity	   in	   men.387	   Hypogonadal	   men,	   presenting	   a	   low	  
level	  of	  testosterone,	  were	  randomized	  to	  receive	   intramuscular	   injection	  of	  testosterone	  
or	   placebo	   every	   two	   weeks	   for	   24	   wks.	   The	   men	   treated	   with	   testosterone	   had	   an	  
increased	  insulin	  sensitivity,	  lean	  mass	  and	  decreased	  subcutaneous	  fat.	  They	  also	  showed	  
a	   higher	   expression	   of	   genes	   implicated	   in	   insulin	   signaling	   such	   as	   IR-­‐β,	   IRS-­‐1,	   Akt2	   and	  
GLUT4	   in	  adipose	  tissue	  compared	  to	  before	   testosterone	  treatment.	  They	  observed	  that	  
low	   testosterone	   levels	   were	   associated	   with	   decreased	   insulin	   sensitivity	   and	   proposed	  
that	  low	  testosterone	  contributes	  to	  T2DM.387	  
	  
Increased	   adiposity	   is	   thought	   to	   be	   implicated	   in	   the	   onset	   of	   insulin	   resistance	   and	  
diabetes	  through	  the	  secretion	  of	  adipokines,	  which	  may	  lead	  to	  pancreatic	  dysfunction.	  As	  
discussed	  above	  (4.3),	  we	  noted	  that	  the	  OVX-­‐female	  mice	  have	  a	  higher	  adiposity	  than	  the	  
sham-­‐female	   after	   CTD	   and	   during	   early	   stages	   of	   HFD	   feeding.	   On	   the	   other	   hand,	   we	  
noticed	  that	  22	  wks	  of	  HFD	  did	  not	  increase	  plasma	  insulin	  in	  these	  OVX	  mice,	  in	  contrast	  to	  
the	  sham-­‐female	  and	  male	  mice	  that	  increased	  their	  plasma	  insulin.	  This	  could	  suggest	  that	  
at	  22	  wks	  of	  HFD	  the	  OVX	  mice	  already	  passed	  the	  first	  stage	  of	  diabetes	  characterized	  by	  
increased	   insulin	   levels	   or	   that	   these	   OVX	   mice	   are	   not	   insulin	   resistant	   at	   all	   at	   this	  
timepoint.	  However,	  their	  increased	  glucose	  intolerance	  tested	  by	  GTT	  would	  rather	  point	  
toward	  a	  more	  advanced	  diabetes	  state	  than	  the	  other	  groups.	  Another	  possibility,	  would	  
be	   that	   the	   absence	   of	   ovarian	   hormones	   is	   directly	   responsible	   for	   the	   absence	   of	  
overproduction	  of	   insulin	  in	  response	  to	  HFD	  as	  the	  sham-­‐female	  and	  male	  groups	  do.	  To	  
further	  investigate	  these	  possibilities,	  it	  would	  be	  interesting	  to	  evaluate	  the	  plasma	  insulin	  
at	  an	  earlier	  timepoint.	  In	  a	  previous	  study,	  we	  observed	  that	  the	  OVX	  mice	  have	  a	  higher	  
level	   of	   visceral	   fat	   than	   the	   sham-­‐female	  mice	   at	   the	   early	   time	  point	   of	   5	  wks	   of	  HFD,	  
which	   could	   contribute	   to	   more	   severe	   insulin	   resistance	   already	   at	   this	   stage.	   This	  
observation	  matches	  our	  hypothesis	  that	  the	  absence	  of	  ovarian	  hormones	  is	  leading	  to	  a	  
premature	  onset	  of	  insulin	  resistance	  compared	  to	  the	  female	  with	  intact	  ovaries.	  
	  
Estrogen	  has	  been	  reported	  to	  be	  involved	  in	  insulin	  secretion	  from	  pancreatic	  beta	  cell	  as	  
reviewed	  in	  this	  article.388	  Prossnitz	  et	  al.	  showed	  that	  activation	  of	  GPER	  by	  E2	  or	  the	  GPER	  
specific	   agonist	   G-­‐1	   induces	   insulin	   secretion	   from	   the	   beta	   pancreatic	   cells	   via	   the	  
activation	  of	  epidermal	  growth	   factor	   (EGF)	   receptor	  and	  ERK	  pathways.	   Insulin	  secretion	  
was	   inhibited	  by	  the	  GPER	  antagonist	  G-­‐15	  and	  absent	   in	  the	   isolated	  islet	  from	  GPER	  KO	  
mice.325	   Another	   study	   demonstrated	   that	   both	   receptors	   ERα	   and	   ERβ	   are	   present	   in	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isolated	   beta	   pancreatic	   islets	   from	  mice.	   They	   observed	   that	   long-­‐term	   exposure	   to	   E2	  
increased	  beta	   cell	   insulin	   content,	   insulin	   expression	   and	   insulin	   release.	  Using	   ERα	   and	  
ERβ	  agonists	  and	  KO	  mice,	  they	  suggested	  that	  it	  is	  the	  ERα	  that	  induces	  this	  effect	  via	  the	  
activation	  of	  ERK1/2	  pathway.389	  Moreover,	  studies	  also	  proved	  that	  testosterone	  acts	  on	  
the	  pancreatic	  beta	  cells.	  Male	  mice	  with	  beta	  cell-­‐selective	  androgen	  receptor	  deficiency	  
(βARKO)	   showed	   a	   decreased	   glucose-­‐stimulated	   insulin	   secretion	   (GSIS)	   resulting	   in	  
glucose	   intolerance.390	  Mice	  developed	  hypoinsulinemia	  and	  hyperglycemia	  after	  western	  
diet	   feeding.	   In	  cultured	  male	  human	  and	  mouse	   islets,	   testosterone	   increased	  GSIS.	  This	  
effect	   was	   absent	   in	   the	   βARKO	   mice	   and	   in	   human	   islets	   treated	   with	   the	   androgen	  
receptor	  antagonist	   flutamide,	  proving	   that	   indeed	   testosterone	   increases	  GSIS	   via	  direct	  
androgen	  receptor	  activation	  in	  islet	  beta	  cells.390	  	  
	  
The	  mechanisms	  involved	  in	  sex	  differences	  in	  glucose	  clearance	  are	  not	  clear	  but	  may	  be	  
related	  to	  insulin	  secretion	  from	  the	  pancreas.	  Different	  studies	  were	  performed	  to	  assess	  
this	  question	  and	  some	  discrepancies	  were	  reported.	  In	  a	  clinical	  study,	  healthy	  young	  men	  
and	  women	  had	  similar	  insulin	  secretion.391	  Flanagan	  et	  al.	  demonstrated	  that	  after	  glucose	  
infusion,	   female	   have	   higher	   first	   phase	   insulin	   secretion	   than	   age-­‐matched	   men,	  
suggesting	  that	  females	  were	  less	  insulin	  sensitive	  than	  males.287	  This	  was	  consistent	  with	  
an	   experimental	   study	   where	   female	   rat	   hearts	   were	   less	   sensitive	   to	   insulin	   than	  male	  
hearts.392	  However,	  other	  rodent	  studies	  show	  that	  female	  have	  greater	  insulin	  sensitivity	  
and	   lower	   insulin	   resistance	   compared	   to	   male	   fed	   a	   high	   fat	   diet,393	   which	   was	   also	  
confirmed	   by	   our	   own	   findings	   as	   plasma	   insulin	   in	   sham-­‐female	   mice	   was	   only	   lightly	  
increased	   after	   HFD	   compared	   to	   the	   male	   group	   where	   the	   effect	   was	   much	   more	  
pronounced.	  On	   the	  other	  hand,	  one	   study	   showed	   that	  OVX	   in	   rats	  did	  not	  alter	   insulin	  
sensitivity,341	   suggesting	   that	  ovarian	  hormones	  are	  not	   implicated	  and	  that	   regulation	  of	  
insulin	  sensitivity	  is	  complex.	  Rats	  fed	  with	  HFD	  for	  12	  wks	  gave	  rise	  to	  a	  similar	  increase	  in	  
body	   weight	   in	   both	   genders,	   nevertheless	   only	   males	   displayed	   hyperinsulinemia,	  
hyperglycemia,	   and	   reduced	   ejection	   fraction,	   underlining	   a	   gender	   difference.394	  
Additionally,	  it	  has	  been	  shown	  that	  in	  cardiomyocytes	  from	  women	  and	  men	  treated	  with	  
estrogen,	  the	  gene	  profile	  was	  different	  on	  36	  estrogen-­‐dependent	  genes,	  supporting	  that	  
estrogen	  effects	  on	  the	  heart	  are	  sex-­‐specific.395	  
	  
Estrogen	  is	  known	  to	  interact	  with	  a	  major	  player	  in	  glucose	  metabolism,	  Akt,	  which	  might	  
explain	  its	  role	  in	  regulating	  insulin	  sensitivity.396	  Indeed,	  consistent	  with	  our	  own	  findings,	  
it	   has	   been	   described	   that	   premenopausal	   women	   have	   greater	   insulin	   sensitivity	   than	  
men,396	   and	   that	   menopause	   or	   OVX	   is	   inducing	   a	   rapid	   decline	   in	   insulin	   sensitivity.397	  
Although	  women	  have	  a	  higher	  body	  fat	  content,	  they	  have	  a	  lower	  risk	  to	  develop	  insulin	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resistance	   and	   T2DM	   than	  men398	   because	   of	   their	   higher	   insulin	   sensitivity	   and	   glucose	  
clearance.399	  Nevertheless,	  postmenopausal	  women	  exhibit	  a	  lesser	  insulin	  sensitivity	  than	  
age-­‐matched	  men,	  underlining	  the	  role	  of	  E2	   in	  regulating	   insulin	  sensitivity	   in	  women.397	  
Concordantly,	   OVX	   mice	   and	   rats	   show	   insulin-­‐resistance	   and	   altered	   contraction-­‐
stimulated	  glucose	  uptake	  into	  muscle.400	  It	  has	  recently	  been	  reported	  that	  a	  specific	  ERα	  
agonist	   is	   necessary	   to	   maintain	   a	   normal	   cardiac	   glucose	   uptake	   in	   a	   mouse	   model.321	  
Moreover,	  women	  and	   female	   rodents	  are	  protected	  against	  high	   fat	  diet	  and	   fatty	  acid-­‐
induced	  insulin	  resistance,	  whereas	  male	  rodents	  fed	  with	  a	  high	  fat	  diet	  showed	  a	  decline	  
of	  40-­‐50%	  in	  insulin-­‐stimulated	  glucose	  disposal,	  indicating	  reduced	  insulin	  sensitivity.401,402	  
A	  mouse	  model	  of	  OVX	  mice	  fed	  with	  high	  fat	  diet	  had	  demonstrated	  that	  E2	  replacement	  
was	  able	  to	  improve	  glucose	  and	  insulin	  sensitivity	  in	  skeletal	  muscle	  of	  wild-­‐type	  mice	  but	  
not	   in	  knock-­‐out	  ERα	  mice,	  confirming	  that	  ERα	  has	  an	   important	  role	   in	  preventing	  from	  
diet-­‐induced	   obesity	   consequences	   and	   could	   be	   a	   potential	   target	   in	   the	   treatment	   of	  
obesity.317-­‐319	   E2	   may	   also	   regulate	   glucose	   and	   energy	   metabolism	   via	   the	   control	   of	  
glucose	  transporters	  GLUT3	  and	  GLUT4.403-­‐406	  	  
	  
In	  summary,	  our	  analysis	  of	  body	  weight,	  fat	  content,	  glucose	  tolerance	  and	  plasma	  insulin	  
demonstrates	  that	  1.	  After	  HFD	  feeding,	  male	  mice	  have	  less	  adipose	  tissue,	  similar	  glucose	  
tolerance	   but	   higher	   plasma	   insulin,	   suggesting	   that	   they	   are	   less	   insulin-­‐sensitive	   than	  
sham-­‐female	  mice.	  2.	  After	  HFD-­‐feeding,	  OVX-­‐female	  have	  a	   similar	   fat	  content	  as	   sham-­‐
female	   mice	   but	   a	   higher	   glucose	   intolerance,	   suggesting	   that	   adipose	   tissue	   is	   not,	  
whereas	  E2	  is	  implicated	  in	  the	  observed	  glucose	  intolerance.	  3.	  The	  absence	  of	  increased	  
plasma	   insulin	   after	   HFD	   in	   the	   OVX-­‐female	   mice	   could	   explain	   their	   more	   pronounced	  
glucose	   intolerance	   compared	   to	   the	   sham-­‐female	   mice.	   The	   lacking	   increase	   in	   plasma	  
insulin	  together	  with	  reduced	  glucose	  tolerance	  suggests	  that	  OVX	  female	  mice	  may	  be	  at	  a	  
more	   advanced	   stage	   of	   insulin	   resistance	   than	   the	   female	  mice.	   However,	   their	   fasting	  
glucose	  concentration	  was	  still	  normal,	  so	  the	  OVX	  mice	  are	  not	  yet	  diabetic.	  	  
	  
 4.5 High	  fat	  diet	  increases	  heart	  rate	  
In	  our	  model,	  HFD	  caused	  an	  overall	  decrease	  in	  systolic	  blood	  pressures	  and	  this	  decrease	  
was	  significant	  in	  the	  OVX	  group	  after	  19	  wks	  of	  feeding.	  An	  initial	  decrease	  in	  the	  systolic	  
blood	  pressure	  of	  the	  OVX	  mice	  compared	  with	  the	  sham-­‐female	  was	  observed	  at	  8	  wks	  of	  
chow	  diet,	  this	  effect	  may	  be	   interpreted	  as	  a	  negative	  feedback	   loop	  to	  compensate	  the	  
absence	   of	   ovarian	   hormones,	   which	   could	   have	   led	   to	   an	   increase	   in	   blood	   pressure.	  
Additionally,	  the	  HFD	  decreased	  the	  diastolic	  blood	  pressure	  in	  the	  male	  at	  8	  and	  19	  wks	  of	  
diet,	  as	  well	  as	  in	  the	  OVX-­‐female	  mice	  at	  the	  8	  wks	  time	  point,	  but	  not	  in	  the	  sham-­‐female	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group.	   The	  diastolic	  blood	  pressure	  was	  higher	   in	   the	  male	   than	   in	   the	   female	   after	  CTD	  
feeding,	  thus	  revealing	  sex-­‐dimorphism.	  	  
	  
Several	   epidemiological	   studies	   showed	   a	   strong	   positive	   correlation	   between	   CVD	   and	  
both	  systolic	  and	  diastolic	  blood	  pressures.407,408	  The	  Framingham	  Study	  demonstrated	  that	  
high	   SBP	   rather	   than	   high	   DBP	   is	   the	   best	   predictor	   of	   all-­‐cause	   and	   cardiovascular	  
mortality.409	  In	  this	  study	  and	  in	  others	  it	  was	  shown	  that	  after	  adjustment	  of	  the	  high	  SBP,	  
the	   DBP	   does	   not	   correlate	   with	   CVD	   risk,	   proving	   that	   DBP	   data	   used	   in	   many	   clinical	  
studies	  are	  not	  sensitive	  enough	  to	  determine	  CVD	  risk.409,410	  Maybe	  the	  decreased	  systolic	  
blood	  pressures	  observed	  in	  our	  obesity	  mouse	  model	  can	  therefore	  be	  seen	  as	  beneficial	  
adaptation?	  Or	  are	  the	  reduced	  pressures	  related	  to	  a	  general	  less	  active	  state	  of	  the	  obese	  
mice	   and	   a	   reduced	   ejected	   volume	  during	   cardiac	   systole?	  Against	   this	   latter	   possibility	  
speaks	  our	  echocardiography	  data,	  which	  did	  not	  reveal	  any	  reduced	  ejected	  volumes.	  	  
	  
Further	   investigations	   are	   required	   to	   assess	   the	   reason	   for	   the	   reduced	   pressures.	   For	  
example,	   measurements	   of	   peripheral	   resistance	   could	   be	   done,	   because	   increased	  
resistance	   elevates	  DBP.	   Also	   the	   large	   arteries	   condition	   could	   be	   investigated,	   because	  
their	   stiffening	   can	   induce	   a	   decrease	   in	   DBP.411,412	   A	   study	   by	   Witteman	   et	   al.	  
demonstrated	   that	   in	   women,	   a	   decrease	   in	   DBP	   during	   a	   nine-­‐year	   follow-­‐up	   was	  
associated	  with	   a	  progression	  of	   atherosclerotic	   lesions	  of	   the	  aorta,	   and	   thus	   suggested	  
that	   the	  DBP	  could	  be	  a	  marker	  of	  atherosclerosis.413	  Based	  on	   these	  clinical	   studies,	   the	  
decrease	  in	  DBP	  observed	  in	  our	  male	  and	  OVX-­‐female	  mice	  at	  8	  wks	  of	  diet	  could	  be	  due	  
to	  a	  stiffening	  of	  large	  arteries,	  however,	  it	  would	  be	  difficult	  to	  verify	  this	  hypothesis	  in	  our	  
mouse	  model,	   because	   this	   effect	  was	  observed	   as	   early	   as	   8	  wks	  of	   diet,	   and	   at	   a	   later	  
stage	   this	   effect	   is	   less	   pronounced.	   Thus,	   we	   cannot	   draw	   any	   conclusion	   on	   the	  
significance	  of	  this	  small	  decrease	  observed	  after	  HFD.	  	  
	  
In	   the	  metabolic	   syndrome,	  obesity	   is	  often	  associated	  with	   increased	  blood	  pressures414	  
and	   therefore	   we	   were	   initially	   surprised	   to	   find	   decreased	   pressures.	   However,	   many	  
experimental	  rodent	  models	  have	  failed	  to	  detect	  spontaneous	  hypertension	  under	  after	  a	  
high	   fat	   diet.415,416	   Generally,	   an	   additional	   hypertension	   inducer	   such	   as	   genetic417	   and	  
environmental	   factors	   (e.g.	  high-­‐salt	  diet418),	   hormones	   (e.g.	   angiotensin	   II)419-­‐421	  or	   renal	  
abnormalities422	  are	  needed	  to	  trigger	  hypertension	  in	  rodents.	  Moreover,	  blood	  pressure	  
changes	  are	  not	  observed	  in	  rodents	  lacking	  of	  estrogen,	  consistent	  to	  our	  findings.349-­‐352	  
	  
Our	   non-­‐invasive	   tail-­‐cuff	   blood	   pressure	   measurements	   also	   revealed	   changes	   in	   heart	  
rates,	   which	   were	   systematically	   increased	   after	   HFD	   in	   all	   three	   groups.	   This	   could	   be	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explained	   by	   the	   fact	   that	   HFD	   feeding	   importantly	   increased	   the	   body	   weight,	   and	  
therefore	  the	  need	  for	  body	  oxygenation	  should	  in	  this	  case	  be	  larger	  than	  in	  the	  mice	  fed	  
with	  CTD.	  Thus,	  to	  sufficiently	  perfuse	  the	  organs	  of	  a	  bigger	  mouse,	  the	  heart	  has	  to	  pump	  
faster.	   This	   may	   also	   help	   to	   reach	   sufficient	   output	   with	   lower	   systolic	   pressures.	   It	   is	  
noteworthy	  however	   that	   the	  tail-­‐cuff	  measurement	  method	  to	  assess	  blood	  pressures	   is	  
not	  the	  most	  reliable	  technique	  although	  it	  has	  the	  advantage	  to	  evaluate	  blood	  pressures	  
of	   wake	   animals.	   To	   obtain	   more	   precise	   and	   reliable	   results	   the	   use	   of	   a	   direct	   blood	  
pressure	  measurement	  method	  such	  as	  radio-­‐telemetry	  would	  have	  been	  preferred.	  	  
	  
 4.6 High	  fat	  diet	  alters	  cardiac	  function	  and	  geometry	  
Ejection	   fractions	   and	   fractional	   shortening	   were	   not	   altered	   by	   HFD,	   gender	   or	  
ovariectomy,	   indicating	   that	   systolic	   function	   was	   preserved.	   We	   used	   the	   E/A	   ratio	   to	  
evaluate	  diastolic	  function.	  Whereas	  the	  male	  mice	  did	  not	  exhibit	  any	  change	  at	  22	  wks,	  
the	   female	  mice	   fed	  with	  HFD	  had	  decreased	  E/A	  ratios,	   suggesting	  diastolic	  dysfunction.	  
Thus,	   female	  and	  male	  mice	   respond	  differently	   to	   the	  HFD	  with	   the	   females	  developing	  
diastolic	  dysfunction	  irrespective	  of	  their	  ovarian	  hormone	  levels.	  It	  is	  known	  that	  the	  E/A	  
ratio	   evolves	   along	   with	   the	   pathology	   development.	   First	   the	   ratio	   is	   elevated	   when	  
diastolic	  dysfunction	  is	  mild	  and	  then	  it	  decreases	  revealing	  severe	  diastolic	  dysfunction.423	  
Therefore,	  our	  data	  suggest	  more	  advanced	  diastolic	  dysfunction	  in	  female	  mice,	  whereas	  
male	  mice	  present	  normal	  function	  after	  22	  wks	  of	  HFD.	  
	  
Interestingly,	   cardiac	   geometry	   was	   modified	   in	   sham-­‐female	   mice	   by	   HFD,	   as	   the	   HFD	  
increased	  the	  relative	  wall	  thickness	  and	  also	  caused	  a	  trend	  toward	  increased	  LVPW	  during	  
diastole	   (p=0.06)	  compared	  with	  CTD.	  The	   increased	  relative	  wall	   thickness	   together	  with	  
the	  unchanged	  LV	  mass	  does	  not	  point	  toward	  a	  hypertrophic	  LV,	  but	  to	  simple	  concentric	  
LV	   remodeling.24	   On	   the	   other	   hand,	   the	   diastolic	   LV	   anteroseptal	   wall	   thickness	   was	  
increased	  only	   in	   the	  OVX-­‐female	  after	  HFD	  compared	  to	  CTD.	  These	  distinct	   increases	   in	  
wall	  thickness	  may	  reflect	  cardiac	  remodeling	  as	  an	  adaptation	  to	  the	  HFD	  in	  both	  female	  
groups,	   albeit	   different	   parts	   of	   the	   ventricular	   wall	   were	   affected.	   No	   increase	   in	  
ventricular	  mass	  was	  measured	  between	  CTD-­‐	  and	  HFD-­‐fed	  sham-­‐	  and	  OVX-­‐female	  mice,	  
and	  this	  absence	  of	  hypertrophy	  was	  confirmed	  by	  the	  WGA	  staining,	  which	  did	  not	  reveal	  
any	  major	   differences	   in	   cross-­‐sectional	   area	   between	  our	   different	   experimental	   groups	  
(Supplement,	   Figure	   S	   VIII).	   The	   effects	   on	   wall	   thickness	   were	   maybe	   too	   small	   to	   be	  
revealed	   as	   a	  weight	   change	   in	   the	  whole	   ventricle.	   Alternatively,	   as	   the	   effect	  was	   only	  
significant	  during	  diastole,	  it	  may	  indicate	  reduced	  relaxation.	  In	  that	  case,	  the	  end-­‐diastolic	  
diameter	   and	   volume	   is	   expected	   to	   be	   smaller.	   In	   fact,	   HFD	   reduced	   end-­‐diastolic	   LV	  
volume	   only	   in	   the	   male	   group.	   This	   moderately	   decreased	   filling	   volume	   may,	   besides	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reduced	   relaxation,	   also	   be	   related	   to	   a	   beginning	   of	   thickening	   of	   the	  wall	   in	   the	  male	  
group.	   Indeed,	   there	  were	   some	   small	   increases	   in	  wall	   thickness	   after	   HFD	   in	   the	  male	  
group,	  but	  these	  did	  not	  reach	  significance.	  	  
	  
To	  summarize,	  the	  E/A	  ratio,	  which	  was	  decreased	  in	  the	  female	  groups	  after	  HFD,	  points	  
toward	   diastolic	   dysfunction,	   however	   the	   absence	   of	   impaired	   cardiac	   relaxation	   or	  
increased	   stiffness	   do	   not	   further	   corroborate	   for	   this	   conclusion.	   Moreover,	   the	  
pathophysiological	  explanation	  of	  diastolic	  dysfunction	  relies	  on	  the	  fact	  that	  filling	  of	  the	  
ventricles	  and	  cardiac	  output	  take	  place	  normally	  to	  the	  detriment	  of	  abnormal	  elevation	  of	  
cardiac	   filling	   pressures.424	  Our	   PVL	   results	   showed	   no	   elevated	   pressures,	   strengthening	  
the	  view	  that	  our	  experimental	  model	  does	  not	  exhibit	  a	  high	  level	  of	  cardiac	  stress.	  Taken	  
together,	  our	  data	  suggest	  that	  our	  female	  mice	  exhibit	  mild	  diastolic	  dysfunction.	  
	  
Our	  results	  obtained	  with	  the	  pressure-­‐volume	  loop	  technique	  showed	  significant	  changes	  
in	  hemodynamic	  parameters.	  The	  peak-­‐filling	  rate	  dV/dt	  max	  represents	  the	  active	  cardiac	  
relaxation	  and	  is	  translated	  as	  the	  speed	  of	  transition	  between	  the	  contracted	  and	  dilated	  
state.	   This	   parameter	   is	   closely	   linked	   to	   the	   calcium	   reuptake	   in	   the	   sarcoplasmic	  
reticulum.	  Noteworthy,	   the	  HFD	   feeding	   in	  males	   caused	   a	   strong	   decrease	   of	   the	   peak-­‐
filling	  rate,	  suggesting	  that	  their	  ventricular	  relaxation	  was	  slower.	  This	  could	  be	  explained	  
by	  a	  lack	  of	  LV	  elasticity	  or	  by	  a	  slower	  reuptake	  of	  calcium	  into	  the	  SR.	  The	  emptying	  peak	  
rate	  dV/dt	  min	  was	  also	  decreased	  in	  the	  male	  group	  after	  HFD.	  This	  parameter	  is	  related	  
to	   the	   rate	  of	   contraction	   and	   could	  be	   affected	  by	   calcium	   storage	   in	   the	   SR.	   Thus,	   our	  
observation	  that	  HFD	  reduces	  the	  contractility	  rate	  in	  males	  suggests	  a	  decrease	  in	  calcium	  
or	  a	  slower	  release	  of	  calcium	  via	  the	  ryanodine	  receptors	  to	  enable	  contraction.	  SERCA2	  
and	   phospholamban	   are	   two	   proteins	   regulating	   contractility.	   When	   phosphorylated	   by	  
PKA,	  phospholamban	  releases	  its	   inhibition	  on	  SERCA2,	  which	  becomes	  activated	  to	  allow	  
calcium	  reuptake	  into	  the	  SR.	  In	  this	  regard,	  these	  regulatory	  proteins	  could	  play	  a	  role	  in	  
the	  calcium	  reuptake	  rate,	  which	  is	  linked	  to	  the	  peak	  filling	  rate	  dV/dt	  min	  and	  the	  calcium	  
availability,	  which	   is	  related	  to	  the	  filling	  rate	  dV/dt	  max.	  Our	  protein	  analysis	  shows	  that	  
SERCA2	   and	   phospholamban	   expression	   were	   not	   regulated	   by	   HFD	   in	   the	   male	   group,	  
suggesting	  that	  other	  players	  should	  be	  involved	  in	  the	  observed	  changes	  in	  dV/dt	  min	  and	  
dV/dt	  max.	  A	  change	   in	  heart	   rate	  could	  also	  have	  explained	   the	  difference	  of	   relaxation	  
and	  contraction,	  indeed	  a	  lower	  heart	  rate	  would	  lead	  to	  a	  lower	  relaxation	  and	  contraction	  
rates.	  However,	  heart	  rate	  was	  not	  different	  between	  male	  fed	  with	  CTD	  and	  HFD.	  
	  
Whereas	  in	  the	  male	  group	  the	  dV/dt	  min	  and	  dV/dt	  max	  were	  negatively	  affected	  by	  HFD,	  
in	   the	   sham-­‐female	   group	   these	   two	   parameters	   were	   already	   lower	   than	   in	   the	   male	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under	  CTD	  conditions,	  and	  were	  not	  affected	  by	  the	  HFD,	  highlighting	  a	  gender	  difference	  
in	   the	   rate	  of	   cardiac	   relaxation	   and	   contraction.	   Thus,	   the	  males	   reached	   the	   relaxation	  
and	   contraction	   stage	   more	   rapidly	   than	   the	   female	   under	   normal	   diet	   conditions.	   Our	  
western	   blotting	   analysis	   showed	   that	   these	   differences	  were	   associated	  with	   decreased	  
phospho-­‐PLN	  pentamer,	  whereas	  SERCA2,	  PLN	  monomer	  or	  cardiac	  contraction	  rates	  were	  
not	  changed.	  This	  suggests	  that	  different	  protagonists	  are	  involved	  in	  the	  decreased	  dV/dt	  
min	   and	   dV/dt	   max	   differences.	   Finally,	   increasing	   cardiac	   work	   with	   dobutamine	   was	  
necessary	   to	   uncover	   an	   effect	   of	   OVX.	   At	   the	   highest	   dose	   of	   dobutamine,	   the	   peak	  
emptying	  rate	  dV/dt	  min	  was	  lower	  in	  the	  OVX-­‐	  than	  the	  sham-­‐female	  mice	  after	  HFD.	  The	  
heart	   rate	   in	   this	   case	   could	   have	   been	   implicated,	   only	   a	   trend	  was	   observed	   toward	   a	  
reduced	  heart	  rate	  in	  the	  OVX-­‐female	  mice	  after	  HFD	  (p=0.08)	  during	  PVL	  measurements.	  
In	  conclusion,	  males	  have	  faster	  filling	  and	  emptying	  rates	  than	  females,	  but	  these	  rates	  are	  
reduced	  after	  HFD	  in	  males	  (reaching	  values	  similar	  to	  those	  observed	  in	  females)	  whereas	  
HFD	  has	  no	  such	  effects	  in	  females.	  The	  absence	  of	  ovarian	  hormones	  decreases	  emptying	  
peak	   rates	   in	   females,	   but	   only	   after	   HFD	   feeding	   and	   under	   conditions	   of	   high	   cardiac	  
work.	  
	  
At	  baseline,	   the	  HFD-­‐fed	  sham-­‐female	  mice	  had	  a	   lower	  end-­‐diastolic	  pressure	   than	  their	  
control	  fed	  with	  CTD,	  this	  effect	  of	  HFD	  was	  not	  observed	  in	  the	  OVX	  neither	   in	  the	  male	  
groups	  highlighting	  a	  specific	  role	  of	  ovarian	  hormones	  and	  a	  gender-­‐specificity.	  As	  for	  the	  
end-­‐diastolic	  pressure	  changes	  under	  dobutamine	  stress	  conditions,	  similarly	   the	  HFD-­‐fed	  
sham-­‐female	  mice	  had	  a	  trend	  towards	  decreased	  end-­‐diastolic	  pressures.	  Again	  this	  effect	  
was	   not	   observed	   after	   OVX	   and	   in	   the	  male	   group.	   Additionally,	   we	   observed	   that	   the	  
infusion	   of	   dobutamine	   decreased	   even	   more	   the	   end-­‐diastolic	   pressure	   in	   the	   sham-­‐
female	  and	  not	  in	  the	  OVX-­‐female	  mice	  creating	  a	  difference	  between	  the	  sham	  and	  OVX	  
mice,	  the	  latter	  having	  a	  higher	  end-­‐diastolic	  pressure.	  	  
	  
In	  the	  sham-­‐female	  group,	  HFD	  caused	  lower	  end-­‐diastolic	  pressures	  than	  CTD,	  suggesting	  
their	  ability	   to	  adapt.	  Knowing	   the	  deleterious	  effect	  of	  HFD,	  we	  propose	   that	   the	   sham-­‐
female	  mice	  adapt	   to	   this	  harmful	   situation	  by	  decreasing	   their	   end-­‐diastolic	  pressure	   to	  
limit	  or	  compensate	   for	   the	  expected	   increase	  of	  pressure	  due	  to	  the	  HFD.378	  Concerning	  
the	  male,	   the	   end-­‐diastolic	   pressure	  was	   not	   changed	   by	   the	   diet	   and	  was	   not	   different	  
compared	  with	  the	  female.	  This	  is	  suggesting	  that	  female	  mice	  and	  not	  male	  nor	  OVX	  are	  
able	  to	  decrease	  their	  end-­‐diastolic	  pressure	  as	  a	  protective	  mechanism	  in	  response	  to	  HFD	  
and	  dobutamine.	  Thus	  our	  results	  indicate	  a	  role	  of	  the	  ovarian	  hormones	  and	  the	  presence	  
of	  a	  gender	  difference.	  The	  end-­‐diastolic	  pressure	   is	  an	   important	  parameter	   to	  evaluate	  
diastolic	   function.	   Menopause	   induces	   a	   higher	   risk	   of	   diastolic	   dysfunction,425,426	   at	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baseline	  no	  differences	  were	  observed	  between	  sham	  and	  OVX-­‐female	  mice	  at	  least	  at	  this	  
stage.	  	  
	  
The	   end-­‐systolic	   pressure	   volume	   relationship,	   ESPVR,	   is	   a	   measure	   of	   contractility.	   The	  
diet,	  the	  gender	  and	  the	  absence	  of	  ovarian	  hormones	  did	  not	  affect	  ESPVR	  in	  our	  mouse	  
model	   after	   22	   wks	   of	   diet.	   Similarly,	   the	   end-­‐diastolic	   pressure	   volume	   relationship,	  
EDPVR,	   was	   not	   modified	   under	   our	   conditions.	   This	   variable	   is	   a	   direct	   indicator	   of	   LV	  
compliance,	  the	  slope	  of	  this	  curve	  is	  inversely	  related	  to	  compliance,	  so	  when	  the	  slope	  is	  
increased,	  the	  compliance	  is	  decreased	  and	  the	  stiffness	  increased	  and	  vice	  versa.	  Our	  data	  
shows	  that	  the	  slope	  is	  not	  affected	  by	  diet,	  OVX	  or	  gender.	  Others	  groups	  have	  reported	  
that	  HFD	   induces	   cardiac	   hypertrophy427,428	   and	   that	   this	   could	  have	   an	   influence	  on	   the	  
end-­‐diastolic	   pressure	   volume	   relationship.	   The	   absence	   of	   striking	   hypertrophy	   is	   thus	  
matching	   the	   absence	   of	   defect	   in	   contractility	   and	   compliance.	   These	   two	   parameters	  
ESPVR	   and	   EDPVR	   were	   determined	   by	   occluding	   the	   vena	   cava	   to	   increase	   the	   venous	  
return.	  This	  method	  is	  well	  accepted	  to	  study	  cardiac	  contractility	  and	  compliance	  but	  was	  
sometimes	   difficult	   to	   perform	   due	   to	   the	   presence	   of	   considerable	   amounts	   of	   white	  
adipose	  tissue.	  This	  difficulty	  could	  explain	  the	  high	  variability	  observed	  in	  our	  experimental	  
groups,	  which	  masks	  possible	  effects.	  
	  
Diastolic	   dysfunction	   is	   characterized	  by	   an	   abnormal	  myocardial	   relaxation	   and	   filling	  of	  
the	  ventricle	  and	  is	  associated	  with	  obesity,	  diabetes,	  renal	  disease	  and	  hypertension.	  This	  
preclinical	  stage	  precedes	  systolic	  dysfunction	  in	  which	  the	  heart	  adapts	  to	  these	  changes	  
by	   increasing	   left	   atrial	   pressure	   to	   load	   the	   LV	   with	   an	   adequate	   volume	   before	  
contraction.424	  Our	  model	  showed	  that	  females	  exhibit	  moderate	  diastolic	  dysfunction	  and	  
that	  males	  are	  more	  sensitive	  than	  females	  to	  develop	  defects	  in	  cardiac	  cycle	  dynamics	  in	  
response	  to	  HFD	  feeding.	  	  
	  
Several	  other	  groups	  worked	  on	  describing	  and	  understanding	  gender-­‐differences	   related	  
to	   the	  cardiovascular	   impact	  of	  obesity.	  Louwe	  et	  al.	  described	  that	  after	  12	  wks	  of	  HFD,	  
cardiac	   function	   was	   defective	   only	   in	   male	   but	   not	   in	   female	   mice,	   independently	   of	  
enhanced	  plasma	  lipids	  that	  occurred	  in	  both	  genders.394	  More	  precisely,	  male	  exhibited	  an	  
increased	  end-­‐diastolic	  volume	  after	  6	  wks	  of	  HFD	  and	  after	  12	  wks,	  end-­‐systolic	  volume	  
was	  also	  increased,	  while	  ejection	  fraction	  was	  decreased,	  whereas	  female	  did	  not	  exhibit	  
any	   differences	   in	   cardiac	   function.	   Our	   own	   echocardiography	   data	   show	   that	   ejection	  
fractions	  stayed	  unchanged,	  suggesting	  no	  alteration	  of	  the	  systolic	  function	  in	  any	  of	  the	  
groups	   consistent	   with	   the	   preserved	   contractility	   (PVL	   experiment)	   and	   cardiac	   output.	  
Other	   studies	   demonstrated	   that	  male	   rats	   fed	  with	   high	   fat	   and	   high	   sucrose	   exhibited	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systolic	  dysfunction	  reflected	  by	  reduced	  fractional	  shortening	  and	  ejection	  fractions.140,429	  
However,	   this	   phenomenon	   was	   not	   found	   in	   male	   mice	   where	   ejection	   fractions	   were	  
unchanged	  after	  18	  wks	  of	  HFD.430	  The	  same	  authors	  described	  the	  presence	  of	  enhanced	  
LV	  posterior	  wall	  and	  interventricular	  septum	  thickness	  in	  HFD-­‐	  compared	  to	  CTD-­‐fed	  mice,	  
suggesting	   an	   adaptive	   answer	   to	   HFD.	   Brainard	   et	   al.	   demonstrated	   that	   HFD	   does	   not	  
influence	  heart	  structure	  and	  function	  in	  male	  mice	  after	  6	  months	  of	  diet431	  whereas	  Park	  
et	   al.	   showed	   a	   significant	   alteration	   of	   cardiac	   function	   after	   20	  wks	   of	   diet	   in	  male.432	  
Therefore,	  different	  opinions	  are	   found	  concerning	   the	  effect	  of	  HFD	  on	   cardiac	   function	  
and	   geometry.	   In	   our	   mouse	  model,	   no	   changes	   in	   ejection	   fraction	   were	   visible	   in	   the	  
male,	   female	   and	   OVX	   mice,	   suggesting	   that	   gender	   and	   ovarian	   hormones	   are	   not	  
implicated	  in	  the	  regulation	  of	  systolic	  function.	  Cardiac	  geometry	  was	  not	  modified	  in	  the	  
male	  group	  but	  only	   in	   the	   female	  after	  HFD,	  perhaps	  due	  to	  the	  ability	   to	  the	   female	  to	  
adapt.	   These	   discrepancies	   between	   studies	   suggest	   that	   duration	   of	   feeding,	   the	  model	  
that	  was	  used,	  and	  gender	  are	  major	  factors	  for	  the	  different	  results	  obtained.	  
	  
 4.7 Male	  and	  ovariectomized	  female	  mice	  have	  increased	  cardiac	  steatosis	  	  
In	  our	  model,	  high	   fat	  diet	   feeding	   induced	  a	  body	  weight	  gain	  associated	  with	   increased	  
visceral	  fat	  in	  all	  groups.	  The	  detection	  of	  lipids	  in	  the	  cardiac	  tissue	  revealed	  that	  after	  HFD	  
feeding,	   the	  male	   developed	  more	   severe	   cardiac	   steatosis	   than	   the	   sham-­‐female	  mice.	  
After	  CTD	  feeding,	  the	  lipid	  droplets	  visible	  in	  the	  male	  group	  were	  less	  numerous	  but	  of	  a	  
bigger	  size	  than	  in	  the	  sham-­‐female	  group.	  Previous	  studies	  have	  demonstrated	  that	  diet-­‐
induced	  obesity	   induces	  an	  abnormal	  accumulation	  of	  triglycerides	   in	  cardiomyocytes,	   i.e.	  
steatosis,	   and	   results	   in	   impaired	   cardiac	   function	   characterized	   by	   an	   increase	   in	   left	  
ventricle	   end-­‐diastolic	   diameter	   and	   altered	   contractile	   performance.433,434	   It	   is	   thought	  
that	   cardiac	   dysfunction	   develops	   because	   cardiac	   steatosis	   is	   associated	   with	   the	  
production	  of	   lipotoxic	   intermediates	   such	  as	   ceramides,	  which	  produce	   reactive	  oxygen,	  
and	  may	   lead	   to	  apoptosis.433	  Cardiac	  geometry	  and	   function	  were	  similar	  between	  male	  
and	  female	  after	  21	  wks	  of	  diet,	  however	  in	  female	  mice	  the	  HFD	  decreased	  the	  E/A	  ratio	  
and	  induced	  an	  increase	  in	  the	  relative	  wall	  thickness	  and	  LVPW	  as	  well	  as	  a	  reduced	  end-­‐
diastolic	   pressure.	   These	   effects	   of	   HFD	   feeding	   were	   not	   present	   in	   the	   male	   mice.	  
Whether	  our	  observation	  of	  a	  gender	  difference	   in	   steatosis	   is	  directly	   related	   to	   cardiac	  
dysfunction	  is	  not	  clear	  at	  this	  moment.	  
	  
In	  our	  study,	  the	  ablation	  of	  estrogen	  triggered	  a	  more	  pronounced	  cardiac	  accumulation	  of	  
lipids	   than	   in	   the	   sham-­‐female	   already	   when	   fed	   with	   CTD,	   and	   the	   HFD	   marked	   this	  
difference	  even	  further.	  Indeed,	  the	  increased	  number	  of	  lipid	  droplets	  associated	  with	  HFD	  
feeding	  was	  more	   important	   in	   the	  OVX-­‐	   group	   than	   in	   the	   sham-­‐
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observation	  might	   be	   linked	   to	   the	   fact	   that	   OVX	   induces	   an	   increase	   in	   total	   adiposity	  
suggesting	   the	   presence	   of	   a	   larger	   amount	   of	   free	   fatty	   acid.	   It	   will	   be	   interesting	   to	  
evaluate	  the	  level	  of	  lipotoxic	  intermediates,	  reactive	  oxygen	  species	  and	  apoptotic	  cells	  in	  
this	  context.	  
	  
 4.8 Effects	  of	  gender	  and	  ovariectomy	  on	  cardiac	  inflammation	  	  
The	   early	   stage	   of	   metabolic	   cardiomyopathy	   is	   associated	   with	   the	   onset	   of	   cellular	  
abnormalities	  such	  as	  oxidative	  stress,	  mitochondrial	  dysfunction,	  ER	  stress,	  and	  defective	  
calcium	   handling	   leading	   to	   impaired	   cardiac	   relaxation,	   however	   no	   structural	   or	  
functional	  changes	  are	  detected	  at	  this	  stage.	  At	  a	  more	  advanced	  stage	  of	  the	  pathology,	  
these	   abnormalities	   are	   enhanced	   and	   are	   accompanied	   by	   infiltration	   of	   inflammatory	  
cells	  and	  neurohumoral	  activation,	   together	  causing	  cardiomyocyte	  apoptosis	  and	  cardiac	  
fibrosis	   and	   leading	   to	   diastolic	   and	   systolic	   dysfunction.212,435	   The	   signs	   of	   diastolic	  
dysfunction	   that	  we	  observed	   in	  our	  model	  went	   along	  with	   small	   changes	   in	   the	  mRNA	  
levels	   of	   different	   important	   players	   of	   inflammation	   and	   fibrosis	   such	   as	   IL-­‐6,	   TNFα,	  
collagen	   I	   and	   collagen	   III.	   However,	   none	   of	   these	   changes	   reached	   significance	   at	   this	  
stage	   of	   the	   experiment	   regardless	   the	   conditions.	   Only	   small	   trends	   appeared	   toward	  
increased	   IL-­‐6	   mRNA	   expression	   in	   the	   OVX-­‐female	   compared	   to	   the	   sham-­‐female	   mice	  
after	  HFD,	  while	  TNFα	  increased	  in	  the	  OVX	  group	  after	  HFD.	  However,	  the	  NF-­‐κB	  inhibitory	  
protein	  IκBα	  was	  decreased	  in	  the	  sham-­‐female	  group	  after	  HFD	  indicating	  increased	  NF-­‐κB	  
activity.	  Consistently,	  we	  observed	  a	  small	  increase	  in	  phosphorylated	  NF-­‐κB,	  suggesting	  an	  
increased	   cardiac	   inflammatory	   response	   due	   to	   the	   HFD	   feeding	   in	   these	   sham-­‐female	  
mice.	   In	  obese	  mice,	   it	  has	  been	  described	  that	  TGF-­‐β-­‐Smad	  signaling	   is	  over-­‐activated	   in	  
the	   heart,436	   which	   is	   known	   to	   be	   triggered	   by	   inflammation	   and	   is	   thought	   to	   cause	  
fibrosis.	  Moreover,	   it	   has	  been	   reported	   that	  HFD-­‐induced	  obese	  mice	  have	  high	  protein	  
levels	  of	  TLR4	  and	  macrophage	  infiltration	  in	  the	  heart.437	  In	  line	  with	  this	  literature,	  in	  our	  
mouse	  model	  the	  Mac-­‐2	  staining	  revealed	  increased	  macrophage	  infiltration	  in	  the	  heart	  of	  
HFD-­‐fed	  mice	  along	  with	  the	  signs	  of	  fibrosis	  that	  we	  observed.	  	  
	  
Diastolic	   dysfunction	   associated	   with	   obesity	   has	   previously	   been	   related	   to	   enhanced	  
inflammation	   and	   collagen	   deposition.438-­‐440	   Consistent	   with	   the	   slightly	   increased	  
inflammation,	  our	  preliminary	  results	  of	  the	  Picrosirius	  red	  staining	  also	  did	  not	  reveal	  any	  
obvious	  difference	  between	  the	  groups,	  although	  a	  proper	  quantification	  still	  remains	  to	  be	  
done.	  It	  has	  been	  suggested	  that	  a	  hypertensive	  stimulus	  is	  needed	  for	  the	  development	  of	  
fibrosis	   in	  obesity,441	  hence	   the	  possible	   reason	  of	  our	  minor	  effects	  of	  HFD	  and	  OVX	  on	  
cardiac	   inflammation	   and	   fibrosis.	   Indeed,	   a	  model	   of	   hypertensive	  OVX	   rats	   showed	   LV	  
remodeling	   associated	   with	   increased	   collagen	   deposition	   and	   hypertrophy,	   which	   was	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reversed	   by	   the	   administration	   of	  GPER	   agonist	  G-­‐1.442	   This	   implies	   an	   important	   role	   of	  
estrogen	   in	   fibrosis.	   These	   results	  were	   partially	   in	   line	  with	   our	   own	   results	   as	   IL-­‐6	  was	  
increased	  in	  the	  OVX-­‐female	  compared	  to	  the	  sham-­‐female	  mice	  after	  HFD.	  Moreover,	  NF-­‐
κB	  and	  TNFα	  were	  also	  enhanced	  in	  the	  OVX	  female	  and	  not	  in	  the	  sham-­‐female	  mice	  after	  
HFD.	  Thus,	   it	  would	  be	  of	   interest	  to	  further	  investigate	  the	  effect	  of	  OVX	  and	  HFD	  in	  our	  
model	   and	   to	   appropriately	   quantify	   the	   histology	   result	   of	   the	   Picrosirius	   Red	   staining.	  
Moreover,	  given	  the	  fact	  that	  collagen	  deposition	  is	  not	  always	  associated	  with	  changes	  in	  
collagen	  and	  pro-­‐fibrotic	   genes	  expression,	   it	  will	   be	  worthy	   to	  evaluate	  other	  molecules	  
involved	  in	  extracellular	  matrix	  changes	  such	  as	  the	  matrix	  metalloproteinase	  (MMP)	  or	  the	  
tissue	  inhibitor	  of	  metalloproteinase	  (TIMP).443	  	  
	  
Taken	  together,	  our	  results	  show	  signs	  of	  inflammation	  and	  fibrosis	  in	  line	  with	  mild	  effects	  
of	  HFD	  and	  OVX	  on	  cardiac	  geometry	  and	  function	  as	  measured	  by	  echocardiography	  and	  
PVL	   analysis,	   and	   are	   suggestive	   of	   diastolic	   dysfunction.	  Moreover,	   our	   results	   indicate	  
that	  E2	  may	  be	  implicated	  in	  the	  maintenance	  of	  anti-­‐inflammatory	  effects	  in	  the	  heart.	  
	  
 4.9 High	  fat	  diet	  decreases	  the	  cardiac	  stress	  marker	  ANP	  in	  female	  mice	  
BNP	  levels	  are	  often	  used	  as	  prognostic	  marker	  of	  heart	  failure	  and	  in	  animal	  models	  both	  
ANP	   and	   BNP	   are	   used	   as	   markers	   of	   cardiac	   stress	   and	   hypertrophy.444,445	   Our	   mouse	  
model	  showed	  unexpected	  results	  concerning	  these	  markers.	  First	  of	  all,	  the	  HFD	  strongly	  
decreased	   ANP	   levels	   in	   both	   female	   groups,	   but	   not	   in	   the	   male	   group.	   A	   possible	  
interpretation	   is	   that	   the	  hemodynamic	  stress	  or	  hypertrophy	   induced	  by	  HFD	   (we	   found	  
only	   small	   effects	   on	   wall	   thickness,	   see	   above)	   was	   not	   sufficient	   to	   increase	   the	  
expression	  of	  ANP.	   It	  was	  even	  decreased	  in	  the	  females,	  suggesting	  that	  their	  hearts	  are	  
less	   stressed.	   The	  decreased	   levels	   in	  both	   female	  groups	  may	  however	  also	  be	  harmful,	  
because	   ANP	   exerts	   beneficial	   effects	   through	   its	   natriuretic	   action,	   by	  which	   it	   reduces	  
blood	  pressure.	  In	  our	  study,	  any	  changes	  in	  blood	  pressure	  that	  may	  have	  happened	  were	  
below	  detection	  level.	  It	  has	  been	  shown	  that	  deregulation	  of	  the	  endogenous	  cardiac	  ANP	  
and	   its	   receptor	   might	   provoke	   cardiomyocyte	   hypertrophy.444-­‐446	   Similar	   to	   our	   study,	  
Nilsson	  et	  al.	  found	  that	  in	  female	  mice,	  cardiac	  ANP	  gene	  expression	  was	  decreased	  after	  a	  
low	  carbohydrate	  and	  high	  fat	  diet	  despite	  any	  changes	   in	  cardiac	  hypertrophy	  evaluated	  
by	  echocardiography.447	  Recently,	  it	  has	  also	  been	  reported	  that	  decreased	  ANP	  expression	  
coincides	   with	   an	   increase	   of	   its	   receptor	   NPR-­‐A,	   and	   was	   associated	   with	   metabolic	  
dysfunction.446	  This	  observation	  was	  similar	   to	  our	   results,	  we	  also	   showed	  a	  decrease	   in	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The	  absence	  of	  increased	  ANP	  expression	  in	  our	  model	  is	  not	  surprising	  as	  it	  is	  in	  line	  with	  
the	  mild	  effects	  on	  cardiac	  function	  and	  geometry	  due	  to	  HFD	  and	  OVX.	  Indeed,	  our	  mouse	  
model	   did	   not	   develop	   strong	   cardiac	   hypertrophy	   as	   only	   small	   increases	   of	   the	   LV	  
posterior	   and	   anterior	  walls,	   as	  well	   as	   the	   relative	  wall	   thickness	  were	   observed	   in	   the	  
female	  mice.	  Overall,	  our	  model	   showed	  only	  a	  moderate	   level	  of	   stress,	  which	  was	  also	  
confirmed	  by	  the	  small	  increased	  level	  of	  inflammation.	  At	  first	  sight,	  the	  decrease	  in	  ANP	  
observed	  in	  our	  study	  could	  be	  deleterious,	  since	  ANP	  acts	  to	  decrease	  blood	  pressure,	  and	  
this	   decrease	  would	   lead	   to	   an	   increase	   in	   pressure.	  However,	   increased	   pressures	  were	  
not	   seen	   in	  our	  model,	  which	  makes	   the	   interpretation	  of	   this	   result	   complex:	   no	   strong	  
hypertrophy	   nor	   effects	   on	   pressures	   were	   observed	   but	   ANP	   was	   modified.	   We	   could	  
hypothesize	  that	  the	  ANP	  decrease	  is	  preceding	  the	  usually	  seen	  increase	  of	  ANP	  in	  cardiac	  
stress	  and	  hypertrophy,	  and	  that	  at	  a	  later	  timepoint	  we	  could	  have	  detected	  a	  higher	  level	  
of	  ANP	  in	  the	  mice	  fed	  with	  HFD.	  Alternatively,	  we	  will	  need	  to	  evaluate	  the	  expression	  of	  
ANP	  at	  the	  protein	  level,	  as	  mRNA	  levels	  do	  not	  always	  reflect	  protein	  levels.	  It	  would	  also	  
be	  interesting	  to	  analyze	  NPR-­‐A	  receptor	  expression	  in	  the	  heart.	  
	  
 4.10 High	  fat	  diet	  and	  ovariectomy	  modify	  metabolic	  signaling	  pathways	  
4.10.1 Ovariectomy	  reduces	  IRS-­‐1	  protein	  level	  after	  high	  fat	  diet	  feeding	  
To	   better	   understand	   the	   functioning	   of	   the	   glucose	   intolerance	   observed	   in	   the	   OVX-­‐
female	  mice	  and	  to	  check	  if	  regulators	  of	  glucose	  metabolism	  were	  altered	  in	  the	  heart,	  we	  
analyzed	  different	  targets	  at	  the	  protein	  level.	  IRS-­‐1	  is	  part	  of	  the	  insulin	  pathway,	  it	  is	  an	  
adapter	  protein	  that	  transduces	  the	  signal	  from	  the	  insulin	  receptor	  to	  PI3K.	  OVX	  resulted	  
in	  decreased	  IRS-­‐1	  protein	  amounts	  under	  CTD	  conditions,	  but	  this	  decrease	  did	  not	  occur	  
after	  HFD	  feeding.	  The	  lower	  IRS-­‐1	  protein	  in	  the	  CTD-­‐fed	  OVX-­‐female	  suggests	  that	  ovarian	  
hormones	   regulate	   the	   balance	   of	   IRS-­‐1	   protein	   synthesis	   and	   degradation,	   with	   a	   shift	  
towards	  more	  degradation	  when	  these	  hormones	  are	  missing.	  	  
	  
Next	  to	  this	  effect	  of	  OVX,	  we	  observed	  a	  gender	  difference	  because	  the	  male	  had	  a	  higher	  
IRS-­‐1	  than	  the	  sham-­‐female	  mice	  after	  HFD,	  which	  could	  be	  a	  consequence	  of	  their	  higher	  
insulin	   resistance	  as	  deducted	   from	  their	  very	  high	  plasma	   insulin.	   Indeed,	   the	  high	   IRS-­‐1	  
observed	   after	   HFD	   could	   indicate	   that	   males	   are	   trying	   to	   compensate	   their	   insulin	  
resistance	   by	   increasing	   IRS-­‐1	   protein.	   In	   line	   with	   this	   high	   insulin	   resistance,	   IRS	  
phosphorylation	   at	   S636-­‐639	   was	   increased	   in	   the	   HFD-­‐fed	   male	   group,	   a	   site	   that	   is	  
thought	  to	  cause	  the	  degradation	  of	  IRS-­‐1.448-­‐451	  Interestingly,	  sham-­‐female	  mice	  showed	  a	  
decrease	  of	  IRS-­‐1-­‐pS636-­‐639	  phosphorylation,	  which	  suggests	  better	  insulin	  responsiveness	  
than	   in	  males.	   The	   gender-­‐specific	   effects	   of	  HFD	   on	   IRS-­‐1-­‐phosphorylation	  matched	   the	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total	   IRS-­‐1	   protein	   levels.	   Both	   IRS-­‐1	   and	   IRS-­‐1	   phosphorylation	   are	   decreased	   in	   OVX-­‐
female	  compared	  to	  the	  sham-­‐female	  mice,	  suggesting	  good	  insulin	  responsiveness	  with	  a	  
higher	   IRS-­‐1	   protein	   degradation	   or	   turnover.	   However,	   the	  OVX	  mice	   are	  more	   glucose	  
intolerant,	  so	  it	  will	  be	  interesting	  to	  evaluate	  for	  example	  the	  activity	  of	  upstream	  targets,	  
the	  insulin	  receptor	  and	  downstream	  targets	  of	  IRS-­‐1,	  PI3K.	  	  
4.10.2 High	  fat	  diet	  decreases	  total	  Akt	  protein	  
We	  found	  no	  effects	  of	  gender,	  OVX	  and	  diet	  on	   the	  phosphorylation	  of	  Akt	  at	   the	  T308	  
site,	  which	  indicates	  that	  Akt	  activity	  was	  not	  affected.	  Given	  the	  increased	  plasma	  insulin,	  
which	  was	   particularly	   high	   in	   the	  male	   and	   also	   elevated	   in	   the	   females	   after	  HFD,	   this	  
highlights	  that	  the	  heart	  is	  not	  affected	  by	  these	  differently	  elevated	  plasma	  insulin	  levels.	  
In	   this	   regard,	   it	  would	   be	  worthy	   to	   analyze	   the	   effect	   of	   insulin	   on	   skeletal	  muscle,	   an	  
important	   organ	   responsible	   for	   glucose	   clearance.	   Consistently,	   downstream	   of	   Akt	  
phosphorylation	  of	  AS160,	  a	  protein	  involved	  in	  glucose	  transporter	  translocation,	  was	  not	  
increased	   in	  any	  of	   the	  groups	  after	  HFD.	  We	  would	  need	  to	  perform	  an	  ex-­‐vivo	  working	  
heart	  experiment	  to	  test	   if	  glucose	  uptake	   is	   indeed	  unchanged	   in	  the	  heart	  of	  OVX	  mice	  
after	  HFD	  and	  to	  conclusively	  prove	  changes	  in	  the	  cardiac	  responses	  to	  insulin.	  
	  
Our	   findings	   that	  Akt-­‐pT308	  and	  AS160-­‐pT642	  were	  not	   influenced	  by	   the	  diet	  at	  22	  wks	  
are	  consistent	  with	   the	   results	   from	  Abel’s	  group,	  which	  showed	   that	  phosphorylation	  of	  
Akt	   and	   its	   downstream	   targets	   were	   not	   affected	   by	   HFD.452	   However,	   another	   study	  
found	   reduced	   Akt	   phosphorylation	   after	   1.5	   wks	   of	   HFD.432	   It	   is	   not	   clear	   how	   glucose	  
intolerance	  and	  insulin	  resistance	  are	  initiated,	  but	  several	  studies	  suggest	  the	  implication	  
of	   ectopic	   lipid	   accumulation,	   endoplasmic	   reticulum	   stress	   activation,	   and	   inflammation	  
responses	  through	  adipokines	  and	  cytokines.453	  Despite	  the	  fact	  that	  estrogen	  is	  involved	  in	  
insulin/Akt	  signaling	  in	  cardiac	  muscle,454-­‐456	  the	  phosphorylation	  of	  Akt	  at	  T308	  showed	  no	  
changes	  after	  HFD	  in	  the	  OVX	  mice.	  In	  line	  with	  the	  absence	  of	  any	  effects	  on	  Akt	  signaling	  
in	  our	  own	  study,	  Wright	  et	  al.	  demonstrated	   that	   insulin	   stimulated	  glucose	  uptake	  and	  
GLUT4	  translocation	  in	  the	  myocardium	  are	  impaired	  without	  any	  Akt	  pathway	  alterations	  
even	  after	  insulin	  stimulation.133	  	  
	  
Interestingly,	   total	   Akt	   protein	   expression	   was	   significantly	   decreased	   by	   HFD	   in	   both	  
female	  groups.	  Despite	  this	  decrease	  in	  total	  Akt,	  phosphorylation	  levels	  remained	  similar	  
to	   those	   in	   the	  mice	   fed	  with	   CTD.	   Since	  Akt	   activation	   is	   thought	   to	   act	   as	   a	   protective	  
mechanism,	   this	   could	   suggest	   that	   despite	   decreased	   total	   Akt	   due	   to	   the	   HFD,	   Akt	   is	  
acting	  normally	  to	  conserve	  a	  normal	  physiological	  condition	  in	  the	  heart.	  In	  this	  context,	  it	  
would	   be	   interesting	   to	   evaluate	   the	   activity	   of	   Akt	   at	   a	   later	   stage	   and	   observe	   if	   this	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implementation	   of	   a	   protective	   pathway	   is	   still	   present.	   Furthermore,	   our	   study	   reveals	  
that	   the	   total	   form	   of	   AS160	   is	   increased	   in	   the	   OVX	   mice	   after	   HFD,	   but	   the	  
phosphorylated	  form	  was	  unchanged,	  which	  again	  reflects	  unmodified	  activity.	  To	  the	  best	  
of	  our	  knowledge,	  our	  study	  is	  the	  first	  to	  describe	  this	  gender	  difference	  and	  to	  show	  that	  
ovarian	  hormones	  are	  not	  implicated.	  
	  
The	  protein	  mTOR	  is	  next	  to	  AS160	  another	  downstream	  effector	  of	  Akt.	  Akt-­‐induced	  mTOR	  
phosphorylation	  at	  S2448	  displayed	  small	  increases	  due	  to	  the	  HFD	  in	  the	  female	  groups,	  as	  
opposed	  to	  the	  male	  group,	  in	  which	  this	  phosphorylation	  was	  slightly	  reduced.	  In	  contrast,	  
other	   studies	   described	   increased	   cardiac	   mTORC1	   activity	   in	   the	   male	   heart	   after	  
HFD.457,458	  In	  our	  own	  study,	  the	  sham-­‐female	  mice	  had	  higher	  mTOR	  phosphorylation	  than	  
the	  male	  after	  HFD	  feeding,	  indicating	  a	  gender	  difference.	  This	  suggests	  that	  female	  mice	  
are	  able	  to	  induce	  an	  adaptive	  mechanism	  in	  response	  to	  HFD,	  which	  the	  male	  mice	  are	  not	  
able	  to	  do,	  at	  least	  at	  the	  timepoint	  that	  the	  animals	  were	  sacrificed.	  As	  the	  mice	  fed	  with	  
HFD	  are	  bigger	  than	  the	  others,	  it	  would	  make	  sense	  that	  the	  heart	  has	  to	  grow	  bigger,	  and	  
that	  mTOR	   could	   be	  more	   activated	   to	   support	   this	   necessary	   growth.	   The	   fact	   that	   the	  
males	   did	   not	   demonstrate	   increased	   mTOR	   phosphorylation	   suggests	   a	   lack	   of	   cardiac	  
adaptation.	  There	  were	  indeed	  no	  differences	  in	  cardiac	  weight	  and	  function	  due	  to	  HFD	  in	  
the	  male	  group.	  We	  found	  slightly	  increased	  raw	  ventricle	  weight	  as	  well	  as	  increased	  wall	  
thickness	  in	  females,	  which	  may	  be	  related	  to	  the	  modest	  mTOR-­‐pS2448	  changes.	  Possibly,	  
the	  lack	  of	  clear	  effects	  on	  mTOR	  phosphorylation	  may	  be	  due	  to	  the	  impaired	  activation	  of	  
this	  pathway	  under	  HFD	  conditions.	  Alternatively,	  the	  absence	  of	  increased	  mTOR	  activity,	  
which	  we	  confirmed	  at	  the	  level	  of	  its	  direct	  target	  p70-­‐S6K1,	  could	  be	  beneficial,	  because	  
recent	   studies	   showed	   that	  mTOR	   inhibition	   could	   be	   protective.	   Indeed,	   rapamycin	  was	  
shown	  to	  enhance	  cardiac	   function	  and	   improve	  metabolic	  disorders	   linked	  to	  T2DM	  and	  
obesity	   including	   reduction	   in	   oxidative	   stress	   and	   a	   correction	   in	   contractile	  
performance.459	  	  
4.10.3 High	  fat	  diet	  increases	  PDH	  in	  female	  mice	  
The	  pyruvate	  dehydrogenase	  lipoamide	  kinase	  isozyme	  4	  (PDK4)	  is	  a	  mitochondrial	  enzyme	  
implicated	   in	   glucose	   oxidation.	   This	   enzyme	   phosphorylates	   and	   inactivates	   the	   PDH	  
complex,	  which	  transforms	  the	  pyruvate	  into	  acetyl-­‐CoA	  that	  can	  then	  enter	  the	  TCA	  cycle.	  
Thus,	  PDK4	  activity	  results	  in	  a	  decreased	  glucose	  oxidation.	  First	  of	  all,	  our	  data	  show	  that	  
the	  OVX	  mice	  had	  higher	  mRNA	  expression	  of	  PDK4	  than	  the	  sham-­‐female	  mice.	  Secondly,	  
the	   HFD	   significantly	   decreased	   the	   OVX-­‐induced	   increase	   in	   PDK4	   mRNA.	   Notably,	   the	  
differences	  in	  PDK4	  gene	  expression	  were	  not	  mirroring	  its	  protein	  expression.	  Thus,	  OVX	  
increased	   only	   PDK4	   mRNA	   but	   not	   PDK4	   protein.	   Only	   the	   sham-­‐female	   group	   had	   a	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decrease	   in	   PDK4	   protein	   expression	   after	   HFD.	   The	   discrepancies	   between	   mRNA	   and	  
protein	   expression	   emphasize	   the	   need	   for	   analyzing	   regulation	   at	   both	   levels.	   PDK4	   is	  
highly	   expressed	   in	   hearts	   of	   fasted	   and	   insulin-­‐resistant	   animal	   models.	   In	   a	  
streptozotocin-­‐induced	  type	  1	  diabetic	  rat	  model,	  PDK4	  mRNA	  was	   increased	  in	  the	  heart	  
and	  skeletal	  muscle.87,88	  In	  human,	  insulin	  resistant	  patients	  also	  exhibit	  a	  high	  PDK4	  level	  in	  
skeletal	   muscle.89	   It	   has	   been	   reported	   that	   insulin	   represses	   PDK2	   and	   PDK4	   through	  
phosphorylation	   of	   FOXO	   via	   the	   PI3K/Akt	   signaling	   pathway.	   The	   negative	   regulation	   of	  
insulin	  on	  PDK4	  mRNA	  expression	  was	  impaired	  in	  an	  acute	  insulin	  resistant	  mouse	  model,	  
proposing	  that	  insulin	  resistance	  increases	  PDK4	  expression.460	  Indeed,	  this	  is	  confirmed	  by	  
the	  fact	  that	  insulin	  treatment	  reversed	  the	  increase	  of	  PDK4	  and	  PDK2	  in	  liver	  and	  skeletal	  
muscle	  induced	  by	  dexamethasone.88,89	  In	  a	  mouse	  model	  fed	  with	  HFD	  for	  10	  days,	  cardiac	  
PDK4	  was	  upregulated	  with	  a	  concomitant	  decrease	  in	  carbohydrate	  oxidation	  as	  a	  result	  of	  
PDH	  activity	   suppression.461	   This	   short-­‐term	   feeding	   is	   contrasting	  with	  our	   study,	  where	  
we	  observed	   that	  PDK4	  mRNA	  was	  decreased	   together	  with	  phosphorylated	  PDH	  protein	  
after	  22	  wks	  of	  feeding.	  It	  could	  be	  speculated	  that	  at	  short-­‐term,	  PDK4	  is	  first	  upregulated	  
and	  is	  decreasing	  glucose	  oxidation	  and	  that	  at	  longer	  term	  it	  gets	  downregulated	  to	  favor	  
glucose	  oxidation	  at	  the	  expense	  of	  decreased	  fatty	  acid	  oxidation.	  Moreover,	  in	  our	  model,	  
the	  mice	  were	  not	  diabetic	  yet,	  insulin	  was	  probably	  still	  able	  to	  decrease	  PDK4	  expression	  
in	  the	  heart	  to	  induce	  increased	  PDH	  activity	  and	  glucose	  oxidation.	  Altogether,	  our	  results	  
propose	  that	  after	  22	  wks	  of	  diet	  OVX	  decreases	  glucose	  oxidation,	  and	  HFD	  reverses	  this	  
effect.	  
	  
As	  PDK4	  is	  known	  to	  inhibit	  PDH	  activity,	  we	  analyzed	  PDH	  expression	  and	  phosphorylation.	  
Overall,	   HFD	   decreased	   PDH	   phosphorylation	   suggestive	   of	   increased	   glucose	   oxidation.	  
Inversely	  to	  our	  observation,	  in	  the	  skeletal	  muscle	  HFD	  induces	  a	  downregulation	  of	  PDH	  
activity	   via	   PDK4	   to	   inhibit	   pyruvate	   entry	   in	   the	   TCA	   cycle	   and	   the	   subsequent	   glucose	  
oxidation.462	  Post-­‐hoc	   testing	  showed	  that	  OVX	  caused	  a	   trend	  toward	  higher	  PDH-­‐pS293	  
under	  CTD	  conditions	  and	  HFD	  significantly	  decreased	  this	  phosphorylation,	  mirroring	  the	  
changes	  observed	  in	  PDK4.	  Taken	  together	  these	  data	  suggest	  that	  ovarian	  hormones	  are	  
increasing	   glucose	   oxidation.	   In	   the	   absence	   of	   ovarian	   hormones,	   HFD	   abolishes	   the	  
decrease	  in	  glucose	  oxidation.	  The	  total	  form	  of	  PDH	  was	  increased	  in	  response	  to	  the	  HFD	  
in	  the	  female	  while	  it	  was	  not	  changed	  in	  the	  male	  mice,	  this	  maybe	  represents	  a	  counter	  
regulatory	  effect	  in	  order	  to	  upregulate	  glucose	  oxidation.	  	  
	  
In	  another	  type	  of	  study,	  Kim	  et	  al.	  used	  a	  rat	  model	  to	  induce	  acute	  insulin	  resistance	  by	  
constant	   infusion	   of	   Intralipid	   (a	   fat	   emulsion)	   and	   lactate	   for	   5h	   in	   fasted	   animals.	   This	  
resulted	   in	   2-­‐	   to	   3-­‐fold	   higher	   PDK4	   expression	   in	   skeletal	   muscle	   after	   insulin	   infusion,	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indicating	   that	   insulin	   was	   not	   able	   to	   suppress	   PDK4	   and	   proposing	   that	   the	   rats	   were	  
insulin	   resistant.	   This	   infusion	   also	   suppressed	   the	   phosphorylation	   of	   Akt	   and	   FOXO1	  
highlighting	   the	   resulting	   insulin	   resistance.460	   Our	   own	   results	   showed	   again	   different	  
effects,	   as	   HFD	   induced	   an	   overall	   decrease	   of	   PDK4	   mRNA.	   One	   interpretation	   of	   this	  
difference	   could	   be	   that	   the	   acute	   insulin	   resistance	   does	   not	   induce	   similar	   effects	   as	  
chronic	   resistance	   induced	  by	   long-­‐term	  HFD	   feeding,	  and	   that	   skeletal	  and	  heart	  muscle	  
react	  in	  a	  different	  manner	  to	  this	  acute	  insulin	  resistance.	  	  
	  
Many	   studies	   related	   to	   the	   understanding	   of	   PDK4	   have	   been	   performed	   on	   skeletal	  
muscle	   but	   very	   little	   is	   known	   about	   its	   activity	   in	   the	   heart.	   It	   was	   observed	   that	  
metabolic	   inflexibility	   correlates	   with	   cardiomyopathy	   occurrence	   especially	   during	  
ischemia	  and	  could	   cause	  heart	   failure.137	   In	   this	   context,	   the	   reason	   for	   reduced	  cardiac	  
efficiency	  is	  linked	  to	  the	  inability	  to	  use	  carbohydrates	  to	  meet	  energy	  demands.	  Indeed,	  a	  
cardiac	   specific	   overexpression	   of	   PDK4	   causes	   a	   loss	   of	   metabolic	   flexibility	   and	  
exacerbates	   cardiomyopathy,	  which	   is	   associated	  with	  decreased	   glucose	   catabolism	  and	  
increased	  FA	  oxidation.463	  	  
	  
The	  mRNA	  level	  of	  GAPDH	  was	  decreased	  in	  all	  HFD	  groups,	  suggesting	  that	  glycolysis	  may	  
be	   decreased	   after	  HFD,	   consistent	  with	   the	   known	   literature.	   This	   possible	   inhibition	   of	  
glycolysis	   after	  HFD	   could	   explain	   the	  decreased	  PDH	   inhibitory	   phosphorylation	   and	   the	  
increased	  total	  PDH,	  which	  would	  increase	  glucose	  oxidation	  as	  a	  compensatory	  feed-­‐back	  
effect.	  This	   is	  explained	  by	   the	   fact	   that	  under	  normal	  conditions	   the	  heart	  preferentially	  
uses	  FA	  oxidation	  as	   first	  source	  of	  energy,	  with	  glucose	  oxidation	  being	  a	  second	  energy	  
source.	   However,	   when	   fed	   with	   high	   fat	   diet	   this	   phenomenon	   is	   exacerbated	   and	   the	  
heart	   switches	   toward	   an	   almost	   exclusive	   FA	   use.464	   Hence	   the	   observed	   decrease	   in	  
glucose	  metabolism	  genes	  and	  increase	  in	  FA	  oxidation	  genes	  such	  as	  CPT-­‐Iβ.	  
4.10.4 High	  fat	  diet	  increases	  PPARα	  in	  male	  mice	  
We	   observed	   HFD-­‐induced	   increases	   in	   PPARα	   gene	   expression	   in	   the	   male	   mice	   and	   a	  
similar	   trend	   was	   seen	   in	   the	   sham-­‐female,	   but	   not	   in	   the	   OVX	   mice.	   PPARα	   regulates	  
several	  genes	  implicated	  in	  fatty	  acid	  uptake	  into	  the	  cytoplasm	  and	  mitochondria	  as	  well	  
as	  genes	  involved	  in	  the	  generation	  of	  fatty	  acyl	  CoA.	  Our	  results	  therefore	  suggest	  that	  the	  
males	  mainly	  have	  an	  increased	  use	  of	  FA,	  which	  could	  be	  the	  consequence	  of	  the	  inability	  
of	   the	  heart	   to	  use	  glucose	  as	  a	   result	  of	   insulin	   resistance.	  The	  OVX-­‐female	  mice	  do	  not	  
show	  this	   increase	  of	  PPARα,	  suggesting	  that	  their	  FA	  metabolism	  is	  not	   increased	  at	  this	  
stage	  after	  HFD.	  Our	  results	  are	  similar	  to	  those	  obtained	  by	  others	  after	  a	  shorter	  period	  of	  
HFD	  feeding.452	  The	  authors	  of	  this	  study	  showed	  that	  PPARα	  target	  genes	  and	  PPARα	  itself	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were	  increased	  after	  5	  wks	  of	  HFD.	  PPARα	  activation	  may	  therefore	  have	  a	  role	  to	  sustain	  
the	   metabolic	   change	   toward	   fatty	   acid	   use.	   At	   the	   early	   stage	   of	   the	   cardiomyopathy	  
pathology,	  a	  defect	  in	  glucose	  transport	  seems	  to	  be	  happening	  as	  a	  first	  cardiac	  metabolic	  
adaptation	  to	  high	  fat	  diet.	  Abel	  proposed	  that	  this	  adaptation	  where	  glucose	  utilization	  is	  
reduced	   is	   the	  main	   cause	   for	   a	   secondary	   increase	   in	   fatty	   acid	  oxidation	  as	   the	  Randle	  
cycle	  describes	  it.465	  	  
4.10.5 Ovariectomy	  modifies	  ULK1	  
We	  aimed	  to	  elucidate	  if	  gender	  and	  ovarian	  hormones	  play	  a	  role	  in	  regulating	  autophagy	  
in	   our	   obesity	  model.	   Our	   western	   blot	   analysis	   shows	   that	   HFD	   induced	   an	   increase	   in	  
ULK1-­‐pS757	  in	  the	  OVX-­‐female	  mice,	  whereas	  in	  sham-­‐female	  and	  male	  mice	  no	  increases	  
were	  observed.	  As	  ULK1-­‐pS757	   is	   known	   to	   inhibit	  autophagy,466,467	   these	   results	   suggest	  
that	  the	  ovarian	  hormones	   increase	  autophagy	  under	  HFD	  conditions.	  Our	  analysis	  of	   the	  
LC3BII/I	  ratio	  did	  not	  allow	  us	  to	  confirm	  this	  conclusion.	  No	  differences	  were	  observed	  due	  
to	   high	   variability,	   which	   made	   the	   autophagy	   analysis	   difficult.	   To	   conclude	   about	   the	  
implication	   of	   autophagy	   further	   experiments	   have	   to	   be	   performed	   such	   as	  
immunofluorescence	  or	   inducing	  an	   in-­‐vivo	  blockage	  of	  autophagy	  to	  measure	  autophagy	  
flux,	  which	  is	  more	  relevant	  since	  autophagy	  is	  a	  dynamic	  process.	  
	  	  
The	  regulation	  of	  autophagy	  is	  highly	  complex	  and	  in	  diabetic	  cardiomyopathy	  it	  is	  not	  clear	  
if	   either	   upregulation	   or	   downregulation	   of	   autophagy	   can	   help	   the	   heart.	   In	   such	  
conditions,	   it	  has	  been	  documented	   that	  autophagy	   is	   suppressed	  and	   that	   this	   could	  be	  
assigned	   to	   an	   inhibition	   of	   the	   AMPKα	   pathway,	   accompanied	   by	   an	   increase	   of	  mTOR	  
activity.468,469	   It	   has	   been	   reported	   that	   Beclin	   1	   knockout,	   which	   leads	   to	   diminished	  
autophagy,	   is	   cardioprotective	   in	  a	  mouse	  model	  of	   type	   I	   diabetes	  by	   improving	   cardiac	  
function,	   reducing	  oxidative	   stress	   level,	   interstitial	   fibrosis	  and	  myocyte	  apoptosis.470	  On	  
the	  other	   hand,	   inducing	   autophagy	  by	   stimulating	  AMPKα	   leads	   to	   an	   improved	   cardiac	  
situation	  by	  preventing	  high	  glucose-­‐induced	  apoptosis	  in	  cardiomyocytes.471	  
	  
These	   contradictory	   results	   lead	   to	   the	   question	   whether	   autophagy	   inhibition	   in	   the	  
diabetic	  heart	  is	  a	  maladaptive	  or	  an	  adaptive	  response.	  The	  answer	  is	  not	  clear	  and	  seems	  
to	  depend	  on	  the	  specific	  stress	  condition.	  Many	  studies	  have	  been	  performed	  to	  elucidate	  
this	  question	  and	  many	  conclusions	  were	  drawn.	  Thus,	  decreased	  autophagy	  was	  reported	  
to	   limit	   cardiac	   injury	   in	  a	  mouse	  model	  of	   type	  1	  diabetes,472	  whereas	  He	  et	  al.	   showed	  
that	   increased	   cardiac	   autophagy	   is	   cardioprotective	   in	   diabetes.473	   In	   a	   model	   of	   diet	  
induced	   obesity	   and	   metabolic	   syndrome,	   Sciaretta	   et	   al.	   found	   that	   autophagy	   was	  
suppressed	   in	  the	  heart	  through	  deregulation	  of	  the	  Rheb/mTORC1	  activation,	  suggesting	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that	   mTORC1	   participates	   in	   the	   cardiac	   growth	   observed	   in	   obesity	   and	   metabolic	  
disorders.474	  Some	  studies	  described	  that	  autophagosome	  formation	  or	  autophagic	  flux	  was	  
impaired	   in	   hearts	   of	   obese	   and	   diabetic	   animals	   and	   it	   was	   associated	   with	   decreased	  
mTORC1	  activity	  and	  cardiac	  dysfunction.	  Indeed,	  in	  a	  swine	  model	  of	  metabolic	  syndrome,	  
a	  decreased	  autophagosome	  formation	  was	  observed	  and	  was	  associated	  with	  decreased	  
mTOR	  activity,	  increased	  apoptosis,	  decreased	  mitochondrial	  function	  and	  abnormalities	  in	  
cardiac	   structure	   and	   function.475	   In	   another	   model	   of	   HFD-­‐induced	   obesity,	   cardiac	  
autophagosome	   formation	   was	   also	   found	   reduced,	   mTOR	   activity	   was	   increased	   and	  
cardiac	   function	  was	  altered,	  effects	  which	  were	  rescued	  by	  rapamycin.476	   In	  obese	  mice,	  
deregulated	   cardiac	   Akt2	   perturbed	   the	   autophagic	   flux.477	   Similarly,	   in	   STZ-­‐induced	  
diabetes,	   cardiac	   autophagosome	   formation	   and	   autophagic	   flux	   were	   impaired	   and	  
associated	  with	  increased	  mTOR	  activity.472	  In	  the	  kidney	  and	  liver	  of	  obese	  mice,	  inhibition	  
of	  autophagosome	  formation	  involved	  mTORC1	  activation.478,479	  
	  
In	  the	  context	  of	  our	  diet-­‐induced	  obesity	  model,	  two	  theories	  can	  be	  proposed.	  Autophagy	  
is	   downregulated	   during	   periods	   of	   energy	   abundance	   obtained	   by	  HFD	   feeding	   because	  
renewal	   of	   metabolic	   precursors	   such	   as	   amino	   acids	   and	   fatty	   acids	   is	   not	   needed.	  
Conversely,	  since	  HFD	  feeding	  exerts	  a	  deleterious	  effect	  on	  cellular	  metabolism	  resulting	  
in	  accumulation	  of	  damaged	  mitochondria,	  lipids	  droplet,	  misfolded	  or	  aggregated	  proteins	  
(ER	   stress),	   autophagy	   has	   to	   be	   upregulated	   to	   counteract	   this	   situation	   and	   bring	  
cardiomyocytes	  back	   to	  a	  physiological	   status.	  The	  question	  whether	  or	  not	  autophagy	   is	  
harmful	   or	   protective	   is	   always	   a	   topical	   question.	   In	   this	   regard,	   our	   results	   can	   be	  
interpreted	  in	  two	  different	  manners.	  Either	  the	  OVX	  mice,	  unlike	  the	  sham-­‐female	  and	  the	  
male	  mice,	  failed	  to	  eliminate	  the	  damaged	  organelles	  and	  lipids	  droplets	  as	  a	  consequence	  
of	   their	   reduced	  autophagy,	  or	   their	   reduced	  autophagy	  may	  have	  been	  beneficial.	  Given	  
the	  observed	  increase	  lipids	  droplet	  accumulation	  in	  the	  OVX-­‐HFD	  group,	  we	  think	  that	  the	  
first	  interpretation	  might	  be	  correct.	  	  
 4.11 Limitations	  
By	   using	   the	   ovariectomized	   model,	   we	   aimed	   to	   mimic	   the	   phenomenon	   observed	   in	  
menopausal	  women	  where	  a	  decline	  of	  ovarian	  hormones,	  mainly	  estrogen,	  is	  present.	  Our	  
goal	  was	  to	  study	  the	  role	  of	  estrogen	  in	  the	  maintenance	  of	  cardiac	  structure	  and	  function.	  
This	   model	   is	   widely	   used	   as	   it	   closely	   resembles	   surgical	   and	   natural	   menopause	   in	  
humans.480	  However,	   the	  model	  has	   some	   limitations.	   First	   of	   all,	   the	   ablation	  of	  ovaries	  
triggers	  a	  sudden	  loss	  of	  ovarian	  hormones	  which	  is	  not	  seen	  in	  natural	  menopause	  as	  the	  
hormone	   level	   decreases	   progressively;	   indeed	   a	   transition	   from	   perimenopause	   to	  
menopause	  exists	  in	  reality.480,481	  It	  was	  reported	  that	  the	  response	  to	  OVX	  is	  more	  robust	  
and	   faster	   in	   young	   rodents	   (2-­‐6	  months)	   with	   regular	   estrous	   cycles	   than	   in	   aged	   rats.	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Indeed,	  one	  week	  after	  OVX,	  young	  rats	  have	  very	   low	  or	  undetectable	  concentrations	  of	  
circulating	   ovarian	   hormones,482-­‐484	   whereas	   middle-­‐aged	   (9-­‐14	   months)	   or	   old	   (18-­‐30	  
months)	  rats	  still	  have	  detectable	  circulating	   level	  of	  estrogen	  and	  progestin	  for	  weeks	  or	  
months	   after	   OVX.482,483	   Thus,	   to	   get	   closer	   to	  what	   is	   observed	   in	   humans,	   it	   would	   be	  
more	  precise	  to	  use	  female	  rodents	  at	  a	  more	  advanced	  age.	  Thus,	  the	  ablation	  of	  ovaries	  
can	  be	  done	  at	  different	  stages	  of	  the	  animal's	  life	  and	  this	  is	  not	  always	  matching	  the	  age	  
where	  menopause	  is	  observed	  in	  human.	  In	  preclinical	  studies,	  the	  ablation	  of	  the	  ovaries	  
could	  be	  performed	  at	  2-­‐6	  months,	  which	  corresponds	  to	  the	  period	  of	  the	  regular	  estrous	  
cycle,	   11	   months,	   corresponding	   to	   the	   beginning	   of	   acyclicity,	   or	   18	   months	   where	   a	  
constant	   estrous	   starts	   to	   appear	   where	   ovaries	   contain	   big	   follicles	   that	   secrete	   large	  
quantities	  of	  estrogen.480,485	  Additionally,	  age-­‐specific	  effects	  are	  present	  and	  influence	  the	  
interpretation	  of	   the	   results,	  but	   these	  effects	  are	  also	   important	   to	  understand	   the	  age-­‐
related	   factors.480,485	   The	   different	   age	   at	   which	   OVX	   is	   performed	   may	   explain	   the	  
discrepancies	   observed	   between	   the	   studies,	   for	   example	   young	   and	   old	   rats	   do	   not	  
respond	   the	   same	   way	   to	   OVX	   and	   hormone	   replacement.486	   Thus,	   ideally	   one	   should	  
perform	  OVX	  at	  the	  rodent’s	  chronologically	  equivalent	  of	  middle	  age.	  
	  
The	   pressure-­‐volume	   loop	   technique	   is	   an	   appreciated	  method	   to	   evaluate	   intra-­‐cardiac	  
pressure	   and	   volume,	   however	   we	   obtained	   some	   negative	   values	   for	   the	   volume	   data,	  
making	  them	  less	  reliable	  because	  of	  specific	  constraints:	  1)	  The	  parallel	  conductance	  varies	  
according	  to	  the	  position	  of	  the	  probe,	  for	  some	  mice	  the	  heart	  orientation	  or	  anatomy	  did	  
not	   allow	   a	   proper	   penetration	   and	   orientation	   of	   the	   catheter	   into	   the	   LV,	   the	   parallel	  
conductance	  is	  not	  reliable	   in	  this	  case.	  2)	  Blood	  is	  used	  for	  the	  volume	  calibration	  at	  the	  
end	  of	   the	   experiment	   and	   the	   blood	   temperature	   is	   critically	   influencing	   the	   calibration	  
itself,	   thus	  artifacts	  can	  appear	  at	   this	  stage	  and	  may	  explain	   the	  negative	  volume	  values	  
obtained.	   3)	   Finally,	   to	   obtain	   trustable	   volume	   values,	   one	   should	   combine	   different	  
methods,	  indeed	  it	  is	  recommended	  to	  use	  MRI	  for	  example	  to	  obtain	  the	  α	  value	  used	  to	  
calculate	  volume	  from	  conductance	   (see	   formula	  1.1.5).	  This	  α	   is	   the	  gain	  coefficient	  and	  
corresponds	   to	   the	   volume	   correction	   or	   calibration	   factor	   and	   is	   important	   for	   volume	  
calculation.	   Unfortunately,	   we	   were	   not	   able	   to	   determine	   this	   value.	   Altogether,	   these	  
reasons	   make	   it	   necessary	   to	   use	   the	   volume	   data	   obtained	   via	   the	   PVL	   method	   with	  
caution.	   Nevertheless,	   our	   analysis	   showed	   differences	   in	   LV	   volume	   between	   our	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Figure	  30:	  Gender-­‐specific	  effects	  of	  HFD	  on	  cardiac	  function	  and	  geometry.	  


















Figure	  31:	  Systemic	  effects	  of	  HFD	  feeding	  in	  our	  mouse	  model.	  
♂,	   male	   mice;	  ♀,	   female	   mice;	   OVX,	   ovariectomized	   mice;	   E2,	   estrogen.	   Arrows	   represent	   an	  
increased	  parameter.	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Women	  are	  less	  prone	  to	  be	  affected	  by	  cardiovascular	  disease	  compared	  to	  age-­‐matched	  
men.	  Nevertheless,	   this	   female	   advantage	   is	   gradually	   lost	  when	   they	   reach	  menopause.	  
This	   raises	   the	   question	   to	   know	   why	   and	   how	   this	   phenomenon	   occurs.	   Many	   studies	  
suggested	  that	  estrogens	  are	  cardioprotective,	  but	  some	  of	  them	  showed	  that	  they	  could	  
also	   be	   deleterious	   in	   certain	   conditions.	   Hence	   the	   need	   to	   characterize	   and	   better	  
understand	   the	   mechanisms	   underlying	   the	   effects	   of	   estrogen	   in	   the	   cardiovascular	  
system.	   In	   this	   context,	   we	   aimed	   at	   describing	   gender-­‐	   and	   ovarian	   hormone-­‐specific	  
consequences	   of	   obesity	   in	   the	   heart.	   Thus,	   we	   analyzed	   the	   effect	   of	   HFD,	   gender	   and	  
ovariectomy	  on	  cardiac	  function	  and	  structure	  and	  investigated	  the	  mechanisms	  involved.	  	  
	  
We	  demonstrated	   that	   high	   sucrose	   and	   fat	   feeding	   causes	   the	   following	   gender-­‐specific	  
changes	  (Figure	  30-­‐31):	  
1.	   stronger	   increases	  of	  plasma	   insulin	   in	  male	   than	   in	   female	  mice,	   suggestive	  of	  higher	  
insulin	  sensitivity	  in	  the	  female	  mice.	  	  
2.	  strong	  decreases	  of	  the	  peak	  filling	  and	  emptying	  rates	  in	  male	  mice	  only,	  suggesting	  that	  
their	  ventricular	  relaxation	  is	  impaired.	  	  
3.	  decreased	  E/A	  ratios	  in	  the	  female	  mice	  only,	  suggesting	  mild	  diastolic	  dysfunction	  	  
4.	  moderate	  wall	  thickness	  increases	  in	  the	  female	  only,	  suggestive	  of	  cardiac	  remodeling.	  
	  
As	  for	  the	  role	  of	  female	  hormones,	  we	  demonstrated	  that	  (Figure32):	  	  
1.	  Ovarian	  hormones	  are	   implicated	   in	   increasing	  plasma	   insulin	  and	  maintaining	  glucose	  
tolerance	   in	   response	   to	  HFD,	   since	  OVX	  abolished	   the	   increase	   in	   insulin	   and	  decreased	  
glucose	  tolerance.	  
2.	  After	  dobutamine	  infusion,	  OVX	  mice	  had	  higher	  end-­‐diastolic	  pressure	  than	  the	  sham-­‐
female	   mice	   after	   HFD,	   suggesting	   that	   estrogens	   are	   implicated	   in	   the	   adaptation	   to	  
increased	  cardiac	  work.	  
3.	  OVX	  mice	  had	  a	  higher	  expression	  of	  PDK4	  and	   its	  downstream	  target	  PDH,	  suggesting	  
that	  ovarian	  hormones	  are	  important	  for	  preserving	  a	  normal	  glucose	  oxidation.	  	  
	  
In	   conclusion,	   our	   mice	   showed	   signs	   of	   diabetic	   cardiomyopathy	   since	   they	   presented	  
overweight,	   hyperglycemia,	   insulin	   resistance,	   hyperinsulinemia,	   and	   altered	   cardiac	  
contraction	   and	   relaxation	   velocities	   without	   blood	   pressure	   changes.	   Moreover,	   we	  
demonstrated	   that	   female	  and	  male	  mice	  are	  not	  affected	  by	  HFD	   in	   the	   same	  way,	  and	  
only	  female	  mice	  are	  able	  to	  implement	  a	  cardiac	  adaptation	  to	  counteract	  harmful	  effects	  
of	   the	  high	   fat	  diet.	  The	  ovarian	  hormones	  are	  playing	  a	  role	   in	  maintaining	  physiological	  
cardiac	  function.	  Our	  study	  helps	  to	  better	  understand	  diastolic	  dysfunction	  and	  may	  in	  the	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future	  be	  translated	  to	  the	  situation	  of	  postmenopausal	  women,	  a	  population	  particularly	  
affected	  by	  cardiovascular	  disease.	  
	  
Hypertension	  is	  a	  major	  cardiovascular	  risk,	  and	  therefore	  it	  will	  be	  interesting	  to	  induce	  an	  
additional	   stress	   to	   trigger	   hypertension	   in	   our	   mouse	   model.	   This	   will	   possibly	   help	   to	  
achieve	  a	  complete	  diastolic	  dysfunction	  phenotype.	  Once	  this	  state	  is	  reached,	  hormonal	  
replacement	  therapy	  could	  be	  applied	  to	  reverse	  the	  cardiac	  dysfunction.	  More	  precisely,	  a	  
specific	   GPER	   agonist,	   G-­‐1,	   would	   help	   to	   evaluate	   the	   short	   and	   long-­‐term	   benefits	   of	  
estrogen	   signaling	   activation	   via	   the	  GPER.	   Similar	   to	   the	   present	   study,	   cardiac	   function	  
would	  be	  assessed	  by	  echocardiography	  and	  pressure-­‐volume	  loop	  techniques.	  The	  effects	  
of	  HFD,	  gender	  and	  ovarian	  hormones	  would	  be	  assessed	  at	  the	  macroscopic	  level	  and	  the	  
underlying	   mechanisms	   at	   the	   protein	   and	   RNA	   levels,	   by	   studying	   insulin/Akt/mTOR	  
pathways,	   inflammation,	   autophagy	   and	   apoptosis.	   For	   further	   investigations,	   a	  
Langendorff	   isolated	   heart	  model	   should	   be	   used	   to	   assess	   the	   direct	   effect	   of	   estrogen	  




Figure	  32:	  Ovarian	  hormones	  -­‐	  specific	  effects	  on	  the	  pancreas,	  adipose	  tissue	  and	  heart.	  
E2,	  estrogen.	  Arrows	  represent	  an	  increased	  or	  decreased	  parameter.	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Figure	  S	  I:	  Post-­‐mortem	  organ	  weights	  of	  male,	  female	  and	  OVX	  mice	  fed	  with	  CTD	  or	  HFD	  
for	  22	  wks.	  
Organs	   were	   weighed	   after	   sacrifice.	   Non-­‐normalized	   values	   are	   shown.	   LW,	   Liver	   weight;	   GW,	  
gastrocnemius	  weight;	  VFW,	  visceral	   fat	  weight;	  VW,	  ventricle	  weight.	  Results	  are	  presented	  with	  
the	  median,	  whiskers	  show	  the	  min	  and	  max	  values.	  *	  Symbol	  corresponds	  to	  CTD	  vs	  HFD,	  #	  symbol	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Figure	  S	  II:	  Effect	  of	  dobutamine	  on	  heart	  rate	  during	  PVL	  experiment	  in	  male,	  female	  and	  
OVX	  mice	  fed	  with	  CTD	  or	  HFD	  for	  22	  wks.	  
Heart	  rates	  significantly	  increase	  with	  the	  increased	  dobutamine	  infusion	  dose	  in	  all	  groups.	  
Under	   CTD,	   male	   mice	   have	   a	   higher	   heart	   rate	   than	   the	   female	   from	   baseline	   to	   3	   µg/kg/min	  





































$$$ $$$$ $$$ $$
Supplementary	  Figures	  and	  Tables	  
	  


































Figure	  S	  III:	  Electron	  micrographs	  of	  hearts	  to	  detect	  autophagy.	  
Hearts	  of	  male,	  female	  and	  OVX	  mice	  (sacrificed	  at	  22	  wks)	  were	  stained	  to	  detect	  autophagy.	  
C:	   capillaries;	   L:	   lipid	   droplet;	  M:	  mitochondria;	   N:	   nucleus.	   Arrows	   point	   to	   possible	   autophagic	  
vacuoles.	  N=2	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Figure	   S	   IV:	   Quantitative	   real-­‐time	   PCR	   analysis	   in	   hearts	   from	  male,	   female	   and	   OVX	  
mice	  fed	  with	  CTD	  or	  HFD	  for	  22	  wks.	  
mRNA	  from	  cardiac	  muscle	  was	  extracted	   to	  evaluate	  mRNA	   levels	  of	   collagen	  genes.	  Results	  are	  
presented	  with	  the	  median,	  whiskers	  show	  the	  min	  and	  max	  values.	  *	  Symbol	  corresponds	  to	  CTD	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Figure	  S	  V:	  Mac-­‐2	  staining	  to	  detect	  macrophages	  on	  heart	  sections.	  
Cryosections	  of	  the	  hearts	  of	  male,	  female	  and	  OVX	  mice	  (sacrificed	  at	  22	  wks)	  were	  stained	  with	  
Mac-­‐2	  and	  TRITC-­‐labeled	  secondary	  antibodies	  to	  detect	  macrophages	  (arrows),	  Dapi	  dye	  was	  used	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Figure	  S	  VI:	  TGF-­‐β1	  staining	  to	  detect	  signs	  of	  fibrosis	  on	  heart	  sections.	  	  
Cryosections	  of	  the	  hearts	  of	  male,	  female	  and	  OVX	  mice	  (sacrificed	  at	  22	  wks)	  were	  stained	  with	  
TGF-­‐β1	   and	   TRITC-­‐labeled	   secondary	   antibodies.	   A	   representative	   picture	   of	   each	   condition	   is	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Figure	  S	  VII:	  Quantitative	  real-­‐time	  PCR	  and	  Western-­‐blot	  analysis	  of	  hearts	   from	  male,	  
female	  and	  OVX	  mice	  fed	  with	  CTD	  or	  HFD	  for	  22	  wks.	  
Cardiac	  muscle	  was	  used	  to	  extract	  mRNA	  and	  protein	  to	  evaluate	  genes	  and	  proteins	   involved	   in	  
metabolism.	  Graphs	  represent	  quantification	  normalized	  to	  the	  corresponding	  control.	  Results	  are	  
presented	  with	  the	  median,	  whiskers	  show	  the	  min	  and	  max	  values.	  *	  Symbol	  corresponds	  to	  CTD	  
vs	  HFD,	  #	  symbol	  corresponds	  to	  OVX	  vs	  sham,	  $	  symbol	  corresponds	  to	  male	  vs	  female;	  N=8-­‐10.	  	  
	  
	  





















































































  Female       OVXMale
Supplementary	  Figures	  and	  Tables	  
	  




























Figure	  S	  VIII:	  WGA	  staining	  to	  evaluate	  cardiomyocyte	  cross-­‐sectional	  area.	  
Cryosections	  of	  the	  hearts	  of	  male,	  female	  and	  OVX	  mice	  (sacrificed	  at	  22	  wks)	  were	  stained	  with	  
WGA	   and	   TRITC-­‐labeled	   secondary	   antibodies,	   DAPI	   dye	   was	   used	   to	   reveal	   nuclei	   (blue).	   A	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Table	   S	   II:	   Sequence	   of	   the	   primers	   used	   to	   quantify	   the	   cardiac	   expression	   of	   targets	  










	   	  
Gene Forward primer Reverse primer 
ANP 5'-TGG GAC CCC TCC GAT AGA TC-3' 5'-TCG TGA TAG ATG AAG GCA GGA A-3' 
BNP 5'-TTC CAA GAT GGC ACA TAG TTC AA-3' 5'-ACA ACC TCA GCC CGT CAC A-3' 
β-MHC 5'-TTG AGA ATC CAA GGC TCA GC-3' 5'-CTT CTC AGA CTT CCG CAG GA-3' 
Collagen I 5'-CTT CAC CTA CAG CAC CCT TGT T-3' 5'-TGA CTG TCT TGC CCC AAG TTC-3' 
Collagen III 5'-CAC CCT TCT TCA TCC CAC TCT T-3' 5'-TGC ATC CCA ATT CAT CTA CGT T-3' 
CPT1β 5'-CCG CAG GAG GAA GGG TAG AG-3' 5'-GTC TCA TCG TCA GGG TTG TAG CT-3' 
GAPDH 5'-CGG CCG CAT CTT CTT GTG-3' 5'-CAC CGA CCT TCA CCA TTT TGT-3' 
GLUT4 5'-AGA GAG AGC GTC CAA TGT CCT T-3' 5'-CCG ACT CGA AGA TGC TGG TTG A-3' 
IL-6 5'-TCG GAG GCT TAA TTA CAC ATG TTC-3' 5'-TGC CAT TGC ACA ACT CTT TTC T-3' 
PDK4 5'-AAC CTC ACA CAA GTC AAT GGA AAA T-3' 5'-TCG ACC GTG GCC CTC AT-3' 
PGC1α 5'-AAC GAT GAC CCT CCT CAC AC-3' 5'-TCT GGG GTC AGA GGA AGA GA-3' 
PPARα 5'-CAA GGC CTC AGG GTA CCA CT-3' 5'-TTG CAG CTC CGA TCA CAC TT-3' 
TNFα 5'-TGT CTA CTG AAC TTC GGG GTG AT-3' 5'-GGA GGC CAT TTG GGA ACT TC-3' 
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Table	  S	   III:	  Echocardiographic	  and	  physiologic	  parameters	   recorded	  at	  baseline,	  prior	   to	  
the	  start	  of	  the	  diet.	  
	  
	   	  
	 MALE	 FEMALE	 OVX	
Echocardiography,	baseline	 CTD	(n	=17)	 HFD	(n	=17)	 CTD	(n	=	16)	 HFD	(n	=	18)	 CTD	(n	=15)	 HFD	(n	=17)	
Heart	rate	(beats/min)	 505±11.7	 507±17.8	 506±11.4	 510±11.3	 498±13	 506±13.9	
Anteroseptal	wall	thickness	(mm)	 	 	 	 	 	 	
						diastole	 0.78±0.02	 0.81±0.02	 0.73±0.02	 0.71±0.01	 0.73±0.02	 0.74±0.02	
						systole	 1.09±0.03	 1.12±0.03	 1.01±0.03	 0.98±0.02	 1.01±0.02	 1.02±0.03	
Left	ventricular	free	wall	thickness	(mm)	 	 	 	 	 	 	
						diastole	 0.68±0.01	 0.70±0.01	 0.57±0.01	 0.61±0.01	 0.60±0.01	 0.60±0.01	
						systole	 0.94±0.02	 1.01±0.02	 0.84±0.02	 0.89±0.02	 0.89±0.02	 0.92±0.03	
Left	ventricular	internal	diameter	(mm)	 	 	 	 	 	 	
						diastole	 4.38±0.08	 4.43±0.06	 4.02±0.05	 4.03±0.06	 4.03±0.06	 3.98±0.04	
						systole	 3.42±0.08	 3.37±0.06	 3.05±0.06	 3.02±0.04	 3.01±0.05	 3.01±0.07	
Relative	wall	thickness	 	 	 	 	 	 	
						diastole	 0.31±0.04	 0.31±0.02	 0.28±0.04	 0.30±0.03	 0.30±0.03	 0.30±0.04	
						systole	 0.55±0.08	 0.60±0.06	 0.56±0.09	 0.59±0.08	 0.59±0.08	 0.62±0.14	
	 MALE	 FEMALE	 OVX	
Echocardiography,	baseline	 CTD	(n	=17)	 HFD	(n	=17)	 CTD	(n	=	16)	 HFD	(n	=	18)	 CTD	(n	=15)	 HFD	(n	=17)	
Ejection	fraction	(%)	 44.4±1.23	 47.7±1.02	 47.7±1.42	 			48.2±1.15	 49.7±1.24	 					50±4.47	
Fraction	of	shortening	(%)	 21.9±0.70	 23.9±0.62	 24.3±0.86	 23.9±0.69	 24.9±0.73	 25.4±0.98	
Cardiac	Output	(ml/min)	 19.8±1.23	 22.1±1.18	 17.4±0.76	 16.9±0.60	 17.2±1.01	 17.9±0.96	
Left	ventricular	volume	(µl)	 	 	 	 	 	 	
						diastole	 87.4±3.62	 89.9±3.27	 71.9±2.87	 69.3±71.1	 71.1±2.43	 71.6±2.44	
						systole	 48.8±2.71	 47±2.09	 36.9±1.89	 35.9±1.22	 35.8±1.67	 35.7±1.84	
E/E’	 23.6±1.18	 23.7±1.87	 24.2±1.82	 21.5±1.99	 25.5±1.64	 25.1±2.46	
Deceleration	(mm/s2)	 -29103±1859	 -27190±2396	 -31570±2340	 -29983±1942	 -30191±3286	 -29582±2588	
Tei	index	 0.49±0.03	 0.49±0.04	 0.52±0.04	 0.5±0.04	 0.54±0.047	 0.51±0.04	
LV	mass	(g)	 98.37±18.47	 103.9±14.26	 73.3±10.38	 72.7±6.15	 74.9±10.4	 76±9.89	
Body	weight	(g)	 28.1±2.67	 29.4±1.52	 21.5±1.68	 22.4±1.32	 22.6±2.64	 23.8±2.67	
	 MALE	 FEMALE	 OVX	
Echocardiography,	baseline	 CTD	(n	=17)	 HFD	(n	=17)	 CTD	(n	=	16)	 HFD	(n	=	18)	 CTD	(n	=15)	 HFD	(n	=17)	
Ejection	fraction	(%)	 44.4±1.23	 47.7±1.02	 47.7±1.42	 			48.2±1.15	 49.7±1.24	 					50±4.47	
Fraction	of	shortening	(%)	 21.9±0.70	 23.9±0.62	 24.3±0.86	 23.9±0.69	 24.9±0.73	 25.4±0.98	
Cardiac	Output	(ml/ in)	 19.8±1.23	 22.1±1.18	 17.4±0.76	 16.9±0.60	 17.2±1.01	 17.9±0.96	
Left	ventricular	volume	(µl)	 	 	 	 	 	 	
						diastole	 87.4±3.62	 89.9±3.27	 71.9±2.87	 69.3±71.1	 71.1±2.43	 71.6±2.44	
						systole	 48.8±2.71	 47±2.09	 36.9±1.89	 35.9±1.22	 35.8±1.67	 35.7±1.84	
E/E’	 23.6±1.18	 23.7±1.87	 24.2±1.82	 21.5±1.99	 25.5±1.64	 25.1±2.46	
Decel ration	(mm/s2)	 -29103±1859	 -27190±2396	 -31570±2340	 -29983±1942	 -30191±3286	 -29582±2588	
Tei	index	 0.49±0.03	 0.49±0.04	 0.52±0.04	 0.5±0.04	 0.54±0.047	 0.51±0.04	
LV	mass	(g)	 98.37±18.47	 103.9±14.26	 73.3±10.38	 72.7±6.15	 74.9±10.4	 76±9.89	
Body	weight	(g)	 28.1±2.67	 29.4±1.52	 21.5±1.68	 22.4±1.32	 22.6±2.64	 23.8±2.67	
	
						diastole	 0.32±0.04	 0.34±0.04	 0.32±0.05	 0.359±0.06*	 0.32±0.03	 0.33±0.06	
						systole	 0.59±0.12	 0.66±0.15	 0.62±0.15	 0.68±0.18	 0.64±0.14	 0.69±0.18	
Ejection	fraction	(%)	 47.9±7.11	 50±6.72	 49.45±8.47	 50.5±8.72	 50.6±8.97	 52.8±8.58	
Fraction	of	shortening	(%)	 24.2±4.34	 25.4±4.27	 24.97±5.22	 25.6±5.37	 25.6±5.48	 27.05±5.51	
Cardiac	Output	(ml/min)	 25.4±1.15	 24.7±1.03	 18.32±0.62	 17.67±0.544	 18.956±1.083	 20.15±0.58#	
Left	ventricular	Volume	
(µl)	
	 	 	 	 	 	
						diastole	 101±0.09	 91.7±3.04*	 77.05±2.28	 72.04±2.46	 74.83±2.45	 75.7±2.59	
						systole	 53±2.51	 46.1±2.07	 29.28±2	 36.22±2.34	 36.95±1.80	 36.47±2.13	
E/A	 1.36±0.26	 1.34±0.24	 1.48±0.24	 1.35±0.18	 1.48±0.19	 1.34±0.14*	
E/E’	 20±1.38	 19.5±1.17	 19.3±1.14	 19.32±1.32	 21.37±1.32	 18.71±0.82	
Body	weight	(g)	 33.1±2.84*	 47.1±4.1*	 26.2±5.52*	 33.9±5.8*	 27.57±4*	 39.43±5.34*#	
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Table	  S	  IV:	  LV	  hemodynamics	  parameters	  of	  female	  and	  male	  mice	  recorded	  with	  the	  PVL	  





	 Male	 Female		 OVX	
LV	Hemodynamics,		
10	µg/kg/min	dobutamine	
CTD	(n	=8)	 HFD	(n	=8)	 CTD	(n	=7)	 HFD	(n	=7)	 CTD	(n	=8)	 HFD	(n	=	9)	
Heart	rate	(beats/min)	 559±13	 542±9	 536±5	 556±8	 514±7	 528±12	
Volume	(µl)	 	 	 	 	 	 	
					End-diastole,	Ved	 20.6±3.85	 14.9±3	 9.97±1.96	 13.1±1.12	 10.5±2	 16.5±3.11	
					End-systole,	Ves	 6.41±3.15	 2.18±0.75	 0.31±0.27	 0.79±0.47	 1.32±0.69	 8±3.52	
					Minimum	Volume,	Vmin	 5.34±3.26	 1.8±0.94	 -1.12±1.46	 -2.01±2.33	 -0.10±1.28	 6.58±2.97	
					Maximal	Volume,	Vmax	 20.8±3.86	 15.85±3.25	 10.24±1.94	 16.97±3.26	 11.03±2.01	 16.37±2.72	
Pressure	(mmHg)	 	 	 	 	 	 	
						End-diastole,	Ped	 4.43±0.35	 4.42±0.42	 4.51±0.37	 3.32±0.36	 4.26±0.36	 4.72±0.44	
						End-systole,	Pes	 67.2±4.28	 73.4±5.05	 69.8±5.55	 64.26±3.66	 64.33±4.89	 65.03±4.57	
						Minimum	Pressure,	Pmin	 1.62±0.34	 0.48±0.61	 1.63±0.47	 0.48±0.38	 1.2±0.55	 1.75±0.44	
						Maximum	Pressure,	Pmax	 80.5±4.76	 86.5±3.22	 83.3±4.78	 79.7±2.74	 82.1±3.41	 76.52±3.18	
Peak	rate	(µL/sec)	 	 	 	 	 	 	
						Filling,	dV/dt	max		 767±90	 476±46	 510±31	 601±88	 503±66	 455±58	
						Emptying,	dV/dt	min	 -724±63	 -540±50	 -515±25	 -671±64	 -476±48	 -458±63	
Rate	of	pressure	(mmHg/sec)	 	 	 	 	 	 	
						Development,	dP/dt	max	 9627±906	 11300±273	 10704±780	 9619±668	 10714±391	 8897±913	
	 Male	 Female		 OVX	
LV	Hemodynamics,		
10	µg/kg/min	dobutamine	
CTD	(n	=8)	 HFD	(n	=8)	 CTD	(n	=7)	 HFD	(n	=7)	 CTD	(n	=8)	 HFD	(n	=	9)	








40.07±7	 60.7±17.5	 68.46±17.9	 65.2±12.7	 52.7±14	 148±43.7	
End-systolic	pressure-volume	
relationship	(ESPVR),	slope	
9.03±3.50	 6.31±0.88	 15.3±4.37	 16.3±3.35	 12.1±3.13	 10.3±2.6	
Heart	rate	(beats/min)	 559±13	 542±9	 536±5	 556±8	 514±7	 528±12	
Volume	(µl)	 	 	 	 	 	 	
					End-diastole,	Ved	 20.6±3.85	 14.9±3	 9.97±1.96	 13.1±1.12	 10.5±2	 16.5±3.11	
					End-systole,	Ves	 6.41±3.15	 2.18±0.75	 0.31±0.27	 0.79±0.47	 1.32±0.69	 8±3.52	
					Minimum	Volume,	Vmin	 5.34±3.26	 1.8±0.94	 -1.12±1.46	 -2.01±2.33	 -0.10±1.28	 6.58±2.97	
					Maximal	Volume,	Vmax	 20.8±3.86	 15.85±3.25	 10.24±1.94	 16.97±3.26	 11.03±2.01	 16.37±2.72	
Pressure	(mmHg)	 	 	 	 	 	 	
						End-diastole,	Ped	 4.43±0.35	 4.42±0.42	 4.51±0.37	 3.32±0.36	 4.26±0.36	 4.72±0.44	
						End-systole,	Pes	 67.2±4.28	 73.4±5.05	 69.8±5.55	 64.26±3.66	 64.33±4.89	 65.03±4.57	
	
						diastole	 0.32±0.04	 0.34±0.04	 0.32±0.05	 0.359±0.06*	 0.32±0.03	 0.33±0.06	
						systole	 0.59±0.12	 0.66±0.15	 0.62±0.15	 0.68±0.18	 0.64±0.14	 0.69±0.18	
Ejection	fraction	(%)	 47.9±7.11	 50±6.72	 49.45±8.47	 50.5 .72	 .6 8.97	 52.8±8.58	
Fraction	of	shortening	(%)	 24.2±4.34	 25.4±4.27	 24.97±5.22	 25.6±5.37	 25.6±5.48	 27.05±5.51	
Cardiac	Output	(ml/ in)	 25.4±1.15	 24.7±1. 3	 8.32±0.62	 17.67 0.544	 8.956 1.083	 20.15±0.58#	
Left	ventricular	Volume	
(µl)	
	 	 	 	 	 	
						diastole	 101±0.09	 91.7± .04*	 77.05±2.28 72.04±2.46	 74.83±2.45	 75.7±2.59	
						systole	 53±2.51	 46.1±2.07	 29.28±2	 36.22±2.34	 36.95±1.80	 36.47±2.13	
E/A	 1.36±0.26	 1.34±0.24	 1 8±0.24	 1.35±0.18	 1.48 0.19	 1.34±0.14*	
E/E’	 20±1.38	 19.5±1.17	 19.3±1.14	 19.32±1.32	 21.37±1.32	 18.71±0.82	



















8. Side-­‐projects	  	  
	  
	  
	   	  
Side-­‐projects	  
	  
	   181	  
I	  had	   the	  opportunity	   to	  work	  on	  several	  projects	  during	  my	  PhD,	  either	  projects	  directly	  
linked	   to	   my	   main	   study	   or	   different.	   The	   first	   project	   in	   which	   I	   was	   involved	   was	   to	  
understand	   the	   role	   of	   phenylephrine	   (PE)	   on	   autophagy	   and	   dissect	   the	  mechanism	   by	  
which	  PE	  decreases	  the	  level	  of	  autophagy	  in	  neonate	  rat	  ventricular	  myocytes	  (NRVM).	  It	  
was	  a	  good	  starting	  experiment	  for	  me	  that	  allowed	  me	  to	  learn	  cell	  culture	  techniques	  and	  
cell	  experimentation	   in	  general.	  Soon	  after	   I	  made	  my	   first	   in	  vivo	   trial	  of	  HFD	   feeding	   in	  
mice,	  this	  experiment	  helped	  us	  to	  determine	  the	  protocol	  that	  we	  will	  follow	  for	  the	  study:	  
the	   type	   of	   diet,	   the	   percentage	   of	   fat,	   the	   duration,	   and	   the	   different	   tests	   to	   be	  
performed.	  In	  parallel,	  I	  was	  involved	  in	  the	  analysis	  of	  the	  effects	  of	  HFD	  in	  cardiac	  rictor	  
KO	  female	  mice,	  a	  study	  that	  was	  performed	  by	  Dr.	  Lifen	  Xu	  earlier.	  I	  was	  also	  implicated	  in	  
the	   analysis	   of	   the	   effects	   of	   fasting-­‐refeeding	   vs	   fasting-­‐insulin	   injection	   on	   cardiac	  
signaling.	  All	  these	  data	  are	  not	  published	  yet.	  Then	  I	  performed	  my	  first	  experiment	  where	  
we	  studied	  the	  effects	  of	  HFD	  on	  cardiac	  function	  of	  sham-­‐	  and	  OVX-­‐female	  mice.	  The	  first	  
results	  were	  conclusive	  so	  we	  decided	  to	  pursue	  this	  study	  involving	  the	  male,	  this	  time	  to	  
describe	  the	  effect	  of	  ovarian	  hormones	  as	  well	  as	  gender-­‐specific	  effects	  of	  HFD	  in	  mice.	  In	  
parallel,	  I	  wanted	  to	  understand	  the	  mechanism	  by	  which	  ovarian	  hormones	  are	  implicated	  
in	  the	  observations	  that	  we	  made	  in	  vivo.	  Thus,	  I	  started	  to	  study	  the	  effects	  of	  activation	  of	  
estrogen	  signaling	  in	  NRVMs	  with	  focus	  on	  the	  GPER	  estrogen	  receptor,	  using	  the	  specific	  
agonist	  G-­‐1	  and	  the	  inhibitor	  G-­‐15.	  Unfortunately,	  the	  results	  were	  not	  convincing	  as	  they	  
were	  not	   reproducible,	  questioning	   the	  quality	  of	   the	  compounds	  used.	  The	  timeline	  and	  
priorities	  forced	  us	  to	  terminate	  this	  part	  of	  my	  studies.	  Additionally,	   I	  participated	  in	  the	  
work	  for	  two	  research	  papers	  (see	  publications	  chapter).	  
	  
As	   important	   continuation	   of	   the	   experiments	   described	   in	   my	   PhD	   thesis	   report,	   I	  
evaluated	  the	  effects	  of	  ovarian	  hormones	  and	  gender	  on	  cardiac	   function	   in	  obese	  mice	  
that	  became	  hypertensive	  after	  angiotensin	   II	   (Ang	   II)	   infusion.	  We	  demonstrated	  that	  22	  
wks	  of	  high	  fat	  diet	  feeding	  was	  not	  sufficient	  to	  trigger	  a	  pronounced	  cardiac	  dysfunction	  
in	  male,	   female	  and	  female	   lacking	  of	  estrogens.	  This	   is	  why	  we	  started	  this	  new	  project,	  
with	  the	  aim	  to	  increase	  cardiac	  stress.	  Thus,	  we	  introduced	  the	  hypertension	  risk	  factor	  in	  
our	  model,	  which	   is	   clinically	   relevant	   for	   the	  understanding	  of	  diabetic	   cardiomyopathy.	  
Moreover,	   hypertension	   is	   the	   primary	   cause	   of	   diastolic	   dysfunction	   in	   postmenopausal	  
women487	   and	   results	   in	   LV	   hypertrophy	   impairing	   myocardial	   active	   relaxation	   and	   the	  
passive	  stiffness	  (compliance).488	  This	  study	  is	  also	  of	  interest	  because	  it	  evaluates	  gender-­‐
specificity	  and	  the	  role	  of	  ovarian	  hormones	  after	  long-­‐term	  feeding	  and	  in	  aging	  mice,	  as	  
the	  mice	  were	  followed	  up	  to	  56	  wks	  of	  feeding.	  Similar	  to	  our	  previous	  study,	  male,	  sham-­‐	  
and	  OVX-­‐female	  mice	  were	  fed	  with	   fed	  a	  high	  fat	  diet	   (HFD,	  45kJ%	   lard-­‐fat)	  or	  a	  normal	  
chow	   diet.	   The	   HFD-­‐fed	   mice	   received	   Ang	   II	   during	   the	   last	   4	   wks	   of	   feeding	   via	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subcutaneous	   infusion	   using	   mini-­‐pumps.	   The	   mice	   were	   followed	   over	   time	   by	   blood	  
pressure	  measurement,	  glucose	  tolerance	  tests	  and	  echocardiography.	  Prior	  to	  sacrifice	  at	  
56	  wks,	  PVL	  analysis	  was	  performed	  to	  evaluate	  cardiac	  hemodynamics.	  While	  this	  study	  is	  
still	  under	  analysis,	  our	  first	  results	  show	  that:	  
1.	  At	  the	   longer-­‐term,	  the	  OVX	  female	  mice	  had	  a	  higher	  BW	  than	  the	  sham-­‐female	  mice	  
when	  fed	  with	  CTD,	  which	  was	  not	  the	  case	  at	  22	  wks	  of	   feeding.	  Similar	  to	  our	  previous	  
study,	  the	  HFD	  triggered	  an	  identical	  body	  weight	  gain	  in	  both	  female	  groups.	  
2.	  Ang	  II	   induced	  the	  expected	  effects,	  as	  systolic	  and	  diastolic	  blood	  pressures	  as	  well	  as	  
heart	  weights	  were	  increased,	  proving	  the	  successfulness	  our	  hypertension	  model.	  Not	  all	  
animals	  answered	  in	  the	  same	  way	  to	  Ang	  II,	  some	  mice	  had	  stronger	  blood	  pressure	  and	  
hypertrophy	   increases	   than	   others,	   hence	   the	   necessity	   to	  make	   subgroups	   and	   analyze	  
them	  separately.	  
3.	  With	  the	  purpose	  of	  evaluating	  the	  glucose	  clearance	  ability	  of	  male,	  sham-­‐female	  and	  
OVX-­‐female	  mice	  in	  response	  to	  longer-­‐term	  HFD	  feeding	  and	  hypertension,	  we	  performed	  
a	   GTT	   after	   2	   wks	   of	   Ang	   II	   infusion.	   In	   HFD-­‐fed	   male	   mice,	   Ang	   II	   decreased	   the	   AUC,	  
indicating	   improved	   glucose	   tolerance.	   Interestingly,	   this	   effect	   was	   opposite	   to	   that	  
observed	  in	  HFD-­‐fed	  sham-­‐female	  mice,	  with	  higher	  blood	  glucose	  in	  sham-­‐female	  than	  in	  
male	  after	  54	  wks	  of	  diet	  and	  2	  wks	  of	  Ang	  II.	  Therefore,	  Ang	  II	  improved	  glucose	  tolerance	  
in	   the	   male	   and	   worsened	   it	   in	   the	   female	   in	   obese	   mice,	   underlining	   another	   sexual	  
dimorphism.	   The	   possible	   explanation	   is	   that	   Ang	   II	   increases	   insulin	   sensitivity	   or	  
stimulated	  insulin	  secretion	  in	  the	  males	  and	  not	  in	  the	  females.	  In	  the	  OVX-­‐female	  group,	  
Ang	   II	   did	   not	   result	   in	   any	   changes,	   as	   for	   the	   effect	   of	   HFD,	   it	   increased	   glucose	  
intolerance	  but	  this	  effect	  did	  not	  reach	  significance	  conversely	  to	  the	  effect	  observed	  at	  22	  
wks	  of	  diet.	  This	  could	  be	  explained	  by	  the	  low	  number	  of	  mice	  analyzed	  so	  far	  (n=6).	  
	  
The	  echocardiographic	  analysis	  demonstrated	  that:	  
1.	  After	  50	  wks	  of	  feeding,	  sham-­‐female	  mice	  had	  higher	  ejection	  fractions	  that	  male	  mice	  
for	  both	  diets,	  suggesting	  that	  their	  systolic	  function	  becomes	  better	  than	  that	  of	  the	  males	  
over	  time.	  The	  OVX-­‐female	  had	  similar	  function	  as	  the	  sham-­‐female	  mice.	  
2.	   The	   relative	  wall	   thickness	   (RWT)	   during	   systole	  was	   also	   affected	   by	   aging,	   since	   the	  
sham-­‐female	  mice	  had	  a	  higher	  value	  than	  the	  male	  after	  CTD	  feeding.	  This	  suggests	  that	  
females	  undergo	  more	  cardiac	  remodeling	  over	  time	  than	  males.	  
3.	   It	   appeared	   that	   the	   E/A	   ratio	   was	   similar	   between	   the	   groups	   at	   this	   time	   point,	  
although	  a	  decrease	  was	  visible	  after	  HFD	  in	  all	  groups	  without	  getting	  significant.	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After	  3	  wks	  of	  Ang	  II	  infusion,	  new	  effects	  appeared:	  
1.	  Ang	  II	  significantly	  increased	  the	  LV	  anterior	  and	  posterior	  wall	  thicknesses	  as	  well	  as	  the	  
RWT	   during	   diastole	   in	   the	   OVX-­‐	   but	   not	   the	   sham-­‐female,	   suggesting	   that	   ovarian	  
hormones	  may	  prevent	  Ang	  II-­‐induced	  hypertrophy.	  
2.	   Ang	   II	   also	   increased	   LV	   posterior	   wall	   thickness	   and	   RWT	   during	   diastole	   in	  male.	   A	  
thickening	  of	   this	  myocardial	  wall	  was	   visible	   in	   sham-­‐female	   too,	  but	   to	   a	   lesser	   extend	  
(not	   significant).	   If	   confirmed	   in	   more	   mice,	   this	   again	   suggests	   that	   ovarian	   hormones	  
attenuate	  the	  cardiac	  hypertrophy	  induced	  by	  Ang	  II.	  
	  
PVL	  analysis	  after	  4	  wks	  of	  Ang	   II	   infusion	  showed	  that	  Ang	   II	   increased	  the	  maximal	  and	  
end-­‐systole	  pressures	  developed	  by	  the	  heart	  in	  OVX-­‐female	  mice	  only.	  This	  result	  suggests	  
that	   ovarian	   hormones	   prevent	   the	   increase	   pressure	   due	   to	   Ang	   II	   and	   thereby	   play	   a	  
protective	  role.	  None	  of	  the	  other	  hemodynamic	  parameters	  were	  affected	  at	  this	  stage.	  
	  
Finally,	   we	   performed	   protein	   and	   genes	   expression	   analysis.	   We	   decided	   to	   start	   our	  
analysis	  with	   the	  male	   group	   and	   our	   first	   results	   showed	   increased	   β-­‐MHC	   protein	   and	  
ANP	  mRNA	  expression	  as	  a	  consequence	  of	  the	  cardiac	  stress	  induced	  by	  Ang	  II.	  Similar	  to	  
what	   we	   observed	   in	   female	   mice	   at	   22	   wks	   of	   diet,	   ANP	   was	   reduced	   in	   the	   HFD-­‐fed	  
compared	   to	   CTD-­‐fed	   male	   mice.	   Therefore,	   male	   mice	   undergo	   the	   same	   cardiac	   ANP	  
changes	  as	  females	  but	  simply	  at	  a	  later	  stage.	  Additionally,	  western-­‐blotting	  demonstrated	  
that	  Akt-­‐pT308	  was	   increased	   in	  the	  HFD	  group	  compared	  to	  the	  CTD.	  Ang	  II	  blunted	  this	  
effect,	  since	  the	  HFD+Ang	  II	  group	  had	  similar	  phosphorylation	  levels	  as	  the	  CTD	  fed-­‐group.	  
Thus,	  Ang	  II	  impairs	  the	  HFD-­‐induced	  Akt	  activation	  and	  thereby	  reduces	  cardioprotection.	  
	  
In	  summary,	  my	  preliminary	  conclusions	  on	  our	  aged,	  HFD-­‐fed	  and	  Ang	  II-­‐treated	  male	  and	  
female	  groups	  are	  as	  follows:	  
-­‐	  female	  mice	  present	  a	  better	  systolic	  function	  than	  male	  mice	  at	  16.5	  months	  of	  age.	  Ang	  
II	  improves	  glucose	  tolerance	  in	  HFD-­‐fed	  male	  mice	  and	  reduces	  it	  in	  female	  mice.	  	  
-­‐	   ovarian	   hormones	   prevent	   or	   attenuate	   Ang	   II-­‐induced	   hypertrophy,	   as	   ovary-­‐deficient	  
mice	  presented	  signs	  of	  hypertrophy.	  
-­‐	  ovarian	  hormones	  are	  essential	   to	  maintain	  normal	  end-­‐systolic	  pressure	   in	  response	  to	  
HFD,	  since	  the	  OVX	  mice	  presented	  increased	  LV	  systolic	  pressures.	  
Altogether,	   these	   results	   suggest	   that	   ovarian	   hormones	   exert	   a	   cardioprotective	   role	   in	  
response	  to	  Ang	  II-­‐induced	  hypertension	  and	  hypertrophy.	  The	  next	  step	  will	  be	  to	  evaluate	  
the	   different	   mechanisms	   involved	   such	   as	   inflammation,	   fibrosis,	   autophagy,	   apoptosis	  
and	  cardiac	  metabolic	  pathways.	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Neuregulin-1! promotes glucose uptake via PI3K/Akt in neonatal rat cardi-
omyocytes. Am J Physiol Endocrinol Metab 310: E782–E794, 2016. First
published March 15, 2016; doi:10.1152/ajpendo.00259.2015.—Nrg1! is
critically involved in cardiac development and also maintains function
of the adult heart. Studies conducted in animal models showed that it
improves cardiac performance under a range of pathological condi-
tions, which led to its introduction in clinical trials to treat heart
failure. Recent work also implicated Nrg1! in the regenerative po-
tential of neonatal and adult hearts. The molecular mechanisms
whereby Nrg1! acts in cardiac cells are still poorly understood. In the
present study, we analyzed the effects of Nrg1! on glucose uptake in
neonatal rat ventricular myocytes and investigated to what extent
mTOR/Akt signaling pathways are implicated. We show that Nrg1!
enhances glucose uptake in cardiomyocytes as efficiently as IGF-I and
insulin. Nrg1! causes phosphorylation of ErbB2 and ErbB4 and
rapidly induces the phosphorylation of FAK (Tyr861), Akt (Thr308 and
Ser473), and its effector AS160 (Thr642). Knockdown of ErbB2 or
ErbB4 reduces Akt phosphorylation and blocks the glucose uptake.
The Akt inhibitor VIII and the PI3K inhibitors LY-294002 and
Byl-719 abolish Nrg1!-induced phosphorylation and glucose up-
take. Finally, specific mTORC2 inactivation after knockdown of
rictor blocks the Nrg1!-induced increases in Akt-p-Ser473 but does
not modify AS160-p-Thr642 or the glucose uptake responses to
Nrg1!. In conclusion, our study demonstrates that Nrg1! enhances
glucose uptake in cardiomyocytes via ErbB2/ErbB4 heterodimers,
PI3K", and Akt. Furthermore, although Nrg1! activates mTORC2,
the resulting Akt-Ser473 phosphorylation is not essential for glu-
cose uptake induction. These new insights into pathways whereby
Nrg1! regulates glucose uptake in cardiomyocytes may contribute
to the understanding of its regenerative capacity and protective
function in heart failure.
phosphatidylinositol 3-kinase; metabolism; tyrosine kinase; ErbB;
signaling; protein synthesis
NEUREGULIN-1! (Nrg1!) and its receptors ErbB2 and ErbB4 are
essential for cardiac development and also play a critical role
in the healthy and diseased adult heart (45, 49, 50). Car-
diomyocyte-specific ablation of ErbB2 (12, 47) or ErbB4 (21)
leads to dilated cardiomyopathy with diminished contractility
under basal or pressure-overload conditions. Experimental
studies in which Nrg1! was administered in various rodent
models of cardiac disease confirmed its beneficial action,
which together with mechanistic insights obtained in cultured
cardiomyocytes (17, 50, 73) led to its use in clinical trials to
treat heart failure (19, 43, 58). The first two trials indeed
showed a transient improvement of cardiac function (20, 30),
whereas the results of several other trials, either with a recom-
binant human Nrg1! isoform or with the naturally occurring
neuronal isoform glial growth factor 2 (GGF2), are to be
expected in the near future. Recent work also implicated
Nrg1! in the regenerative potential of neonatal and adult hearts
(3, 25, 53). Nevertheless, the molecular mechanisms whereby
Nrg1! exerts these effects in cardiac cells are still poorly
understood.
Upon stimulation of cardiomyocytes by Nrg1!, the ErbB
receptors act via the Src/focal adhesion kinase (FAK), the
extracellular-regulated kinase (Erk)1 and 2, and the phos-
phatidylinositol 3-kinase (PI3K)/Akt pathways, which have
been linked to distinct functions (50). Cardiac developmen-
tal and postnatal growth as well as physiological or patho-
logical adaptations of the adult heart are regulated by the
serine/threonine kinase mammalian target of rapamycin
(mTOR). mTOR modulates cellular processes such as pro-
tein synthesis and energy metabolism (10, 37) and has
distinct functions depending on whether it is part of mTOR
complex (mTORC)1 or mTORC2. In the developing and
adult heart mTORC1 activity is associated with protein
synthesis and physiological hypertrophy, and mTORC2 may
modulate glucose uptake, as demonstrated previously in
skeletal muscle (35, 40, 57). Increased glucose uptake is
critical for the survival of cardiomyocytes during the acute
phase of ischemic injury, when lipid metabolism will be-
come not only insufficient for the energy demands of the
heart but will also lead to a significant increase in oxidative
stress (3, 46, 72). Nrg1! is cardioprotective during ischemia
(38), but its effects on glucose uptake and the involvement
of mTOR have not been investigated.
In other contexts, ErbB receptor activity has been related to
mTOR signaling. In breast cancer, pathological ErbB2 over-
expression is associated with constitutive activation of Akt/
mTOR and predicts tumor progression (52, 67, 79), and mTOR
inhibitors improve the outcome of ErbB2-positive breast can-
cer (72). Whereas mTOR inhibition appears to be of therapeu-
tic value in cancer, cardiomyocyte mTORC1 deficiency leads
to cardiac dysfunction in mice (62, 77). The observation that
recombinant human GGF2 causes phosphorylation of the
mTORC1 target 70-kDa ribosomal S6 kinase (p70S6K) in
cardiomyocytes (2) and that Nrg1! causes phosphorylation of
Akt on the mTORC2 target site Ser473 (59, 76) led us to
investigate whether and how mTORC1 and mTORC2 mediate
one or more of the Nrg/ErbB-related cardioprotective activi-
ties.
Our study demonstrates in a model of rat neonatal cardio-
myocytes that Nrg/ErbB signaling enhances glucose uptake
and protein synthesis. The glucose uptake is mediated by
PI3K"/Akt/AS160. Nrg1!-induced mTORC1 activation plays
a small role in the protein synthesis, whereas mTORC2 appears
to not be implicated in the glucose uptake.
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MATERIALS AND METHODS
Growth factors and inhibitors. Nrg1! was from R & D Systems,
IGF-I was from Genentech, insulin, PP242, and wortmannin were
from Sigma, Lapatinib and Dasatinib were from LC Laboratories, and
PP2, PP3, LY-294002, Akt inhibitor VIII, U-0126, SB-203580, rapa-
mycin, and PF573228 were from Calbiochem. Byl-719, TGX-221,
Cal101, and AS605240 were kind gifts from Matthias P. Wymann,
University of Basel.
Antibodies. Antibodies against mTOR-p-Ser2448, mTOR-p-Ser2481,
mTOR, Erk1/2-p-Thr202/Tyr204, Akt-p-Thr308, Akt-p-Ser473, Akt,
p70S6K1-p-Thr389, p70S6K1, ULK1-p-Ser757, eukaryotic initiation
factor 4E-binding protein-1 (4E-BP1)-p-Ser65, 4E-BP1, phosphory-
lated Akt substrate, AS160, and AS160-p-Thr642 were from Cell
Signaling Technology. Antibodies against GAPDH, FAK, c-Src,
ErbB2-p-Tyr1248, ErbB2, and ErbB4 as well as normal goat IgG were
from Santa Cruz Biotechnology. Antibodies against FAK-p-Tyr861
and ErbB4-p-Tyr1248 were from Abcam. Antibodies against FAK-p-
Tyr397 were from BD Biosciences. Antibodies against Src-p-Tyr215
were from ECM Biosciences, and antibodies to ULK1 were from
Sigma.
Primary neonatal cardiomyocyte isolation and transfection. Neo-
natal rat ventricular myocytes (NRVMs) were isolated from 1- to
2-day-old rats and transfected with nontarget ErbB2 and ErbB4
siRNA (Dharmacon) at 1 "g/3 # 106 cells using cardiomyocyte
AMAXA nucleofactor (Lonza), as published previously (26). Two
days later, the cells were treated with inhibitors and growth factors
after an overnight incubation in serum-free albumin, carnitine, crea-
tine and taurine-enriched medium (ACCT). ACCT medium consisted
of 2 g/l albumin, 2 mM L-carnitine, 5 mM creatine, and 5 mM taurine
(all from Sigma) in DMEM (Gibco).
Glucose uptake. NRVMs were treated with inhibitors for 30 min,
followed by 30 min in the presence of growth factors and another 30
min in the presence of deoxy-D-glucose, 2-[1,2-3H(N)] (Perkin-Elmer)
and D-($)-glucose (1 "Ci/ml and 100 "M, respectively) in Krebs-
Ringer bicarbonate buffer (115 mM NaCl, 4.7 mM KCl, 2.5 mM
CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 24 mM NaHCO3, 10 mM
HEPES, pH % 7.4, and 0.1% BSA). The glucose uptake was stopped
by three washes with ice-cold PBS and lysis in NaOH. Part of the
lysate was mixed with scintillation liquid, and 3H was measured with
a !-counter. A micro BCA protein assay (Thermo Scientific) was
performed with the remaining lysate to normalize the counts/min.
Protein synthesis. To analyze the pathways by which Nrg1!
stimulates protein synthesis, NRVMs were incubated for 30 min with
inhibitors, as indicated in RESULTS, and then stimulated in the presence
of 1 "Ci/ml [3H]phenylalanine (Amersham Biosciences) for 24 h.
Cells were then washed with ice-cold PBS, precipitated with 10%
ice-cold trichloroacetic acid for 30 min, washed with glacial EtOH
95%, dried, and lysed in NaOH for 45 min. Part of the lysate was
mixed with scintillation liquid for measurement of 3H with a !-coun-
ter. A DNA assay with Hoechst (Invitrogen) was performed with the
remaining lysate and used to normalize the counts/min.
Protein extraction and Western blot analysis. Total protein was
extracted with RIPA buffer [50 mM Tris·HCl, pH % 7.4, 150 mM
NaCl, 1% Nonidet P-40, 0.25% Na deoxycholate, 0.1% SDS, 5 mM
EDTA, and 0.5% phosphatase inhibitor cocktail 2 and 3 (Sigma)], and
1% protease inhibitor cocktail (Sigma) was separated by SDS-PAGE
and transferred to a PVDF membrane (Amersham-GE Healthcare).
After incubation with antibodies, the signal was revealed with Super-
Signal West Pico Chemiluminescent Substrate (Thermo Scientific),
CL-XPosure Film (Thermo Scientific), or the ChemiDoc MP System
(Bio-Rad). Blots were quantified with Image Lab (Bio-Rad) and
ImageJ (National Institutes of Health).
Immunoprecipitation. All procedures for immunoprecipitation
were done at 4°C. Protein lysates (300 "g) were cleared with 25 "l of
protein A-sepharose (Amersham-GE Healthcare) and incubated over-
night with 2 "g of antibody to AS160 or normal goat IgG. A 50%
slurry of protein A-sepharose (40 "l) was added for 4 h, and the beads
were then washed five times with RIPA buffer and collected by
centrifugation for 3 min at 3,000 rpm. The beads were resuspended in
loading buffer and heated at 95°C. Supernatants were loaded on an 8%
SDS-PAGE, and proteins transferred to PVDF, and phosphorylated
Akt substrate and AS160 were detected as described above.
Isolation of adult mouse ventricular myocytes. Hearts were dis-
sected from C57BL/6 mice, briefly washed in ice-cold Ca2$-free
perfusion buffer (135 mM NaCl, 4 mM KCl, 1 mM MgCl2, 10 mM
HEPES, 0.33 mM NaH2PO4, 10 mM glucose, 10 mM 2,3-butanedi-
one-monoxime, and 5 mM taurine), and cannulated through the aorta
for retrograde perfusion. After 5 min of acclimatization at 37°C,
hearts were perfused for 7 min with digestion solution, consisting of
5,000 U collagenase (Worthington) and 5.24 U protease (Sigma) in
Ca2$-free perfusion buffer. The dissociated myocytes were passed
through a 100-"m cell strainer and incubated with increasing concen-
trations of Ca2$ (0, 0.06, 0.24, 0.6, and 1.2 mM) that were obtained
by mixing appropriate amounts of transfer buffer A (perfusion buffer
with 5 mg/ml of BSA) with transfer buffer B (137 mM NaCl, 5.4 mM
KCl, 0.5 mM MgCl2, 10 mM HEPES, 1.2 mM CaCl2·H2O, and 5 mM
glucose). Cells were seeded on laminin-coated dishes and kept in
ACCT medium overnight before treatment.
Statistics. All results are expressed as means & SE. One-way
ANOVA analysis was followed by Sidak’s post hoc testing using
Prism 6 (GraphPad).
RESULTS
Nrg1! induces phosphorylation of the mTORC1 targets
4E-BP1, S6K, and ULK and the mTORC2 target Akt-p-Ser473.
First, we analyzed the temporal pattern of activation of kinases
known to be part of the mTOR and Akt signaling pathways
using NRVMs. Figure 1A shows that at 5 min, Nrg1! treatment
caused phosphorylation of both ErbB2 and ErbB4 at Tyr1248.
At the same time, the phosphorylation of FAK and Akt was
already strongly increased. The phosphorylated amounts of
mTOR and the mTORC1 targets 4E-BP1, p70-S6K1, and ULK
were increased later at 15 and 30 min. Lapatinib, a well known
inhibitor of ErbB1 and ErbB2, blocked the phosphorylation of
ErbB2 and ErbB4 as well as that of all downstream effectors
(Fig. 1A). Moreover, a dose response experiment at 30 min
confirmed specificity of the Akt response and established 10
ng/ml as optimal Nrg1! concentration for further experiments
(Fig. 1B). Nrg1! also activated mTOR signaling in cardiomy-
ocytes isolated from adult mouse hearts, in which increases in
mTOR-pS2448 were similar to those obtained with IGF-I, and
an upward bandshift was observed for 4E-BP1, indicating
increased phosphorylation (Fig. 1C). Thus, we conclude that
Nrg1! has immediate and specific stimulatory effects on
mTOR-mediated signaling cascades in cardiomyocytes.
In Fig. 1D, the effects of Nrg1! are compared with those of
IGF-I to evaluate the potency of either growth factor to activate
mTOR and its effectors over a longer period of time. At 30
min, IGF-I and Nrg1! similarly increased mTOR-p-Ser2448,
p70-S6K1-p-Thr389, Akt-p-Ser473, and 4E-BP1 phosphoryla-
tion. For Nrg1!, the p70-S6K1-p-Thr389 and Akt-p-Ser473
signals decreased more rapidly than for IGF-I. Thus, at 3 h the
Nrg1!-treated samples already displayed a much lesser in-
crease compared with controls than the IGF-I-treated samples,
for which the increase remained very pronounced for at least 6
h. On the other hand, the phosphorylation of 4E-BP1 persisted
for up to 24 h for both growth factors. PP242, an mTOR
inhibitor that blocks mTORC1 as well as mTORC2, abolished
all of the Nrg1!-induced increases in phosphorylation (Fig.
E783Nrg1! PROMOTES GLUCOSE UPTAKE
AJP-Endocrinol Metab • doi:10.1152/ajpendo.00259.2015 • www.ajpendo.org
1D). As expected, rapamycin decreased phosphorylation of
p70-S6K1 and 4E-BP1 in line with its function as mTORC1
inhibitor in short-term experiments. Interestingly, rapamycin
increased IGF-I-induced phosphorylation of the mTORC2 tar-
get site Ser473 in Akt, consistent with earlier studies (44, 68,
69, 74), whereas it did not modify the Nrg1!-induced phos-
phorylation of Akt at Ser473. We conclude that Nrg1!/ErbB
activates mTORC1-4E-BP1 in a similar manner as IGF-I,
whereas it activates p70-S6K1 and mTORC2-Akt more tran-
siently than IGF-I.
Nrg1! stimulates protein synthesis. Given the well-estab-
lished function of mTORC1, we tested whether Nrg1! stimu-
lates protein synthesis in cardiomyocytes via mTORC1. Incu-
bation with Nrg1! for 24 h increased phenylalanine incorpo-
ration in a Lapatinib-sensitive manner (Fig. 2A), and
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Fig. 1. Neuregulin-1! (Nrg1!) activates mammalian target of rapamycin (mTOR) complex (mTORC)1 and mTORC2 in ventricular myocytes. A: after overnight
incubation in serum-free albumin, carnitine, creatine, and taurine-enriched medium, neonatal rat ventricular myocytes (NRVMs) were treated with Nrg1! (10
ng/ml) for 5, 15, and 30 min. Cells were pretreated with Lapatinib (Lap; 10 "M) or vehicle (DMSO) for 30 min. B: dose response for Nrg1! in NRVMs at 30
min. C: adult mouse ventricular myocytes were treated with Nrg1! (10 ng/ml) or IGF-I (20 ng/ml) and lysed for analysis by Western blotting at the time points
indicated. D: NRVMs were treated with Nrg1! (10 ng/ml) or IGF-I (20 ng/ml) for "24 h in the absence or presence of rapamycin (Rap; 20 ng/ml) or PP242
(20 "M), and lysates were analyzed as in A. D: total proteins (20 "g) were analyzed by Western blotting to test for total and phosphorylated proteins as indicated.
FAK, focal adhesion kinase; 4E-BP1, eukaryotic initiation factor 4E-binding protein-1; Ctl, control; S6K, p70S6K1.
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extent (Fig. 2B), which suggests that mTORC1 contributes to
the Nrg1!-induced protein synthesis. However, since a strong
increase persisted after PP242 or Rap inhibition, mTOR-inde-
pendent alternate pathways are also important in the Nrg1!-
induced phenylalanine uptake. Consistent with previous stud-
ies, the Erk1/2 inhibitor U-0126 partially inhibited phenylala-
nine incorporation (Fig. 2C). Moreover, the Akt inhibitor VIII
abolished the protein synthesis response, in line with the
established role of Akt as upstream activator of mTORC1. We
conclude that Akt and Erk1/2, as well as mTORC1 via sus-
tained phosphorylation of 4E-BP1 (Fig. 1D), are implicated in
the enhanced global protein synthesis after Nrg1! treatment of
neonatal cardiomyocytes.
Nrg1! enhances glucose uptake. Given our observation that
the effect of PP242 on protein synthesis was only modest, we
next aimed at identifying other functions of mTOR in cardio-
myocytes. Very little is known about the cardiac function of
mTORC2, and therefore, we decided to focus on the function
of the Nrg1!-induced phosphorylation of Akt at Ser473, which
in Fig. 1D was shown to be rapamycin resistant and PP242
sensitive and, therefore, most likely mTORC2 dependent. Akt
is implicated in the translocation of glucose transporters to the
plasma membrane and thereby contributes to insulin-induced
glucose uptake after feeding (34). As mTORC2 has been
reported to regulate glucose metabolism in some tissues (35,
40), we hypothesized that mTORC2-mediated phosphorylation
of Akt contributes to Nrg1!-induced glucose uptake in our
cardiomyocyte model. We tested this hypothesis while using
IGF-I and insulin as a reference. The three stimuli induced
similar increases in glucose uptake, and combinations of
Nrg1! with either IGF-I or insulin did not yield any further
increase (Fig. 3A), indicating that Nrg1! depends at least in
part on the same signaling molecules as IGF-I and insulin.
Lapatinib abolished the effect of Nrg1! on glucose uptake
(Fig. 3B), implicating ErbB2 and/or ErbB4 in the response.
Figure 3C shows that rapamycin did not have any effect at all,
which excludes a role for mTORC1. On the other hand, PP242
preincubation reduced the Nrg1!-induced glucose uptake com-
pared with that of DMSO-preincubated cells (Fig. 3C). In fact,
PP242 reduced the Nrg1!-induced glucose uptake from 1.77-
to 1.56-fold compared with the corresponding unstimulated
DMSO- and PP242-preincubated controls, respectively, and
therefore, the inhibition was 27% of the total increase. In
additional independent experiments, PP242 reduced Nrg1!-,
IGF-I-, and insulin-induced glucose uptake from 1.88-, 1.64-,
and 1.90- to 1.52-, 1.56-, and 1.52-fold, respectively, vs. the
corresponding unstimulated controls. This represents an inhi-
bition of 41, 13, and 42%, respectively, for the three growth
factors. Together, our data suggest that common pathways are
used by the three growth factors to link receptor activation to
glucose uptake and that mTORC2 may mediate part of the
insulin- and Nrg1!-induced responses. Additional nonpharma-
cological approaches are required to prove this further (see
below).
The Nrg1!-induced glucose uptake is mediated by Akt and
AS160. To further characterize the PP242-sensitive signaling
branch of the Nrg1!-induced glucose uptake, we assessed
which kinases, in addition to those already shown in Fig. 1,
were inhibited by PP242 (Fig. 4). At 30 min, Nrg1! enh-
anced Akt phosphorylation at Thr308 and Ser473, although the
effect was somewhat weaker than that observed for IGF-I.
PP242 abolished both increases completely for Nrg1! and
partially for IGF-I (Fig. 4A). Together with the generally
accepted view that Akt-p-Ser473 is a direct target of mTORC2
and our finding that rapamycin does not reduce Akt-p-Ser473
(Fig. 1D), this complete inhibition by PP242 supports that
mTORC2 is implicated in this Nrg1!-induced Akt phosphor-
ylation in cardiomyocytes. In Fig. 1A, we showed that Nrg1!
increases Akt-p-Ser473 already at 5 min, before mTOR phos-
phorylation is detectable, and therefore, we tested whether
Nrg1! has a rapid, mTOR-independent phase of Akt activa-
tion. Figure 4B shows that PP242 inhibited the Akt-Ser473
phosphorylation at 5 min after Nrg1! stimulation, which indi-
cates that mTORC2 was active and required for this early
phosphorylation of Akt. Notably, Akt-p-Thr308 was somewhat
reduced but not abolished in the PP242-pretreated cells, con-
sistent with the notion that PDK1-mediated Akt-Thr308 phos-
phorylation is possible in the absence of mTORC2-mediated
Akt-Ser473 phosphorylation. These reduced Akt-p-Thr308
amounts may explain the partially reduced glucose uptake
response to Nrg1! after PP242 pretreatment. Figure 4C shows


































































































































Fig. 2. Nrg1! enhances protein synthesis in part via mTORC1, Erk1/2, and
Akt. After preincubation with vehicle (DMSO), Lap (10 "M), Rap (20 ng/ml),
PP242 (20 "M), U-0126 (10 "M), or Akt inhibitor VIII (VIII; 20 "M) for 30
min, NRVMs were treated with Nrg1! (10 ng/ml) in the presence of [3H]phe-
nylalanine (1 "Ci) for 24 h. The [3H]phenylalanine incorporated into the cells
was normalized for DNA content; n # 3. *P $ 0.05, **P $ 0.01, ***P $
0.001, and ****P $ 0.0001, Nrg-treated vs. Ctl; $P $ 0.05, $$P $ 0.01, and
$$$$P $ 0.0001, inhibitor- vs. corresponding DMSO-treated control.
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cose uptake, which indeed supports that Akt is a main actor in
this effect.
IGF/insulin-induced Akt activation is known to cause the
translocation of glucose transporters to the sarcolemma via its
downstream mediator AS160 (56), but whether or not Nrg1!
acts via this mechanism in cardiomyocytes is not known.
Immunoprecipitation experiments demonstrated that Nrg1!
raised the phosphorylation of Akt substrate AS160 in a manner
similar to IGF-I (Fig. 4D). Moreover, an antibody to AS160-
p-Thr642 confirmed its phosphorylation after Nrg1! stimula-
tion (Fig. 4E), which is consistent with the known function of
this specific phosphorylation site being indicative of enhanced
glucose transporter type 4 (GLUT4) translocation to the sar-
colemma. Together, these data support that Nrg1! induces
glucose uptake in NRVMs via Akt and AS160 and suggest that
mTORC2-mediated Akt-Ser473 phosphorylation may contrib-
ute to this response.
Nrg1!-induced mTORC2-mediated Akt phosphorylation at
Ser473 is not required for the glucose uptake response. To
further investigate the role of mTORC2, we knocked down
its specific and essential component rictor using siRNA
technologies. Figure 4F shows that reduced rictor protein
levels were associated with lower Akt-p-Ser473, confirming
that mTORC2 activity was efficiently reduced. However,
this was not associated with lower AS160-p-Thr642 (Fig.
4F), and consistently, glucose uptake responses to Nrg1!
were not impaired (Fig. 4G). Together with our observations
that PP242 only modestly and Akt inhibitor VIII completely
inhibited the glucose uptake, these data indicate that
mTORC2-mediated Akt phosphorylation is not essential for
this response to Nrg1!. Thus, whereas our data demonstrate
that Nrg1! activates mTORC2 and stimulates glucose up-
take, the mTORC2-mediated Akt-p-Ser473 phosphorylation
appears not to modulate this glucose uptake.
Upstream of Akt, PI3K is implicated in the Nrg1!-induced
glucose uptake. We next aimed at identifying other upstream
signaling molecules that mediate the Nrg1!-induced Akt
activation and glucose uptake. The class 1 PI3K inhibitor
LY-294002 (LY) abolished the Nrg1!-induced glucose up-
take (Fig. 5A), whereas effects of the p38 inhibitor SB-
203580 (SB) and the Erk1/2 inhibitor U-0126 did not reach
significance (Fig. 5B). Consistently, LY blocked whereas
SB only had small effects on Akt phosphorylation (Fig. 5E).
Others have demonstrated that SB decreases glucose uptake
independently of p38 MAPK inhibition (1). Therefore, PI3K
is most likely the main actor upstream of Akt in the
Nrg1!-induced glucose uptake. LY has been reported to
also inhibit other kinases, including mTORC1, at concen-
trations similar to those that inhibit PI3K (13). Additional
experiments with the isoform-specific PI3K inhibitor Byl-
719 revealed that Nrg1! activates glucose uptake via PI3K"
(Fig. 5C), and this was associated with lower Akt (Thr308
and Ser473) and Akt substrate (160 kDa) phosphorylation
(Fig. 5D), which suggests that PI3K" is activating both
PDK1 and mTORC2. Consistently, inhibition of PI3K!, -#,
and -$ with TGX-221, Cal101, and AS605240, respectively,
had no effect (data not shown).
Effect of Src family kinase inhibitors on the Nrg1!-induced
glucose uptake. How does Nrg1!-induced ErbB2/ErbB4
phosphorylation lead to PI3K activation? Given our obser-
vation that the Nrg1!-induced Akt phosphorylation was
paralleled over time by increased FAK-p-Tyr861 (Fig. 1A),
we tested whether Src family kinases are implicated, be-
cause FAK is one of their direct targets (7, 61). PP2, a
compound that inhibits Src family protein kinases such as
c-Src, reduced the Nrg1!-induced glucose uptake (Fig. 6A)
as well as phosphorylation of FAK at Tyr861 and Akt at
Thr308 and Ser473 (Figs. 5E and 6E), whereas it had no effect on
p70-S6K1-p-Thr389 (Fig. 5E). None of the effects was observed
with PP3, a negative control for PP2. Recent studies reported
that PP2 may inhibit other kinases with similar affinities and
that it is less Src selective than the Src family kinase inhibitor
dasatinib (Das) (4). Therefore, we also tested Das and found














































































































Fig. 3. Nrg1! increases glucose uptake,
which is partially inhibited by PP242. A:
NRVMs were treated for 30 min with Nrg1!
(10 ng/ml), IGF-I (20 ng/ml), or insulin (Ins;
20 ng/ml) either alone or in combination as
indicated. This was followed by 30 min of
incubation with 1 %Ci/ml [3H]deoxy-D-glu-
cose. Data were normalized for the total
protein/well; n & 3. B–D: NRVMs were
treated with Nrg1! (10 ng/ml) after 30 min
of preincubation with vehicle (DMSO), Lap
(10 %M), Rap (20 ng/ml), or PP242 (20
%M), and glucose uptake was assessed as in
A; n & 6 (B), 7 (C), and 3 (D). *P ' 0.05,
**P ' 0.01, and ****P ' 0.0001 (vs. Ctl);
$$$P ' 0.001 inhibited vs. corresponding
DMSO; $$P ' 0.01, inhibitor- vs. corre-
sponding DMSO-treated control.
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sites (Figs. 5E and 6E), and the 160-kDa Akt substrate (not
shown). A dose response experiment demonstrated that strong
inhibition was obtained already at 100 ng/ml and was complete
at 1 !g/ml (data not shown). Notably, Das potently reduced the
Nrg1"- but not the IGF-I-induced glucose uptake (Fig. 6B),
indicating that Das sensitivity is a unique feature of Nrg1"-
induced ErbB signaling. Similarly, only Nrg1" led to increased
phosphorylation of FAK at Tyr861 (Fig. 6C). In an attempt to
further identify the implicated kinase, we analyzed over time
the phosphorylation of Src at Tyr215 and Tyr416, the latter site
being indicative of c-Src activation. Src-p-Tyr215 increased at
30 min, which is much later than FAK-p- Tyr861, Akt, and Akt
substrate phosphorylation, excluding a role of this site in the
rapid activation of Akt (Fig. 6D). Src-p-Tyr416 was already
high under basal conditions and did not increase any further
after Nrg1" stimulation. Das but not PP2 inhibited phosphor-
ylation of this site (Fig. 6E), whereas both inhibitors negatively
affected Nrg1"-induced Akt activation and glucose uptake
(Fig. 6, A and B), which altogether excludes a causative role of
c-Src. In conclusion, our findings indicate that one or more
members of the Src kinase family (but not c-Src) are involved
in the phosphorylation of FAK at Tyr861 and in the glucose
uptake response to Nrg1", although a causal relationship
between FAK-p861 and glucose uptake and the precise mech-
anism involved remain to be established.
Nrg1!/ErbB-induced glucose uptake does not depend on
integrin/FAK397. Src family kinases have been implicated in
integrin signaling, and recent data suggest that integrin
activation may promote glucose uptake (29). Ligand-in-
duced integrin activation involves, as a first step, autophos-
phorylation of FAK at Tyr397, which induces a conforma-
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Fig. 4. The Nrg1"-induced glucose uptake is
mediated by ErbB2, phosphatidylinositol
3-kinase (PI3K), and Akt. A: NRVMs were
treated for 30 min with Nrg1", IGF-I, or
vehicle (Ctl) after 30 min of pretreatment
with DMSO, PP242 (20 !M), or Lap (10
!M). Western blot (WB) analysis was per-
formed to assess the phosphorylation status
of the kinases indicated. B: as in A, LY-
294002 (LY; 10 !M) was used during the
preincubation, and Nrg1" treatment was
done for 5 and 30 min. Images shown are cut
from the same Western blot. C: after 30 min
of pretreatment with DMSO or Akt inhibitor
VIII (20 !M), NRVMs were treated for 30
min with Nrg1" or vehicle (Ctl), followed by
30 min of 1 !Ci/ml [3H]deoxy-D-glucose;
n# 4. D: NRVMs were treated with IGF-I or
Nrg1" for 30 min, and total protein extracts
were immunoprecipitated (IP) for Akt sub-
strate of 160 kDa (AS160). WBs of the pre-
cipitated proteins were analyzed with anti-
bodies to phosphorylated Akt substrate
(pAS) and AS160. E: after Nrg1" stimula-
tion, total protein extracts were analyzed with
a phosphospecific antibody to AS160-p-
Thr642. F and G: cardiomyocytes were trans-
fected with small-interfering RNA (siRNA)
to rictor immediately after their isolation us-
ing AMAXA. Stimulation with Nrg1" and
protein extraction (F) or glucose uptake as-
says (G) followed 2 days after the transfec-
tion. **P $ 0.01 and ***P $ 0.001, Nrg1"
vs. Ctl; $$P $ 0.01 and $$$$P $ 0.0001,
inhibitor vs. corresponding DMSO. Lck,
lymphocyte-specific protein tyrosine kinase;
Scrbl, scrambled.
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containing Src-family kinases. After binding, these kinases
further phosphorylate FAK at multiple sites and thereby
activate it (60). To investigate whether the Nrg1!-induced
glucose uptake requires signaling via integrin/FAK-p-
Tyr397, we used the potent FAK inhibitor PF-573228 (PF).
Figure 7A shows that Nrg1! increased FAK-p-Tyr861 but
did not change FAK-p-Tyr397 compared with untreated
controls. Consistent with an earlier report (33), PF had no
effect on the Nrg1!-stimulated FAK-p-Tyr861, but it effec-
tively reduced FAK-p-Tyr397, Src-p-Tyr416, and phosphor-
ylation of the integrin-FAK target paxillin. Nevertheless, PF
neither inhibited Nrg1!-induced mTOR and Akt signaling,
as phosphorylation of mTOR and its targets Akt (Ser473) and
p70S6K remained high (Fig. 7A), nor did it affect the
glucose uptake response (Fig. 7B), from which we conclude
that these effects are integrin/FAK-p-Tyr397/c-Src-indepen-
dent. The data also indicate the presence of high basal
integrin/FAK/Src activity in our model.
Specific downregulation of ErbB2 and ErbB4 with siRNA.
Lapatinib blocked the glucose uptake and all Nrg1!-induced
signaling, but as it reduced phosphorylation of both ErbB2
and ErbB4 it did not distinguish between the two receptors
(Fig. 1). To define the specific role of ErbB2 and ErbB4 in
the Nrg1!-induced pathways that enhance glucose uptake,
we used pools of siRNA specific for ErbB2 and ErbB4. Both
targeted proteins were effectively downregulated, whereas
GAPDH and vinculin were not altered (Fig. 8). Knockdown
of ErbB4 resulted in reduced Nrg1!-stimulated levels of
FAK-p-Tyr861, Akt-p-Ser473, Akt-p-Thr308, mTOR-p-
Ser2448, ULK-p-Ser757, and p70-S6K1-p-Thr389. ErbB2
knockdown, on the other hand, only reduced Akt-p-Ser473
and Akt-p-Thr308 (Fig. 8). Both the ErbB2 and ErbB4
siRNA knockdown abolished the Nrg1!-induced glucose
uptake, showing that both ErbB2 and ErbB4 are needed for
this response. The signaling data suggest that ErbB4 is
implicated in the Nrg1!-induced activation of mTORC1 as
well as mTORC2. ErbB2 is implicated in mTORC2 but does
not seem to be required for mTORC1 activation by Nrg1!.
However, as our knockdown approach was more efficient
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Fig. 5. Upstream of Akt, PI3K" is implicated in the
Nrg1!-induced glucose uptake. A–D: NRVMs were
pretreated with the PI3K inhibitor LY (10 #M), the
p38 inhibitor SB-203580 (SB; 10 #M), and the
PI3K" inhibitor Byl-719 (1 #M; D) for 30 min.
NRVMs were then stimulated with vehicle (Ctl) or
Nrg1! (10 ng/ml) for 30 min, and glucose uptake
was assessed as in Figs. 3 and 4. E: inhibitors were
used and cells stimulated as in A–D and Fig. 6.
Protein extracts were analyzed by Western blotting
as in Fig. 1. *P $ 0.05, **P $ 0.01, and ****P $
0.0001 (vs. Ctl); $$$$P $ 0.0001, inhibitor vs.
DMSO.
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plete knockout approaches are required to further investi-
gate receptor involvement. Our data are in line with the
notion that ErbB4 is the main receptor for Nrg1!, whereas
ErbB2 has no extracellular binding pocket for Nrg1! but
transduces specific signals when it is part of a heterodimer
complex with one of the other ErbB isoforms.
DISCUSSION
Under stress conditions, cardiac microvascular endothe-
lial cells release Nrg1!, which in a paracrine manner acti-
vates the receptor dimers ErbB2/ErbB4 and ErbB4/ErbB4,
both of which are expressed in cardiomyocytes (11, 78).
Upon stimulation, the ErbB receptors may act via the
Erk1/2, PI3K/Akt, and Src/FAK pathways, each of which
has been linked to distinct protective functions. For exam-
ple, Nrg1! diminishes doxorubicin-induced sarcomere dis-
array in cardiomyocytes via Erk (48, 51, 59), whereas
PI3K/Akt activation is responsible for the protection against
basal or anthracycline-induced apoptosis (16, 22, 78) in part
by reducing oxidative stress and improving mitochondrial
function, calcium handling, and contractility (22, 23, 66).
Independently of PI3K/Akt and Erk1/2, Nrg1! influences
focal adhesion formation via Src/FAK (36).
Consistent with previous studies (2, 11, 78), we show here
that Nrg1! increases global protein synthesis in neonatal car-
diomyocytes. Whereas early studies implicated ErbB2 and
Erk1/2 in the protein synthesis response to GGF2, here we
extend the mechanistic insights by demonstrating how Nrg1!
activates mTORC1 over time and by providing data that
suggest its involvement in protein synthesis. However, it
should be mentioned here that a large part of the Nrg1!-
induced protein synthesis was not inhibitable by the mTOR
inhibitor PP242, indicating pathway redundancy. Nevertheless,
we show that Nrg1! increases mTOR-p-Ser2448 (a site that
indicates mTORC1 activity) and the phosphorylated levels of
two direct mTORC1 targets that regulate protein synthesis,
namely p70-S6K and 4E-BP1. The Nrg1!-induced increase in
4E-BP1 phosphorylation lasted as long as that induced by
IGF-I, which may explain the similar potency of the two
factors to enhance protein synthesis. In contrast to IGF-I,
Nrg1! only transiently affects p70-S6K phosphorylation, and
rapamycin does not lead to hyperphosphorylation of Akt.
These findings suggest that Nrg1! activates mTORC1 and
protein synthesis without inducing the negative feedback loop
that is perceived as one of the causes of insulin resistance.
Our study also demonstrates that Nrg1! increases glucose
uptake. Nrg1! was reported to enhance glucose uptake in
cardiomyocytes only in one earlier study, in which it was
shown that the endothelium generates both Nrg1" and
Nrg1!, but that only Nrg1! causes ErbB2 tyrosine phos-
phorylation with functional consequences such as increased
glucose uptake (11). Whereas that study did not analyze the
underlying pathways, our study now shows that Nrg1!
increases glucose uptake via ErbB2/ErbB4 heterodimers and
enhanced signaling via PI3K", Akt, and AS160. Given the
well-established function of Akt/AS160, our data suggest
that the increase in glucose uptake after Nrg1! stimulation
is a consequence of GLUT4 translocation to the sarcolemma
(56). Thus, whereas others have linked Akt activation by
Nrg1! to pro-survival pathways (16, 22, 23, 66, 78), here
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Fig. 6. Effect of Src family kinase inhibitors
on Nrg1!-induced signaling and glucose up-
take. A and B: NRVMs were pretreated with
the inhibitor PP2 (5 #M) or dasatinib (Das;
1 #M) for 30 min. PP3 (5 #M) was used as
negative control for PP2. NRVMs were then
stimulated with vehicle (Ctl) or Nrg1! (10
ng/ml) or IGF-I (20 ng/ml) for 30 min, and
glucose uptake was assessed as in Figs. 3–5.
C–E: protein extracts were analyzed by
Western blotting as in Fig. 1. **P $ 0.01
and ****P $ 0.0001 vs. Ctl; $P $ 0.05,
$$P $ 0.01, and $$$P $ 0.001, inhibitor vs.
corresponding DMSO.
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This novel ErbB2/ErbB4-specific mechanism of glucose
uptake may be particularly important under conditions of
acute stress such as ischemic events, when the heart has to
rapidly respond to maintain performance and survival of
contractile cells. Whereas fatty acid and glucose oxidation
are tightly regulated in the healthy heart to optimally pro-
vide it with the high amounts of energy needed for contrac-
tion, substrate use for ATP production changes under hy-
poxic conditions associated with, e.g., ischemia or hyper-
trophy. A shift from predominant fatty acid oxidation to
increased carbohydrate use and glycolysis ensures continued
ATP production under conditions of oxygen deficiency (31,
39). Ischemia has previously been associated with the trans-
location of glucose transporters to the sarcolemma (5, 46,
75). At the early stages of ischemia, the glucose allows a
better adaptation and survival (5). In support of this concept,
cardiac deletion of GLUT4 leads to a lower tolerance to
ischemic events associated with a higher rate of ATP de-
pletion (65). Indeed, ischemic insults acutely caused the
rapid release of Nrg1! from microendothelial cells and
phosphorylation of ErbB4 (15, 36), and Nrg1! ablation in
endothelial cells aggravated the harmful consequences of
ischemia (38), whereas intravenous injections of the EGF-
like domain of Nrg1! or GGF2 improved ventricular func-
tion in rat and swine models of myocardial infarction (18,
27, 41). Our present findings suggest that an increase in
glucose uptake is one of the protective mechanisms induced
by Nrg1! in these conditions.
The ability of Nrg1! to stimulate glucose uptake has been
reported previously for a skeletal muscle cell line (8, 64),
and consistent with those in vitro studies, acute infusion of
GGF2 or Nrg1! was recently shown to lower blood glucose
in swine (18), rats (6), and a mouse model of type 2 diabetes
(14). Whereas in L6E9 myotubes PKC" was implicated in
the glucose uptake response, here we show that in cardio-
myocytes Akt activation is implicated, because Nrg1! in-
creases AS160 phosphorylation, and the Akt inhibitor VIII
abolishes this as well as the glucose uptake response.
Another new finding of our study is that Nrg1! activates
mTORC2 because it phosphorylated the mTORC2-specific
site Ser473 of Akt in a PP242-sensitive manner. However,
consistent with our recently published in vivo data in adult
mice (63), Akt-p-Ser473 phosphorylation appears to not be
needed for phosphorylation of substrates involved in glu-
cose uptake. This conclusion is supported by our observa-
tion that rictor knockdown efficiently reduces Akt-p-Ser473
without having any effects on AS160 phosphorylation and
glucose uptake. Thus, whereas a role has previously been
attributed to mTORC2 in skeletal muscle (35, 40, 57), fat,
and liver (24), our own data demonstrate that mTORC2 is
not implicated in glucose uptake of the heart. In this setting,
it should be mentioned that PI3K was recently reported to
directly phosphorylate Akt at Ser473 and induce glucose
transporter translocation (70), and thus mTORC2-dependent
Ser473 phosphorylation of Akt appears to be dispensable in
this pathway.
To the best of our knowledge, our study is the first to
identify Nrg1! as an activator of PI3K/Akt-mediated glucose
uptake in cardiac cells. We show unique features of this
Nrg1!-induced pathway, such as its Das sensitivity, which was
not observed in IGF-I-stimulated cells. Consistently, Nrg1!,
but not IGF-I or insulin, induced phosphorylation of FAK at
Tyr861. LY did not block FAK phosphorylation, whereas Das
and PP2 blocked phosphorylation of FAK and Akt as well as
the glucose uptake response, suggesting that Src family kinases
and FAK may be implicated either upstream of or in parallel to
PI3K, consistent with previous studies in the heart (9) and
noncardiac cells (42). Whether or not Src-dependent FAK-
Tyr861 phosphorylation is implicated in transmitting the signal
from ErbB to PI3K remains to be proven. Others have dem-
onstrated that ErbB activation may also directly stimulate PI3K
in cardiomyocytes (70).
Our observation that Nrg1! rapidly increases FAK-p- Tyr861
is consistent with a previous study on adult cardiomyocytes
(36). In contrast to that study, phosphorylation of c-Src at
Tyr416 was high in our unstimulated NRVMs, and Nrg1! did
not increase this further. Das decreased c-Src-p-Tyr416, sug-































































Fig. 7. FAK-p-Tyr397 is not implicated in the glucose uptake response to
Nrg1!. A: NRVMs were pretreated with FAK inhibitor PF-573228 (PF; 1
#M), followed by Nrg1! treatment for 30 min. A: WB analysis was performed
for FAK and mTOR signaling. PF preincubation was done for 30 min, 1 h, and
2 h; the DMSO control matched the 30-min time point. B: glucose uptake was
performed as in Fig. 3 to assess the influence of integrin/FAK-p-Tyr397
inhibition on the Nrg1!-stimulated glucose uptake; n $ 4. *P % 0.05 vs. Ctl.
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model. On the other hand and consistent with Kuramochi et al.
(36), Nrg1! increased the signal detected with an antibody to
Src-p-Tyr215. PP2 and Das, but not PP3, blocked this increase
as well as the glucose uptake response. However, our obser-
vation that this phosphorylation happens later than the Akt
phosphorylation excludes its role in the specific activation by
ErbB2/ErbB4. We conclude that the presence of a PP2/Das-
sensitive kinase, but most likely not c-Src, is important for the
phosphorylation of FAK at Tyr861 and the glucose uptake
response to Nrg1!, although the causal relationship between
FAK-p-Tyr861 and Akt remains to be proven.
Interestingly, we found that phosphorylation of FAK at
Tyr861 by Nrg1! does not depend on FAK phosphorylation at
Tyr397, a site that autophosphorylates upon integrin stimulation
and leads to additional phosphorylation events after Src family
kinase recruitment to SH2 domains. Our conclusion is sup-
ported by the observation that PF reduces integrin-related
FAK-p-Tyr397 and paxillin-p-Tyr118 but not the Nrg1!-in-
duced phosphorylation of FAK at Tyr861. Differential inhibi-
tion by PF of these two phosphorylation events has also been
reported for lung and breast cancer cells (28, 33). Thus, Nrg1!
induces FAK phosphorylation independently of the classical
integrin pathway.
A limitation of our own as well as other studies with
different cell types and hormonal stimuli (32, 54, 71) is that
pharmacological inhibition was used to implicate Src family
kinases in glucose uptake responses. Since PP2 and Das,
besides inhibiting multiple Src family kinases, have recently
been described to have off-target effects, further studies are
needed to determine which kinases inhibited by PP2 and Das
are responsible for FAK-Tyr861 phosphorylation and the glu-
cose uptake response to Nrg1!. It also remains possible that
although the time course and PP2/Das sensitivity of FAK-
Tyr861 phosphorylation parallels that of Akt and AS160 phos-
phorylation, FAK is not causally implicated in the glucose
uptake. Moreover, it is also possible that ErbB directly acti-
vates PI3K (55).
Taken together, we show that Nrg1! enhances glucose
uptake via ErbB2/ErbB4, PI3K", Akt, and AS160 (Fig. 9) and
that these effects are sensitive to PP2 and Das. These novel
insights provide a basis for future experimental and clinical
studies in which this pathway may be exploited to increase
glucose uptake, especially in states of irresponsiveness to
insulin.
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siRNA ErbB4 Scrbl 
Fig. 8. The Nrg1!-stimulated glucose uptake
is mediated by the ErbB2/ErbB4 heterodimer.
A: ErbB2 and ErbB4 receptors were down-
regulated with pools of specific siRNAs. WB
analysis was performed to assess the effi-
ciency of the ErbB2 and ErbB4 knockdown as
well as the effects on mTORC1 and mTORC2
targets. B: glucose uptake was measured as in
Fig. 3 at 2 days after the siRNA transfection.
***P # 0.001, Nrg-treated vs. control;
$$$P # 0.001, inhibitor- vs. corresponding
DMSO-treated control.

















Fig. 9. Working model for the pathways that link Nrg1! to glucose uptake in
cardiomyocytes.
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Aims Mammalian target of rapamycin (mTOR), a central regulator of growth and metabolism, has tissue-specific functions
depending on whether it is part of mTOR complex 1 (mTORC1) or mTORC2. We have previously shown that
mTORC1 is required for adaptive cardiac hypertrophy and maintenance of function under basal and pressure-overload
conditions. In the present study, we aimed to identify functions of mTORC2 in the heart.
Methods
and results
Using tamoxifen-inducible cardiomyocyte-specific gene deletion, we generated mice deficient for cardiac rapamycin-
insensitive companion of mTOR (rictor), an essential and specific component of mTORC2. Under basal conditions,
rictor deficiency did not affect cardiac growth and function in young mice and also had no effects in adult mice. How-
ever, transverse aortic constriction caused dysfunction in the rictor-deficient hearts, whereas function was maintained
in controls after 1 week of pressure overload. Adaptive increases in cardiac weight and cardiomyocyte cross-sectional
area, fibrosis, and hypertrophic and metabolic gene expression were not different between the rictor-deficient and
control mice. In control mice, maintained function was associated with increased protein levels of rictor, protein kinase
C (PKC)bII, and PKCd, whereas rictor ablation abolished these increases. Rictor deletion also significantly decreased
PKC1 at baseline and after pressure overload. Our data suggest that reduced PKC1 and the inability to increase PKCbII
and PKCd abundance are, in accordance with their known function, responsible for decreased contractile performance
of the rictor-deficient hearts.
Conclusion Our study demonstrates that mTORC2 is implicated in maintaining contractile function of the pressure-overloaded
male mouse heart.
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1. Introduction
Recent studies have identified mammalian target of rapamycin (mTOR)
as an important regulator of cardiac adaptations to pressure overload.1
mTOR, an evolutionary conserved serine/threonine kinase belonging
to the phosphatidylinositol 3-kinase (PI3K)-related kinase family of
proteins, matches cell growth and metabolism with environmental re-
sources and other cues.2 Thus, it senses nutrient and energy status,
growth factors, oxygen levels and stress, and adapts a range of cellular
functions related to growth and metabolism correspondingly. In line
with its important regulatory function, mTOR overexpression is
protective in pressure-overloaded mouse hearts,3 whereas conditional
mTOR deletion causes cardiac dysfunction.4
mTOR has different functions depending on whether it is part of the
multiprotein complex termed mTOR complex 1 (mTORC1) or
mTORC2.5,6 We recently showed that raptor (regulatory-associated
protein of mTOR) is required for basal cardiac function and that adequate
mTORC1 activity is even more critical in the pressure-overloaded heart.
Reduced mTORC1 activity in raptor-deficient cardiomyocytes leads to
heart failure and death within 2 weeks of aortic constriction.7 While
increased autophagy and apoptosis as well as changed metabolism
were observed in the raptor-deficient hearts, one of the primary reasons
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for the observed dysfunction is reduced protein synthesis and a lack of
adaptive hypertrophy.7
Much less is known about mTORC2 owing to the unavailability of
selective inhibitors. Early work demonstrated that by phosphorylating
members of the AGC kinase family such as protein kinase C (PKC),
PKB/Akt, and SGK1, mTORC2 regulates cytoskeletal actin organiza-
tion, cell survival, and other processes.8 The availability of tissue-
specific knockout models for essential components of mTORC2
has recently given more insights into the in vivo functions of
mTORC2 for some tissues. Knockout of the mTORC2 component
rapamycin-insensitive companion of mTOR (rictor) in skeletal muscle
showed either no phenotype9 or impaired insulin-stimulated glucose
transport and enhanced glycogen synthase activity.10 Adipose-specific
rictor-deficient mice showed increased body size, an enlarged pan-
creas, and hyperinsulinaemia,10,11 whereas liver-specific rictor knock-
out mice revealed that mTORC2 regulates hepatic glucose and lipid
metabolism.12 mTORC2 was recently also shown to regulate size,
shape, and synaptic plasticity of neurons13,14 as well as oligodendrocyte
differentiation.15 These and other studies demonstrate that the func-
tions of mTORC2 are diverse and specific for the tissue or cell type
being analysed.
The mTORC1 inhibitor rapamycin is used as an immunosuppressant
and an anticancer drug, and the interest to use it for ageing-related dis-
ease including cardiac disease is also high. Notably, rapamycin does not
fully block mTORC116 and it was reported to activate mTORC2 and
Akt, which may be anti-apoptotic.17 On the other hand, long-term ra-
pamycin treatment can also inhibit mTORC2.18,19 Our present study
therefore aims to uncover the cardiac function of rictor/mTORC2
using a conditional knockout approach. We report that deletion of
rictor from cardiomyocytes inactivates mTORC2, but does not modify
basal cardiac function and geometry during postnatal growth and up to
an age of 54 weeks. However, rictor-deficient hearts perform less well
when challenged by aortic constriction-induced pressure overload,
despite the fact that their reactive hypertrophy is similar as in controls.
Our data suggest that mTORC2 is implicated in the contractile
response to pathological haemodynamic stress and further molecular




Male rictor knockout and control mice on a C57BL/6 background were
generated using tamoxifen-inducible Cre-recombinase under control of
the cardiomyocyte-specific a-myosin heavy chain (MHC) promoter.7
Transverse aortic constriction (TAC) and echocardiography were per-
formed as published, using ketamine/xylazine and isoflurane, respectively.7
Animal experiments were performed according to Guidelines for the Care
and Use of Laboratory Animals and with approval of the Swiss Cantonal
Authorities.
2.2 Cardiomyocyte isolation
Cardiomyocytes were isolated from control and cardiac rictor knockout
(rictor-cKO) mice at 12 weeks of age as published.20
2.3 Protein and RNA analysis
Equal amounts of protein or RNA extracted from tissues and cultured
cardiomyocytes were analysed by immunoblotting and quantitative
real-time PCR as reported.7
2.4 Microscopic analysis
Paraffin sections of 4% paraformaldehyde-fixed tissue were processed for
Picrosirius red staining to visualize fibrosis. Deoxynucleotidyl transferase
dUTP nick end-labelling (TUNEL) assay was performed using an in situ
apoptosis detection kit (Roche Diagnostics, Rotkreuz, Switzerland). Wheat
germ agglutinin (WGA) staining, collagen, and caspase-3 labelling were
done on cryosections fixed with 4% paraformaldehyde.7 Cross-sectional
areas were quantified by measuring at least 100 cardiomyocytes in three in-
dependent sections of 3–4 mice per group.
2.5 Statistical analysis
Data are presented as mean+ SEM. Differences in means were evaluated
with two-way ANOVA (P-values in text), followed by Sidak’s multiple com-
parisons tests (P-values in figures). For multiple measurements of the same
mice, repeated-measures ANOVA was used. All statistics was performed
with GraphPad Prism 6.0. P-values of ,0.05 were considered statistically
significant.
Detailed procedures, antibody sources, and buffer compositions are
provided in Supplementary material online.
3. Results
3.1 Rictor deficiency does not affect cardiac
weight, function, or geometry in adult mice
up to 54 weeks of age or in growing young
mice
To analyse the cardiac function of mTORC2, we generated cardiac-
specific rictor knockout mice by crossing mice containing the floxed
rictor gene9,21 with mice transgenic for inducible cre-recombinase
driven by the a-MHC promoter.22 The resulting rictorfl/fl a-MHC-
MerCreMerTg/0 micewere, at an age of 10weeks, injectedwith tamoxifen
to induce the deletion. These mice are hereafter referred to as
rictor-cKO mice. Control mice (rictor+/+ a-MHC-MerCreMerTg/0)
underwent the same tamoxifen treatment. 18 days after the tamoxifen
injections, rictor protein was lower in the rictor-cKO mice compared
with the control mice in cardiac muscle, but not in skeletal muscle.
Moreover, insulin-stimulated increases in Akt-pS473 were dramatically
impaired while 4E-BP1 phosphorylation was not affected in the
rictor-cKO hearts (Figure 1A). This confirms specificity of the deletion
and efficient inactivation of mTORC2, because Ser473 in the hydropho-
bicmotif (HM) of Akt is the best-established direct target of mTORC2. At
this time point after induction of the deletion, no cardiac functional or
geometric differences were revealed by ultrasound analysis between
the control and rictor-cKO mice. To evaluate the consequences of pro-
longed mTORC2 inactivation under basal conditions, we performed
echocardiography at 4, 6, 10, 16, and 25 weeks after tamoxifen to assess
cardiac parameters at 14, 16, 20, 26, and 35weeks of age (see Supplemen-
tary material online, Figure S1A and Table S1). At all time points, the ejec-
tion fraction (EF) and fractional shortening (FS) values of the rictor-cKO
mice were similar to those of control mice. Systolic and diastolic septum
and left ventricular (LV) posterior wall thickness, LV internal diameters,
and LV mass-to-body weight ratios were also indistinguishable over the
time period that these mice were followed. Consistently, post-mortem
analysis at the age of 35 weeks revealed no differences in ventricular
weight to tibia length ratios between the control and rictor-cKO mice.
In an independent experiment with a different batch of mice, we found
that even at 54 weeks of age, rictor-cKO mice were indistinguishable
from control mice (Table 1). Notably, at both 35 and 54 weeks, rictor
protein and mTORC2 activity, as assessed by the amount of Akt-pS473,
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were still significantly decreased (see Supplementary material online,
Figure S1B).
As mTOR and Akt have been implicated in growth regulatory me-
chanisms, we next deleted cardiac rictor in growing mice at 4 weeks
of age. We observed a normal increase in LV mass over time with no
differences between the rictor-cKO and control mice. Cardiac growth
was in proportion to whole body growth for both groups, as
LV mass-to-body weight ratios were identical over time (Figure 1B).
Moreover, EFs and all other echocardiographic parameters were nor-
mal during growth and up to an age of 16 weeks (see Supplementary
material online, Table S2). Thus, rictor deficiency does not affect
physiological cardiac growth in young mice and has no adverse
effects on cardiac function in healthy adult mice kept under laboratory
conditions up to 54 weeks of age, the latest time point analysed in
our study.
3.2 Rictor deficiency accelerates the
development of cardiac dysfunction after
aortic constriction
The above data show that despite significant changes in Akt phosphor-
ylation at Ser473, rictor-cKO mice have a virtually normal functional
cardiac phenotype.We reasoned that mTORC2may primarily function
as a modulator of cardiac function during cardiac stress and therefore
assessed the effect of rictor deficiency in the cardiac response to
pathological pressure overload induced by TAC. Rictor-cKO and con-
trol mice were assigned randomly to sham or TAC groups for surgery
at 18 or 19 days after tamoxifen. Echocardiography was performed be-
fore (see Supplementary material online, Table S3) and 1 week after
TAC (Figure 2A and Table 2). Prior to TAC, no differences were detect-
able between any of the experimental groups. In the control mice, 1
Figure 1 Baseline characterization of rictor-deficient mice at 18 days after induction of the deletion (A), and analysis of the consequences of rictor
deficiency in young growing mice (B). (A) At 18 days after tamoxifen, overnight-fasted male mice were stimulated with vehicle (‘fasted’) or insulin for 2 h,
sacrificed, and the left ventricle was dissected and snap-frozen for analysis by western blotting with antibodies as indicated. (B) Ultrasoundmeasurements
of EF, diastolic LV posterior wall thickness (LVPWd), LVEDD, and LVmass-to-body weight ratios are shown at the indicated ages. Rictor deletion at 10 (A)
and 4 (B) weeks of age. Rictor-cKO: tamoxifen-injected a-MHC-MerCreMer/rictorfl/fl (N ¼ 9). Controls: tamoxifen-injected a-MHC-MerCreMer/
rictor+/+ (N ¼ 4). Statistical analysis: repeated-measures ANOVA.
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week of TAC significantly increased the LV posterior and anteroseptal
wall thickness while not changing the LV end-systolic and end-diastolic
internal diameters. Moreover, the control mice maintained cardiac
function after TAC, as their EF and FS values were similar to those mea-
sured after sham surgery. In the rictor-cKO, however, TAC significantly
reduced EF and FS compared with sham-operated rictor-cKO or
TAC-operated control mice. The rictor-cKO mice had higher LV end-
diastolic diameters (LVEDD), an effect that was strongest at the end of
systole. Moreover, although after TAC the rictor-cKO mice displayed
increases in anteroseptal and LV posterior wall thickness, these
increases were less pronounced than those measured in control
mice. Taken together, these data indicate that the rictor-cKO mice
developed signs of eccentric LV hypertrophy with a decline in cardiac
function, whereas control mice were in the compensatory phase of
hypertrophy after 1 week of TAC.
3.3 Rictor deficiency does not affect
hypertrophy, fibrosis, or metabolic gene
expression after TAC
Post-mortem analysis at 1 week after TAC revealed that the ventricular
weight to tibia length ratios were not different between control and
rictor-cKOmice. Thus, both groups produced similar increases in cardiac
weight compared with the corresponding sham-operated groups
(Figure 2B). In line with an unaltered hypertrophic response, atrial natri-
uretic peptide (ANP) and brain natriuretic peptide (BNP) were induced
similarly in both groups (Figure 2B and D). TAC also increased skeletal
muscle actin and decreased a-MHC mRNA levels but again, these
changes happened irrespective of the absence or presence of rictor
(Figure 2C). Notably, b-MHC mRNA transcript levels were higher in
the rictor-cKO mice than in controls under sham and TAC conditions
(Figure 2C), although the effect did not reach statistical significance at
the protein level (Figure 2D). WGA labelling (Figure 3A), Picrosirius red
staining (Figure 3B), collagen I (Figure 3C) and collagen III immunolabelling
(not shown), as well as gene expression analysis (Figure 3D and see Sup-
plementary material online, Figure S2) showed that cardiomyocyte cross-
sectional areas, fibrosis, andmetabolic gene expressionwere not affected
by the rictor deletion. Thus, after 1 week of pressure overload, the altered
geometry and decreased function of the rictor-deficient hearts is not as-
sociated with any differences in cardiac weight, fibrosis, or hypertrophic
and metabolic gene expression compared with the control mice.
3.4 TAC increases rictor in control mice
and rictor deficiency reduces protein levels
of multiple PKC isoforms
Figure 4A shows that TAC caused a significant 1.65-fold increase in rictor
protein in control mice, an observation that per se provides support for a
role of rictor/mTORC2 in pressure-overload conditions. TAC also aug-
mented rictor protein somewhat in the knockout mice (P ¼ 0.12), which
is explained by the fact that the gene is not excised from all cardiac cells.22
To obtain insights into the mechanisms whereby mTORC2 supports car-
diac function during pressure overload, we proceeded to analyse the
phosphorylation state of several AGCkinases, direct targets ofmTORC2,
in cardiac protein extracts. Since rictor deficiency did not modify the
hypertrophic growth response to TAC, we directed our attention to
the PKC family of kinases, which have been implicated in metabolism
and contractility.23–25 One of the classical PKCs (cPKC), namely PKCa,
is a well-established direct target of mTORC2,26 and recent work shows
that several other PKCsmay also be regulated bymTORC2.13Given their
known importance in cardiac disease, we set out to analyse which of the
PKC isoforms were regulated in our TACmodel and towhat extent rictor
deficiency modified this regulation. Figure 4B shows that in control mice,
TAC increased total protein levels of the classical PKCbII as well as PKCd,
a novel PKC (nPKC) by 1.5- and 2.3-fold, respectively. For PKCbII, the
increase was paralleled by enhanced phosphorylation of its HM residue
Ser660 (Figure 4B and see Supplementary material online, Figure S3A).
An antibody to Thr638/641 in PKCa/bII revealed that phosphorylation
of this turn motif (TM) was also increased (Figure 4B). Probing with a
PKCbII-specific TM site antibody confirmed that this indeed concerned
phosphorylation of the PKCbII isoform and that the difference between
control and rictor-cKO mice was already visible prior to surgery (see
Supplementary material online, Figure S3B). As the above-mentioned
phosphorylation sites are all typical mTORC2 targets and the increases
in total and phosphorylated PKCs paralleled those observed for rictor
shown in Figure 4A, we next assessed whether rictor/mTORC2 is re-
quired for their increased abundance under pressure-overload condi-
tions. Indeed, the significant increases in PKCbII and PKCd protein
were absent in the rictor-cKO hearts and consistently, PKCbII-pS660
and -pT641 were lower in rictor-cKO than in control mice (Figure 4B).
While the rictor-cKO group had lower PKCa and -bII levels com-
pared with the control group, the abundance of PKCd appeared not
affected by rictor ablation under basal (sham) conditions (Figure 4B).
We also analysed PKC1, the other main nPKC expressed in the heart.
Its protein levels were lower in the rictor-cKO than in the correspond-
ing sham or TAC controls, and did not increase after TAC (Figure 4B
and see Supplementary material online, Figure S3C).
In conclusion, our observation that TAC increases PKCbII and PKCd
along with rictor in control, but not in the rictor-cKO hearts, suggests
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Echocardiographic parameters of control and






Heart rate (b.p.m.) 500+28 563+16
Anteroseptal wall thickness (mm)
Diastole 0.97+0.04 0.82+0.07
Systole 1.36+0.05 1.17+0.11
LV wall thickness (mm)
Diastole 0.75+0.02 0.82+0.04
Systole 1.05+0.06 1.11+0.07
LV internal diameter (mm)
Diastole 4.11+0.05 4.11+0.2
Systole 2.88+0.04 3.03+0.24
Ejection fraction (%) 61.3+1.4 55.9+4.0
Fractional shortening (%) 32.6+1.0 29.0+2.7
Post-mortem analysis
Body weight (g) 40.6+1.6 39.8+2.2
Ventricular weight (VW, mg) 123.2+5.4 120.0+5.9
VW/body weight (mg/mm) 3.05+0.15 3.03+0.09
Rictor deletion was induced in a-MHC-MerCreMer/rictorfl/fl mice at the age of 10
weeks by an intraperitoneal injection with tamoxifen for 5 consecutive days. Controls
consisted of mice homozygous for the wild-type rictor gene (a-MHC-MerCreMer/
rictor+/+), injected with tamoxifen. Ultrasound analysis was performed at 44 weeks
after tamoxifen. N ¼ 5 for rictor-cKO and N ¼ 6 for control.
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that the inability to increase these isozymes contributes to the reduced
cardiac performance observed in our rictor-cKO mice under
pressure-overload conditions. As PKCbII was already affected under
basal conditions, its decrease is likely implicated directly in the develop-
ment of dysfunction. Although PKC1 was not increased after TAC, its
strongly reduced levels in rictor-cKO hearts may have contributed to
the dysfunction.
3.5 Rictor deficiency reduces Akt-pS473,
Akt-pS450, as well as total Akt1 and
2 protein, while increasing Akt-pT308
Akt is the most frequently analysed target of mTORC2 and serves as an
important survival kinase in the heart (for review, see Sussman et al.27).
Consistent with the baseline data obtained at 18 days after tamoxifen
(Figure 1A) phosphorylation of Akt at its HM residue, Ser473 was also
strongly reduced in the rictor-deficient hearts at 1 week after surgery,
i.e. 25 days after tamoxifen, confirming that mTORC2 was to a large
extent inactivated. Notably, total Akt protein was also lower in the
rictor-cKO mice than in controls. Antibodies specific for total Akt1
and Akt2 protein (Figure 4C) revealed that both isoforms were reduced
significantly. As previous studies have shown that mTORC2-mediated
TM phosphorylation determines the stability and thereby abundance of
Akt,28,29 we analysed Akt-pS450. Figure 4C shows that phosphorylation
of this site was indeed strongly diminished in the rictor-cKO hearts.
Notably, Akt phosphorylation at Thr308, thought to be key for Akt
activity,30 was not reduced despite a clear lack of phosphorylation at
Figure 2 Rictor deficiency causes cardiac dysfunction without changing hypertrophic responses after TAC. Rictor deletion was induced by tamoxifen at
10 weeks of age and TAC or sham surgery performed 18–19 days later. Ultrasound was performed before (see Supplementary material online, Table S1)
and 1 week after surgery (A), and the mice were sacrificed for molecular analysis immediately afterwards (B–D). (A) Echocardiography data of the EF,
LVEDD, and diastolic LV posterior wall thickness (LVPWd). (B) Post-mortem ventricular weight to tibia length ratios (VW/TL) and quantitative RT-PCR
analysis of ANP and BNP. (C) Quantitative RT-PCR analysis of b-MHC, a-MHC, and skeletal muscle (SkM) actin mRNA levels. (D) Western analysis of
ANP and b-MHC proteins. Rictor-cKO are tamoxifen-injected a-MHC-MerCreMer/rictorfl/fl mice (N ¼ 5 for sham, N ¼ 7 for TAC). Controls are
tamoxifen-injected a-MHC-MerCreMer/rictor+/+ mice (N ¼ 6 for sham, N ¼ 6 for TAC). Two-way ANOVA post hoc testing: **P, 0.01,
***P, 0.001 for TAC vs. sham; $P, 0.05, $$P, 0.01, $$$P, 0.001 for rictor-cKO vs. control.
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Ser473 and Ser450. Consistent with earlier studies,4,31 Akt-pT308 ap-
peared even somewhat higher in the rictor-cKO than in control mice
(P ¼ 0.035 in two-way ANOVA), although upstream of Akt-pT308
no compensatory change in phosphoinositide-dependent kinase 1
(PDK1) phosphorylation was observed (see Supplementary material
online, Figure S4A). In sham-operated mice, this went along with slightly
enhanced phosphorylation of the Akt targets GSK3b and TSC2 (see
Supplementary material online, Figure S4A). In an independent cohort
of mice sacrificed at 18 days after tamoxifen in the fasted or insulin-
stimulated state, rictor deficiency did not change phosphorylation of
the Akt targets AS160 and FoxO1/3a (see Supplementarymaterial online,
Figure S4B). Our results are consistent with the view that Akt phosphor-
ylation by mTORC2 is not required for its Thr308 phosphorylation by
PDK132 and with what has been described for liver,12 skeletal muscle,9
Purkinje cells,13 and other studies in which it was reported that Akt is still
activated to a significant extent in mTORC2-deficient cells. Our findings
show that also in the heart, the loss of mTORC2-mediated Akt
phosphorylation does not reduce Akt activity towards several of its
substrates.
3.6 Analysis of apoptosis in rictor-deficient
hearts and adult cardiomyocyte cultures
Akt is known to propagate the effects of PI3K within the nucleus via
FoxOs and thereby may regulate apoptosis.33,34 Some studies support
that mTORC2 is needed specifically for the function of Akt to phos-
phorylate FoxO, but not for other functions of Akt.35 A recent study
shows in cultured cardiomyocytes and ischaemic hearts that mTORC2
inactivation by Torin or shRNA enhances, whereas mTORC2 activa-
tion via PRAS40 decreases oxidative stress-induced apoptosis, and
suggests that this happens via Akt-pS473 and FoxO.36 We therefore
tested whether mTORC2 deficiency increased apoptosis in our model
by analysing cleaved caspase-3 and performing TUNEL assays. After
TAC, the rictor-cKO mice (N ¼ 6) had 2.2-fold more cleaved
caspase-3-positive cells than the control mice (N ¼ 5) and consistently,
they also contained more TUNEL-positive cells (Figure 5A and B). How-
ever, only very few apoptotic cells were detectable and these were all
part of the non-cardiomyocyte compartment of the heart as identified
by double labelling with antibodies to myomesin. Our finding that car-
diomyocyte apoptosis was not detectable in sections of the whole
heart was in apparent contrast with previous work,36 and we therefore
went on to analyse apoptosis by western blotting after isolation of car-
diomyocytes from the adult control and rictor-cKO hearts. Figure 5C
shows that rictor was below detection levels in this cardiomyocyte
fraction of the heart, which confirms efficiency and cardiomyocyte spe-
cificity of the deletion. Cleaved caspase-3 was higher in rictor-depleted
cardiomyocytes immediately (0 h) or 24 h after their isolation. These
data show that mTORC2 prevents apoptosis in adult cardiomyocytes,
at least during the isolation procedure of these cells, which is very likely
associated with hypoxic and/or other stress. Nevertheless, our obser-
vation that overall cardiac weight, fibrosis, and cardiomyocyte cross-
sectional areas were not changed by the deletion together with the
fact that we did not detect any apoptotic cardiomyocytes in the in
situ heart indicates that apoptosis is not a primary reason for the dys-
function measured in rictor-deficient pressure-overloaded hearts. This
conclusion is further supported by our observation that phosphory-
lated FoxO1/3 was not altered by the rictor deletion (see Supplemen-
tary material online, Figure S4B) and consistently, multiple FoxO target
genes (ERRa, MCD1, and CPT1b) were indistinguishable between con-
trol and rictor-cKO hearts (data not shown).
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Table 2 Physiological and echocardiographic parameters of control and rictor knockout mice at 1 week after sham or TAC
surgery
Control Rictor-cKO
Sham (N 5 7) TAC (N 5 6) Sham (N 5 5) TAC (N 5 7)
Echocardiography
Heart rate (b.p.m.) 539+25 495+14 473+16 514+13
Anteroseptal wall thickness (mm)
Diastole 0.77+0.01 1.04+0.02*** 0.73+0.02 0.89+0.03***,$$$
Systole 1.03+0.02 1.39+0.03*** 0.97+0.04 1.12+0.04*,$$$
LV posterior wall thickness (mm)
Diastole 0.78+0.01 1.15+0.03*** 0.72+0.02 0.92+0.03***,$$$
Systole 1.03+0.02 1.36+0.03*** 0.97+0.04 1.07+0.05*,$$$
LV internal diameter (mm)
Diastole 3.79+0.10 3.46+0.13 3.73+0.13 4.06+0.20$
Systole 2.67+0.10 2.55+0.16 2.70+0.18 3.38+0.26$$
Ejection fraction (%) 57.2+1.7 52.8+3.2 54.6+3.7 36.2+4.5**,$$
Fractional shortening (%) 29.6+1.1 26.6+2.0 27.9+2.4 17.3+2.3**,$$
Post-mortem analysis
Body weight (g) 29.0+0.4 26.6+1.1** 26.9+0.8 27.1+0.7
Ventricular weight (VW, mg) 112.4+2.0 143.7+4.2*** 103.9+3.1 135.9+4.1***
VW/tibial length (mg/mm) 6.17+0.13 7.84+0.24*** 5.69+0.18 7.49+0.22***
*P, 0.05, **P, 0.01, ***P, 0.001: TAC- vs. corresponding sham-operated group.
$P, 0.05, $$P, 0.01, $$$P, 0.001: knockout vs. corresponding control group.
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3.7 Rictor deficiency blunts signalling via
PRAS40, mTORC1, and rpS6
Next to the Akt targets GSK3b, TSC2, and AS160 described under
Section 3.5, reduced Akt levels in rictor-deficient hearts could, via
PRAS40 and TSC, diminish mTORC1 activity. Since changed signal-
ling via mTORC1 may, at least in part, explain the functional pheno-
type of the rictor-cKO mice, we tested whether mTORC2
inactivation modified signalling via mTORC1. Whereas Figure 6A
shows that phosphorylation of the mTORC1 targets 4E-BP1 and
UNC-51-like kinase 1 (ULK1) were not affected by rictor ablation,
Figure 6B shows a trend towards lower S6-pS240/244 in rictor-
deficient hearts (P ¼ 0.068 in two-way ANOVA), suggesting reduced
signalling via mTORC1/p70-S6K1. Consistently, mTOR phosphoryl-
ation at Ser2448, a target of p70-S6K1 indicative of mTORC1 activa-
tion, was decreased after rictor deletion (P ¼ 0.006 in two-way
ANOVA, Figure 6B). Furthermore, PRAS40, a target of Akt and com-
ponent and negative regulator of mTORC1, was less phosphorylated
in the rictor-cKO mice (P ¼ 0.011 in two-way ANOVA, Figure 6B).
Our findings suggest that mTORC2 may, possibly via Akt and
Figure 3 Rictor deficiency does not change cardiomyocyte cross-sectional areas or fibrosis after aortic constriction. Cardiac tissue of mice of Figure 2
was either frozen in OCT (A and C) or fixed in paraformaldehyde, followed by dehydration and embedding in paraffin (B), or snap-frozen in liquid ni-
trogen for isolation of RNA and quantitative RT-PCR analysis (D). (A) WGA staining (left) and quantitative analysis of the cardiomyocyte cross-sectional
area (right). (B) Picrosirius red staining for analysis of fibrosis. (C) Immunolabelling with an antibody to collagen I followed by a rhodamine-labelled sec-
ondary antibody. (B and C) TAC-operated mice. (D) Quantitative RT-PCR of collagen I and III and transforming growth factor (TGF)b to evaluate fibrosis
(N ¼ 5–6 mice per group). Two-way ANOVA post hoc testing: *P, 0.05; ***P, 0.001 for TAC vs. the corresponding sham control. The scale bars
represent 100 mm.
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PRAS40, regulate mTORC1-mediated p70-S6K1 and rpS6 phosphor-
ylation. We also analysed AMPKa, as it is known to independently re-
press mTORC1 signalling through specific phosphorylation sites on
mTOR, raptor, and TSC2 (reviewed in Shimobayashi and Hall37).
AMPKa phosphorylation was increased in the rictor-deficient hearts
(P ¼ 0.012 in two-way ANOVA). Thus, AMPK may have blocked
mTORC1 activity towards p70-S6K1 in parallel to PRAS40. Notably,
the observed increase in AMPKa phosphorylation is indicative of
increased AMP/ATP ratios, suggesting that energy availability is
decreased in the rictor-cKO hearts. Indicative of metabolic stress is
also the observed induction of b-MHC gene expression in the rictor-
deficient mice (Figure 2).
Figure 4 Effects of TAC and rictor ablation on AGC signalling at 1 week after surgery. Examples of western blots incubated with the antibodies as
indicated (left). Quantification after normalization to the corresponding loading controls (right). The normalized data are expressed relative to the
sham-operated controls. Control and rictor-cKO mice as in Figure 2. N ¼ 5–7 per group. Two-way ANOVA post hoc testing: *P, 0.05, **P, 0.01,
***P, 0.001 for TAC vs. sham; $P, 0.05, $$P, 0.01, $$$P, 0.001 for rictor-cKO vs. control.
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4. Discussion
4.1 Rictor/mTORC2 is implicated in the
response to pressure overload
Themain objective of the present study was to elucidate the function of
mTORC2 in the heart. Our experiments demonstrate that haemo-
dynamic stress causes cardiac dysfunction in mice deficient for rictor,
an essential component of mTORC2, whereas control mice with nor-
mal mTORC2 activity display maintained function. Cardiac mTORC2
inactivation does not cause any obvious basal phenotype during post-
natal growth or adulthood up to 54 weeks of age. Interestingly, TAC
increased overall ventricular weight in the rictor-cKO mice as much
as in the control mice, but increases in LV wall thickness were less pro-
nounced and associated with increased LV internal diameters, reminis-
cent of eccentric hypertrophy. Rictor deficiency did not affect any of
the TAC-induced hypertrophic markers ANP, BNP, smooth muscle ac-
tin, and skeletal muscle actin, nor did it modify metabolic gene expres-
sion or fibrosis. Taken together, our results indicate that mTORC2 is
important for contractile performance in acute pressure-overload con-
ditions, without affecting reactive hypertrophic responses.
4.2 Rictor/mTORC2 is required for
increased PKCbII and PKCd protein levels
during pressure overload
The role of mTORC2 during haemodynamic stress is further sup-
ported by our observation that rictor protein levels increase concomi-
tant with maintained function in pressure-overloaded control hearts.
This increase is paralleled by enhanced phosphorylation of PKCa and
PKCbII. Because mTORC2 has been implicated in the phosphorylation
of multiple PKC family members,13,26,28,38,39 our results suggest that
cardiac mTORC2 participates in the response to haemodynamic stress
via these effectors. The reduced phosphorylated levels of these PKCs
after cardiac rictor ablation consolidate this view.
Total protein levels of PKCbII, PKCd, and, albeit to a lesser extent,
PKCa (P ¼ 0.16) are also higher after TAC in control hearts, but not in
rictor-deficient hearts. Consistent with earlier work in murine embry-
onic fibroblasts, where evidence was provided that co-translational TM
site phosphorylation by mTORC2 regulates stability and thereby the
abundance of PKCa,27,39 we here show that enhanced TM phosphor-
ylation of PKCa and PKCbII after TAC is associated with their in-
creased abundance, whereas decreased phosphorylation of the same
sites after rictor deletion is associated with their reduced abundance.
Notably, the decrease in phosphorylated PKC was stronger than that
in total PKC, indicating that the remaining protein was less phosphory-
lated. Similarly, the strongly reduced Akt and PKC1 abundance in our
rictor-deficient hearts is very likely related to reduced mTORC2 phos-
phorylation, in line with previous mechanistic studies.13,28 On the other
hand, mTORC2 did not appear to regulate PKCd in MEFs28,39 or neu-
rons,13 and earlier work demonstrated TM autophosphorylation of
PKCd.40,41 Our data therefore suggest that PKCd stability may be regu-
lated in a cell type-specific manner. It remains to be provenwhether the
decrease in PKCd is explained by a direct mTORC2-mediated mechan-
ism because unlike Akt and other PKCs that we measured, PKCd ap-
peared not reduced under basal conditions. We therefore cannot
exclude the possibility that decreased PKCd abundance after TAC is
secondary to, for example, the observed cardiac or metabolic stress.
Speaking against this is that cardiac stress has previously been asso-
ciated with increased rather than decreased PKCd. Alternatively,
mTORC2-mediated PKC1 reductions could be responsible for the
lowered PKCd, as published previously,42 because PKC1 is an estab-
lished direct mTORC2 target.26,28,39
4.3 Functional consequences of reduced
PKCbII and PKCd after TAC
Phosphorylation of the three conserved serine/threonine residues on
cPKCs and nPKCs takes place shortly after synthesis and is needed
for their intracellular distribution, stability, and catalytic activity.43,44
These phosphorylation events cause a stable but still ‘closed’ inactive
enzyme conformation and prepare them for subsequent activation by
lipid second messengers, such as diacylglycerol (DAG) and Ca2+. In
pressure-overload models, stimulation of angiotensin AT1 and a1-
-adrenergic receptors will, via Gq and DAG, stimulate the PKCs. In-
creased PKC expression and activity was previously thought to cause
the pathological hypertrophy together with ERK1/2 and p38
stress-activated kinases. However, consistent with our observation
that decreased levels of two cPKCs were not associated with any
Figure 5 mTORC2 inactivation increases apoptosis in non-
myocyte cells of the heart. Cardiac tissue of the mice of Figure 2
was frozen in OCT (A) or fixed in paraformaldehyde, followed by de-
hydration and embedding in paraffin (B). (A) Immunostaining with an
antibody against cleaved caspase-3 fragment followed by an Alexa555-
labeled secondary antibody. Double labelling of the same section with
an antibody to myomesin followed by an Alexa488-labelled antibody
was performed to identify cardiomyocytes. (B) TUNEL assay was per-
formed on paraffin sections. (A and B) Nuclei were stained with DAPI.
For C, primary cardiomyocyte cultures were prepared from adult con-
trol and rictor cardiac knockout (cKO) mice and proteins extracted
immediately (0 h) or 1 day after the isolation (24 h). Caspase-3 was
analysed by western blotting.
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effects on the hypertrophic response, genetic ablation of the cPKC
family members does not prevent cardiac hypertrophy.45 Instead, the
cPKCs are today thought to be involved in the regulation of cardiac
contractility.23 Studies with PKC knockout mice have demonstrated
that the b and g isoforms are, in contrast to PKCa, positively affecting
contractility. Thus, PKCb/g null mice showmore severe failure, where-
as PKCa null mice are less susceptible to heart failure following long-
term pressure-overload or myocardial infarction injury.45 Based on
these studies, we think that our phenotype is related to the inability
of the rictor-deficient hearts to increase PKCbII and perhaps also
PKCg, which we did not test in the heart but was strongly decreased
after rictor ablation in neuronal tissue.13
Regarding the nPKCs, a study published during the revision of our
manuscript demonstrated that PKCd and PKC1 depress reactive
hypertrophy, but that it required deletion of both genes to reveal
this function, because redundancy masked the effect after ablation of
the individual genes. The lack of a phenotype under basal conditions
in our study with both nPKCs being strongly decreased after rictor
ablation is consistent with that study, in which combined embryonic
ablation of PKCd and PKC1 showed no phenotype under basal condi-
tions.35 The lack of a significant effect on pressure-overload hyper-
trophy in the rictor-deficient mice may be due to residual PKCd and
PKC1 protein, inherent to the inducible MerCreMer model that
we used.
Besides contractile deficiency, the decreased cardiac perform-
ance may be related to the energy resources available for contrac-
tion, as mTORC2 has been implicated in the regulation of
metabolism in various tissues.37,46 In support of this idea, AMPK
phosphorylation levels were increased in the rictor-cKO hearts
indicative of a reduced ATP availability. Moreover, b-MHC expres-
sion was induced, which, as this isoform generates force in an ener-
getically more economic manner than the a-isoform, may represent
a compensatory energy-preserving effort after rictor ablation. Akt2
regulates Glut4 translocation to the sarcolemma, a process that is
enhanced during the cardiac pressure-overload response to ensure
that energy supplies match the increased work. However, although
Akt2 abundance was strongly reduced in the rictor-cKO hearts, the
phosphorylation of its downstream mediator AS160 was not
affected (see Supplementary material online, Figure S4B). Finally,
the lack of a robust PKCd increase after TAC, possibly secondary
to decreased PKC1,42 may explain metabolic insufficiency after
rictor ablation, because it has been shown previously that hearts
lacking PKCd lose their capacity to adapt metabolically.47,48 In con-
clusion, our data suggest that the lacking increases in PKCbII and
Figure 6 Effect of rictor deletion on mTORC1, PRAS40, and AMPK. Examples of western blots incubated with antibodies as indicated (left). Quan-
tification after normalization to the corresponding loading controls (right). The normalized data are expressed relative to the sham-operated controls.
Control and rictor-cKOmice as in Figures 2 and 4. N ¼ 5–7 per group. Two-way ANOVA post hoc testing: *P, 0.05, **P, 0.01, ***P, 0.001 for TAC
vs. sham; $P, 0.05 for rictor-cKO vs. control.
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PKCd contributed to the dysfunction observed after pressure over-
load for the rictor-deficient hearts.
4.4 Reduced phosphorylation of Akt at
Ser473 and Ser450 after rictor ablation does
not reduce Akt substrate phosphorylation
Next to the above-discussed PKCs, the protein abundance of the
best-established mTORC2 target Akt was reduced in the rictor-cKO
mice and this applies to Akt1 as well as Akt2. Because Akt was not
increased in our TAC model, its reduced expression is most likely
not a primary cause of the dysfunction measured in the rictor-cKO
mice. The lack of a functional or morphological phenotype under
physiological conditions in growing and adult mice suggests that the
residual protein amounts were sufficient for normal cardiac function
or that a high level of redundancy in cardiac signalling exists and alter-
nate pathways compensate for the deletion. The latter possibility is
supported by the fact that phosphorylation of Akt at Thr308 was not
impaired and that the Akt targets GSK3b, TSC, and AS160 mirrored
the Akt-pT308 levels, indicating normal Akt activity under basal condi-
tions. These results imply that the mTORC2-mediated Akt phosphor-
ylation is not essential for basal cardiac function. Consistently, cardiac
deletion of mTOR4 caused a basal phenotype that was very similar to
that of mice in which raptor was lacking,7 which indicates that mTOR
acts predominantly as part of mTORC1. Similar observations were
noted for other organs, including skeletal muscle,9,10 kidney,49 or adi-
pose tissue11 in all of which rictor deficiency does not cause any strong
baseline phenotype. Along similar lines, mTORC2-mediated HM site
phosphorylation appears not essential for the growth regulatory activ-
ity of Akt at physiological levels of insulin stimulation.50 The latter study
suggests that only the maximal levels of Akt activity are limited in the
absence of HM phosphorylation, for example, when insulin stimulation
is increased.50 In analogy, our data obtained with the TAC model sug-
gest that in the heart, the mTORC2-mediated phosphorylation be-
comes functionally important when mTORC2 targets are significantly
activated, which we demonstrated for PKCbII and PKCd, but not for
Akt. It is of note that our study was performed with male mice. Given
the known effect of female hormones on Akt signalling, it remains to be
demonstrated whether mTORC2 deficiency impacts one or more
targets of Akt in the female heart.
4.5 mTORC2 inactivation does not modify
physiological or pathological cardiac growth
Our previous work shows that mTORC1 is essential for the cardiac
adaptation to pressure overload with protein synthesis inherent to car-
diomyocyte hypertrophy being one of the prior mechanisms impli-
cated.7 Upstream of mTORC1 and downstream of mTORC2 Akt
can activate protein translation via TSC1/TSC2 and Rheb. Akt regulates
normal postnatal cardiac growth,51 it may get activated by pressure
overload,52 and transgenic overexpression of active Akt1 induces
cardiac hypertrophy.53,54 Whether or not mTORC2, via Akt or other
pathways, contributes to cardiac growth responses was unclear at the
onset of our study. As rictor deletion neither affected cardiac weight and
cardiomyocyte cross-sectional areas after TAC, nor changed physio-
logical postnatal cardiac growth, we conclude that mTORC2 is not
required for cardiac protein synthesis. This is further supported by
our observation that 4E-BP1, main mediator of protein synthesis down-
stream of mTORC1, was increased after TAC in the rictor-cKO as
much as in control mice. Moreover, Akt-pT308 was increased along
with enhanced phosphorylation of targets involved in growth re-
sponses, such as TSC2 andGSK3b. In contrast, rictor ablation decreased
S6K1 phosphorylation. While this effect may be secondary to de-
creased PKC activity,41,41,55,56 it had no consequences for cardiac
weight or cardiomyocyte cross-sectional area in our model, consistent
with earlier work.57 Thus, the heart behaves like several other organs
from which rictor has been removed without affecting an increase in
organ weight, including skeletal muscle,9,10 adipose tissue,11 and
kidney.49 We conclude that increased global protein synthesis intrinsic
to physiological growth or pathological cardiac hypertrophy does not
depend on mTORC2.
Taken together, our study points to a beneficial function of
mTORC2 in the heart during haemodynamic stress. We identified
several kinases that were reduced in rictor-deficient hearts. As cardiac
dysfunction occurred only after haemodynamic stress, we conclude
that the kinases that were increased concomitant to rictor in control
but not in rictor-cKO hearts, namely PKCbII and -d, are implicated in
the beneficial effects of mTORC2. As several compounds inhibiting
both mTOR complexes are in clinical trials for the treatment of cancer,
special attention should be paid in these studies to patients with con-
current cardiovascular diseases such as hypertension or valve disease.
On the other hand, our insights into cardiac mTORC2 signalling may
also open new avenues for the treatment of cardiac disease.
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